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1. INTRODUCTION 
1.1 Enzymes 
Enzymes are protein molecules whose roles are to catalyze and control thousands of 
chemical reactions that take place in living organisms. They can be produced from any 
living organism and are essential to sustain life. Life depends on a complex network of 
chemical reactions catalyzed by specific enzymes, and any modification of enzyme 
pattern may result in far-reaching consequences for the living organism.1  
Enzymes are most often globular proteins which assume an approximately spherical 
conformation in solution. Their molecular weights vary from ten thousand to millions. 
Over 5000 enzymes have been identified and they can be classified according to their 
functions into six major classes: (1) Oxido-reductases (transfer hydride between two 
substrates), (2) Transferases (transfer groups other than hydrogen), (3) Hydrolases 
(hydrolytic cleavage enzymes, substrate cleaved by water), (4) Lyases (removing or 
adding groups to double bonds), (5) Isomerases (catalyze structural or geometric changes 
within their single substrate molecules), (6) Ligases (synthetases joining two groups 
together, coupled with the breakdown of ATP or a similar triphosphate).2 
Proteases, also known as peptidases or proteinases, are globular, water-soluble 
enzymes which regulate many physiological processes. They are biology’s version of 
Swiss army knives, cutting long sequences of peptides into fragments which can fold into 
proteins.3 They belong to the family of hydrolases and play an essential role in the 
hydrolysis of the peptide bonds. More than 500 proteases (accounting for approximately 
2 % of human genes) with different functions and tasks have been identified.4 Proteases 
have adapted to a wide range of conditions (e.g. pH, reductive environment, etc.) through 
the evolutionary development. Moreover, different catalytic mechanisms have been 
identified for substrate hydrolysis. According to the catalytic residue in their active site 
which effects enzymatic hydrolysis, proteases can be classified into six different classes: 
serine, cysteine, threonine, aspartate, glutamic and metallo-proteases. Proteases are very 
selective for the cleavage of specific substrates, each of which is responsible for cutting 
the specific amino acid sequences under preferred environmental conditions. 
Proteases regulate numerous vital physiological processes (e.g. activation, synthesis 
INTRODUCTION 
2 
 
and turnover of all proteins) and hence play a key role in signaling pathways in all living 
organisms. They are consequently essential regulators related to all stages of a life cycle, 
namely, from conception, birth through growth, maturation and aging to diseases and 
death of all organisms. In general, proteases act reasonable if they are regulated and 
tightly controlled. However, endogenous and exogenous factors can disturb the balance of 
proteolysis processes, resulting in abnormal development, thus leading to diseases and 
death. Due to the importance of proteases in health and disease, the substances that 
interact with them thus decrease their activity, which are called inhibitors have been 
developed to shut down the enzymes, thus preventing the excessive proteolysis 
processes.5  
1.2 Serine Protease β-Tryptase 
Serine proteases are one of the most abundant groups of proteolytic enzymes in the 
human genome which play crucial roles in health and disease.6-8 Over one-third of all 
known proteases are serine protease. Their members are essential to a variety of biological 
activities, including digestion, blood clotting, immune response and inflammation, as well 
as reproduction. Among these, human β-tryptase is the predominant serine protease in 
human mast cells and is known to be involved in the pathogenesis of asthma and other 
allergic and inflammatory diseases.9-11 The x-ray structure of β-tryptase (Figure 1.1, left) 
is known since 1998 and has revealed unique and interesting structural features that 
distinguish it from other serine proteases.12 It is a tetramer consisting of four monomers 
pointing towards a central pore and the four active sites are buried deep inside of the 
hollow structure. Due to its unique structure β-tryptase is resistant to nearly all known 
standard endogenous proteinase inhibitors. Therefore, a number of small synthetic 
inhibitors of β-tryptase have been reported.8 Likewise in our working group, a focused 
combinatorial library of 216 tetravalent peptide ligands (1) obtained by using six amino 
acids (Arg, Lys, Glu, Phe, Ala, Trp) in the variable positions to ensure a sufficient degree 
of structural and chemical diversity within the library  (Figure 1.1, right) were 
synthesized and screened to identify potent inhibitors of β-tryptase. By taking the 
advantage of multivalent interaction, the tetravalent peptide ligands were shown to bind to 
β-tryptase through electrostatic interactions between the positively charged residues of the 
ligands and the anionic hotspots on the surface of the enzyme, sterically blocking access 
of the substrate to the active site thus shutting down the enzyme in a reversible and 
noncompetitive way with nanomolar affinity.13  
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Figure 1.1 Left: Cartoon and surface representation of the β-tryptase tetramer. Right: Schematic 
representation of combinatorial library of 216 tetravalent peptide ligands. 
For the protein surface recognition, besides the multivalency effects, the artificial 
binding motifs featuring more than one possible interaction means (e.g. electrostatic 
interaction plus hydrogen bonding) also play a crucial role in stabilizing the host-guest 
complex as well as increasing the binding affinity and specificity. For example, in our 
working group, a guanidiniocarbonyl pyrrole (GCP) binding motif was developed for 
efficient binding of carboxylates and anionic biomolecules such as oligopeptides or 
proteins.14-15 This artificial arginine analog GCP as a tailor-made binding motif can be 
incorporated to the natural peptide sequence to improve the binding affinity and 
specificity, which is very interesting not only for understanding the interaction events but 
also for the development of new therapeutics or drug candidates. 
The present work focuses on the design of novel and efficient inhibitors of the serine 
protease β-tryptase. A docking study is performed to have a better understanding of the 
possible binding sites on the protein surface. Within this work novel peptide ligands 
containing the artificial arginine analog GCP as a tailor-made binding motif in the peptide 
arms are developed for the inhibition of β-tryptase through the binding to the anionic 
hotspots on the surface of the enzyme. Furthermore, dynamic combinatorial libraries are 
used to identify new and potent inhibitors of β-tryptase by selecting the active building 
blocks featuring recognition units as well as the multivalent scaffolds. A new approach is 
also developed by using gold nanoparticle as the scaffold which is functionalized by the 
peptide ligands featuring inhibitory potentials. Both the inhibitory properties of the 
inhibitors and the inhibition mode to shut down the enzyme are investigated. The results 
are a valuable proof for the possibility of using these inhibitors and methods to the field of 
drug discovery. 
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2. BACKGROUND INFORMATION 
2.1 Enzyme Inhibition 
Enzymes are powerful biological catalysts that are essential in physiological processes, 
leading to the acceleration of the reaction rates by more than millions of times relative to 
the corresponding reactions without catalysts. Enzymes are not only efficient catalysts but 
with also high specificity. They are highly specific for catalyzing certain definite chemical 
reactions as well as the substrates which are involved in the reactions. Due to these 
properties, enzymes are candidates as therapeutic targets to combat diseases by 
modulating their activities with inhibitors or activators which can either decrease or 
increase enzyme activities. Therefore, the processes of the development and 
characterization of inhibitors or activators to regulate the enzyme activity are very 
important. This chapter will introduce the approaches used to the study of the enzyme 
kinetics and enzyme assays. 
2.1.1 Enzyme Kinetics 
Enzyme kinetics is the branch of enzymology that deals with the factors affecting the 
rates of enzyme-catalyzed reactions. The first general rate reaction equation for reactions 
involving enzymes was proposed by Henri in 1903.16 Based on Henri’s experimental 
work, Michaelis and Menten presented the simplest and best known Michaelis-Menten 
model of enzyme kinetics in 1913.17 It describes the rate of enzyme-catalyzed reactions by 
relating the reaction rate to the concentration of the substrate. The simplest reaction 
involves one substrate and one enzyme featuring one catalytic site. In this process the 
enzyme (E) and substrate (S) participate in an equilibrium with the enzyme-substrate 
complex (ES), which can then subsequently dissociate to the substrate and enzyme again, 
or can lead to catalysis and form the product (P) of the reaction and release enzyme again. 
The equilibrium is assumed to be not disturbed by product formation during the period 
initial rate of reaction is measured. 
 
The rate constants for the individual steps are depicted with k1, k-1 and k2 which are 
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used for the definition of Michaelis constant Km: 
 
Assuming that the enzyme-substrate complex is in rapid equilibrium with the reactants 
enzyme and substrate, which means that the equilibrium takes place on a much faster 
time-scale than the product is formed, the Michaelis-Menten equation (3) is obtained as 
follows: 
 
In this equation, the initial reaction rate v0 relates to the substrate concentration [S] and 
the maximum rate of the reaction Vmax.  
The plot of the reaction rate and the substrate concentration in the enzyme-catalyzed 
reaction is a hyperbolic curve (Figure 2.1, left) and from this the Km value is described as 
the substrate concentration when the reaction rate is the half of Vmax. The parameters can 
be obtained as well by linearizing the Michaelis-Menten equation, which can be done by 
taking the reciprocal of both sides of the equation to give Lineweaver-Burk equation (4): 
 
The parameters Vmax and Km can be determined directly from this representation by 
checking the intercept on the y axis and the slope of the plot (Figure 2.1, right). 
 
Figure 2.1 Left: Graphical plot of reaction rate v against substrate concentration [S] according to 
Michaelis-Menten equation. The enzyme concentration is fixed. Right: Lineweaver-Burk plots of 1/v against 
1/[S]. Km and Vmax can be determined directly by the intersection on the x- and y-axis. 
As already described above, an inhibitor can reduce the velocity of enzyme-catalyzed 
reaction and thus can be used as candidates for drugs, antibiotics and toxins, etc. The 
studies of enzyme inhibition most often bring us the knowledge about the enzyme 
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specificity, the properties of the enzyme active site and the kinetic mechanism of the 
enzyme-catalyzed reaction. According to the nature of the inhibitors binding to the 
enzymes, two types of inhibitors are described: reversible and irreversible inhibitors. 
Irreversible inhibitors usually bind to the enzyme in a covalent way and change it 
chemically via covalent bond formation. These inhibitors most often modify the side 
chains of key amino acid residues that are needed for enzymatic activity and cannot be 
easily removed afterwards. In contrast, reversible inhibitors often bind to the enzyme with 
non-covalent interactions, e.g. hydrogen bonding, electrostatic and hydrophobic 
interactions. These inhibitors generally do not undergo chemical reactions upon 
interaction with the enzyme and can be easily removed by dilution, dialysis, ultrafiltration, 
centrifugation or replacement processes. Reversible inhibitors can be classified as 
competitive, uncompetitive or noncompetitive inhibitors depending on whether the 
inhibitors bind to the enzyme, the enzyme-substrate complex or both of them.  
A competitive inhibitor is a compound that combines with the free enzyme and 
competes with the substrate for the same binding site of the enzyme. Most often the 
competitive inhibitor resembles the substrate structurally and geometrically. It could be a 
nonmetabolizable analog or derivative of the substrate, or an alternate substrate of the 
enzyme, or the product of the enzyme-catalyzed reaction. The effect of a competitive 
inhibitor on the kinetics of an enzyme-catalyzed reaction is illustrated in Figure 2.2 (left). 
The inhibitor concentration [I] is arbitrarily chosen as Ki for comparison with the 
equilibrium in the absence of an inhibitor. It shows that the rate of the reaction rises more 
slowly in the presence of inhibitor but will ultimately reach the same Vmax at a higher 
substrate concentration and the Km value is increased. The Lineweaver-Burk plots which 
have the intersection on the y-axis and the increased slope confirm that the Vmax is 
unaffected by a competitive inhibitor but the Km value is increased.  
A noncompetitive inhibitor can bind to both the enzyme and the enzyme-substrate 
complex and has no effect on substrate binding and vice versa because inhibitor and 
substrate do not compete for the same binding site. As shown in Figure 2.2 (middle), the 
inhibitor and substrate bind randomly and independently at different sites. Namely, I binds 
to E and ES, S binds to E and EI. The binding of one ligand has no effect on the 
dissociation of the other. Most often the noncompetitive inhibitor changes the enzyme 
conformation sufficiently to prevent the proper positioning of the catalytic center which 
has no effect on substrate binding but the ESI complex is nonproductive. The effect of a 
noncompetitive inhibitor on the enzyme kinetics shows that the Vmax cannot be reached in 
the presence of a noncompetitive inhibitor even at an infinitely high substrate 
concentration. This can be explained by the equilibria shown: no matter how high amount 
of substrate is added, as long as the inhibitor exists, a portion of the enzyme will remain 
as the nonproductive ESI complex. Because at any inhibitor concentration the enzyme 
forms (E and EI) have equal affinities for the substrate, the Km value should be constant. 
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The Lineweaver-Burk plots also show clearly a constant intersection on the x-axis which 
means the Km value is unchanged by a noncompetitive inhibitor but the Vmax is decreased.  
An uncompetitive inhibitor binds to the enzyme-substrate complex. It does not bind to 
the free enzyme, so it does not compete with the substrate for the same binding site. In 
this inhibition mode, most often the free enzyme has an inappropriate binding site for the 
inhibitor but when the substrate binds to the active site of the enzyme, a conformational 
change occurs in the enzyme which makes the binding site accessible to the inhibitor, 
yielding a catalytically inactive ESI complex. The effect of an uncompetitive inhibitor on 
the enzyme kinetics (Figure 2.2, right) shows that the Vmax cannot be reached in the 
presence of an uncompetitive inhibitor because at any inhibitor concentration an infinitely 
high substrate concentration will not drive the entire enzyme to the ES form. However, 
unlike the noncompetitive inhibitor, the Lineweaver-Burk plots show that the intersection 
on the x-axis changes but the slope remains the same which means the Km value is 
decreased as well and in the same extent as the Vmax. 
 
Figure 2.2 Enzyme kinetics of three different types of inhibitions, namely competitive (left), 
noncompetitive (middle) and uncompetitive inhibition (right).18 a) The plots of reaction rate v against 
substrate concentration [S] according to the velocity equation in the absence and in the presence of a fixed 
concentration of an inhibitor. b) Lineweaver-Burk plots of 1/v against 1/[S] in the absence and in the 
presence of an inhibitor. c) Schematic representation of the reaction equilibria of the enzyme (E), substrate 
(S), inhibitor (I) and the complexes (ES, EI and ESI) between them as well as the product (P). d) The 
velocity equations in the presence of an inhibitor. 
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Although the Lineweaver-Burk plot has been widely used as a linear transformation 
method to determine kinetic parameters and different types of enzyme inhibitors, it has 
one major limitation. As the line of the plot is primarily defined by the data points at low 
substrate concentration, which is liable to cause big errors, the kinetic parameters 
determined from linear fitting curve may not accurately reflect the true values. Some other 
linear plots derived from the rearrangement of the Michaelis-Menten equation or the 
Lineweaver-Burk equation are also used for the determination of kinetic parameters. For 
example, the Hanes-Woolf plot is obtained by multiplying the Lineweaver-Burk equation 
by [S] yields a function that relates [S]/v linearly with [S] and the Eadie-Hofstee plot is 
derived from the Michaelis-Menten equation to yield a linear relation between v and v/[S]. 
However, with these two methods small deviation can cause large errors as well. 
Therefore, nowadays the nonlinear regression based on computational analysis is 
preferred which can lead to more accurate results.19  
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2.1.2 Enzyme Assays 
Enzyme assays are methods to study enzyme activities. They are used to determine the 
rates of enzyme-catalyzed reactions and play a vital role in enzyme kinetics and enzyme 
inhibition studies. They are of considerable importance, not just for the detection of 
enzyme activities, but in regards to the search for novel enzymes and specifically cleaved 
substrates as well. Enzyme assays are very important for bio-engineering, drug discovery 
and medical diagnostics which are used as essential tools for the understanding of the 
functions and actions of different enzymes in biological systems.  
Enzyme activity measures the amounts of active enzyme present in a reaction. The 
measurement of enzyme catalytic activity is mainly based on two ways by quantifying 
either the concentration of substrate consumed ([S]) or that of product produced ([P]) 
during the course of the experiment. Measuring the production of the product is usually 
more accurate because detecting small changes in [P] (initially [P] = 0) is easier than 
detecting small changes in large amounts of substrate [S]. 
At present, two major types of methods are used to measure the rates of enzymatic 
reactions: a continuous assay by Tian and Tsou20 and a discontinuous (dilution) assay by 
Kitz and Wilson.21 In both cases, it is important to have steady-state conditions which 
mean that the concentrations of substrate and inhibitor are much larger than the enzyme 
concentration ([S] >> [E], [I] >> [E]) to result in a steady concentration of 
enzyme-substrate complex during the reaction.  
The discontinuous (dilution) assay measures enzyme activity in a fixed period of time. 
In this assay, the enzyme and inhibitor are first incubated under steady-state conditions. 
To this sample the substrate is added and aliquots are then taken from the enzyme reaction 
at intervals and the residual enzyme activities in these reaction samples are measured. The 
reaction aliquots are known as the time points of the reaction and the amount of product 
production at each time point can be determined by UV/Visible (UV/Vis) or fluorescence 
spectroscopy. Then the initial rate of the reaction can be determined from the slope within 
the linear region of the curve by plotting the formed product concentration against time. 
This assay is very useful in the chemical reactions yielding products that are not 
spectroscopically distinct from the substrate. The product should be rapidly converted into 
a chromophore or a fluorophore that can be quantified by the related spectroscopy. 
The more convenient and simple method to monitor enzyme kinetics is the continuous 
assay. It has been widely used, allowing measuring the rate of reaction in one single 
experiment as compared to the discontinuous assay. The continuous assay often uses 
spectroscopic techniques to measure the production of product, or consumption of 
substrate in situ, which resemble the more accurate situations in vivo where the 
modification of the enzyme and the turnover of the substrate take place simultaneously. In 
this assay, the enzyme is mixed with the substrate and inhibitor to start the reaction, the 
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concentration of the product formed from the substrate hydrolysis is then determined as a 
function of time. There are many different methods of detection in the continuous assays. 
Some of the more common techniques used to quantitatively distinguish product from 
substrate include the UV/Vis spectroscopy and fluorescence spectroscopy. These spectra 
measure the absorbance or fluorescence changes of the substrate or product at a specific 
wavelength over time. Then the reaction rate can be observed as a function of time. Due 
to the linear correlation of the observed spectra signals with the concentration of the 
compound, the rates of the absorbance or fluorescence changes can be converted to the 
rates of substrate consumed or product yielded. Due to the high relevance for this thesis, 
the following description will focus on the continuous assay. 
The spectrophotometric assay is the most common method of detection in enzyme 
assays due to its simplicity, non-destructivity, selectivity, and sensitivity. The increase of 
the fluorescence due to the production of the product can be measured during the assay. 
The recorded fluorescence increase over time yields linear curves with different slopes. 
One thing to pay attention to is that the enzyme assay should be done at the beginning of 
the experiment to make sure it is in the initial velocity range (linear range) of the 
enzyme-catalyzed reaction.20 
In order to measure the efficiency of the inhibitor to inhibit the enzyme activity, 
normally two experiments should be performed. In the first experiment the Km and Vmax of 
the enzyme-catalyzed reaction alone (without inhibitor) can be determined as described in 
Chapter 2.1.1. The second experiment can be done similarly in the presence of an 
inhibitor. It is also possible to determine the binding mode of the inhibitor. Therefore, by 
measuring the velocity slopes in the presence of inhibitors at different concentrations (vi), 
which are smaller than the initial velocity in the absence of inhibitor (v0), the dissociation 
constant (Ki) of the inhibitor can be determined according to the Dixon equation (5).22  
 
Linear plots can be obtained by the rearrangement of this equation, resulting in a 
function that relates 1/v linearly with [I]. The Ki value as well as the inhibition mode can 
be determined by plotting 1/v against [I] at different substrate concentrations. The Dixon 
plots are shown in Figure 2.3. The intersection on the x-axis indicates the half maximal 
inhibitory concentration (IC50) while the intersection of the curves at different substrate 
concentrations reveals the Ki value. For noncompetitive inhibition, the IC50 value is 
independent of the substrate concentration and is equal to the Ki value. For competitive 
and uncompetitive inhibition, the IC50 value is varied with different substrate 
concentrations and the substrate concentration has to be considered for the calculation of 
the Ki value. 
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Figure 2.3 Dixon plots (1/v against [I]) for the determination of Ki values of three different types of 
inhibition at different fixed substrate concentrations: competitive (left), noncompetitive (middle) and 
uncompetitive inhibition (right).23 The intersection points in the Dixon plot of the competitive and 
noncompetitive inhibitions resulting from different substrate concentrations indicate the Ki value, whereas 
the intersection point of the uncompetitive inhibition provides the Ki value when the substrate concentration 
is infinitely high.  
Normally, the Ki value can be calculated from the IC50 value corrected by the Km and 
substrate concentration. For example, the IC50 value can be determined by using the direct 
nonlinear regression analysis with the program GraFit and the Ki value can then be 
calculated from that. For a competitive inhibitor, the apparent Kiapp value is first calculated 
by nonlinear regression analysis, then with the known or determined Km value of the 
enzyme-substrate complex the concentration independent Ki value can be determined with 
the following equation (6): 
 
Similarly, for the uncompetitive inhibitor, the true Ki value can be determined with 
following equation (7): 
 
The calculated dissociation constant Ki is then independent of the substrate 
concentration and its affinity to the enzyme, so it is possible to compare it accurately with 
literature known inhibitors. 
Since the suitable measurement methods are necessary to measure the product 
production of the enzymes, a large variety of different enzyme assays has been developed. 
Therefore, the following part describes some common methods for enzyme assays which 
make it possible to determine the production of the product by testing natural or artificial 
substrates and inhibitors. 
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As mentioned above, the simplest and most practical way is based on a chromogenic or 
fluorogenic substrate whose absorbance or fluorescence properties changes during the 
enzyme-catalyzed reactions, e.g. releasing a colored or fluorescent product upon enzyme 
cleavage or inducing a directly detectable change upon reaction (e.g. a precipitation). 
Therefore, most often the enzyme assays is based on direct fluorescence or absorbance 
readout in 96-well microtiter plates either in solution or in culture suspensions.24 However, 
in many enzyme reactions, changes in substrates or products are not observable by 
spectrophotometric methods because they do not absorb light. This kind of enzyme 
reactions can be detected with the help of indicators which respond directly to substrate 
consumption or product formation. A number of assays have been established as well by 
using other different analytical instruments such as HPLC, GC, MS, NMR and IR besides 
fluorescent and UV/Vis spectrometers. 
Since enzymes are often specific for substrates, different chromogenic or fluorogenic 
substrates are necessary for each of the enzyme assays. A large variety of examples 
focuses on a small family of chromophores or fluorophores which are incorporated into 
different synthetic substrates to provide the spectral signal during the enzyme reactions. 
An example is indican which is a chromogenic substrate belonging to the family of 
glycosides. It is present in plants such as Woad (Isatis tinctoria, the root of which is used 
as a traditional Chinese medicine herb) and Polygonum tincorum. The glycosidic bond of 
the indican (2) can be cleaved by a glycosidase, resulting in an indoxyl (3) and glucose as 
the product. The indoxyl is unstable and then oxidized by a mild oxidizing agent such as 
atmospheric oxygen to form the blue indigo dye (4, Figure 2.4).25 
 
Figure 2.4 Cleavage of chromogenic substrate by a glycosidase-catalyzed reaction. Indican (2) is 
hydrolyzed by the enzyme followed by the oxidation with oxygen to form the dimer indigo (4). 
This natural product example is used as a model following which a wide range of 
artificial enzyme substrates have been designed. For example, nitrophenyl β-galactoside 
(5), in which p-nitrophenol is linked to β-galactose, can also be used to detect the activity 
of β-galactosidase by releasing a yellow nitrophenolate (λmax = 405 nm) at alkaline pH 
which can be easily measured in a spectrophotometer.26 Similarly, p-nitrophenyl caproate 
(6)27 and p-nitrophenyl octyl ether (7) are used as chromogenic substrates for lipase and 
cytochrome P450,28-29 respectively, releasing the nitrophenolate (8) for detection (Figure 
2.5). 
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Figure 2.5 Cleavage of chromogenic p-nitrophenyl substrates by enzyme-catalyzed reactions, releasing a 
yellow nitrophenolate which can be measured in a spectrophotometer. 
Another example reported by Wang is using a synthetic fluorogenic substrate carrying 
a morpholinecarbonyl-derived rhodamine 110 (MC-R110) as the detectable species.30 The 
substrate Ac-Asp-Glu-Val-Asp-MC-R110 (9) was used for determining the activity of 
caspase-3. Before cleavage, the substrate is non-fluorescent in buffer solution. Upon the 
enzyme cleavage, N-MC-R110 (11) is formed which has a high fluorescence emission at 
525 nm (485 nm excitation) and can be detected directly by the luminoscope (Figure 2.6). 
 
Figure 2.6 Cleavage of fluorogenic substrate by the enzyme-catalyzed reactions. The product formation can 
be determined by the fluorescent emission at a wavelength of 525 nm resulted from the released MC-R110 
(11). 
Additionally, indirect release mechanisms have been used as well for a number of 
substrates. For example, Reymond and co-workers reported a fluorogenic assay (Figure 
2.7) based on the detection of carbonyl oxidation product (16), which undergoes a 
β-elimination reaction catalysed by bovine serum albumin (BSA) to form the fluorescent 
product umbelliferone anion (17).31 This method is very useful for the detection of 
precursors (substrates) that are resistant to oxidation. As shown in Figure 2.7, the 
substrates bis-phosphate (12) for phosphatases, diester (13) for lipases and esterases, and 
expoxide (14) for epoxide hydrolases are hydrolyzed by the specific hydrolytic enzymes 
to form 1,2-diol (15). The diol (15) was rapidly and quantitatively oxidized to aldehyde 
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(16) in the presence of sodium periodate (NaIO4), which is transformed into a blue 
fluorescent product 17 (λex = 360 nm, λem = 440 nm) by a β-elimination reaction. By using 
this method, the enzyme reactive moieties of the substrate can be separated from the 
fluorophore, thus the large aromatic group will have no effect on the binding properties. 
 
Figure 2.7 Periodate-coupled fluorogenic enzyme assays for phosphatase, lipases and esterases, and 
epoxide hydrolases with indirect release of umbelliferone (17). 
Besides nitrophenols, rhodamines and umbelliferones, fluoresceins32 and BODIPY33 
dyes are also well established to incorporate into substrates. All of these agents have 
rather large aromatic groups that have the tendency to influence the solubility of the 
substrate and the binding behavior of the substrate compared to the non-labeled substrates. 
Therefore, one must be careful when using such large chromophores or fluorophores.24 
Alternatively Nau and co-workers reported recently that new types of assay based on 
fluorescence resonance energy transfer (FRET) by using new and non-aromatic 
fluorophores are possible.34-35  
FRET is a distance-dependent transfer of excited state energy from an initially excited 
donor to an acceptor. Typical effective distances between the donor and acceptor 
molecules are within 10-100 Å. Another requirement is that the fluorescence emission 
spectrum of the donor must overlap with the absorption spectrum of the acceptor. The 
FRET efficiency is dependent on both the donor-acceptor distance and the spectral 
overlap. Normally the donor molecule is a fluorophore while the acceptor molecule can be 
either another fluorophore or a non-fluorescent molecule (quencher). Most often a 
fluorescent donor and an acceptor are located on opposite sides of the substrates in an 
appropriate distance to ensure the intramolecular FRET. Before enzyme cleavage, because 
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the emission of the donor is absorbed by the acceptor, only the emission of the acceptor or 
no fluorescence (when the acceptor is a quencher) can be observed. Upon enzyme 
cleavage at a protease cleavage site between donor and acceptor, the double-labeled 
substrate is separated into two single-labeled fragments, resulting in the recovery of the 
fluorescence of the donor due to the increase in the donor-acceptor distance which causes 
the decrease of the FRET efficiency (Figure 2.8). 
 
Figure 2.8 Principle of enzyme assays based on FRET between the labeled donor and acceptor on the 
substrates.  
A lot of enzyme assays are based on the mechanism of FRET. For example, Nagano et 
al. developed a fluorescent substrate for detecting the activity of phosphodiesterase based 
on FRET mechanism (Figure 2.9).36 A coumarin group was used as the donor and the 
fluorescein group as the acceptor. The artificial substrate (18) was designed by attaching 
both of the donor and acceptor to two phenyl linkers to prevent the dye-to-dye close 
contact37 with the phosphodiester moiety situated in the middle. In aqueous buffer 
solution, when excited at 370 nm, the emission of the coumarin donor was strongly 
absorbed by the fluorescein acceptor and the emission of the acceptor (λem = 515 nm) was 
observed due to the FRET from the donor to the acceptor. Upon the hydrolysis of the 
phosphodiester group by the phosphodiesterase, the donor (19) and acceptor (20) were 
separated, resulting in an increase in the donor fluorescence (λem = 450 nm) and a 
decrease in the acceptor fluorescence. The enzyme activity can then be detected by the 
changes of the fluorescence. Recently, they designed a different FRET method using the 
coumarin-fluorescein as the donor-acceptor pair as well. Upon changing the two isomeric 
forms of fluorescein (from lactone form to quinoid form) by enzyme hydrolysis reaction, 
resulting in the dramatically changes in absorption properties, the intramolecular FRET 
occurred and thus the enzyme activity can be determined by the ratiometric fluorescent 
detection method.38  
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Figure 2.9 The FRET-based enzyme assay mechanism for phosphodiesterases.  
A number of FRET substrates based on the fluorophore-quencher (donor-acceptor) 
systems to measure the enzyme hydrolytic reactions have been also developed.39-42 In 
most of these systems, the substrates have no fluorescence before the enzyme reaction 
because of the intramolecular quenching FRET effect. However, the fluorescence of the 
donor is increased after the enzyme-catalyzed reaction due to the diminishment of the 
intramolecular quenching effect which can then be detected to determine the enzyme 
activity.  
The above described enzyme assays are based on chromogenic and fluorogenic 
substrates which result in a direct change in the absorbance of light or the emission of 
light. However, for some specific reactions with unlabeled substrates, the 
enzyme-catalyzed reactions do not result in detectable light signals. In this case, the 
indicator assays can be used to detect such reactions. One of the most straightforward 
methods is the enzyme-coupled assay. It is based on using the product of one reaction as 
the substrate of a second enzyme, converting it to a second product and so on, until one of 
these following reactions produces the detectable signal. For example, the reduction of 
hydrogen peroxide to water catalyzed by peroxidases occurs with the concomitant 
oxidation of various chromogenic dyes, such as 2,2'-azino-di-(3-ethyl- 
benzthiazoline-6-sulphonic acid) (ABTS).43 In a recent report, Turner and co-workers 
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have designed a novel high throughput screening (HTS) method to detect both the activity 
and enantioselectivity of asymmetric ketone reduction by ketoreductases (KRED) in the 
presence of an R-selective alcohol oxidase, and horseradish (HRP) and ABTS for 
monitoring the precise amount of concomitant production of H2O2 and hence R-alcohol.44  
Some indicator assays are based on functional group selective reagents. For example, 
pH indicators have been used to monitor enzyme-catalyzed reactions which release or 
consume protons. An early example is the characterization of serine proteases by using the 
simple ester substrates to monitor their esterase activity.45 This method can reduce the 
reagent costs and shorten analysis time compared with the conventional techniques and 
substrates. pH indicators have also been used for the development of a colorimetric assay 
to screen the enantioselectivity of hydrolases by using the fact that ester hydrolysis lowers 
the pH of the reaction medium.46-47 Selective chromogenic or fluorogenic reagents with 
functional groups have also been used to measure enzyme activities. For example, the 
only well-known fluorescence assay for aminopeptidase is based on a fluorescence off-on 
chemosensor for amino acids which can be used to monitor the proteolytic activity of 
proteases on whole protein substrates in real time by using the released amino acids for 
displacement of Cu(II) from calcein, thus turn on the green fluorescence.48 
The main drawback of the indicator assays is that they are often sensitive to 
interferences, for example, a signal may be produced by other events rather than catalytic 
turnover or by which the catalytic turnover may be masked. It may require narrow assay 
conditions which might be incompatible with specific enzymes. Therefore, in order to 
overcome the drawbacks, a HTS application with the help of proper controls should be 
used. This is a very useful and necessary assay whenever a very specific reaction is to be 
optimized. 
In order to obtain more information in less time, the fingerprinting method has been 
developed which is based on measuring and analyzing multiple substrates simultaneously. 
Enzyme fingerprinting focuses the analysis on a single enzyme by using a series of 
structurally related substrates to detect its selectivity.49 The screening data may be used to 
identify reactive substrates, or for classification of the enzymes.50 Selectivity for 
structures or solvents can be performed either by parallel assays in microtiter plates51 or 
by on-bead assays which are based on the identification of protease substrates created on 
beads with the help of combinatorial chemistry.52 
The combinatorial chemistry is a useful technology that allows the simultaneous and 
fast synthesis of large libraries containing a large numbers of different but related 
compounds. Recently, the more sophisticated and faster technique such as ‘split and mix’ 
synthesis53 have been used. The output of the ‘split and mix’ synthesis is multiple 
compounds attached to the synthesis beads, each bead having one type of compound 
bound to its surface. Therefore, by using this method, it is possible to synthesize the 
‘one-bead-one-compound’ combinatorial libraries.54-55 To know which compound is 
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bound to which bead, either the compound itself needs to be identified by appropriate 
analytical tools, or the bead needs to be encoded.56 Such method can then be used to 
synthesize substrates and inhibitors. In order to screen such a large number of compounds 
in the libraries, a reliable high-throughput assay is essential. The commonly used assays 
for such combinatorial library methods are the on-bead assays without the cleavage step 
to avoid the complicated purification steps. Methods have been developed for the on-bead 
screening, including either the commonly used direct binding of fluorescence-labeled 
target molecule to the on-bead library and visually identification of beads that display 
compounds able to bind to the target,57-58 or detection of functional properties of the 
on-bead compound such as identifying phosphorylation59 or proteolytic substrates.60 
Because the compounds are still covalently attached to the solid support in the on-bead 
assay, in order to perform the biological assays in aqueous media, the solid support has to 
be biocompatible. Therefore, the resin beads should have good swelling properties in both 
organic and aqueous solvents. Ideally, the beads should be uniform in both size and 
loading. Furthermore, the resin must be inert towards the tested enzymes. The most 
common used resin for on-bead screening of enzymes is the PEGA resin which is based 
on solely hydrophilic polyethylene glycol (PEG) chains and shows excellent swelling 
properties in aqueous buffers. This resin has been widely used in solid phase peptide 
synthesis (SPPS) for the synthesis of ‘one-bead-one-compound’ combinatorial libraries, 
following which the on-bead screening can be performed.61-63 
In summary, a considerable number of enzyme-catalyzed reactions can be analyzed by 
direct or indirect assays through monitoring fluorescence or absorbance readout in 
microtiter plates where the enzymes, substrates and inhibitors are mixed in aqueous buffer 
solution. Moreover, the enzyme assays for the on-bead screening of combinatorial 
libraries allow easy, fast and quantitative analysis of all the library members with less 
effort. 
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2.2 Serine Protease β-Tryptase 
Human β-tryptase belongs to the family of serine proteases and is the predominant 
protein released from most human mast cell secretory granules. Serine proteases adopt 
two principle structure folds: trypsin-like (chymotrypsin-like) and subtilisin-like structure. 
Most members have the trypsin-like structure, e.g. trypsin, chymotrypsin, tryptase, 
elastase, plasmin and thrombin, etc. The trypsin-like structure consists of two β-barrels 
with the catalytic amino acids located at the interface of the two domains.64 The shape and 
properties of the enzymes’ binding pockets account for their substrate specificities. For 
example, for the three digestive enzymes, trypsin cleaves peptide bonds located on the 
C-terminal side positively charged residues (Lys/Arg preferred at P1 position), 
chymotrypsin prefers large hydrophobic residues such as Phe/Tyr/Trp at P1 position while 
elastase prefers small hydrophobic residues such as Gly/Ala/Val.65 Like trypsin, tryptase 
has a preference for positively charged lysine or arginine (Arg > Lys) at the P1 position of 
the substrate.66 Here the nomenclature is defined by Schechter and Berger.67 
Nomenclature for the substrate amino acid residues from N-terminus to C-terminus is 
defined as Pn, . . . P2, P1, P1’, P2’, . . . Pn’, where P1-P1’ denotes the cleaved peptide 
bond. In other words, the amino acid residues from the position of the hydrolyzed bond to 
the N-terminus are referred as Pn and those to the C-terminus are referred as Pn’. 
Accordingly, the adjacent binding sites of the enzyme called ‘subsites’ are numbered as 
Sn and Sn’ (n = 1, 2, 3…). They are located on both sides of the catalytic site of the 
enzyme and the cleavage site is between S1 and S1’ pocket.  
Serine proteases are named after the nucleophilic serine residue at the active site. The 
unusual reactivity of serine is due to a charge relay system, known as the so-called 
catalytic triad which is located in the active site of the enzyme and is directly involved in 
the catalytic reactions. For tryptase, the triad consists of three amino acid residues: 
aspartic acid (Asp-102), histidine (His-57) and serine (Ser-195). As shown in Figure 2.10, 
with the help of the proton-withdrawing oxyanion of Asp-102 binding to His-57, the 
histidine acts as a better proton acceptor and deprotonates the hydroxyl group of Ser-195, 
allowing it as a powerful nucleophile to attack the carbonyl group of the substrate. 
Another important characteristic feature of serine protease is the so-called oxyanion hole. 
In the case of tryptase, the oxyanion hole is formed by the backbone NHs of Gly-193 and 
Ser-195. These atoms form a pocket of partial positive charge that activates the carbonyl 
group of the scissile peptide bond and stabilizes the tetrahedral intermediate state.68 
The generally accepted mechanism for trypsin-like serine proteases is shown in Figure 
2.11.7 On binding of the substrate, His-57 as a base attracts the proton from the hydroxyl 
group of Ser-195 while it attacks the carbonyl carbon of the peptide substrate, to yield a 
tetrahedral intermediate which is stabilized by H-bond from backbone NHs of Ser-195 
and Gly-193 in the oxyanion hole. The resulting H+ of His-57 is stabilized by the H-bond  
BACKGROUND INFORMATION 
20 
 
 
Figure 2.10 The catalytic triad (Asp-102, His-57 and Ser-195) and the oxyanion hole (formed by the 
backbone NHs of Ser-195 and Gly-193) of trypsin-like serine proteases. 
 
 
Figure 2.11 The catalytic cleavage mechanism for trypsin-like serine proteases by the catalytic components 
(triad and the oxyanion hole).7 
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with the side chain of Asp-102. The next step is the reconstruction of the carbonyl group 
with expulsion of the leaving group, assisted by proton donation by His-57, resulting in 
the breakdown of the peptide bond to release the first product-the free amine, and the 
formation of the acylenzyme intermediate. Then a water molecule protonates His-57, and 
the resulting hydroxyl ion attacks the carbonyl carbon atom of the acyl enzyme, yielding a 
second tetrahedral intermediate. This intermediate collapses, assisted by protonated 
His-57 acting as an acid, releasing the second peptide fragment with free C-terminus and 
the catalytic triad is restored. 
Tryptase was found in mast cells more than 50 years ago.69 With an amount of 10-35 
pg per mast cell, tryptases represent up to one fourth of the total protein content of the cell, 
and even 90 % are stored in the secretory granules.70-71 Human tryptase comprises several 
isoenzymes (α1, α2, β1a, β1b, β2, β3, mMCP-7-like-1, mMCP-7-like-2) derived from human 
lung and skin tissues.72-73 β-tryptases are the main isoenzymes isolated from lung and skin 
mast cells whereas α-tryptases are mainly expressed in basophils,74 both of which are 
granulated cells rich in histamine and heparin. Mast cells play an important role in the 
immune system. When stimulated with antigens or allergens (proteins or polysaccharides), 
mast cell degranulation can be induced, for example with the aid of receptor FcεRI-bound 
antigen-coated immunoglobulin E (IgE), resulting in the extracellular release of 
inflammatory mediators such as histamine, tryptase, etc.75-77 Assessment of the increase in 
tryptase levels has been used as a specific mast cell activation marker and mediator for the 
diagnosis of anaphylaxis and even a greater specificity could be obtained from selective 
measurement of the increase of β-tryptase.78-79 A number of studies have demonstrated 
that tryptase participates in allergic and inflammatory processes, causing 
bronchoconstriction and airway hyperresponsiveness, which is the key characteristic of 
asthma.80-83 Furthermore, tryptase acts as a neuropeptidase, cleaving the bronchodilating 
neuropeptides vasoactive intestinal peptide (VIP) and peptide histinine methionine (PHM), 
as well as the vasodilator/bronchoconstrictor neuropeptide calcitonin gene-related peptide 
(CGRP). Tryptase also activates prekallikrein and generates kinins,84-85 which has been 
suggested as a mechanism by which tryptase enhances bronchoconstriction in asthmatic 
patients.86 Tryptase stimulates cellular response through activation of protease-activated 
receptor-2 (PAR-2), a G-protein-coupled receptor, which is related to the increased 
collagen deposition in the asthmatic airway.83, 87 For these reasons, tryptase has become an 
interesting target for studies of therapeutic agents for asthma and other allergic and 
inflammatory disorders. Therefore, to identify potential inhibitors for tryptase, the enzyme 
structure, catalytic site and the interaction with inhibitors should be studied. 
Specificity of trypsin-like serine proteases is usually categorized in terms of P1-S1 
interaction. The active site of the tryptase monomer is structurally quite similar to trypsin. 
In particular, the S1 specificity pockets of both enzymes are nearly identical and well 
suited to accommodate Arg or Lys at P1 position. The combination of Asp-189, Gly-216 
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and Gly-226 create a negatively charged S1 pocket that accounts for their specificity. The 
S2 subsite of tryptase monomer is open and larger than that of trypsin, and the S3/S4 
subsite is fully blocked. Even though β-tryptase has significant sequence similarity with 
other trypsin-like serine proteases, it has unique properties. For example, human 
β-tryptase is resistant to most of the endogenous proteinase inhibitors. The well-known 
proteinaceous inhibitors are the leech-derived tryptase inhibitor (LDTI)88 and tick-derived 
protease inhibitor (TdPI).89 Tryptase has highly preference for small peptide substrates to 
larger proteins. To understand the unique behaviour of β-tryptase and obtain a reliable 
model for drug design, its structure is analyzed. 
The x-ray structure of human β-tryptase12, 90 revealed that it has a tetrameric structure 
composed of four quasi-equivalent monomers which are arranged in two different 
orientations within the tetramer. The tetramer has a molecular weight of approximately 
134 kDa. Four monomers A, B, C and D are arranged in a flat rectangular frame with each 
monomer sitting in the corner and facing to a central pore (Figure 2.12). The tetramer 
shows almost perfect 222 symmetry and the three 2-fold axes are arranged nearly 
perpendicular. The quasi-symmetry is due to the different conformations of Tyr-75 
residues located in the monomer-monomer interfaces. Therefore, only two pairs of 
monomers (A and C, B and D) are equivalent in the tetramer structure. Each monomer 
contains one active site and the four active sites are directed towards a central oval pore 
measuring approximately 50 × 30 Å. Within the central pore, the four negatively charged 
S1 binding pockets (containing residue Asp-189) are shown in defined distances. 
 
Figure 2.12 Left: Tetrameric structure of β-tryptase tetramer (PDB code: 1A0L). The four monomers (A, B, 
C, D) are shown as ribbons surrounded by semitransparent surfaces. Two monomers each (A and C, B and 
D) are arranged in the same orientation. Right: Schematic representation of the β-tryptase tetramer with the 
inter-S1 subsite distances. Residue Asp-189 is at the bottom of each S1 pocket.91-92  
Tryptase monomers connect with their neighbours through different interactions. 
Monomers A and D (Figure 2.13, left) interact with each other through hydrophobic 
contacts, salt bridges as well as hydrogen bonding interactions. The surface area size of 
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the A-D interface (and the equivalent B-C interface) is 1075 Å, which is almost twice as 
large as the A-B interface (and the equivalent C-D interface) with a size of 540 Å 
connecting only via hydrophobic interactions.86 The tetrameric structure of β-tryptase is 
stabilized in vivo by heparin, a negatively charged polysaccharide, which can interact with 
a number of positively charged amino acid residues on both sides of the interfaces of the 
monomers (Figure 2.13, right). β-tryptase is only enzymatically active in the form of this 
non-covalently linked tetramer and it dissociates into inactive monomers in the absence of 
heparin or high salt concentrations.93  
 
Figure 2.13 Solid-surface structure of human β-tryptase. The blue and red colors indicate positive and 
negative electrostatic potentials, respectively. Left: Front view onto the four monomers. The four monomers 
(A, B, C, D) are arranged at the corners of a frame-like structure towards to a central pore. A cluster of 
negatively charged residues is centred at the entrance to the central pore. Middle: Side view towards the AB 
homodimer. The positively charged patches on the periphery of the AB dimer (and CD dimer) extend 
towards the front side of monomer B and the back side of A. Right: Binding model of heparin chain along 
the A-B edge of the tetramer. Heparin can bind to the positively charged patches, thus spanning and 
stabilizing the monomer-monomer interface. (Reprinted with permission from C. P. Sommerhoff, W. Bode, G. 
Matschiner, A. Bergner, H. Fritz, Biochim. Biophys. Acta 2000, 1477, 75-89. Copyright 2000 Elsevier).86 
As shown in Figure 2.13, the four active sites of β-tryptase are buried inside the central 
pore which is surrounded by a number of negatively charged amino acid residues such as 
glutamate and aspartate, thereby attracting the positively charged substances. However, 
the access to the active sites is significantly limited by the two narrow openings of the 
pore. This pore displays a rectangular cross-section but twisted by approximately 30o 
about the tetramer axis. It has an inner pore size of approximately 50 × 25 Å but two 
openings of the pore are much narrower (approximately 40 × 15 Å). Even though the 
entrances of the pore are just large enough for elongated peptides of the diameter of an 
α-helix to thread through and to interact with the active sites,90 the narrow pore restricts 
the size of accessible substrates and inhibitors to the active sites and that is why most of 
proteinaceous inhibitors fail for tryptase.  
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2.3 Inhibitors of Serine Protease β-Tryptase 
Since tryptase was found in pathophysiologic conditions responsible for asthma and 
other allergic and inflammatory disorders, it has become an attractive drug target and a 
number of efficient inhibitors have been reported. In terms of different inhibition 
mechanisms, the reported inhibitors can be classified into three types: heparin antagonists, 
active site inhibitors and protein surface binding inhibitors. 
2.3.1 Heparin Antagonists 
As mentioned above, β-tryptase is only enzymatically active in the tetrameric form. 
Thus, it is not surprising that compounds which can bind to heparin have the capability to 
inhibit tryptase. Heparin antagonists are defined as compounds that compete with 
β-tryptase to bind heparin, resulting in the denaturation of β-tryptase into four inactive 
monomers by the removal of heparin from the tetramer. 
In an earlier study, antithrombin III, a small protein known as the thrombin inhibitor, 
was reported to partially compete with tryptase for heparin binding, accelerating the loss 
of tryptase activity in vivo.94 Various kinds of cationic molecules have been reported as 
heparin antagonists and represent an interesting type of inhibitors. For example, 
lactoferrin, a cationic 78 kDa protein released from activated neutrophils, was reported as 
a potent (IC50 = 24 nM) and selective inhibitor for tryptase.95 Myeloperoxidase (MPO), a 
118 kDa cationic protein released from primary neutrophil granules, was shown to be 
efficient and selective tryptase inhibitor with an IC50 value of 16 nM.96 The inhibition is 
prevented by the presence of an excess amount of heparin. Other smaller tryptase 
inhibitors are the arginine-rich 4.5 kDa protein protamine (IC50 = 65 nM), and nonprotein 
polybrene (hexadimethrine bromide, 5-10 kDa) (IC50 = 3.6 nM), two polycationic 
compounds which are commonly used clinically as heparin antagonists for neutralization 
of the anti-clotting effect of injected heparin during surgery.97 The inhibition modes of 
these two inhibitors are different. Protamine appears to be a reversible inhibitor indicated 
by the reactivation of the enzyme by addition of excess heparin whereas polybrene seems 
to be an irreversible inhibitor as excess heparin failed to reactivate the enzyme. Recently, 
synthetic polycationic heparin inhibitors based on a calix[8]arene scaffold have shown 
competitive inhibition of human tryptase with a very high specificity and affinity towards 
heparin neutralization. However, the inhibitory effect, e.g. the IC50 value has not been 
determined in detail in this report.98 
2.3.2 Active Site Inhibitors 
The classical active site inhibitors of β-tryptase are able to enter the entrance of the 
central pore and interact with the active sites in a competitive way. They normally have 
small molecular weight due to the pore size and geometry restriction of β-tryptase and 
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represent the biggest group of tryptase inhibitors so far. Some small proteins can also 
inhibit tryptase acting as active site inhibitors. For example, the well-known atypical 
Kazal-type proteinaceous inhibitor LDTI, a small protein isolated from the medical leech 
Hirudo medicinalis consisting of 46 amino acid residues, was shown to bind to two of the 
four active sites of tryptase due to the steric hindrance and thus only inhibiting the 
enzyme activity by approximately 50 %.88 Even though it inhibits the tryptase with high 
affinity (Ki = 1.4 nM), it lacks selectivity relative to other related serine proteases such as 
trypsin (Ki = 0.9 nM) and chymotrypsin (Ki = 20 nM). TdPI, a Kunitz/BPTI (bovine 
pancreatic trypsin inhibitor)-related protein found in Rhipicephalus appendiculatus 
consisting of 97 amino acid residues, was shown to inhibit β-tryptase in the nanomolar 
range.89 In the inhibition course (Figure 2.14), a first TdPI molecule was cleaved by 
tryptase and fits into two diagonal active sites, followed by the second molecule binding 
to another active site from behind, resulting in blockage of three of catalytic sites and thus 
75 % inhibition was reached.  
 
Figure 2.14 Binding model of the TdPI to β-tryptase. The first TdPI molecule binds to the active site D and 
A after the cleavage by tryptase. The second molecule binds from the behind side to active site C. 
(Reprinted with permission from G. C. Paesen, C. Siebold, K. Harlos, M. F. Peacey, P. A. Nuttall, D. I. 
Stuart, J. Mol. Biol. 2007, 368, 1172-1186. Copyright 2007 Elsevier).89  
Recently, MCoTI-II, a member of a class of microproteins known as cyclotides that 
possess a macrolactam-cystine knot scaffold, isolated from the seeds of Momordica 
cochinchinensis, was reported to inhibit tryptase with some sequence modifications with 
nanomolar affinity (Ki = 9 nM) but also has no selectivity relative to trypsin (Ki = 2.6 
nM).99 Other efficient proteinaceous inhibitors derived from a linear variant of the cyclic 
cysteine knot miniprotein MCoTI-II, with 28 amino acid residues, belong to the smallest 
serine proteinase inhibitors. They were reported to bind all the four active sites of 
β-tryptase with four miniprotein inhibitors and completely inhibit the enzyme activity 
with a Ki value of 1 nM but also lack selectivity to trypsin.100  
There are a number of synthetic small molecules that can efficiently inhibit β-tryptase 
by binding to the active sites. Normally they are derived from non-reactive substrate 
analogues which bind in the active site but cannot be processed by the enzyme and thus 
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competitively prevent the substrate from binding. For example, one of the first tryptase 
monovalent inhibitors was APC-366 (21), an active site-directed competitive inhibitor 
which went into the clinical trial for treatment of asthma (Figure 2.15).9 However, it only 
underwent phase II clinical trials and was discontinued due to the only small beneficial 
effect. This might be because of the poor efficiency (Ki = 0.33–450 μM) and selectivity 
relative to other serine proteases.101-103 Other inhibitors such as Babim (22)101, 104 and 
RWJ-56423 (23)103 have been used for testing the role of tryptase. They are potent 
inhibitors binding to the active sites with Ki values of 5 nM and 10 nM, respectively but 
still have low selectivity against other serine proteases. The trypsin-like serine proteases 
inhibitors leupeptin (24) and p-aminobenzamidine (pAb, 25) can inhibit β-tryptase as well. 
They act as competitive inhibitors with Ki values of 1.0 μM and 65 μM, respectively.105 
However, due to the lack of selectivity of these monovalent inhibitors, it is not possible to 
determine if their effect in vivo is because of the inhibition of mast cell tryptase or other 
target proteases. Therefore, more selective inhibitors of tryptase need to be designed. 
 
Figure 2.15 Chemical structures of monovalent inhibitors of β-tryptase. 
The crystal structure of β-tryptase led to the design of new inhibitors, such as bivalent 
inhibitors. By playing around with the spacer length between two functional groups, this 
type of inhibitors can interact simultaneously with two active sites as they are relatively 
spatially close to each other within the central pore. This may allow the discovery of more 
potent and selective inhibitors by using the advantage of the multivalent effect by 
bridging two active sites.106-108 For example, AMG-126737 (26) has been shown to be a 
potent (Ki = 90 nM) and selective dibasic inhibitor of tryptase to block the development of 
airway hyperrespinsiveness in allergen-challenged guinea pigs (Figure 2.16).109 By testing 
different substitution positions of the amidine group and changing –SO2 to –CO, an even 
more potent inhibitor (27) was discovered to inhibit tryptase by bridging two adjacent 
active sites with a Ki value lower than 0.01 nM.110 This inhibitor also showed excellent 
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selectivity over other serine proteases such as trypsin and plasmin. 
 
Figure 2.16 Chemical structures of bivalent inhibitors of β-tryptase. 
APC-2095 (28) is an active site inhibitor of tryptase which showed not only high 
inhibition efficiency (Ki = 0.1 nM) but also good selectivity against other serine proteases 
(Figure 2.17).108 It has shown to block late phase bronchoconstriction and airway 
hyper-responsiveness in allergic sheep and has been tested in phase II clinical trials for the 
treatment of both psoriasis and ulcerative colitis.111 Another example is MOL-6131 (29), a 
reversible and competitive bivalent inhibitor of tryptase (Ki = 45 nM), which showed 
effects on airway inflammation and hyper-reactivity in a mouse model of asthma.112 
Dibasic inhibitors based on deketopiperazine templates and m-aminomethyl- 
phenylalanine as arginine mimetic were investigated by Schaschke et al.91 By varying 
spacer length, compound (30) was found to span the distance between the active sites of 
two neighboring subunits of tryptase tetramer and thus inhibiting β-tryptase with a Ki = 
value of 10 nM. Based on the same scaffold, a combinatorial library of dibasic 
compounds featuring guanidine or amidine functional groups were designed to identify 
inhibitors of β-tryptase with a micromolar affinity.113 
 
Figure 2.17 Chemical structures of bivalent inhibitors (28–30) of β-tryptase. 
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In addition to the bivalent inhibitors featuring flexible spacers, Schaschke et al. also 
reported an efficient inhibitor (31) based on the rigid cyclodextrin template to which two 
3-(aminomethyl)benzenesulfonyl-glycine groups were attached.92 The template has the 
appropriate size to bridge the space between two active sites of tryptase with 
3-(aminomethyl)benzene as a functional group occupying the specific S1 subsites (Figure 
2.18). It was shown to have a high inhibition efficiency to β-tryptase (Ki = 0.6 nM) and 
selectivity over other serine proteases such as trypsin (Ki = 4.8 μM) and thrombin (Ki > 
160 μM).  
 
Figure 2.18 Left: Chemical structure of inhibitor (31) for β-tryptase based on β-cyclodextrin. The functional 
groups are colored red. Right: The x-ray structure of β-tryptase with the bivalent inhibitor 31. It binds to the 
two shortest active sites of the tetramer. The two related tryptase subunits A and D (cf. Figure 2.12) are 
shown as green and yellow ribbons with the catalytic triad as stick and ball models. The inhibitor is shown 
in stick and ball representation in red color. (The modeling image is reprinted with permission from N. 
Schaschke, G. Matschiner, F. Zettl, U. Marquardt, A. Bergner, W. Bode, C. P. Sommerhoff, L. Moroder, 
Chem. Biol. 2001, 8, 313-327. Copyright 2001 Elsevier).92 
Leatherbarrow et al. reported a series of peptides based on the sequence 
SCTKSIPPQCY derived from the solvent exposed loop of the so-called Bowman-Birk 
inhibitor (BBI), which are potent inhibitors of chymotrypsin-like proteases but do not 
inhibit human β-tryptase. This type of tri-functional inhibitors can inhibit β-tryptase with 
a Ki value as low as 1 nM.114 
Based on the natural product cyclotheonamide E4, which was modified by replacing 
the S1 ligand with basic β-homoamino acids derived from arginine and implementing a 
basic P3 residue that determines the extended substrate specificity of β-tryptase, a highly 
efficient and selective inhibitor (32) of β-tryptase was obtained with a Ki value of 7 nM 
(Figure 2.19).115 Furthermore, by using the arginine mimic β-homoaminomethyl- 
phenylalanine as a privileged S1 ligand, compound (33) was shown to be a potent 
inhibitor of β-tryptase as well with a Ki value of 25 nM. It showed excellent selectivity 
over other serine proteases and stability in human plasma and serum.116 
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Figure 2.19 Chemical structures of cyclotheonamide E4 based inhibitors (32–33) of β-tryptase. 
The above mentioned bivalent inhibitors of β-tryptase were all based on basic P1 
groups which are favored by the acidic S1 pocket. Neutral P1 inhibitors have not been 
reported for β-tryptase, even though they have been identified for trypsin-like serine 
proteases containing Ala-190, such as factor Xa (fXa) and thrombin.117-118 Recently, Liang 
et al. investigated whether dimeric inhibitors with two neutral P1 moieties from a known 
fXa inhibitor could offer potent inhibition of tryptase. The S1 pocket of β-tryptase is 
identical to that of fXa or thrombin except it contains Ser-190 instead of Ala-190. The 
mutation from Ala-190 to Ser-190 shrinks the binding space for inhibitor and decreases 
the hydrophobic interaction between the inhibitor and the residue. However, no detectable 
binding was obtained, which revealed the importance of Ala-190 for the binding of neutral 
P1 inhibitor and casted doubt on the possibility of developing neutral P1 inhibitors of 
β-tryptase.119 This example clearly demonstrated the necessity of the basic P1 groups for 
the design of the efficient active site inhibitors of β-tryptase. 
2.3.3 Protein Surface Binding Inhibitors 
A new approach developed recently to inhibit the human β-tryptase is based on the 
binding to the surface of the protein. Most likely this type of inhibitors binds to the 
entrance of the negatively charged central pore of β-tryptase, blocking the access of the 
substrate to the active sites and thus preventing it from binding. 
Calix[8]arene based receptors with different basic amino acids (Figure 2.20) were 
designed and synthesized for tryptase surface binding by Cunsolo et al.120 The inhibitors 
have Ki values between 2 and 80 nM and had selectivity over trypsine, but the inhibition 
mode is unclear. On one hand, tryptase was indirectly inhibited due to the interaction of 
the inhibitor with heparin. On the other hand, competitive inhibition was also obtained. 
However, the exact binding site is still unknown. Only the surface interaction between the 
inhibitor and the acidic area close to the enzymatic active sites was proposed.  
BACKGROUND INFORMATION 
30 
 
 
Figure 2.20 Left: Chemical structures of calix[8]arene based inhibitors (34) of β-tryptase. Right: Proposed 
representation for the complex between tryptase and inhibitor 34d (green CPK model). (The image of the 
proposed binding mode is reprinted with permission from T. Mecca, G. M. L. Consoli, C. Geraci, F. Cunsolo, 
Bioorg. Med. Chem. 2004, 12, 5057-5062. Copyright 2004 Elsevier).120 
Schmuck et al. recently designed a type of ligand which can bind to the surface of the 
protein, close to the entrance of the central pore. Most likely this ligand acts as a 
‘molecular plug’ upon binding, blocking the access to the active sites and thus preventing 
the substrate from binding.13 To identify the most efficient ligands a focused 
combinatorial library of 216 tetravalent peptide ligands with four identical arms was 
designed (1, see page 3, figure 1.1). Six amino acids (Arg, Lys, Glu, Ala, Phe, Trp) were 
used in the variable positions to cover a wide range of characteristics, such as basic, acidic, 
aliphatic and aromatic properties. The most efficient ligands combined basic and aromatic 
amino acids in the arms and inhibit the enzyme with nanomolar affinity in a reversible 
and noncompetitive way. For example, the best ligand (RWKG)4 (35) was shown to 
inhibit β-tryptase with a Ki value of 170 nM (Figure 2.21). Ligands with negative charges 
in their arms showed only weak or no inhibition confirming that binding to the negatively 
charged surface around the pore is crucial. Force field calculations confirmed that the 
ligands have indeed the correct molecular size to span the central pore upon protein 
surface binding even though no structural proof for this binding mode could be obtained. 
 
Figure 2.21 Left: Chemical structure of the best peptide inhibitor (RWKG)4 (35) of β-tryptase obtained 
from the combinatorial library. Right: Force field calculations confirm that the ligand (35) can bind to the 
protein surface, closing the central pore and thus preventing the substrate from binding to the active sites.  
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2.4 Protein Surface Binding 
In general, a protein has a folded conformation featuring a solvent-exposed (exterior) 
surface and a solvent-excluded (interior) surface (Figure 2.22).121 Most often concave and 
well-defined enzyme active sites are situated at the interior of proteins, containing 
convergent functional groups that are shielded from solvents and solutes. Therefore, the 
corresponding highly functionalized small molecules can efficiently inhibit their action. 
By contrast, the exterior surfaces are flat and most often in direct contact with water and 
solutes. Functional groups on the protein exterior surface are in general divergent. In 
comparison to the well-defined pockets in the active sites of enzymes, exterior protein 
surfaces are more challenging targets due to the relatively large solvated surfaces 
(500-2000 Å2). Most often protein binding areas are focused on critical hot spot of ca. 600 
Å2 size with a predominance of Try, Tyr and Arg residues as shown in Figure 2.22.122 
Hence, binding to the protein surface by designed molecules must account for the 
extensive solvation of the exterior surface of a protein, as well as the topology of the 
recognized surface.123-125 Tight binding of protein surfaces based on non-covalent 
interactions requires the involvement of large surface areas and multiple points of 
functionality. Therefore, in order to achieve the sufficient binding affinity to protein 
surface, the multivalent interaction between the protein surface and the designed molecule 
is important and necessary. The advantages of the multivalency were described by Wich in 
his PhD thesis.126  
 
Figure 2.22 Schematic illustration of a protein (enzyme) interior, exterior, and hot spot.121 
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There are a number of biomolecules and synthetic ligands that can interact with the 
protein surface. Protein surface interactions contribute to study or disrupt protein-protein 
interactions which are of crucial importance in many biological processes, such as cellular 
communication, immune response, signal transduction, enzyme inhibitions, apoptosis, 
etc.127-129 The protein surface interaction between yeast iso-1-cytochrome c and yeast 
cytochrome c peroxidase was one of the first examples illustrated by the crystallographic 
investigation.130 Cytochrome c is a small heme protein with a highly basic surface (12 
kDa, pI ≈ 10) and plays key roles in electron transfer and apoptosis. This crystal structure 
reveals that a specific electron transfer pathway occurred within this complex. The 
interaction areas are between a hydrophobic patch centered on the solvent exposed heme 
region of cytochrome c surrounded by a number of positively charged basic lysine and 
arginine residues and a complementary hydrophobic patch surrounded by negatively 
charged residues on the cytochrome c peroxidase (Figure 2.23, left). This conformation of 
the protein complex was observed in solution as well as determined by paramagnetic 
NMR.131 Calorimetric data indicated that the binding depends on ionic strength, which is 
based on the structural information involving desolvation of charged residues to form salt 
bridges.132 Another example is the interaction between the tumor suppressor p53 and the 
cellular oncoprotein MDM2 (also known as HDM2). They were found to form a negative 
feedback loop which contributes to limit the growth of the suppressing activity of p53.133 
The crystal structure of the transactivation domain of the protein p53 forms an 
amphipathic α-helix conformation, binding to a deep hydrophobic cleft on the MDM2 
protein surface (Figure 2.23, right).134 In particular, only three key residues (Phe-19, 
Trp-23 and Leu-26) of p53 are essential for binding by inserting deep into the MDM2 
cleft due to the steric complementarity between the hydrophobic face of the p53 α-helix 
and the cleft of the MDM2. 
 
Figure 2.23 Left: The interaction between yeast iso-1-cytochrome c and yeast cytochrome c peroxidase with 
recognition domains highlighted by a green circle (PDB code: 2PCB). Right: The interaction of the MDM2 
oncoprotein with the p53 tumor suppressor. The three key amino acid residues of p53 are shown as sticks. 
(PDB code: 1YCR).  
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Protein surface binding by artificial molecules that can lead to protein 
modification/modulation or the inhibition of protein-protein interaction has become an 
interest of current research in recent years.135-136 In comparison to the recognition of 
proteins by biomolecules such as antibodies, recognition by synthetic molecules has 
higher chemical stability but lower selectivity and specificity. The key issue of the design 
of artificial molecules which can bind to a relatively large surface area of a protein is the 
development of supramolecular or multivalent ligands based on different scaffolding 
structures for the presentation of related binding functional groups in a specific 
orientation.137-138 The design feature of ligand functionalities should match the 
hydrophobic and charged domains on the protein surface with complementary regions on 
the synthetic ligands. Most often so far the designed multivalent ligands were based on 
calixarene, porphyrin, G-quadruplex, anthracene, or gold nanoparticles as scaffolds and 
were developed by using both rational design and combinatorial approaches (Figure 2.24). 
 
Figure 2.24 Schematic representation of the various multivalent scaffolds. (Reprinted with permission from 
V. Martos, P. Castreño, J. Valero, J. de Mendoza, Curr. Opin. Chem. Biol. 2008, 12, 698-706. Copyright 
2008 Elsevier).137 
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Calixarenes are cavity-shaped cyclic oligomers formed by formaldehyde with 
p-alkylphenols under alkaline conditions. The valence of these oligomers can vary from 1 
to 8, depending on the reaction conditions. They have a semirigid cone structure with a 
hydrophobic cavity, a wider upper rim and a relative narrow lower rim. Calixarenes have 
been used as one of the most common scaffolds for preparing host molecules in host-guest 
chemistry due to their attractive architecture.139-140 Their derivatives can bear a variety of 
functional groups for molecular recognition. In particular, water-soluble calixarene 
derivatives have great potential for binding to proteins or other biomolecules.141-142  
For example, Neri and co-workers developed a surface recognition of tissue and 
microbial transglutaminases (tTG and mTG) by peptidocalix[4]arene diversomers. TG is 
an enzyme that catalyzes the posttranslational modification of proteins by transamidation 
of available glutamine residues.143 Calix[4]arene was used as scaffold in a locked cone 
conformation, bearing tetrapeptide chains linked to the upper rim by their N-terminus. 
Derivatives bearing a Gly-Phe-Gly-Tyr tetrapeptide sequence (36) showed the most 
effective inhibition towards both TG isomers. Most likely these inhibitors bind to a 
specific surface of TG on a region noncomprising the enzyme active site (hot spot). 
Consequently, a conformational rearrangement of the active form occurred by the 
enzyme-inhibitor interaction which leads to the enzyme inhibition.144 The same group also 
investigated the use of this calixarene scaffold to construct inhibitors (37) of histone 
deacetylase enzymes (HDACs) which play key role in removing acetyl groups from 
ε-N-acetyl lysine residues on histone, allowing histones to wrap DNA more tightly. Based 
on the measured affinity it was possible to show that the Ki values are strictly dependent 
on the size of the hydrophobic arms on the upper rim of calixarene. The most efficient 
candidate 37i (IC50 = 0.14 μM) was shown to bind to the surface of the protein via 
occupying the hydrophobic pockets by the aromatic arms mainly through hydrophobic or 
aromatic stacking interactions, as well as interacting with the ZnII ion at the bottom of the 
channel by carboxylate moieties (Figure 2.25, Right).145  
 
Figure 2.25 Left: Calixarene based receptor for transglutaminase inhibition.144 Middle: Structural features 
of calixarene derivatives for HDAC inhibition. Right: 3D model of the putative binding mode of the most 
efficient candidate 37i to the surface of the histone deacetylase like protein (HDLP, PDB code: 1C3R). (The 
modeling image is reprinted with permission from M. G. Chini, S. Terracciano, R. Riccio, G. Bifulco, R. 
Ciao, C. Gaeta, F. Troisi, P. Neri, Org. Lett. 2010, 12, 5382-5385. Copyright 2010 American Chemical 
Society).145 
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Hamilton et al. reported a synthetic protein surface binding ligand (38) as an antibody 
mimic bearing four peptide loops linked to a central core of a calix[4]arene scaffold 
(Figure 2.26). The loops contained negatively charged peptide sequence 
Gly-Asp-Gly-Asp with a prepared surface area of approximately 450 Å2 to recognize the 
cationic surface of the protein. The ligand showed a competitive inhibition of the serine 
protease α-chymotrypsin with a Ki value of 0.81 μM by binding close to the active site 
cleft of the enzyme and blocking the access of the substrate. It showed slow binding 
kinetics in an analogous manner to natural protein proteinase inhibitors.146 Furthermore, 
by binding to the exterior surface of chymotrypsin, it was able to disrupt the interaction 
between the serine protease and its proteinaceous inhibitors, particularly in blocking the 
chymotrypsin-soybean trypsin inhibitor complex.147 This ligand also showed strong 
binding to the complementary cationic regions on the surface of cytochrome c, forming a 
1:1 complex with a binding constant of 3 × 108 M-1. The surface binding to cytochrome c 
is very efficient so that it could disrupt the protein-protein interactions and displace its 
natural high affinity protein partner, cytochrome c peroxidase (see Figure 2.23), which 
indicated that it binds close to its heme region as its natural protein partner. The ligand 
could inhibit the reduction of the Fe (III)-cytochrome c by ascorbate by binding to the 
protein surface and preventing the approach of ascorbate to the heme edge.148-149  
 
Figure 2.26 Top: Artificial receptor base on calix[4]arene scaffold for the recognition of protein surface. 
Bottom: Presentation of protein surfaces of α-chymotrypsin and cytochrome c. 
Giralt and Mendoza recently designed a ligand (39) based on a calix[4]arene scaffold 
with four cationic guanidiniomethyl groups at the upper rim and hydrophobic loops at the 
lower rim. It can stabilize the tetrameric structure of the tumor suppressor protein p53 by 
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fitting into the hydrophobic clefts between two of the monomers at each side of the 
protein through both electrostatic and hydrophobic interactions. Two molecules of this 
calixarene can bind to the protein sequentially in a cooperative manner with dissociation 
constants of KD1 ≈ 130 μM and KD2 ≈ 65 μM for both binding events (Figure 2.27).150 
 
Figure 2.27 Left: Primary p53 dimer showing the major Arg-Asp interactions that stabilize the tetramer. 
Middle: Structure of calixarene based ligand 39 for tetramerization domain of p53. Right: The 2:1 complex 
between ligand 39 and p53 is formed through electrostatic and hydrophobic interactions. (Reprinted with 
permission from S. Gordo, V. Martos, E. Santos, M. Menendez, C. Bo, E. Giralt, J. de Mendoza, Proc. Natl. 
Acad. Sci. USA 2008, 105, 16426-16431. Copyright 2008 National Academy of Sciences, U.S.A.).150 
A recently reported crystal structure of a calixarene-protein complex by Crowley and 
co-workers provides solid evidence and allows a better understanding of the interaction 
between ligand and a protein surface. The complex formation between the anionic 
tetra-sulfonato-calix[4]arene and cytochrome c was investigated by using both NMR 
spectroscopy and x-ray crystallography. The crystal structure revealed that the ligand 
explores several binding sites on large surfaces of cytochrome c through weakly 
non-covalent interactions, each of which involves one lysine side chain trapped inside the 
cavity of calixarene, and one or more neighboring lysine residues providing additional 
electrostatic interactions. This study provided important structural information on a 
typical multivalent ligand that does not bind to the active site, but to the protein exterior 
surface with hydrophobic or charged areas. It is a valuable model for future 
scaffold-based design of artificial ligands targeting protein surfaces.151 
Porphyrins are also very attractive for preparation of receptors for protein surface 
recognition because of their unique structural features, such as rigid structures, 
multifunctionality, diagnostic photophysical properties, easy synthetic manipulation, and 
large aromatic surfaces allowing hydrophobic and π-π stacking interactions. The charge, 
hydrophobicity, size, and symmetry of the functionalities at the periphery of porphyrin 
derivatives can be used as binding characteristics to target various proteins. Most often 
porphyrin derivatives are highly fluorescent and show changes in emission intensity upon 
binding to the target protein. This fluorescent readout has been used for the detection of 
the protein surface binding receptors. 
Cytochrome c is an attractive target because the unpaired electrons in the ferro form 
BACKGROUND INFORMATION 
37 
 
could quench fluorescence upon binding to the receptor. Hamilton et al. have designed 
receptors based on a tetraphenylporphyrin scaffold bearing various anionic and 
hydrophobic groups at the periphery for the surface recognition of cytochrome c. The 
tetraphenylporphyrin scaffold could closely match the arrangement of the hydrophobic 
and basic domain in the heme edge surface of cytochrome c. The derivative bearing 
Tyr-Asp residues (40), which contain a combination of eight phenyl groups and eight 
carboxylate groups (Figure 2.28), was identified to be the strongest receptor for 
cytochrome c with a dissociation constant (KD) of 20 nM.152 Metalloporphyrin derivatives 
have also been investigated by this group for complexation with cytochrome c, which 
resulted in selective denaturation and acceleration of proteolysis with dimeric Cu 
(II)-porphyrins, and proteolysis of cytochrome c by trypsin.153-154  
Several other metal-containing proteins with unpaired electrons could also quench the 
porphyrin fluorescence upon binding due to the proximity of the metal to the porphyrin 
ring in the complex. This has been used for the design of an array of porphyrin derivatives 
for protein fingerprinting. For example, Hamilton et al. developed an porphyrin array 
system which can detect various metal-containing proteins based on their distinct 
fluorescent quenching patterns upon binding to protein surfaces, providing a characteristic 
fingerprint for a specific protein.155 Furthermore, a more comprehensive identification of 
both metal- and nonmetal-containing proteins and protein mixtures has been demonstrated 
by using porphyrin array combined with pattern recognition techniques.156  
 
Figure 2.28 Top: Porphyrin based receptors for the surface binding of cytochrome c. Bottom: A structure of 
the ternary complex of cytochrome c, CDM-β-CD, and TGPP. (The bottom image is reprinted with 
permission from K. Kano, Y. Ishida, Angew. Chem. Int. Ed. 2007, 46, 727-730. Copyright 2007 John Wiley 
and Sons).157 
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Porphyrin based compounds could also be used as a guest molecule which is not 
involved in the direct binding to the protein surface, but plays a key role in selectively 
controlling the protein functions. For example, Kano et al. recently developed a ternary 
complex consisting of a target protein, a supramolecular receptor and an additional guest 
that is bound to the receptor. This supramolecular complex consists of a 
tetrakis(4-glucaminocarbonylphenyl) porphyrin (41), tethered by two polyanionic 
heptakis(6-O-carboxymethyl-2,3-di-O-methyl)-β-cyclodextrin (CDM-β-CD), which could 
recognize the surface of cytochrome c (Figure 2.28, bottom) through the electrostatic 
interactions.157 
A smaller aromatic compound anthracene was also used as a fluorescent hydrophobic 
scaffold for the design of receptors for protein surface binding by Hamilton et al. The 
anthracene core was functionalized by hydrophobic and acidic groups for the hydrophobic 
and electrostatic interactions with the surface of cytochrome c and lysozyme. Receptors 
42 (Figure 2.29) with eight appropriately spaced carboxylate groups showed efficient 
binding in a cooperative manner over a large surface area. Receptors 42a and 42b bind to 
cytochrome c with low micromolar affinity of 0.66 μM and 0.30 μM, respectively. Further 
investigations of 42a revealed that the binding to the surface of cytochrome c and 
lysozyme is selective against some other proteins, like cytochrome c551, myoglobin, 
α-lactalbumin which showed an order of magnitude lower affinity.158 
 
Figure 2.29 Structures of receptors based on anthracene scaffold for the surface recognition of cytochrome 
c.  
Recently, molecular self-assembly based on non-covalent interactions by small 
molecular components was used to generate versatile scaffolds providing sufficient 
multivalency and surface area for protein surface recognition. Hamilton et al. have 
reported that functionalized G-quartets (Figure 2.30) are capable of binding to the surface 
of cytochrome c. G-quardruplexes are formed from the π stacking of G-quartets by intra- 
or inter-molecular Hoogsteen base-pair associations in parallel or antiparallel orientations. 
The 5′-end of the assembled G-quartet was functionalized with peptide binding groups 
that can bind to both hydrophobic patch and acidic residues near the heme edge surface of 
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cytochrome c as used for the porphyrin derivative (40, see Figure 2.28). The 
oligoanionic-functionalized G-quadruplex (43) was shown to bind to the protein surface 
through hydrophobic and electrostatic interactions, leading to the denaturation and 
acceleration of proteolysis of cytochrome c. The binding of 43 to cytochrome c was 
demonstrated to be selective when compared to RNAseA, α-lactalbumin and cytochrome 
c551.159 
Another receptor (44) based on a G-quadruplex scaffold with peptide loops 
functionalized on the 5′-end of the assembled G-quartet for the protein surface binding 
was developed by the same group as well. Receptor 44 displayed efficient inhibition of 
α-chymotrypsin with the apparent dissociation constant (Kiapp) of 0.33 μM. It is at least 
four times more potent than the earlier reported calixarene derivative 38 (see Figure 2.26, 
Kiapp = 1.4 μM) bearing the same peptide loops. The improvement of the efficiency might 
be due to the flexible alkyl linker to allow the delivery of the peptide loops to a larger 
protein surface area and the additional electrostatic interaction contributed by the 
negatively charged oligophosphate scaffold.160  
 
Figure 2.30 Representation of the structure of G-quartet and the functionalized parallel G-quardruplex with 
different artificial fragments for the self-assembly. Functionalized G-quardruplexes 43 and 44 are used for 
the surface recognition of cytochrome c and α-chymotrypsin, respectively. 
Several alternative scaffolds such as polymers,161 ruthenium trisbipyridine 
complexes,162-163 and gold nanoparticles164 have been used to develop efficient protein 
surface binders. The latter scaffold is promising due to their large surface area, the tunable 
size (1.5 nm to > 10 nm, comparable to proteins),165 the ability to cover the surface with a 
wide range of desirable functionalities,166 and the scaffolding properties for preparing the 
multivalent receptors.167 Furthermore, the inherent physical properties such as optical, 
electronic and magnetic properties of the metal core of nanoparticles provide unique 
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opportunities to create biosensors, diagnostic agents and to control the interactions of the 
surface.168 Monolayer-protected clusters (MPCs) and mixed monolayer-protected clusters 
(MMPCs) have been used as promising candidates for the creation of bimolecular 
receptors.169-171 Further, MPCs and MMPCs using functional organic groups on the 
nanoparticle surface can be used as multivalent recognition elements for targeting the 
surfaces of biomolecules, allowing comparisons of biological complex formation such as 
protein-protein interactions based on surface complementarity.172 
Rotello and co-workers have demonstrated that functionalized gold nanoparticles have 
great potential for binding to the protein surfaces. For example, they used 
mercaptoundecanoic acid (MUA) functionalized gold nanoparticles (45, Figure 2.31) to 
bind to α-chymotrypsin (ChT) by electrostatic interactions between the anionic particle 
surface and the cationic ‘hot spot’ around the ChT active site, resulting in the inhibition of 
enzyme activity through a two-step mechanism with a fast reversible inhibition followed 
by a slower irreversible denaturation process. The highly efficient binding led to a Kiapp of 
approximately 10 nM and a binding stoichiometry of five protein molecules to one 
nanoparticle.173 Here the molar concentration of gold nanoparticles can be calculated by 
expressing the nanoparticles in moles. The volume of a particle can be predicted from its 
size by assuming it as a sphere. By using density equivalent to that of bulk gold (19.3 
g/cm3), an average particle mass can be calculated, as well as the molar mass. Then the 
molar concentration can be calculated from the number of moles and the volume.174 The 
molar concentration is not often used because most particles have size distributions and 
only using the mean size for calculating the molar mass does not really reflect the nature 
of the colloids. The denaturation of ChT at the interface was ascribed to the hydrophobic 
interactions with the alkyl chains of the monolayer. A certain level of selectivity was 
revealed through this electrostatic complementarity, as elastase, β-galactosidase (β-Gal) 
and cellular retinoic acid binding protein showed no significant interaction with MMPC 
45. Importantly in their subsequent studies the binding of MMPC 45 to ChT was found to 
be tuned by the ionic strength of the solution due to the nature of electrostatic 
interactions.175 Further efforts were put to disrupt this irreversible inhibition of ChT 
through the modification of the nanoparticle surface using cationic surfactants. The 
release of the ChT molecules from the nanoparticle surface with up to 50 % restoration of 
their activity were demonstrated by using DLS and enzyme activity assays. Two 
prevailing mechanisms by which this recovery is accomplished were illustrated based on 
different surfactants. The thiol- and hydroxyl-teminated surfactants directly modify the 
monolayer by intercalation and/or chain displacement resulting in diminishing the surface 
charge and release of the protein. Alkyl surfactant could liberate the protein by the 
formation of a bilayer-type structure, as indicated by the approximately 4.5 nm increase in 
hydrodynamic radius (Figure 2.31).176 
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Figure 2.31 Schematic representation of ChT surface binding by MMPC 45 and monolayer modification 
upon addition of various surfactants, leading to the release of ChT from the surface of MMPC. (Reprinted 
with permission from N. O. Fischer, A. Verma, C. M. Goodman, J. M. Simard, V. M. Rotello, J. Am. Chem. 
Soc. 2003, 125, 13387-13391. Copyright 2003 American Chemical Society).176 
The example described above revealed that MMPCs can be used as an effective tool 
for the modification/modulation of enzyme activity. The interaction of ChT with MMPC 
45 resulted in protein denaturation. However, the native structure of a protein is required 
to retain upon binding in many biological applications such as in vivo protein delivery and 
in vitro enzyme stabilization. To achieve this goal, oligo(ethylene glycol) (OEG) was 
often introduced as spacer between thioalkyl chain and the terminal functionality to 
prevent both nonspecific binding to protein surface and denaturation by shielding of the 
hydrophobic interior of the monolayer from the protein surface.177 Water soluble CdSe 
nanoparticles 46 and 47 featuring OEG spacers were fabricated by Rotello and co-workers 
to improve the stability of ChT at the interface of nanoparticles (Figure 2.32). 
Nanoparticles containing the carboxylate-terminated ligands (46) were demonstrated to 
bind to the protein surface through spatial blocking of the active site via electrostatic 
interactions, resulting in a reversible inhibition without protein denaturation. Circular 
dichroism (CD) and fluorescence studies showed that the structure of ChT upon binding 
to the nanoparticles is retained. The enzyme activity can be completely restored through 
disruption of the electrostatic interactions with an increase in ionic strength of the solution. 
In contrast to the complexation between anionic 46 and ChT, no interaction was observed 
with 47 which terminated with hydroxyl groups. This study demonstrated that both 
protein activity and structure can be modulated by functionalized nanoparticles.178  
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Figure 2.32 Schematic depiction of control of ChT structure and function through protein surface binding 
by CdSe nanoparticles 46 and 47. (Reprinted with permission from R. Hong, N. O. Fischer, A. Verma, C. M. 
Goodman, T. Emrick, V. M. Rotello, J. Am. Chem. Soc. 2004, 126, 739-743. Copyright 2004 American 
Chemical Society).178 
Further studies to tune the interaction and structure of protein upon the binding of 
functionalized nanoparticles were investigated by using more elaborate monolayers. For 
example, Rotello and co-workers reported that functionalized gold nanoparticles with 
different surface charges can bind selectively to cytochrome c or cytochrome c peroxidase, 
thus disrupting the protein-protein interaction.179 They also systematically investigated the 
interaction of protein surfaces with a series of amino acid-functionalized gold 
nanoparticles. Both electrostatic and hydrophobic interactions between the hydrophobic 
patches of receptors and protein were shown to contribute to the complex stability. ITC 
measurements revealed that the enthalpy and entropy changes for the complex formation 
depend on the functionality of nanoparticles and the surface characteristics of proteins, e.g. 
distributions of charged and hydrophobic residues on the protein surface.180-181  
Array-based sensing, the so-called “chemical nose/tongue” strategies have been 
successfully applied for protein detections, such as the use of porphyrins as described 
above. It uses selective interactions with analytes to generate patterns that can be used for 
identifying different targets, as well as the analysis of changes in complex mixtures. 
Recently, Rotello et al. have developed a protein sensor array using chemical nose 
technology. The sensor array was generated using six cationic gold nanoparticles (48) 
featuring different ligand structures and a highly fluorescent anionic 
poly(p-phenyleneethynylene) (PPE) polymer PPE-CO2 as a fluorescence indicator. These 
nanoparticles (48) were used as both selective binding elements and fluorescence 
quenchers for the polymer. The binding of the anionic polymer to the cationic surface of 
nanoparticles through electrostatic interactions resulted in fluorescence quenching of the 
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polymer (fluorescence “OFF”) through energy transfer. The subsequent addition of 
proteins displaced the polymer bounded to the surface of the gold nanoparticles, leading 
to the fluorescence recovery of the polymer (fluorescence “ON”). A fingerprint 
fluorescence response pattern for individual proteins was then generated based on the 
different protein-nanoparticle interactions (Figure 2.33) that was characterized using 
linear discriminate analysis (LDA).182 By using the same strategy, they reported a sensor 
generated by using arrays of gold nanoparticle and green fluorescent protein (GFP) to 
detect and identify proteins in both buffer and human serum. Distinct and reproducible 
fluorescence response patterns were obtained from five serum proteins including human 
serum albumin, immunoglobulin G, transferrin, fibrinogen and α-antitrypsin with high 
sensitivity (500 nM).183 
 
Figure 2.33 Schematic representation of ‘chemical nose’ sensor array based on gold 
nanoparticle-fluorescent polymer conjugates. Top: The competitive binding between protein and the 
quenched gold nanoparticle-polymer complexes leads to the restoration of fluorescence. Bottom: The 
combination of an array of sensors generates fingerprint response patterns for individual proteins through 
different release of fluorescent polymers from nanoparticle surfaces. (Reprinted with permission from C. C. 
You, O. R. Miranda, B. Gider, P. S. Ghosh, I. B. Kim, B. Erdogan, S. A. Krovi, U. H. F. Bunz, V. M. Rotello, 
Nat. Nanotechnol. 2007, 2, 318-323. Copyright 2007 Nature Publishing Group).182 
Rotello et al. have also reported an enzyme-nanoparticle sensor array for detecting 
proteins in which the sensitivity is amplified via enzymatic catalysis. In this approach, 
cationic gold nanoparticles (49) can bind to the surface of β-galactosidase (β-Gal) through 
electrostatic interaction, resulting in the inhibition of the enzyme activity. The release of 
β-Gal from gold nanoparticle surface with restoration of their enzymatic activity was 
observed upon addition of analyte proteins through competitive binding, providing an 
amplified readout of the binding event (Figure 2.34). The enzyme-amplified array sensing 
approach increased the sensitivity of the array, allowing the detection of a range of 
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biomedical relevant proteins at a concentration of 1 nM in both phosphate buffer and 
desalted human urine.184 By using a similar strategy, a colorimetric test-strip sensor was 
developed for identifying E. coli with high sensitivity (104 bacteria/mL).185 
 
Figure 2.34 Schematic representation of sensor system comprised of β-galactosidase and cationic gold 
nanoparticles. β-Gal is displaced by protein analytes, restoring the enzyme catalytic activity toward the 
fluorogenic substrate 4-methylumbelliferyl-β-D-galactopyranoside. (Reprinted with permission from O. R. 
Miranda, H. T. Chen, C. C. You, D. E. Mortenson, X. C. Yang, U. H. F. Bunz, V. M. Rotello, J. Am. Chem. 
Soc. 2010, 132, 5285-5289. Copyright 2010 American Chemical Society).184  
The above examples illustrate the successful strategies in the design of synthetic small 
molecules and functionalized nanoparticles that have potentials for the protein surface 
recognition. It is well established that multivalent interactions are essential to achieve 
high affinity protein surface binding with some selectivity. Protein surface binding is 
often driven by a combination of electrostatic and hydrophobic or aromatic interactions by 
multivalent ligands based on a variety of scaffolds. The scaffolds play a key role in 
providing a variety of functionalities in a specific geometrical configuration and large 
surface area to complement the surface characteristics. For example, gold nanoparticles 
have been demonstrated to be attractive scaffolds providing large surface area and easy 
access to the attachment of different functional groups. However, even though ligand 
multivalency can provide high affinity to the target protein, selectively binding to a 
specific protein is still difficult to achieve. The development of new scaffolds and 
recognition elements to provide the multivalent, complementary interaction with the 
target protein is still of current interest. The selection of efficient binding elements and 
scaffolds simultaneously to provide efficient recognition can be achieved with less effort 
by using a new approach-dynamic combinatorial chemistry. The following chapter will 
present the principles and applications of this approach.   
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2.5 Dynamic Combinatorial Chemistry 
Dynamic combinatorial chemistry is a concept that developed in the mid-1990s.186-189 
It uses reversible covalent or non-covalent interactions between a set of building blocks to 
generate a mixture of all possible combinations of the available components under 
thermodynamic control. It is assumed that all the components in the mixture continuously 
interconvert. The composition of this mixture at equilibrium is referred to as a dynamic 
combinatorial library (DCL). The thermodynamic nature of DCL allows changes in the 
library composition upon external stimuli. It can respond to various external influences 
including the change of pH, temperature, pressure, concentration and addition of a guest 
molecule or template, which can drive the constituents to reorganize to reach the minimal 
total free energy of the system under the new conditions. Chemical template was the most 
used stimuli for the identification of receptors or ligands in DCLs. By adding a target to 
the DCL, the composition of the DCL will adjust to form good binders for the target to 
minimize the free energy of the overall system, resulting in the selection and amplification 
of the strong binding compounds at the expense of the weak ones.190-191 
In comparison with traditional combinatorial chemistry, dynamic combinatorial 
chemistry has several unique features.192-193 As depicted in Figure 2.35, the reversibility of 
the formation of library constituents is an essential feature. It allows a continuous 
interchange of building blocks between all possible constituents in the library. Whereas 
traditional combinatorial chemistry is static as the library mixture consists of 
non-interconverting library members. The composition of a DCL is governed by 
thermodynamics rather than kinetics, which give it the access to respond to external 
influences. The dynamic process is conducted in the presence of the target, leading to the 
shift of the equilibrium towards formation of library members which can strongly bind to 
the target. Thus, the desired compounds are amplified in the library mixture at the expense 
of undesired ones that contain the same building blocks. Furthermore, the amplification of 
the desired compounds can be efficient enough to allow isolation of the molecule directly 
from the library. In contrast, the members of traditional combinatorial library are 
constructed by synthesis with a defined variety of components. The composition of the 
library is fixed and the addition of a target will not lead to any rearrangement of molecular 
fragments into more favorable library members. Additionally, complex topologies and 
sometimes unpredictable structures can be obtained from DCL by the self-assembly of 
building blocks around a target molecule or a template. In addition to the differences in 
composition, both approaches also have different requirements on screening of the library 
members. A traditional combinatorial library often requires high throughput screening 
(HTS) method due to the large number of individual library members. Whereas the library 
members of a DCL can be reduced to a few or ideally a single one, allowing easily 
identification of the active compounds. 
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Figure 2.35 Schematic illustrations of the principles of dynamic combinatorial chemistry (top) and 
traditional combinatorial chemistry (bottom). (Reprinted with permission from S. Otto, R. L. E. Furlan, J. K. 
M. Sanders, Drug Discovery Today 2002, 7, 117-125. Copyright 2002 Elsevier).193 
Besides the described advantage of dynamic combinatorial chemistry, some limitations 
should be considered as well when preparing the dynamic combinatorial libraries. The 
most important constraint is that every single building block and library member should 
be sufficiently soluble during the equilibration. The insolubility of one or more 
components in the library will affect all members of the library that contain any of the 
involved building blocks. This is because the re-dissolving rate of the precipitated 
compound is very often slow enough to effectively trap it in the solid form, thus resulting 
in an equilibrium shift towards this kinetic trap which leads to wrong result. Furthermore, 
the mandatory use of reversible linkage between building blocks is also a limitation, as 
the number of chemical reactions that are appropriate to use for the construction of DCLs 
is limited. In addition, in contrast to traditional combinatorial libraries where all chemical 
bonds are formed fixed and unaffected by subsequent reactions, the control of the DCL is 
difficult due to the reversible reactions, since all library constituents are in equilibrium 
and no bond is fixed unless the exchange is switched off to prevent any further 
equilibrium. Thus, many techniques developed in traditional combinatorial chemistry 
(such as split and mix method) are not suitable to use in dynamic combinatorial chemistry.  
Despite these drawbacks, the unique advantages of DCL make it an attractive and 
powerful technique, in particular in the field where molecular recognition can be 
implemented through the interaction with a template and thus leading to the selection, 
stabilization and amplification of active library members.194 The facilitated 
characterizations of the constituents of a DCL by using efficient analytical methods such 
as HPLC, capillary electrophoresis, NMR and mass spectrometry make it even a more 
useful tool in the fields of molecular recognition, enzyme inhibition, drug delivery, and 
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functional material and devices.195-200 Due to the relevance for this thesis, the following 
description will focus on its application to host-guest interactions, especially the 
identification of ligands for biomolecules. 
The use of DCL technique requires appropriate reversible reactions that can proceed 
rapidly under mild conditions and are compatible with a wide range of functional groups 
and the recognition events. Additionally, the exchange process should be possible to be 
tuned (switch on or off) as required, which is often achieved by oxidation, reduction, pH 
and temperature changes, etc. The resulting characteristic of the library members should 
not be affected by the switching-off process, as this may change the binding properties of 
the active compounds. Since the introduction of this concept, a number of reversible 
covalent and non-covalent exchange reactions (Table 2.1) have been developed for 
construction of DCLs including the most exploited disulfide, imine and hydrazone 
exchange.191-193 The selection of suitable reaction for DCL is very important to fulfill the 
needs of the reaction conditions and the target. In particular, the use of DCL in biological 
systems is tremendously challenging because it must proceed under physiological 
conditions required by the biomolecule target as well as satisfying the thermodynamic 
conditions of the suitable reversible reactions due to the requirement of the dynamic 
process. So it is not surprising that the reversible reactions to generate adaptive DCLs 
which can be applied to biological systems are limited. So far disulfide, imine and 
hydrazone exchanges have been extensively used in DCL with success in biological 
systems. Due to their suitability for biological systems and the relevance of this work, the 
following text describes some applications of DCL based on these three reactions for 
identifying synthetic receptors, ligands for biomolecules and inhibitors of enzymes. 
The disulfide exchange reaction is widely used in biology and plays a key role in the 
folding of proteins,201 the maintenance of the redox state of cells and the protection the 
organism from oxidative stress,202 etc. The mechanism involves the displacement of a 
thiolate anion from the disulfide through a nucleophilic attack by the thiolate anion and 
the liberated thiolate anion can attack another disulfide (Figure 2.36, left).203 The 
exchange requires deprotonated thiol and thus is highly dependent on the pH. At near 
neutral conditions (pH 7-9) it is possible to generate a sufficient amount of thiolate anion 
to enable an exchange. The exchange can be easily switched off by adjusting the pH value 
to slightly acidic conditions (pH ≤ 5). On the basis of their biological compatibility as 
well as the mechanistic reversibility, disulfide exchange has been developed as one of the 
most widely used reactions in DCL. Normally two different starting points are possible 
for the generation of DCLs by using this reaction: either from thiols or from disulfides 
(Figure 2.36, right). In solution, thiols are readily oxidized to disulfides upon exposure to 
air, which are immediately subject to exchange reaction mediated by residual thiolate. The 
exchange can also start from disulfides under mild conditions in the presence of a 
catalytic amount of reducing agent such as dithiothreitol (DTT) or ‘free thiol’. Both  
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Table 2.1 Examples of reversible processes that are used in dynamic combinatorial chemistry. Different 
building blocks are colored as red and blue.  
Reversible Covalent Reactions 
Ester Exchange 
 
Amide Exchange 
 
Acetal Exchange 
 
Michael Reaction 
 
Diels-Alder Reaction 
 
Imine Exchange 
 
Oxime Exchange 
 
Hydrazone Exchange 
 
Disulfide Exchange 
 
Alkene Metathesis 
 
Non-covalent interactions 
Metal-Ligand 
Coordination  
Hydrogen Bonding 
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approaches can lead to the same library composition. The disulfide exchange reaction 
ends if insufficient thiolate anion is available. 
 
Figure 2.36 Left: Mechanism of disulfide exchange reaction. Right: Different approaches to DCLs of 
disulfide from two starting positions, (a) air oxidation, (b) reducing agent, (c) ‘free thiol’. 
Otto and Sanders have established that disulfide exchange can be used to generate 
diverse DCLs of macrocyclic disulfides formed by a series of structurally diverse dithiol 
building blocks, including carbohydrate and α-amino acid.204 Later on, many efforts were 
put to identify new receptors from larger libraries based on useful changes in library 
composition induced by molecular recognition as a driving force. Inspired by a family of 
cyclophane receptors of general architecture 50 developed by Dougherty,205 Otto et al. 
synthesized three dithiol building blocks 51-53, which formed a DCL containing a large 
number of macrocyclic receptors upon oxidation (Figure 2.37). The amplification of DCL 
was then analyzed by HPLC upon addition of different ammonium guests (54-56). 
Surprisingly, guest 54, which is one of the best guests for the Dougherty’s receptor (50), 
resulted in the amplification of cyclic heterotrimer 57, instead of the analogue of 
Dougherty’s receptor (50). Binding studies revealed that the affinity of 57 (Ka = 2.5 × 105 
M-1) is in the same range as 50 even though they feature different structures. Moreover, 
addition of a larger guest (quaternized morphine 55) induced the amplification of a bigger 
trimer 58 with a binding constant of 7.1 × 105 M-1, whereas surprisingly the amplification 
of an even larger tetramer 59 was found by addition of a smaller guest 
(tetramethylammonium iodide 56) with higher binding affinity (4 × 106 M-1).206-207 These 
results demonstrated that DCL can be used as a powerful and practical method for the 
discovery and synthesis of new unexpected receptors.208 One single library with sufficient 
diversity is possible to identify more than one receptor by addition of different guests. The 
difference in binding affinity allows the selective amplification of the active compounds 
from a large number of similar structures. In addition to the application in molecular 
recognition field, DCLs based on this kind of dithiols were also developed for the 
discovery of receptors with catalytic activities.209-210 
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Figure 2.37 Dithiol building blocks 51-53 for constructing DCL inspired by Dougherty’s receptor 50. 
Amplification of three different active compounds 57-58 was achieved in the presence of three different 
guest molecules 54-56. 
Disulfide exchange reactions have also been successfully applied in discovery of 
ligands for biomolecules. For example, Ravoo et al. recently developed DCLs of 
tripeptides by using disulfide exchange for the identification of biomimetic carbohydrate 
receptors.211 Balasubramanian et al. reported that assembly of molecules that bind to 
DNA quadruplex can be templated from a small DCL of nine different species for the 
generation of G-quadruplex ligands.212 A small disulfide DCL formed by three polyamide 
building blocks was also applied by them to the selection and discrimination of ligands 
that bind to DNA secondary structures (duplex or quadruplex) specifically.213 Inspired by 
a set of quadruplex-binding ligands based on an oxazole-peptide macrocycle,214 they 
recently investigated a higher level of discrimination in G-quadruplex binding by using 
disulfide libraries (Figure 2.38) containing thiol analogue of oxazole-peptide macrocycle 
(60) and two sets of different side-chain motifs based on para-benzylic thiols (61a-e and 
61f-i). The DCLs generated from L1 and L2 were screened against two intramolecular 
quadruplex-forming sequences (c-Kit21, c-Myc22) and a 22-mer duplex DNA for 
comparison. In the L1 library in the presence of the quadruplex, the two guanidinium 
disulfides 60-61a and 60-61e were amplified, whereas no amplification was observed 
when the same library was equilibrated with duplex DNA. In the case of L2 library, 
60-61f were most strongly amplified. All the amplified compounds were found with 
higher binding affinities (4- to 12-fold) to be superior to the analogue macrocycle (60). 
BACKGROUND INFORMATION 
51 
 
This example demonstrated that by exploring the effect of chemical modifications, 
different amplified ligands in the libraries can be identified.215 However, these libraries 
have relatively modest sizes; a similar level of discrimination could be achieved with the 
help of regular parallel synthesis. Moreover, larger DCLs have a higher potential of 
containing stronger binders, although the concentration of the strong binders decrease due 
to spreading the building blocks out over an increasing number of library members which 
can lead to detection problems but to a lesser extent. Furthermore, larger DCLs have a 
smaller probability of failing to show any amplification than smaller DCLs. Therefore, the 
generation of DCLs with large size has become a topic of major interest.216 
 
Figure 2.38 Structures of building blocks used to generate two DCLs based on oxazole-based peptide 
macrocycle 60 and side chains that cationic (61a-e) and neutral (61f-i) through disulfide exchange. 
The imine formation discovered by Schiff,217 is most often generated from the reaction 
of aldehydes or ketones with amine derivatives. This reversible imine reaction has been 
widely used in DCLs which are often generated at mildly acidic and even basic pH 
(aqueous buffer between 5.0 and 8.5 or weak acids in organic media) at room temperature, 
preventing aldol side reactions. The imine formation and interchange process is dependent 
on pH value, allowing the control of the reaction rate and efficiency by adjusting the pH 
value which is very important in the subsequent equilibrium for the generation of DCLs. 
The reaction is most often carried out under slightly acidic conditions as well as at neutral 
conditions with a slower rate (Scheme 2.1). However, the pH value must not be too high 
or too low, because the leaving group (OH) is not sufficiently protonated at higher pH and 
the amine is protonated at lower pH. Because of the inherent thermodynamic instability in 
aqueous media, it may cause screening and isolation problems. Analysis usually relies on 
NMR analysis of the complete mixture. A subsequent reduction process to convert the 
hydrolytically sensitive imines into amines by using selective reducing agents such as 
sodium cyanoborohydride (NaBH3CN) or tetrabutylammonium cyanoborohydride (TBC) 
is required in imine exchange DCLs. This reduction facilitates the isolation and analysis 
of the final equilibrated mixture and allows a subsequent HPLC or LC-MS analysis. It is 
very important to make sure different library members have similar reactivity in the 
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reduction process, so that the amine product distribution indeed reflects the imine 
distribution in the library.189 However, care has to be taken to ensure that the structurally 
similar amines maintain the binding properties of the selected imines.  
 
Scheme 2.1 Left: Mechanism of imine formation at neutral (top) and acidic (bottom) conditions. 
Due to the imine formation at or near physiological conditions, this reaction has been 
used in DCC for identification of ligands for biomolecules and enzyme inhibitors.218-219 
The first example reported by Lehn et al. has clearly described the characteristic and 
potential of DCLs interacting with biomolecules.189 Three aldehydes and four amines 
were used as building blocks to generate 12 imine-linked library members for identifying 
carbonic anhydrase inhibitors. The imines were reduced to the corresponding amines to 
allow a subsequent HPLC analysis. Several library species were amplified in the presence 
of carbonic anhydrase template. They pointed out that it is important to use an excess of 
amine building blocks to avoid unwanted imine reactions on the amine groups of 
biomolecules such as proteins or peptides. A recent study was based on 
N-acetyl-D-glucosamine, a low affinity inhibitor (Ki = 20-50 mM) for hen egg-white 
lysozyme (HEWL), an enzyme that cleaves oligomers of N-acetyl-D-glucosamine.220 Two 
amines (62 and 63) with N-acetyl-D-glucosamine and D-glucose motifs and six aromatic 
aldehydes (64-69) were used as building blocks to create the imine-based DCL for the 
discovery of HEWL inhibitors (Figure 2.39). A 4-methylumbelliferyl chromophore was 
connected to the carbohydrate group to allow comparable HPLC detection of different 
adducts. After the equilibration and reduction, amplification of two adducts (70 and 71) 
was found in the presence of HEWL by using HPLC-MS analysis. The most amplified 
compound 70 was shown to inhibit HEWL in a competitive way with much higher 
affinity (Ki = 0.6 mM) than N-acetyl-D-glucosamine, and was able to compete with 
chitobiose (Ki = 0.2 mM), a known successful inhibitor of the enzyme. This example 
showed the capacity of imine-based DCL to discover efficient inhibitor of enzyme and 
discriminate subtle affinity variations induced by the different substitution on the 
structure. 
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Figure 2.39 Structures of amine (62-63) and aldehyde (64-69) building blocks used to generate imine-based 
DCL. After reduction, amplification of two adducts (70-71) were found in the presence of HEWL. 
The mechanism of hydrazone formation is similar to that of imine formation. Unlike 
imines that condense and hydrolyze quickly at neutral to acidic conditions but are 
unstable in the presence of water, hydrazones formed from hydrazines and aldehydes are 
thermodynamically stable even at low pH while they tend to be kinetically inert under 
neutral conditions. This is because the mesomeric effect decreases the electrophilicity of 
hydrazone, slowing down the hydrolysis and exchange rate. The hydrazone formation and 
exchange can be carried out only under acidic conditions (pH ≤ 4) or at high temperatures. 
Most often acyl hydrazones which are formed by hydrazides and aldehydes (Scheme 2.2) 
are used in DCL. The acyl group is introduced to moderate the stabilizing effect of the 
amine subunit in C=N-NRR′. Without the acyl group or similar other electron 
withdrawing groups hydrazones are probably too stable to be used in DCLs, because the 
reversible exchange would be very slow.191 The acyl hydrazone exchange reaction enables 
rapid library generation in which dynamic properties can be easily controlled by adjusting 
pH value. The formation and component interchange processes take place at lower pH (≤ 
4) and can be essentially stopped at high pH (> 7). Furthermore, acyl hydrazone libraries 
are compatible with a wide range of solvents and functional groups due to the orthogonal 
nature of the different components (hydrazides and aldehydes).  
 
Scheme 2.2 Reversible acyl hydrazone formation under acidic conditions. 
DCLs based on acyl hydrazone exchange have been used for identifying new receptors 
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for metal ions or small guest molecules. For example, Sanders et al. investigated an acyl 
hydrazone DCL based on the pseudo-dipeptide building block pPFm (72), containing 
L-proline (P), L-phenylalanine (F), and a p-substituted (p) aromatic linker (Figure 2.40). 
DCLs of this building block without template contained a series of macrocycles (73-76) 
of different ring sizes. Addition of LiI, as well as NaI, to a lesser extent, induced the 
amplification of the cyclic trimer (74). The amplified trimer 74 accounts for 98 % of the 
overall peptide material in the library in the presence of Li+, allowing isolation of the 
receptor. The subsequent analysis demonstrated that the trimer is a good receptor for Li+, 
with a binding constant of 4 × 104 M-1 as estimated by 1H NMR titration. FT-IR and NMR 
studies revealed significant signal shifts of the carbonyl group of the receptor indicating 
that there is a conformational change upon Li+ binding. This indicated that macrocycles 
can fold in a suitable conformation to optimize their binding to the guest molecule.221 The 
replacement of the phenyl group of phenylalanine unit in pPFm by a cyclohexyl group to 
give an analogous building block pPCm led to a very similar library, from which similar 
results were obtained, indicating the aromatic side chain is not essential for the binding.222 
The other remarkable and unexpected result achieved from this acyl hydrazone DCL is 
the generation of a catenane receptor that strongly binds to the neurotransmitter 
acetylcholine.223 The DCL generated from the same pseudo-dipeptide building block (72) 
dramatically shifted the equilibrium to the formation of a new product 77 at the expense 
of all the other library members by the addition of acetylcholine chloride (Figure 2.40). In 
the presence of acetylcholine, the new library member 77 appeared within an hour. It was 
found to be an isomer of the cyclic hexamer but with different retention time revealed by 
HPLC-MS analysis. The two isomers showed distinct electrospray MS/MS fragmentation 
behavior: the simple hexamer fragmented into a pentamer and successively smaller 
components, whereas the new product fragmented directly to the trimer. This 
fragmentation behavior is typical of a [2]-catenane and indicates that the new library 
member consisted of two identical interlocked cyclic trimers. Due to the chiral nature of 
each ring, there are two possible diastereomers of the [2]-catenane. However, NMR 
studies confirmed that only one of two possible diastereomers is amplified. The DCL took 
an unusually long time to equilibrate, and eventually after 44 days the catenane reached 
its maximum concentration, accounting for 70 % of the total material in the library. It is 
most likely that the catenane formation pathway is inherently not favored, but it can 
effectively be captured and stabilized by the template acetylcholine as soon as it is formed. 
The catenane 77 is shown to be a good receptor for acetylcholine with a binding constant 
of 1.4 × 107 M-1 as determined by ITC. Whereas binding affinity of acetylcholine to the 
trimer 74 (Ka = 1.5 × 103 M-1) and the tetramer 75 (Ka = 5.7 × 103 M-1) were much weaker. 
This example further demonstrated the great power of DCC for identification and 
synthesis of unexpected receptors, in particular a catenane receptor would have been more 
difficult to prepare without the template.224  
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Figure 2.40 An acyl hydrazone DCL based on the pseudo-dipeptide building block pPFm for identifying 
different synthetic receptors by using different guest molecules as templates. (Reprinted with permission 
from R. T. S. Lam, A. Belenguer, S. L. Roberts, C. Naumann, T. Jarrosson, S. Otto, J. K. M. Sanders, Science 
2005, 308, 667-669. Copyright 2005 The American Association for the Advancement of Science).223 
In contrast to imines, hydrazones are stable to analysis and isolation in aqueous 
solution, but their formation and exchange generally requires acidic conditions (pH 4 or 
below) which are not compatible with most biomolecules. Lehn et al. have developed 
pre-equilibrated DCLs based on reversible hydrazone formation to identify efficient 
binders for biomolecules by using a dynamic deconvolution process.225-227 In this 
pre-equilibrated DCL protocol, the equilibration of the library has to be carried out in the 
absence of the biological target. For target screening the used conditions are then adjusted 
to the required physiological pH based on the enzymatic assays freezing-out the library 
composition. In order to identify the active components of the libraries, a “dynamic” 
deconvolution strategy can be utilized (Figure 2.41). In this approach, a full library is 
prepared by using all the building blocks. In addition, a set of different sub-libraries is 
prepared under similar conditions, in which one building block each is missing. The 
removal of a single building block from the full library results in the redistribution of the 
remaining constituents, and thus all constituents containing this building block will be 
eliminated from the library. To this aim, for each building block contained within the DCL, 
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a sub-library is prepared from which all library constituents based on this unit are 
removed. All the libraries are then subjected to enzyme screening. By comparison of the 
screening results of the full library with different sub-libraries, it is often possible to 
deduce which building blocks are necessary for high activity. Namely, a decrease in 
inhibitory effect or an increase in enzyme activity of the sub-library indicates the 
importance of the removed building blocks in the formation of active compounds in the 
dynamic library. Thus the best library members can be identified by the construction from 
two active components with orthogonal functional groups.  
 
Figure 2.41 Cartoon representation of the principle of dynamic deconvolution. (Reprinted with permission 
from P. T. Corbett, J. Leclaire, L. Vial, K. R. West, J. L. Wietor, J. K. M. Sanders, S. Otto, Chem. Rev. 2006, 
106, 3652-3711. Copyright 2006 American Chemical Society).191  
By using the dynamic deconvolution strategy, DCLs for targeting 
acetylcholinesterase,225 HPr kinase/phosphatase,226 and the plant lectin concanavalin A 
(Con A)227 have been successfully established by Lehn et al. For example, in the recent 
study targeting the plant lectin Con A, acyl hydrazone DCLs were prepared by mixing a 
series of six carbohydrates functionalized benzaldehydes (78-83) and a set of 
oligohydrazide (84-92) core building blocks (Figure 2.42).227 The structural core building 
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blocks were chosen as scaffolds bearing one, two or three hydrazide groups, onto which 
the carbohydrate binding units can be attached and arranged in a given geometry to 
construct multivalent library constituents. The deconvolution strategy was pursued, 
generating one large full library and 15 sub-libraries in which one specific aldehyde or 
hydrazide building block is missing. The full library formed from all of the 15 
components is capable of containing 474 different library species. It was found to 
efficiently inhibit the binding of Con A, determined with the help of an enzyme-linked 
lectin assay. A series of sub-libraries was then screened, and those lacking the mannose 
unit 83, and trihydrazides 90, 92 were found to have a significantly increase in enzyme 
activity. Clearly component 83 is essential for inhibition to occur. In order to further probe 
the individual effects of the hydrazide components, a reduced library containing only one 
aldehyde unit 83 and all of the scaffolds, as well as 10 corresponding sub-libraries were 
prepared and profiled, showing significantly reduced inhibition in the library without 90. 
The compound 93 was then synthesized separately by connecting the most active 
components 83 and 90 from the library and its inhibitory effects further evaluated. It was 
shown to have an IC50 of 22 μM, which is 36-fold better than the reference compound, 
methyl-α-D-mannoside (IC50 = 0.8 mM).  
 
Figure 2.42 Structures of aldehyde (78-83) and hydrazide (84-92) building blocks for hydrazone libraries, 
and the best library member (93) was selected from DCL targeting concanavalin A using a dynamic 
deconvolution strategy. 
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Recent studies have shown that the equilibration of hydrazones can be accelerated at 
weak acidic conditions close to physiological pH by using aniline as nucleophilic catalyst 
(Scheme 2.3).228 In the presence of aniline catalyst, equilibration of the hydrazone library 
can be rapidly complete within one day at room temperature under weak acidic conditions, 
which would take weeks in the absence of aniline. Due to the inherent instability of 
imines in water, the catalyst can be used in a high concentration to accelerate the 
exchange process. Moreover, aniline, being a mild nucleophile, has good solubility in a 
variety of solvents and is compatible with many functional groups. This strategy allows 
the application of DCL based on acyl hydrazone exchange in identifying ligands for 
biological target. 
 
Scheme 2.3 Mechanisms of imine formation (top) and transimination (bottom) under acidic conditions.229 
Recently, Greaney et al. developed a hydrazone DCL in the presence of aniline catalyst 
for the discovery of Glutahione S-Transferase (GST) inhibitors. One reactive aldehyde 
94a, related to the known GST substrate chlorodinitrobenzene (CDNB), and ten aryl 
hydrazides (95a-j) were used as building blocks for the generation of DCL (Figure 2.43). 
The equilibration of the library was complete after 6 h in the presence of aniline at pH 6.2. 
Two active compounds were amplified in the presence of recombinant GST isomers 
hGST P1-1 and SjGST. However, due to the poor solubility of the resulting library 
members, further binding studies were not possible. Therefore, the solubility of the library 
members was enhanced by replacing the -Cl with a glutathione moiety to get aldehyde 
94b. The DCL generated from 94b led to the amplification of compounds 96c and 96g 
from the DCL templated by recombinant GST isomer hGST P1-1 or SjGST, respectively. 
Subsequent studies confirmed that the amplified compounds have efficient inhibitory 
effects by binding to the GST H-site. By extending the inhibitor structure, 96c (IC50 = 57 
μM) was found to have six-fold higher affinity for hGST P1-1 than the precursor 96b 
(IC50 = 331 μM), while 96g (IC50 = 22 μM) had over one order of magnitude higher 
affinity for SjGST, relative to 96b (IC50 = 279 μM). 96g also showed selectivity for 
SjGST against all the other library members in accordance with the screening results. 
However, unlike the screening results, both of the compounds showed similar affinity to 
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hGST P1-1 (57 μM and 50 μM).230 Recently, bivalent GST inhibitors were identified by 
using the similar approach.231 
 
Figure 2.43 Building blocks for aniline-catalyzed acyl hydrazone DCL and the amplification of two active 
compounds in the presence of protein targets.  
The above examples demonstrate that dynamic combinatorial chemistry has great 
power and practicality in identifying synthetic receptors for small guest molecules and 
ligands for biological targets. DCC is also a useful tool to identify molecules with unusual 
structures and binding properties. It provides an attractive synthetic route to complex 
molecules that are more challenging to obtain through the normal synthetic method. 
However, although strong amplification of the selected library members has been 
observed in many cases, it is not always in good correlation with the binding affinity. 
Severin et al. revealed that this correlation could break down, or even reverse depending 
on the template concentration. It was shown that a high concentration of template could 
lead false positive results as the amplification of the weaker binders may compete with 
that of stronger ones. In particular, small oligomers and hetero-compounds are favored to 
be amplified over larger ones and homo-compounds respectively, even though they have 
similar binding affinity or even reverse as the amplification results showed.232-233 These 
predictions were also confirmed by simulated lager complex DCLs234 and the 
experimental work.235 Even though the false results can be avoided by using low template 
concentration, DCL system seems not as simple as we initially thought. However, these 
effects are not a significant limitation to the DCL approach, because even if the most 
amplified library member may not have the strongest binding affinity to the target, it is 
most likely to be one of the better binders in the dynamic libraries. In particular, the use of 
DCLs combined with the dynamic deconvolution strategy to identify potent enzyme 
inhibitors is of major interest in this work. 
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3. PROJECT AND OBJECTIVES 
This dissertation is focused on the discovery of novel and potent inhibitors with 
high affinity for the serine protease β-tryptase. The aim of this work is to identify new 
peptide structures containing the tailor-made binding motif for binding to the surface 
of the enzyme. New approaches for inhibitor identification will also be developed. 
Moreover, various scaffolds ranging from rational designed scaffolds with diverse 
structure, flexibility and valency to nanoparticles scaffolds with large surface area and 
tunable functionalities will be used to build up multivalent inhibitors. The tetrameric 
structure of β-tryptase has A2B2 arrangement with two pairs of monomers equivalent 
(Figure 3.1, left). The protein surface of β-tryptase has a pI value around 5.0 to 6.6, 
indicating only a slightly negatively charged surface.236 However, the surface features 
some highly acidic “hot spots” with clusters of negatively charged amino acids (e.g. 
glutamic acids and aspartic acids) which are mainly located at the entrance to the 
central pore and around the catalytic active sites of β-tryptase buried within this cavity 
(Figure 3.1, right). Therefore, the blocking of the entrance to the central pore would 
prevent the access of substrate to the active sites thus inhibiting the enzyme activity. 
 
Figure 3.1 Left: Tetrameric structure of β-tryptase (PDB code: 1A0L). Two pairs of equivalent 
monomers (coloured as red and green) are arranged in the same orientation. Right: Surface of the 
β-tryptase features some highly acidic “hot spots” around the central pore. The colors indicate positive 
(blue) and negative (red) electrostatic potential on the surface of β-tryptase 
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3.1 Design of Tetravalent Peptide Ligands with Two Different Sets of 
Arms as Potent Enzyme Inhibitors 
The first project of this thesis is based on the previous work concerning the 
enzyme inhibition by designing a new class of inhibitors. In the previous work, a type 
of inhibitors of β-tryptase with four identical arms was identified from a focused 
combinatorial library of 216 tetravalent peptide ligands (1) which bind to the surface 
of β-tryptase, sterically blocking access of the substrate to the active site thus shutting 
down the enzyme in a reversible and noncompetitive way. Inspired by the structure of 
β-tryptase with its A2B2 arrangement of the four monomers and a docking study 
suggesting that the enzyme has at least two different binding sites for cationic peptide 
ligands, ligands with two different sets of arms should be even more promising 
candidates for the inhibition of β-tryptase. Therefore, this project is now to design 
new tetravalent ligands 97 by incorporating two different types of arms instead of the 
four identical arms into the tetrapeptides in order to improve the binding affinity to 
β-tryptase (Figure 3.2). Furthermore, besides proteinogenic amino acids, the artificial 
arginine analogue, the guanidiniocarbonyl pyrrole unit (GCP) should be incorporated 
in the arms to improve the binding affinity to β-tryptase. To further test how the 
artificial GCP group influences the inhibition of β-tryptase, the ligands 98 with four 
identical arms tailored with GCP groups were designed to compare them with the 
previous ligands. 
The combinations of cationic and aromatic amino acids will be chosen to build up 
the arms based on the previous findings that these combinations provides most 
efficient inhibitors for β-tryptase. Therefore, ligands 97 could be identified that 
contain the original best sequence RWKG as the first set of arms and a different 
second sequence for the other set of arms. Ligand 98 with four identical arms will 
carry three or four amino acids, ending with the GCP group in each arm. The basic 
residues (lysine, arginine, GCP) should allow for the binding of the acidic area that 
mainly bearing carboxylates from side chains of aspartic and glutamic acid residues at 
the entrance to the central pore and around the active cleavage sites of β-tryptase. The 
inhibition properties of these ligands towards β-tryptase will be studied by enzyme 
assay. 
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Figure 3.2 Tetravalent ligands (97) with two different sets of arms (colored in red and blue, 
respectively) and four-armed ligands (98) with four identical arms terminating with the GCP units. The 
design was inspired by the previous findings from the combinatorial library and now the docking 
studies. 
3.2 Dynamic Combinatorial Chemistry: New Method for the 
Discovery of Inhibitors of β-Tryptase 
In this project, dynamic combinatorial chemistry will be used as a new method for 
the identification of inhibitors of β-tryptase. The pre-equilibrated DCLs based on the 
reversible acyl hydrazone formation reaction will be used for the discovery of new 
and potent inhibitors of β-tryptase with the help of a dynamic deconvolution strategy 
(Figure 3.3). The hydrazide will carry different peptide arms featuring the recognition 
elements binding to the enzyme. The aldehydes with diverse spacer, flexibility and 
valency can be chosen as scaffolds to build up multivalent library species. The 
formation of hydrazones can be monitored by HPLC, MS and NMR. The full library 
and different sub-libraries in which one specific building block is removed can be 
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prepared. By using a deconvolution strategy to compare the enzyme screening results 
for different sub-libraries with the full library, the active building blocks will be 
selected and this way the influence of the peptide sequence on the enzyme inhibition 
can be studied as well as the influence of the scaffolds.  
The next step will be the synthesis of the active library members by the 
construction of the selected active building blocks featuring orthogonal functional 
groups. Then the individual acyl hydrazones can be subjected to independent enzyme 
assays to investigate the inhibitory properties. Such a method could give new insight 
to the discovery of potent enzyme inhibitors with less effort than the traditional 
combinatorial library. 
 
Figure 3.3 Schematic representation of the acyl hydrazone based DCL for identifying inhibitors of 
β-tryptase. 
3.3 Gold Nanoparticles: Promising Scaffold for Protein Surface 
Recognition 
The aim of this project is to take advantage of the gold nanoparticles (Au NPs) as 
attractive scaffold due to their large surface area, tunable size and the ability to feature 
the surface with a wide range of desirable functionalities to design multivalent ligands 
for the protein surface binding. To achieve this goal, the surface of the functionalized 
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gold nanoparticles should present complementary recognition elements that are 
required for the interaction with the surface of protein. Therefore, the peptide ligands 
with basic amino acids should be used to bind to the acidic hot spots of β-tryptase. 
The peptide ligands (99) shown in Figure 3.4 will contain three subunits: the thioalkyl 
chain to stabilize the gold core, the triethylene glycol as a linker to improve the 
solubility and prevent both nonspecific interactions with enzyme and protein 
denaturation, and the positively charged peptide chain to bind to the enzyme. Neutral 
ligand 100 with the terminal hydroxyl is used to compare the binding affinities with 
the peptide ligand. The Au NPs (101) featuring the peptide ligands will be prepared 
by laser ablation which will be done together with our cooperation partner, the 
working group of Prof. Stephan Barcikowski in the Institute of Technical Chemistry at 
the University of Duisburg-Essen. 
 
Figure 3.4 Schematic representation of the structure of the ligands 99, 100 and the functionalized gold 
nanoparticles 101 featuring peptide ligand 99. 
The monovalent and bivalent conjugated Au NPs will be generated to investigate 
their enzyme inhibitory properties. The functionalized gold nanoparticles should be 
characterized by NMR, IR, UV/Vis, disc centrifugation, DLS and TEM to verify and 
determine the functionality on the surface, as well as the particle size. The influence 
of the amino acid composition of the peptide chain, the functionalization degree, as 
well as the gold concentration on the enzyme inhibition will be studied. 
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4. RESULTS AND DISCUSSIONS 
4.1 Design of Tetravalent Peptide Ligands with Two Different Sets of 
Arms as Potent Enzyme Inhibitors 
The first project of this thesis is based on the previous work from Peter Wich 
concerning the discovery of a new class of inhibitors of β-tryptase by using tetravalent 
peptide ligands with two different sets of arms. The previous work revealed a protein 
surface binding approach to shut down the enzyme through the interaction of a tetravalent 
peptide ligand with the entrance to the central pore of β-tryptase sterically blocks access 
of the substrate to the active site thus inhibiting the enzyme in a reversible and 
noncompetitive way.13 The best ligand (RWKG)4 (Ki = 0.17 µM) containing basic and 
aromatic amino acids in their arms was chosen from the combinatorial library of 216 
tetravalent peptide ligands (1) with four identical arms attached to a lysine dendrimer 
scaffold (Figure 4.1). Most likely this ligand acts as a ‘molecular plug’ upon binding to 
the central pore of the enzyme thus preventing the substrate from binding. The structure 
of the enzyme with the A2B2 arrangement of the four monomers (see Figure 3.1) and a 
docking study (see Figure 4.3) suggest that the enzyme has at least two different binding 
sites for cationic peptide ligands and hence ligands with two different types of arms might 
also be promising candidates for inhibiting tryptase giving access to an even higher 
structural diversity. Therefore, the first project of this thesis is focused on the discovery of 
novel and potent inhibitors with high affinity for serine protease β-tryptase by design and 
synthesis of tetravalent ligands with two different sets of arms. In addition, the artificial 
GCP group was also incorporated into the arms to test its effects on the enzyme inhibition. 
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Figure 4.1 Left: The structure of the combinatorial library of 216 tetravalent peptide inhibitors. Right: The 
illustration of the interaction between the best ligand (RWKG)4 and β-tryptase: The inhibitor can bind to the 
surface of the protein acting as a tight “molecular plug” closing the central pore and thus blocking access to 
the active sites. 
4.1.1 Statistical Analysis of the Inhibition Data and Docking Studies 
The statistical analysis and docking studies were performed by Dr. Dominik Heider in 
the working group of Prof. Daniel Hoffmann from the Institute of Bioinformatics at the 
University of Duisburg-Essen. In the previous work a focused combinatorial library of 
216 tetravalent peptide ligands with four identical arms on a lysine dendrimer had been 
screened for inhibition of β-tryptase. These ligands varied in the composition of the 
tripeptide unit within their arms. A quantitative on-bead screening had been performed so 
that a set of inhibition data from 216 ligands was available.13 The data was now used to 
perform a statistical analysis to identify which is the most important position of the 
variable tripeptide part in the arms and what kind of properties of the respective amino 
acids in the arms are beneficial for the inhibition. Therefore, the amino acids of the 
tripeptide sequences were numerically encoded using two scales, namely the hydropathy 
index of Kyte and Doolittle237 normalized to range 0 to 1, and the net charge in unit of 
elementary charge. In this way, every tripeptide sequence from the previous combinatorial 
library was now translated into a vector of six numerical values. The hydropathy and 
charge vectors were plotted separately using the R-package rgl238-239 for the 25 % 
strongest and weakest inhibitors, respectively (Figure 4.2). The linear and nonlinear 
correlation of inhibition with the six descriptors was evaluated computationally with the 
statistics software “R”,238 and nonlinear regression was performed with random forests as 
implemented in R.240 The results showed that enzyme inhibition by the tetravalent ligands 
was clearly correlated with the amino acid composition of the tripeptide sequences as 
expressed by charge and hydropathy: An adjusted R2 = 0.63 for multiple linear correlation 
and only marginally higher values with nonlinear regression were found. The linear 
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correlation of highest significance was found for the charge of the first variable position 
(p < 2e-16) with a positive charge leading to stronger inhibition. Positive charges are 
favored as well at the other two positions but to a lesser extent. This is in agreement with 
the negative correlation of inhibition with hydropathy as the favored amino acids arginine 
and lysine have the lowest values of hydropathy.237 Figure 4.2 shows that the 25 % 
strongest and 25 % weakest inhibitors can be well separated in the space of the chosen 
physico-chemical descriptors hydropathy and charge, with the first amino acid having the 
greatest impact on enzyme inhibition: low hydropathy and positive charge at this position 
result in strong inhibitors, while high hydropathy and negative charge at this position are 
characteristic of weak inhibitors. 
 
Figure 4.2 The distribution of tripeptide sequences of the 25 % strongest (green) and 25 % weakest 
inhibitors (red) from the previous combinatorial library in the space of the described hydropathy (left) and 
charge (right) vectors. The three dimensions V1, V2, V3 correspond to the three amino acid positions in the 
tripeptide sequences. Note that in the right every position marked by a ball is occupied by several 
superimposed balls. 
Besides the studies on the correlation of enzyme inhibition with the amino acid 
composition of the tripeptide sequences, we were also interested in identifying possible 
binding sites for this kind of ligands on the protein surface. Therefore, docking studies 
with the simple tripeptide sequence KWR derived from the strongest inhibitor (RWKG)4 
in the previous combinatorial library were performed. We wanted to see to which position 
of the enzyme this tripeptide can bind and hopefully this binding sites information could 
help us in the development of improved inhibitors. The tripeptide was modeled with 
Yasara241 and WhatIF242 and then docked with Autodock Vina243 into the crystal structure 
of human β-tryptase (PDB code: 1A0L). Water molecules within the crystal structure as 
well as the bounded ligand in this structure were removed. In the docking process, the 
tripeptide was flexible and the enzyme conformation was retained, and the whole surface 
of the enzyme was scanned. With the help of computational docking, we identified four 
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potential binding sites of the tripeptide KWR on the enzyme. Two predicted binding sites 
are located at the interfaces of two monomers within the tryptase tetramer (green in Figure 
4.3). These two binding sites are predicted to bind to the peptide with the highest affinities. 
Two peptides bound at these two binding sites would have a distance between 26-27 Å. 
This distance could just be bridged easily by the tetravalent ligands that we used in our 
previous study. The other two predicted binding sites are located around the catalytic 
centers within the monomers (red in Figure 4.3). Because of the symmetry of the enzyme, 
there should be potentially four of these binding sites in the tetramer. The six ligand poses 
with the highest affinities (out of nine best obtained from AutoDock vina) are all located 
at the monomer-monomer interfaces; they have significantly higher affinities than poses 
located round the catalytic centers. The minimum distance between peptides docked at the 
two different binding sites is 16-17 Å, which means that the tetravalent ligand could in 
principle easily bind to both types of binding sites at the same time. This docking study 
therefore nicely confirms the previous experimental results:13 The monovalent peptide 
RWKG is indeed a competitive inhibitor of β-tryptase but only with moderate affinity (Ki 
= 306 μM). This result is in agreement with the now predicted binding sites around the 
catalytic active centers. The binding at the interface of two monomers is preferred as well 
for the monovalent ligand. However, binding of just one linear peptide at this binding site 
is not enough to inhibit the enzyme. Obviously substrate access to the active sites is not 
blocked. This only occurs when both binding sites at the monomer-monomer interfaces 
are occupied by one ligand which binds across the central pore of the enzyme.  
 
Figure 4.3 Potential binding sites of β-tryptase derived from a computational docking study with the 
tripeptide KWR. The four monomers of the enzyme are named A, B, C and D. Two types of binding sites 
were found, one with higher affinity at the two monomer-monomer interfaces (green), and one around the 
four catalytic centers (red). 
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Therefore, the statistical analysis confirmed that peptide sequences with a combination 
of cationic and aromatic amino acids are preferred. Moreover, low hydropathy and 
positive charge at the first position of the peptide sequence has the greatest positive 
impact on the enzyme inhibition. Docking study indicated that multivalent ligands should 
be superior to monovalent ones for enzyme inhibition. The size of the multivalent ligands 
should span the distance between the binding sites at the monomer-monomer interfaces or 
the binding sites around the catalytic centers. This way the central pore of the enzyme can 
be blocked and access of the substrate to the active site is prevented. 
4.1.2 Synthesis of the Guanidiniocarbonyl Pyrrole Moiety (GCP) as Tailor Made 
Binding Motif 
The basic GCP motif has been demonstrated by our working group to be an efficient 
binding site for oxoanions and had already been used for the design of artificial receptors 
for amino acids, oligopeptides or oligonucleotides and found to be an efficient artificial 
transfection vector for gene delivery.14-15 We know that this binding motif in its 
protonated form has superior anion binding affinities compared to the natural basic amino 
acids lysine and arginine used for this purpose. So it is used as an artificial arginine 
analogue and can be incorporated into the peptide ligands to test how this motif affects the 
enzyme inhibitory properties. Because the synthesis of the GCP group has been reported 
in the literature and is well known and frequently used in our working group, it is 
described only briefly in a short overview (Scheme 4.1).  
Scheme 4.1 Synthesis of the guanidiniocarbonyl pyrrole (GCP) binding motif. 
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The synthesis of the GCP started with commercially available pyrrole (102) which was 
acylated with trichloroacetyl chloride in diethylether through an electrophilic aromatic 
substitution reaction to give trichloroacetyl pyrrole (103). This compound was then 
subjected to a haloform reaction with benzyl alcohol in the presence of a small amount of 
sodium to give the benzyl ester (104) which was purified by a flash column 
chromatography. In the following Vilsmeier-Haack formylation, the Vilsmeier reagent, 
produced by adding phosphoryl chloride to dimethylformamide (DMF) was added to the 
benzyl ester solution to give the 5-formyl pyrrole-2-carboxylate acid benzyl ester (105). 
In this step a byproduct 4-formyl pyrrole-2-carboxylate acid benzyl ester was formed as 
well but in a lower amount which can be easily separated by chromatography. The 
aldehyde (105) was then oxidized to the carboxylic acid (106) with potassium 
permanganate in a mixture of acetone and water. In the next coupling reaction, the 
N-Boc-guanidine (109) which was obtained from the reaction of guanidinium chloride 
(107) with Boc2O (108) was reacted with the acid (106) by using PyBOP as the coupling 
reagent and N-methylmorpholine (NMM) as a base to give 110. In the last step, the benzyl 
ester group was cleaved off by hydrogenation with a catalytic amount of palladium on 
activated charcoal in methanol in the presence of triethylamine to give Boc-protected 
guanidinocarbonyl pyrole (111). 
4.1.3 Solid Phase Peptide Synthesis of Tetravalent Peptide Ligands 
The peptide ligands were synthesized with 9-fluorenylmethyloxycarbonyl (Fmoc) solid 
phase peptide synthesis (SPPS).244-246 By using this method, the peptide ligands can be 
easily prepared on a solid support in a high yield and purity. The principle of this method 
is to attach the first amino acid via a linker to a polymeric solid support and then grow the 
desired peptide sequence which can be cleaved from the solid support under appropriate 
acidic conditions. Generally, the syntheses take place from C- to N-terminus and the 
amino acids which are temporarily protected via base labile Fmoc protecting group at 
their N-termini are attached to the free N-terminus of the growing peptide chain by 
activating the C-termini with a coupling reagent. In the Fmoc strategy the side chains of 
the amino acids have to be protected to avoid the cross-reaction, most commonly with 
acid-labile protecting groups, e.g. tert-butyloxycarbonyl (Boc), tert-butyl (tBu) and 
2,2,4,6,7-pentamethyldihydro- benzofuran-5-sulfonyl (Pbf) groups.247 These protecting 
groups on the side chains need to be stable during the syntheses and should be easy to 
remove in the end. The amino acids and the protecting groups used for the SPPS in this 
project are shown in Figure 4.4. Generally the coupling reactions are carried out by using 
an excess of amino acids and coupling reagents with respect to the resin-bound functional 
groups to ensure complete conversion. One advantage of solid phase peptide synthesis is 
the easy removal of byproducts or coupling reagents from the resin by filtration and 
washing steps during the synthesis so that no purification steps are needed in between the 
synthetic steps. The purification is needed only after the cleavage of the product from the 
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resin under acidic conditions. Therefore, as a convenient method for peptide synthesis, 
SPPS is adapted to various conditions and requirements of the preparation of 
oligopeptides with high yields and purities. 
 
Figure 4.4 The amino acids and the protecting groups used for the Fmoc-SPPS in this project. 
The peptides in this work were synthesized with either the acid-labile modified Rink 
amide linker (Rink amide MBHA resin) or an equivalent linker directly linked to a 
polystyrene base matrix (Rink amide resin) via the formation of peptide C-terminal 
amides. The polymer matrix is 1 % divinylbenzene (DVB) cross-linked polystyrene, 
100-200 mesh. Because attachment of the peptide to amine supports is made via an amide 
bond, coupling of the first amino acid can be achieved using normal methods of amide 
bond formation. Since 4-dimethylaminopyridine (DMAP) is not required for this step, 
there is no risk of racemization or dipeptide formation. Cleavage of the peptide amide 
from the solid supports can be done in a single step by treatment with 95 % trifluoroacetic 
(TFA). Figure 4.5 showed the Rink amide linker and Rink amide MBHA linker both with 
Fmoc-protected amine.248-249 The linker used for the resin is to provide the reversible 
linkage between the solid support and the growing peptide chain, and to protect the 
C-terminal α-carboxyl group during the process of peptide chain extension. It is also 
RESULTS AND DISCUSSIONS 
72 
 
important for the cleavage of the peptide from the solid support. Both of the resin linkers 
are designed to release peptide amides upon treatment with TFA. The Rink amide resin is 
more acid sensitive than the Rink amide MBHA resin. Cleavage with high concentration 
of TFA can lead to the breakdown of the linker, with the concomitant formation of 
byproducts that are hard to remove by simple washing steps. However, these problems 
can be minimized by the use of low concentration of TFA or by the addition of 
trialkylsilanes to the cleavage mixture. Rink amide MBHA resin consists of the modified 
Rink amide linker attached to MBHA resin via an unusual amino acid norleucine which is 
less acid sensitive.249-250 Both of them are used very often in Fmoc-strategy by providing 
peptide C-terminal amides in high yields and purities. 
 
Figure 4.5 Rink amide resin (left) and Rink amide MBHA resin (right). 
 
Determination of the Loading Values of Rink Amide Resin and Rink Amide MBHA 
Resin  
Since the Rink amide resin and Rink amide MBHA resin were used most commonly in 
this work for the SPPS. The loading of these two resins was determined to test the amount 
of coupling positions on the resin. Each of the resins was weighed into a vessel. After the 
resins were allowed to swell in dichloromethane (DCM) for 1 hour, the Fmoc protecting 
group attached to the linker was removed by using 20 % piperidine/DMF, the solutions 
were filtered and collected and combined with the washing solutions as well to ensure the 
complete collection of the removed Fmoc groups. The dibenzofulvene-piperidine adduct 
(114) formed during the Fmoc deprotection could be detected with the help of its 
absorption at 301 nm by monitoring the UV/Vis spectrum between 250 and 350nm 
(Figure 4.6).251 
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Figure 4.6 UV/Vis absorption spectra of dibenzofulvene-piperidine adduct (114) formed by the Fmoc 
deprotection from Rink amide resin (left) and Rink amide MBHA resin (right). 
The concentration c of this adduct can be calculated by the measured absorption A at 
301 nm with the help of Lambert-Beer Law (A = εbc). The specific absorption coefficient 
ε of this adduct251 is 7800 L mol -1 cm-1 and with the cuvette of width b = 1 cm, the 
loading L in mmol/g can be calculated using the following equation (8): 
 
Where D is the dilution factor, V is the total volume of the collected solution, and m is 
the mass of the weighed resin beads.  
Therefore, the amount of available coupling position is determined from the amount of 
cleaved Fmoc groups. For both resins the loading concentration was calculated via 
equation 8. The calculated loading value of the Rink amide MBHA resin is 0.67 mmol/g, 
which is in the range of the given value of the manufacturer (0.5-0.8 mmol/g). The 
calculated loading of Rink amide resin is 0.99 mmol/g which is a bit less than the given 
value (1.29 mmol/g). This could be due to the adsorption of moisture so that the real 
loading of the resin is less because the amount of resin contains some water due to a long 
time storage and use. Another possible reason could be due to the damage of some resin 
beads after a long storage time because the materials of the resin are somewhat friable and 
have a tendency to degrade over the course of long storage. The obtained loading values 
were used to calculate the amounts of the reactants for the couplings and the yields in the 
end. 
Fmoc-SPPS of Tetravalent Peptide Ligands with Two Different Sets of Arms 
For designing the tetravalent ligands 115-120 (Figure 4.7) with two different sets of 
arms, the best peptide sequence RWKG obtained from the previous library was always 
114 114 
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chosen for the first set of arms except for ligand 116 which contained peptide sequence 
KWKG to allow a comparison of lysine and arginine at the first place. The basic amino 
acids lysine, arginine or its artificial analog GCP moiety and hydrophobic amino acid 
leucine and aromatic amino acids phenylalanine or tryptophan were selected to construct 
the second set of arms to test the influence of the new combination of different types of 
amino acids on the enzyme inhibition. The choice of these amino acids was based on the 
previous results obtained from the focused combinatorial library, now confirmed by the 
above discussed statistical analysis in chapter 4.1.1. These findings demonstrated that the 
combinations of cationic and aromatic amino acids provided the most efficient inhibitors 
of β-tryptase. Ligand 120 was designed by incorporating the artificial arginine analog 
GCP (111) into the first place of one set of arms replacing either arginine (115) or lysine 
(116) at this position in order to test how the artificial GCP moiety influence the enzyme 
inhibition. We chose again a second generation lysine dendrimer as a scaffold to build up 
the new type of tetravalent ligands. However, in order to attach two different sets of 
peptide arms two orthogonal protecting groups on the scaffold were needed. The Fmoc 
and allyloxycarbonyl (Alloc) groups were then chosen as the two orthogonal protecting 
groups for the lysine scaffold so that we can use standard Fmoc solid phase peptide 
synthesis. The Fmoc and Alloc protecting groups were used for the α-amino groups and 
the amino groups on the lysine side chains, respectively. The correspondingly protected 
lysine is commercially available. The Fmoc protecting group can be removed by using 20 % 
piperidine/DMF which is compatible with acid-labile side chain protecting groups. The 
Alloc group is fully compatible with the conditions encountered during solid phase 
peptide synthesis and can be removed with the well-established palladium-catalyzed 
hydrosilylolysis procedure without affecting the other acid labile protecting groups on the 
side chains of the used amino acids.252-253 
 
Figure 4.7 Schematic representation of variations on the two different sets of arms of the tetravalent peptide 
ligands (115-120) for enzyme inhibition. The three positions on the two different arms are varied with 
cationic and aromatic amino acids, as well as the artificial arginine analog GCP moiety. The two different 
sets of peptide arms are colored in blue and red, respectively.  
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The synthesis of peptide ligand 115 was performed according to a standard Fmoc solid 
phase peptide synthesis (Scheme 4.2). Completion of each coupling and deprotecting step 
were monitored by a Kaiser test,254 a color test for the detection of free amines which 
shows positive if free amines are present on the solid support most often after Fmoc 
deprotection while negative if all amines have been converted to amides after a 
quantitative coupling reaction. The synthesis was started on Fmoc-protected Rink amide 
resin (loading value: 0.99 mmol/g). After the resin was swollen in DCM for 1h to increase 
the accessibility of the Fmoc-amino groups inside the resin, the removal of Fmoc 
protecting group was achieved by treatment with 20 % piperidine/DMF for 20 min (2 
times). The resin was thoroughly washed with DMF. The first coupling reaction using 
Fmoc-Lys(Fmoc)-OH and benzotriazol-1-yl-N-oxy-tris(pyrrolidino)phosphonium 
hexafluorophosphate (PyBOP) as coupling reagent in 4 % N,N -´diisopropylethylamine 
(DIPEA) in DMF with 2.5 equivalents of each reactant was achieved by shaking the 
mixture for 6-12 h under argon (Ar) atmosphere. Since very often the first coupling step 
of the solid phase peptide synthesis is rather difficult, resulting in incomplete conversions 
and thus in low yields and purities, this step was repeated to ensure a complete reaction of 
all free amino groups on the resin. A negative Kaiser test indicated the complete reaction. 
After the removal of Fmoc groups from both the α-amino group and the side chain amino 
group of lysine, the orthogonally protected amino acid Fmoc-Lys(Alloc)-OH was attached 
similarly by using 5 equivalents of each reactant to obtain the orthogonally protected 
lysine scaffold (122) with two sets of different protecting groups on the α-amino groups 
and the amino groups of the side chains. After removing Fmoc groups, the first two arms 
consisting of four amino acids: Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH 
and Boc-Arg(Pbf)-OH were attached similarly to obtain 123 by using standard conditions 
according to Fmoc-SPPS. If necessary, the coupling step was repeated as indicated by the 
Kaiser test. Then the removal of the Alloc protecting group was achieved under neutral 
conditions with catalytic amount of tetrakis(triphenylphosphine) palladium(0) (Pd(PPh3)4) 
in the presence of phenylsilane (PhSiH3) as a scavenger for the allyl unit.252-253 After 
thoroughly washing with DCM and DMF, the second two arms consisting of four amino 
acids: Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Leu-OH and Boc-Arg(Pbf)-OH were 
attached to the resin, again using standard conditions for Fmoc-SPPS. After successful 
completion of all the couplings as indicated by the Kaiser test, the resin was washed 
extensively with DCM, methanol (MeOH) and DCM again. Then the resin was dried for 1 
h and treated with a mixture of TFA/TIS/H2O (95:2.5:2.5) for 3 h which led to the 
cleavage of the product from the Rink amide resin and the simultaneous removal of all the 
side chain protecting groups. Triisopropylsilane (TIS) and water are necessary as 
nucleophilic scavenger to intercept reactive cationic species which are formed from the 
protecting groups under these harsh conditions, e.g. t-butyl cationic species from the Boc 
deprotection.255-256 The cationic species could be subject to the addition of the liberated 
amino acids containing electron-rich functional groups, e.g. tryptophan, tyrosine, etc. thus 
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reducing the yield and purity. After precipitation from diethyl ether the crude product was 
purified by reversed phase medium-pressure liquid chromatography (RP18-MPLC) using 
appropriate conditions (H2O/MeOH + 0.1 % TFA). Pure product was transferred into its 
hydrochloride salt by dissolving in water with hydrochloric acid and lyophilizing several 
times. The product was obtained with > 95 % purity according to analytical high 
performance liquid chromatography (HPLC) analysis. The other ligands 116-120 were 
synthesized accordingly.  
 
Scheme 4.2 Solid phase peptide synthesis of the peptide ligand 115 with two different sets of arms. 
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Syntheses of Tetravalent Peptide Ligands with Four Identical Arms Terminating 
with GCP Groups via Microwave-Assisted SPPS 
As mentioned above, the GCP group was demonstrated by us to be an efficient anion 
binding motif which has superior binding affinities compared to both lysine and arginine. 
However, compared to side chain amino groups of lysine (pKs ca. 10.5) and arginine (pKs 
ca. 12.5), this GCP group is only partially protonated at neutral pH because of the reduced 
basicity (pKs ca. 6.5). So it is unclear whether the use of this group can indeed improve 
the enzyme inhibitory efficiency under the physiological assay conditions. Therefore, in 
order to study the influence of this artificial arginine analog on the inhibitory properties 
compared to our previous results in more detail, the ligands 124-125 (Figure 4.8) with 
four identical arms ending with GCP groups were synthesized and tested for their 
inhibition of β-tryptase. A number of reports have advocated that the use of 
microwave-assisted solid phase peptide synthesis to obtain peptides represents a very 
efficient way not only accelerating both the coupling and deprotection reactions by 
increasing the temperature which is uniform in the whole reaction mixture volume in 
contrast to the oil bath, but also improving the purity and yield of difficult peptide 
sequences via the avoidance of aggregation as well as incomplete reactions as compared 
to the conventionally room temperature SPPS.257-259 Traditionally, the heating method 
utilized by organic synthesis is carried out by conductive heating with an external heat 
source such as an oil bath or electric plate heater. This is comparatively slow and 
inefficient way for transferring energy into the reaction system since it depends on 
convection currents and the thermal conductivity of the various materials that have to be 
penetrated. In addition, a temperature gradient can develop within the sample and local 
overheating can lead to the formation of unwanted byproduct. In comparison, microwave 
technology uses electromagnetic waves that pass through material and cause the 
molecules in the material to oscillate, thus generating heat. The heat is generated mainly 
by dipolar polarization through the interaction of the polar molecules with the microwave 
irradiation. Generally, irradiation of microwave can heat the reaction mixture in a 
homogeneous and very efficient way. Since the preceding vessels are typically made out 
of microwave-transparent materials the radiation passes through the walls of the vessel 
directly into the whole reaction mixture volume, this way all reactants have the same 
energy and any temperature or energy gradient are avoided.  
Therefore, we also tested microwave-assisted SPPS to synthesize ligands 124-125. 
Again a second generation poly-lysine dendrimer was chosen as the scaffold to attach four 
identical arms consisting of a tri- ro tetra-peptide and the terminal GCP group. Ligand 
(GCP-RWKG)4 (124) is derived from the best sequence (RWKG)4 obtained from our 
previous work containing the same tetrapeptide sequence but with an additional GCP 
group at the end. Ligand (GCP-RWK)4 (125) contains the terminal GCP group as well, 
but in contrast to 124, the glycine was removed from the sequence. Initially, glycine was 
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added to the sequence as an invariable amino acid to increase the flexibility and the length 
of the arms allowing better interaction with the enzyme. However, it is not clear whether 
the glycine is necessary for the enzyme inhibition. Hence, both the influence of the 
glycine and the effect of the artificial GCP group on β-tryptase inhibition can be examined 
with these two ligands 124 and 125.  
 
Figure 4.8 Schematic representation of the structure of tetravalent peptide ligands (124-125) with four 
identical arms terminating with the GCP groups. 
Ligand 124 was synthesized using microwave-assisted Fmoc solid phase peptide 
synthesis (Scheme 4.3). The microwave conditions (power, temperature and reaction time) 
were tested before starting the synthesis. Different power and temperature were tested by 
Kuchelmeister in his PhD thesis.260 It was shown that variation of the power (10-100 W) 
did not cause big differences in the yields. Therefore, 20 W was chosen for the reactions. 
It has been reported that the microwave-assisted coupling reaction could be done without 
racemization at a temperature of 80 oC.258 Therefore, 60 oC was used for the coupling and 
Fmoc deprotection reactions which worked very well with good yields. The next step was 
testing the time of the coupling and Fmoc deprotection reactions. The results showed that 
the coupling reaction was almost quantitative after 20 minutes. Therefore, the reaction 
conditions at 20 W with maximum temperature of 60 oC for 20 min were chosen for the 
coupling steps. If the Kaiser test was positive after the first coupling, 30 min was used for 
the second run. The Fmoc deprotection time was rather shorter, almost all the Fmoc 
groups were removed after 1.5 min, but to ensure quantitative deprotection, this reaction 
was repeated twice at 20 W with maximum temperature of 60 oC for 1.5 min and 5 min 
respectively. The synthesis was started from Fmoc-protected Rink amide MBHA resin 
(loading value: 0.67 mmol/g), which was swollen in DCM for 1 h at ambient temperature 
under Ar, followed by the Fmoc removal by treatment with 20 % piperidine in DMF first 
for 1.5 min and then for 5 min (20 W, Tmax = 60 °C, ΔT = ± 5 °C). Afterwards the first 
amino acid Fmoc-Lys(Fmoc)-OH was attached using PyBOP as coupling reagent in 4 % 
DIPEA/DMF with 2.5 equivalents of each reactant. The reaction mixture was irradiated 
for 20 min (20 W, Tmax = 60 °C, ΔT = ± 5 °C). The first coupling step was repeated to 
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ensure the complete conversion of all accessible amino groups on the resin. After Fmoc 
deprotection, Fmoc-Lys(Fmoc)-OH was attached again similarly using 5 equivalents of 
each reactant to obtain the lysine scaffold (126) with four identical branches featuring 
Fmoc protected amino groups. Then after removing all the four Fmoc groups on the lysine 
scaffold with the help of microwave irradiation, the following four amino acids: 
Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH, and Fmoc-Arg(Pbf)-OH, as 
well as the Boc-protected GCP group (111) were attached similarly using 10 equivalents 
of each reactant to build up the four identical arms. Completion of each coupling and 
deprotecting step was monitored by Kaiser test. After the last coupling step, the resin was 
thoroughly washed with DCM, MeOH and DCM again, then the resin was dried for 1 h 
and treated with a mixture of TFA/TIS/H2O (95:2.5:2.5) for 3 h at room temperature 
without microwave irradiation which led to the cleavage of the product from the resin and 
the simultaneous removal of all protecting groups. After precipitation from diethyl ether, 
the crude product was purified by RP18-MPLC using appropriate conditions (H2O/MeOH 
+ 0.1 % TFA). Pure product was transferred into its hydrochloride salt by dissolving in 
water with hydrochloric acid and lyophilizing several times. The product was then 
obtained with > 95 % purity according to analytical HPLC analysis. The other ligand 125 
with four identical arms and tailor-made GCP groups were synthesized accordingly.  
 
Scheme 4.3 Microwave-assisted solid phase peptide synthesis of the peptide ligand 124 with four identical 
arms and tailor-made GCP groups. 
RESULTS AND DISCUSSIONS 
80 
 
4.1.4 Enzyme Assay 
The enzyme activity is regularly examined by fluorescence measurements which 
measure the fluorescence change of the cleaved product over time, resulting in linear 
curves with varying slopes depending on different enzyme activities. The theoretical 
background information about the principles of the enzyme assays has been already 
described in Chapter 2.1.2. The specific procedures according to literature known 
procedures,13, 114, 120 but with some modifications applied to the serine protease β-tryptase 
used in this project will be explained in the following section. 
As described in Chapter 2.2, the tetrameric structure of β-tryptase is stabilized by 
heparin, and in the absence of heparin β-tryptase dissociates into monomers and is not 
enzymatically active anymore. Therefore, the heparin-stabilized Skin β Tryptase, Human, 
Recombinant (rhSkin β-tryptase) was used in this work. The enzyme was commercially 
available in aqueous solution at a mass concentration of 200 μg/mL. For easier use the 
enzyme (0.5 mL) was separated into aliquots in 50 vials, so that it was available in single 
vials each containing 2 μg of the enzyme in 10 μL solution at the same concentration of 
200 μg/mL.  
Tryptase is known to cleave peptides on the C-terminal side of lysine and arginine 
amino acid residues. Therefore, the fluorogenic substrate N-p-Tosyl-Gly-Pro-Arg 
7-amido-4-methylcoumarin hydrochloride (Tos-Gly-Pro-Arg-AMC, 127) can be used for 
determining the enzymatic activity of β-tryptase. Upon cleavage by the enzyme a strong 
increase of fluorescence emission at 460 nm (380 nm excitation) occurs due to the release 
of the free 7-amino-4-methylcoumarin (AMC, 129) which can be used to monitor the 
kinetics of the enzymatic cleavage (Figure 4.9). 
 
Figure 4.9 Hydrolysis of the fluorogenic substrate Tos-Gly-Pro-Arg-AMC (127) by β-tryptase. The 
fluorescence active AMC (129) was released upon enzyme cleavage. 
Enzyme Kinetic Assay Method 
In order to measure the kinetic parameters for the hydrolysis of the fluorogenic 
substrate Tos-Gly-Pro-Arg-AMC by rhSkin β-tryptase, the experiments were performed in 
a high throughput kinetic assay using a fluorescence spectrophotometer with a microplate 
reader unit and white 96 well plates. The assay was carried out in a 50 mM Tris-HCl 
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buffer at pH 7.4, containing additional 50 µg/mL heparin (to stabilize the enzyme), 0.02 % 
Triton-X (to minimize aggregation) and 100 mM NaCl. The enzyme was prepared in 
assay buffer and the final concentration of the enzyme used in the assay had to be 
determined prior the tests. In order to avoid the detection problems, the appropriate 
concentration of the enzyme should be tested to make the slope of the linear graph (the 
product conversion over time) between 15 and 30 by measuring the enzyme at different 
dilutions in the absence of inhibitor. The stock solution of substrate was prepared in 
dimethyl sulfoxide (DMSO) at a concentration of 2 mM. All the inhibitors were prepared 
as a stock solution of 1 mM in DMSO. The kinetic assays (at 25 oC) were carried out in a 
final volume of 200 µL in assay buffer (165 µL) wherein the enzyme (10 µL, final 
concentration 0.25 nM) was incubated with various concentrations of inhibitors (20 µL) 
and finally the substrate (5 µL, final concentration 50 µM) was added. All the solutions 
were thoroughly mixed and finally the increase of fluorescence activity was measured at 
460 nm emission (380 nm excitation) over the time of 15 min.  
The inhibitory activities (in %) of all the inhibitors was first determined four-fold at an 
inhibitor concentration of 100 µM. If the enzyme inhibition was higher than 80 % also the 
half maximal inhibitory concentration (IC50) was determined at varying inhibitor 
concentrations and the enzyme inhibition constant (Ki) can be calculated from the IC50 
depending on the binding mechanism to the enzyme. For this purpose the assay was done 
by measuring a dilution series of the stock solution of inhibitors in DMSO resulting in the 
following final concentrations: 100 μM, 80 μM, 60 μM, 40 μM, 20 μM, 10 μM, 8 μM, 6 
μM, 4 μM, 2 μM, 1 μM, 0.1 μM. Depending on the inhibition activity, sometimes bigger 
and smaller concentrations had to be prepared (1000-0.01 μM). Figure 4.10 shows the 
inhibition profile for the rate of hydrolysis in the presence of different concentrations of 
inhibitor 115 as a representative example. The resulting data were processed with the 
Excel and GraFit program to obtain the kinetic parameters and the IC50 value was 
determined by nonlinear regression analysis. 
The Michaelis constant (Km) for the combination of β-tryptase and the substrate 
Tos-Gly-Pro-Arg-AMC was determined by measuring the reaction rate with different 
substrate concentrations but the same enzyme concentration in the absence of any 
inhibitors by Wich.126 The Km value was obtained as 368 μM. 
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Figure 4.10 Left: Product conversion over time at different concentrations of inhibitor 115. Right: Nonlinear 
regression analysis of the residual enzyme activity versus the inhibitor concentration for the determination 
of the IC50 value. 
 
Enzyme Inhibition Results 
The six peptide ligands with two different sets of arms and the two tetrapeptide ligands 
with four identical arms were tested for the enzyme inhibition. All structures are shown in 
Figure 4.11 and Figure 4.12. The inhibitory activities (in %) of all the ligands was first 
determined at the ligand concentration of 100 µM. All the ligands showed inhibition of 
more than 80 % at this concentration (Table 4.1 and Table 4.2). We then determined the 
IC50 value and from this the Ki value can be evaluated. A 4-parameter equation (9) was 
used to calculate the IC50 values of the inhibitors with the help of GraFit program. 
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x is the concentration of the inhibitor, y is the enzyme activity, Range is the fitted 
uninhibited value minus the Background, and s is a slope factor. The equation assumes 
that y falls with increasing x.  
Since this type of ligands binds to the enzyme noncompetitively (see page 89), IC50 and 
Ki values are identical in this case.261 The Ki values of all ligands are summarized in Table 
4.1 and Table 4.2. 
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Figure 4.11 Structures of the ligands (115-120) with two different sets of arms tested for the enzyme 
inhibition (including short form of the names for easy comparison with the inhibition results). 
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Figure 4.12 Structures of the ligands (124-125) with four identical arms and terminal GCP groups in all 
four arms tested for the enzyme inhibition and the influence of the artificial GCP units (including short form 
of the names for easy comparison with the inhibition results). 
The results of the enzyme screening assay (Table 4.1) clearly showed that the 
tetravalent peptide ligands (115-120) with two different sets of arms based on the 
orthogonally protected lysine scaffold efficiently inhibit β-tryptase. Ligands 115-119 show 
similar enzyme inhibitory potency in a lower micromolar range. The similar Ki values of 
ligands 115 and 117, as well as 116 and 117 revealed that there are no significant 
differences of enzyme inhibitory efficiency upon varying the first amino acid arginine or 
lysine of one pair of arms. Furthermore, most of these combinations of two different arms 
tested so far are not superior to the original best tetravalent peptide ligand (RWKG)4 (Ki = 
0.17 µM) obtained from the initial focused combinatorial library. However, ligand 120 
containing the artificial GCP groups in one set of arms is the most effective ligand in this 
series. This ligand is approximately two orders of magnitude more potent than ligands 
115-119, which consist of similar peptide sequences but without the artificial GCP groups. 
More interestingly ligand 120 is even more efficient than the best original ligand 
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(RWKG)4 as the apparent Ki value of ligand 120 calculated from a monophasic inhibition 
profile is 0.067 μM. Obviously the presence of the GCP group has a significant influence 
on the inhibition properties of this kind of peptide ligands. For example, the comparison 
of ligand 120 with its analogs 115 and 117 revealed that the artificial GCP group can 
significantly improve the inhibition of β-tryptase: replacing the amino acid arginine in 
ligand 115 with the GCP group increases the affinity by a factor of 60 whereas the 
replacement of lysine in ligand 117 with the GCP group increases the affinity by a factor 
of 200. 
Table 4.1 Enzyme inhibitory activities of peptide ligands 115-120 with two different sets of arms at a 
concentration of 100 µM and their corresponding Ki values.  
Ligands Inhibition 
Ki [μM]
 a 
rhSkin β-tryptase Trypsin α-Chymotrypsin 
(RWKG)2(RLFG)2 (115) 94 % 4.04 ± 0.81 > 100 > 100 
(KWKG)2(KLFG)2 (116) 94 % 12.77 ± 3.77 > 100 > 100 
(RWKG)2(KLFG)2 (117) 97 % 13.37 ± 2.45 > 100 > 100 
(RWKG)2(KWKG)2 (118) 98 % 10.37 ± 1.64 > 100 > 100 
(RWKG)2(FRKG)2 (119) 98 % 8.16 ± 1.14 > 100 > 100 
(RWKG)2(GCP-LFG)2 (120) 96 % 0.067 ± 0.024
 b > 100 > 100 
a Ki values were calculated by fitting the inhibition data to a 4-parameter equation. 
b 
Apparent Ki value for a monophasic inhibition profile. The more detailed biphasic analysis 
provides a high and a low affinity binding mode (see Figure 4.13). 
 
Figure 4.13 Biphasic inhibition curve of β-tryptase by inhibitor 120. The plot represents the sum of two 
overlapping sigmoid curves separated by a plateau. The IC50 values for the high affinity (0.056 ± 0.026 μM) 
and low affinity (19.59 ± 2.63 μM) binding processes were estimated by GraFit program. 
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If we take a closer look on the inhibition profile of ligand 120, it is found that the 
behavior of this ligand is even more complex. Instead of fitting well to a monophasic 
inhibition profile, the inhibition data (Figure 4.13) can be fitted best to biphasic 
kinetics,262-263 showing two modes of inhibition with different binding affinities: one with 
high affinity (Ki = 0.056 ± 0.026 μM) and the other one with low affinity (Ki = 19.59 ± 
2.63 μM). The biphasic inhibition profile illustrates the sum of two overlapping sigmoid 
curves which is separated by a plateau. Most likely this reflects the two different sets of 
binding sites on the surface of β-tryptase, with one being favored and the other one being 
less favored. This is consistent with the results identified from the docking study as 
described in Chapter 4.1.1 (Figure 4.3). The two different sets of arms of ligand 120 most 
likely bind to the two different binding sites of β-tryptase with different binding affinities. 
The reason why ligands 115-119 did not show similarly pronounced biphasic kinetics is 
unclear at this moment. Perhaps the binding affinity of ligands 115-119 to the two 
different sets of binding sites on the enzyme is not significantly different enough to lead to 
a biphasic inhibition mode. The artificial GCP group might also play an important role in 
the different inhibition behaviors which is the main difference between these two types of 
ligands. In ligand 120 the presence of GCP groups in one pair of arms instead of the 
proteinogenic amino acids changes the binding affinity to the anionic hot spots of the 
enzyme and differs much from the binding affinity of the other pair of arms. Whereas in 
ligands 115-119 the two different sets of arms contained only proteinogenic amino acids 
which perhaps do not allow discriminating significantly between the two sets of binding 
sites. Since the sequences of the two different arms in ligand 120 are yet to be optimized 
(e.g. using a combinatorial approach), the discovery of even more potent inhibitors based 
on this scaffold is possible. 
Table 4.2 Enzyme inhibitory activities of peptide ligands 124-125 with four identical arms terminated with 
GCP groups at a concentration of 100 µM and their corresponding Ki values. 
Ligands Inhibition 
Ki [μM]
 a 
rhSkin β-tryptase Trypsin α-Chymotrypsin 
(GCP-RWKG)4 (124) 98 % 4.93 ± 0.96 >100 >100 
(GCP-RWK)4 (125) 96 % 10.67 ± 2.27 >100 >100 
a Ki values were calculated by fitting the inhibition data to a 4-parameter equation. 
 
The Ki values in Table 4.2 showed that ligands 124-125 featuring four identical arms 
terminating with GCP groups are also efficient inhibitors of β-tryptase. These two ligands 
show similar inhibitory properties for β-tryptase in a lower micromolar range. Initially, 
glycine as an invariable amino acid was added to the sequence to increase the flexibility 
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and the length of the linker, it was also interesting for us to vary the linker length but with 
exactly the same binding sequence in the arms to test how the linker length would affect 
enzyme inhibition. Hence, ligands 124 and 125 were designed with different linker 
lengths by incorporating the same binding sequence but with or without an additional 
glycine. The presence or absence of glycine has no significant influence on the Ki values, 
as identified by the comparison of ligand 124 with 125, indicating that the tripeptide 
sequence plus the terminal artificial GCP group has the appropriate length to bind to the 
different binding sites on the surface of β-tryptase. 
To obtain a better understanding of the interaction between the inhibitor and the 
enzyme, we then focused on the most potent inhibitor within this series (120), which has 
two different sets of arms and the artificial GCP group, to investigate the enzyme 
selectivity, the reversibility and the enzyme inhibition mode.  
Enzyme Selectivity Assay 
Human β-tryptase is from the family of serine protease but has a unique tetrameric 
structure. However, the other two archetypal serine proteases trypsin and α-chymotrypsin 
have significant sequence similarities with the corresponding β-tryptase monomer. Of the 
245 residues of the tryptase monomer, 162 and 168 amino acid residues are topologically 
equivalent to chymotrypsin and trypsin, respectively, with an rms deviation of the 
α-carbon atoms of only 0.65 Å for both comparisons. Moreover, the active sites of the 
tryptase monomer and trypsin are quite similar in structure to each other. In particular, the 
S1 specificity pocket of tryptase is nearly identical to that of trypsin and it is well suited to 
accommodate P1 arginine and lysine side chains.90 
Therefore, enzyme selectivity was tested against these two archetypal serine proteases 
trypsin and α-chymotrypsin. The enzyme assays with these two enzymes were performed 
in a 50 mM Tris-HCl buffer at pH 8.0, containing 5 mM EDTA and 100 mM NaCl 
according to the literature known procedure.13 Fluorogenic substrates Z-Phe-Arg-AMC 
and Suc-Leu-Tyr-AMC were used for trypsin and α-chymotrypsin, respectively. However, 
our ligands showed no inhibition against either trypsin or α-chymotrypsin even at a 
concentration of 100 μM (Table 4.1 and Table 4.2). Hence the inhibitors seem to have no 
effect on the other two proteases, indicating our synthesized ligands are highly specific for 
β-tryptase compared to other closely related serine proteases. Also, these types of ligands 
might not bind to the active cleavage sites but interact with the entrance to the central pore 
or around the active catalytic center as identified by the docking studies in Chapter 4.1.1. 
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Reversibility of β-Tryptase Inhibition 
The reversible binding between the inhibitors and the enzymes is based on rather weak 
non-covalent interactions and not the formation of chemical bonds or chemical reactions 
between inhibitors and enzymes. Therefore, the inhibitor-enzyme complex can rapidly 
dissociate with the recovery of the enzyme activity compared to an irreversible interaction. 
To verify that the enzyme inhibition in this work is rather caused by a reversible 
interaction than the decomposition of the enzyme, the reversibility of the β-tryptase 
inhibition was tested.  
The first test on reversibility of β-tryptase inhibition was performed in a dialysis 
experiment. The principle of this experiment is that reversible inhibitors can be exchanged 
and washed away by buffer solution, thus the enzyme activity will be recovered over time. 
The Float-A-Lyzer G2 dialysis separation tubes (20 kDa) which contained a mixture (total 
volume of 800 µL) of assay buffer (Tris-HCl, 50 mM, pH 7.4), β-tryptase and inhibitor 
120 in DMSO or pure DMSO (160 µL) as the reference were used. The dialysis tubes 
were floated vertically in the dialysate reservoir containing a stirring bar to adjust the 
stirring rate to form a gentle rotating current. The samples were dialyzed at room 
temperature and with 4 complete buffer changes (every 12 h) over a period of 48 h. The 
activity tests were done from time to time by taking a 100 µL sample from the dialysis 
tube, adding 95 µL assay buffer and the substrate (5 µL, final concentration 50 µM) 
before the mixtures were submitted to a fluorescence assay to determine the residual 
activity of the enzyme. With pure buffer even over a period of 48 h no significant 
recovery of enzyme activity was observed (the enzyme was reactivated only by 2 %). This 
is, however, not too surprising as it is well known that multivalent inhibitors with high 
binding affinity bind to the enzyme so tightly that they sometimes show kinetics similar to 
irreversible inhibitors.264-265 Whereas the binding of a multivalent ligand to its target is 
similar to that of a monovalent ligand, the release of the ligand from the protein (the 
“off-rate”) is extremely slow. This is the main reason for the multivalency effect, 
responsible for the significantly increased binding affinity of multivalent ligands 
compared to monovalent ones.  
Therefore, a second experiment was performed to test the reversibility of enzyme 
inhibition. The inhibitor-enzyme complex was treated with the addition of excess heparin 
(a polyanion as a competing binding substrate for the ligand) in this test. If the inhibition 
is reversible, the cationic inhibitor should prefer to interact with heparin rather than the 
enzyme, which will lead to a recovery of the enzyme activity. In this experiment the 
enzyme was incubated with the inhibitor or blank DMSO in assay buffer (Tris-HCl, 50 
mM, pH 7.4) for 5 minutes. Then in a parallel experiment, either heparin in buffer or 
buffer alone (5 µL) was added to the vials. All the vials were mixed and incubated for 
another 5 minutes, then the substrate was added and the residual activity of the enzyme 
was measured using the standard fluorescence assay.266 16 % recovery of tryptase activity 
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was observed, which confirms that the inhibition of β-tryptase by our tetravalent 
inhibitors is in principle reversible. Also, it indicated that the binding of the inhibitor to 
the enzyme does not damage the active tetrameric structure of β-tryptase. 
Enzyme Inhibition Mode 
The mode of enzyme inhibition was further determined in the following experiments to 
investigate how the inhibitors interact with the enzyme. The modes of inhibition are 
typically classified into three main types: competitive, uncompetitive, and noncompetitive 
inhibition. The theoretical background information of all these types of inhibition is 
described in Chapter 2.1.1. With the help of this determination, it is possible to test if the 
inhibitor binds into the active cleavage sites of the enzyme and where the inhibitor 
interacts with the β-tryptase.  
Therefore, the rate of the enzyme reaction was measured at different substrate 
concentrations (10-600 μM) but always with a fixed enzyme concentration for different 
inhibitor concentrations (0, 5, 10 and 100 μM). The type of the inhibition was determined 
by interpretation of the nonlinear regression fits (Figure 4.14) as well as the linear 
Lineweaver-Burk plots (Figure 4.15). The analyses of both plots clearly indicate that the 
enzyme inhibition is noncompetitive. In the nonlinear representation, the maximum 
reaction velocity (Vmax) is different for different inhibitor concentrations even at high 
substrate concentrations. In contrast, for competitive inhibition, increasing the substrate 
concentration would lead to the same maximum velocity independent of the inhibitor 
concentration. Furthermore, the half maximum reaction rate in each case is reached at 
similar substrate concentrations independent of the present amount of inhibitor, which 
confirms that the Km value of the substrate is constant in the presence of different inhibitor 
concentrations. All the information is an indication for a noncompetitive inhibition. 
Moreover, the double-reciprocal Lineweaver-Burk representation shows that the plots for 
different inhibitor concentrations have no common interception on the y-axis which 
would be a sign for competitive inhibition. But they have a common intersection on the 
x-axis which indicates a noncompetitive inhibition. Hence, with the help of these 
experiments it is possible to prove that our tetravalent inhibitors do not compete with the 
substrate for the same binding site (active cleavage sites) and hence most likely interact 
with the surface of the enzyme. Therefore, these types of synthesized tetravalent ligands 
with tailor-made binding motifs are the reversible and noncompetitive inhibitors of 
β-tryptase. 
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Figure 4.14 Nonlinear representation of reaction velocity against total substrate concentration according to 
the Michaelis-Menten equation. With increasing inhibitor (120) concentration, the Km values are constant 
but the maximum reaction velocity decreases even for high substrate concentration which indicates 
noncompetitive inhibition. 
 
Figure 4.15 Lineweaver-Burk plots of 1/v against 1/[S] for inhibitor 120. The plots at different inhibitor 
concentrations have a common intersection on the x-axis but not on the y-axis, which again indicates a 
noncompetitive inhibition. 
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4.1.5 Molecular Modeling Studies 
The findings in the above chapters led to the most likely conclusion that the inhibitor 
rather blocks the accessibility to the active sites than binding directly to the active 
catalytic sites buried inside of the tryptase. To further verify how the inhibitor might 
inhibit β-tryptase, force field calculations were used to visualize possible binding modes 
between the inhibitor and β-tryptase. The central pore of β-tryptase features many 
negatively charged amino acid residues such as aspartic acids or glutamic acids and the 
synthesised inhibitors bear complementary charged amino acids in their side chains such 
as the basic lysine, arginine and the artificial GCP groups. Thereby most likely the 
calculations should demonstrate the ability of such inhibitors blocking the acidic pore of 
β-tryptase by building salt bridges via electrostatic interaction and hydrogen bonding. The 
calculations were performed by Wilhelm Sicking in our working group using the software 
Schrödinger MacroModel Version 9.6 with the optimized potential for liquid simulation 
(OPLS) 2005 force field choosing water as solvent. The enzyme input is based on the 
reported crystal structure of β-tryptase from the RCSB Protein Data Bank (PDB code: 
1A0L). All water molecules and substrates within the PDB crystal structure were removed 
from the binding pore. 
In order to start the calculation a start conformation of the inhibitor connecting to the 
acidic pore of β-tryptase was chosen. The structure of the enzyme was retained during the 
conformational search while the inhibitor was flexible. Therefore, the calculations began 
at the potential energy of the start conformation and by simulating new conformations a 
minimal potential was searched. The resulting structure was obtained from the result of 
1000 calculation cycles. 
The calculated binding mode of inhibitor 120 to the surface of β-tryptase is shown in 
Figure 4.16. A cluster of acidic amino acids accumulates at the entrance to the central pore 
and around the active cleavage sites of β-tryptase and thus attracts the basic amino acids 
of the inhibitor. The four arms of the inhibitor 120 can bind to these anionic residues 
around the entrance to the central pore via complementary electrostatic interactions and 
thus spread out across the pore of the enzyme, blocking the access of the substrate to the 
active cleavage sites.  
Ribbon cartoon of the crystal structure of β-tryptase showed more clearly how the 
inhibitor binds to the central pore of the enzyme (Figure 4.17). The four monomers of the 
β-tryptase are named A, B, C and D. Key residues that interact with the inhibitor are 
displayed as sticks and numbered according to the protein sequence and monomers, 
respectively. The calculations reveal a number of key interactions for this inhibitor 
binding to the entrance of the central pore. Namely, the inhibitor is bound to the surface of 
β-tryptase by 14 hydrogen bonds. The side chains of arginine and lysine from one arm of 
the ligand bind to the interface of two monomers (A and D) of the enzyme mainly through 
the electrostatic interactions with Asp-145A, Asp-147A and Glu-149A. The lysine side 
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chain from the other arm of the ligand can bind to the interface area of the other two 
monomers (B and C) of β-tryptase by interacting with Glu-149C while the guanidinium 
group from the side chain of arginine forms a hydrogen bonded ion pair with Asp-145C 
from monomer C. Two GCP groups from the other two set of arms form 
hydrogen-bonding networks with Glu-217C and Gln-221C, Glu-217A and Asp-60B, 
respectively.  
Figure 4.18 illustrates the schematic representation of the interactions between the 
ligand and the residues around the entrance to the central pore of β-tryptase. Only two 
different arms of the ligand are shown according to the symmetry of the molecule. As 
shown clearly, the basic arms of the ligand can indeed interact with the glutamic acids and 
the aspartic acids around the anionic hot spots of the enzyme. Note that one guanidinio 
group of GCP can form ion pairs with two residues of the enzyme at the same time. These 
modeling results agree very well with the findings from the docking studies (Figure 4.3) 
which showed that the two interfaces between the two sets of monomers within the 
tetramer are favored binding sites for this type of ligands. Therefore, the modeling also 
confirms that tetravalent peptide inhibitors with two different sets of arms can bind to the 
entrance to the central pore of β-tryptase as required for blocking access of substrate to 
the active sites of the enzyme. 
 
Figure 4.16 Calculated structure of a possible binding mode of the inhibitor 120 (shown as spheres with 
carbon atoms colored cyan) to the surface of β-tryptase (PDB code: 1A0L). Nonpolar hydrogens of the 
inhibitor were removed for clarity. The colors indicate positive (blue) and negative (red) electrostatic 
potential on the molecular surface of β-tryptase. A cluster of acidic amino acids is centered on the entrance 
to the central pore in which the active sites are buried. The inhibitor interacts with these acidic residues and 
spans over the central pore, thus blocking the access to the active sites. 
RESULTS AND DISCUSSIONS 
93 
 
 
Figure 4.17 A close-up view of the binding region on the surface of β-tryptase. Inhibitor 120 is shown as 
sticks with carbon atoms colored cyan. The four monomers of the enzyme are named A, B, C and D. Key 
residues that interact with the inhibitor are displayed as sticks (carbon atoms colored yellow) and numbered 
according to the protein sequence and monomers, respectively. Binding interactions in the enzyme-inhibitor 
complex are shown as black dashed lines. 
 
Figure 4.18 Schematic representation of the interaction between the ligand and the protein residues. Only 
two different arms of the inhibitor are shown according to the symmetry of the molecule. Non-polar 
hydrogen atoms have been omitted. The hydrogen bonds are presented as black dashed lines. 
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In conclusion, the first part of this thesis focused on the synthesis and evaluation of a 
series of tetravalent ligands featuring two different sets of arms and also containing the 
artificial arginine analog GCP as a tailor-made binding motif. Tetravalent ligands with 
four identical arms with the terminal GCP group were also investigated. They can bind to 
anionic hotspots on the surface of the enzyme near the entrance to the central pore, 
blocking the access to the active sites and thus inhibit β-tryptase in a reversible and 
noncompetitive way. All ligands efficiently inhibit β-tryptase with lower micromolar to 
nanomolar affinity and are highly selectivity for tryptase against other related serine 
proteases (e.g. trypsin, α-chymotrypsin). In collaboration with the group of Prof. D. 
Hoffmann and with the help of W. Sicking, we could demonstrate by docking studies and 
force field calculations that inhibition is most likely based on the complementary 
electrostatic interactions between the positively charged amino acids of the four-armed 
ligands and two kinds of favored anionic binding sites of the enzyme situated at the 
monomer-monomer interface (more favored) and around the active sites (less favored). 
The inhibition data show that the terminal artificial GCP groups can significantly improve 
the enzyme inhibitory activity compared to analogous ligands with only proteinogenic 
amino acids. The tripeptide arm plus the terminal GCP group on the lysine dedrimer 
scaffold is demonstrated to provide the appropriate length to bind to the different binding 
sites on the surface of the enzyme. Hence, we do not only demonstrate that multivalent 
ligands which can bind to the surface of the enzyme are efficient inhibitors but also that 
the design of tailor-made binding sites for specific amino acid residues is an attractive 
strategy for the design of high-affinity inhibitors. Because the peptide arms and the 
scaffolds are yet to be optimized, the discovery of more potent inhibitors by the 
combination of different peptide arms and scaffolds should be possible by using a 
dynamic combinatorial approach. Such an approach will be used to identify more efficient 
inhibitors of β-tryptase in the next chapter. 
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4.2 Discovery of Potent Inhibitors of Human β-Tryptase from Dynamic 
Combinatorial Libraries 
We have successfully utilized the lysine dendrimer as scaffold for designing the 
tetravalent peptide ligands as the inhibitors of β-tryptase. It is also interesting for us to test 
other scaffold to build up the multivalent inhibitors, e.g. the scaffolds with various linker 
lengths, core flexibilities and functionalities. It has been demonstrated by the previous 
findings and the statistical analysis that the combinations of the cationic and aromatic 
amino acids in the binding arms provided the most efficient inhibitors of β-tryptase. More 
interestingly the artificial GCP group is demonstrated to have a beneficial effect on 
tryptase inhibition. Thus it is also interesting to utilize different potent combinations of 
the amino acid sequences and the artificial GCP group to provide the binding elements for 
inhibiting the enzyme. Therefore, in this project we describe a dynamic combinatorial 
approach to the discovery of new and potent inhibitors of β-tryptase with the help of 
dynamic deconvolution strategy. By using this approach it is possible to study various 
combinations of binding sequences and scaffolds for their inhibitory properties and hence 
to discover the efficient inhibitors of β-tryptase with less effort. 
4.2.1 Design of Dynamic Combinatorial Libraries 
As described in Chapter 2.5, the reversible acyl hydrazone formation by hydrazides 
and aldehydes in acidic aqueous media has been proven to be a highly suitable reaction 
for generating DCLs. Acyl hydrazone libraries are compatible with a wide range of 
solvents and functional groups. For example, the hydrazide functionality can be attached 
to the recognition elements and the aldehyde functionality can be reserved as the 
structural scaffolds (vice versa), leading to the formation of the multivalent ligands.  
In this project, the dynamic combinatorial libraries were generated from the assembly 
of a series of peptide-derived hydrazide and aldehyde building blocks. In order to inhibit 
β-tryptase, the peptide sequences which have the capability of interacting with the enzyme 
were attached to the hydrazide moiety to form the peptide-derived hydrazides. The 
aldehyde building blocks were used as scaffolds to arrange the binding components in a 
given geometry and to provide the multivalent interactions. The aldehydes feature two or 
three aldehyde groups with various spacer distance and core rigidity to determine how 
these factors influence the inhibitory properties. 
To identify the active compounds from such acyl hydrazone based DCLs, a dynamic 
deconvolution protocol was utilized.225-227 The pre-equilibrated full library containing all 
the building blocks was prepared in the absence of the enzyme as well as different 
sub-libraries in which one specific building block is missing. By comparing the enzyme 
screening results for the full library with sub-libraries, the active building blocks can be 
selected from the libraries. 
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Design and Syntheses of Peptide-Derived Hydrazides 
In order to use the Fmoc SPPS strategy to synthesize the peptide-derived hydrazides, 
the hydrazine should be modified with a dicarboxylic acid on one side to provide the 
hydrazide with one free carboxylate group to couple with the amino groups on the 
growing peptide arms. Therefore, the general strategy for this synthesis employed here 
was adapted from the literature with some modifications.267-268 The synthesis (Scheme 4.4) 
started with commercially available hydrazine monohydrate (130) which was reacted with 
Boc anhydride (Boc2O) to get the Boc-protected hydrazine (131). This compound was 
then reacted with succinic anhydride in water to give compound 132. The reaction 
proceeded cleanly, and full conversion to 132 was confirmed by ESI-MS. The reaction 
mixture was lyophilized to obtain 132 which can be used in Fmoc SPPS without any 
further purification. 
 
Scheme 4.4 Synthesis of the Boc protected butanedionic monohydrazide (132). 
As depicted in Figure 4.19, the general design of the peptide-derived hydrazides (133) 
was to attach the various peptide sequences to the butanedionic monohydrazide part. The 
peptide chains are designed as the binding arms for β-tryptase. It has been demonstrated 
in the previous work that the combinations of cationic and aromatic amino acids in the 
peptide arms provide the highest affinity to inhibit β-tryptase whereas the introduction of 
anionic amino acids in their arms showed weak or no inhibition of β-tryptase. For 
example, Wich demonstrated that the best ligands (RWKG)4 and (KWKG)4 obtained from 
the screening results of the focused combinatorial library combined the positively charged 
and aromatic amino acids in their arms and showed efficient inhibition of the enzyme.13 
Therefore, in order to efficiently inhibit the enzyme, the same peptide sequences GKWR 
and GKWK were now chosen for the binding arms. I could also already confirm that the 
arginine analog GCP group has a beneficial effect on tryptase binding and inhibition. 
Therefore, this artificial GCP group was also incorporated into the peptide arm GKWK by 
attaching it to the different lysine side chains in the arm to test its influences on the 
inhibition of β-tryptase compared to the related natural peptide sequence GKWK. 
Furthermore, for comparison the negatively charged glutamic acid was introduced into 
one peptide arm as a negative control as the negative charge in the peptide chain is 
unfavorable for the inhibition of β-tryptase.  
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Figure 4.19 Schematic representation of the peptide-derived hydrazides (133) with variations on the peptide 
sequences for enzyme inhibition. The three positions on the peptide sequence are varied with cationic and 
aromatic amino acids, as well as the artificial GCP moiety. 
Based on this design, the first peptide-derived hydrazide 135 was synthesized on the 
Rink amide MBHA resin using a microwave-assisted Fmoc SPPS procedure (see Chapter 
4.1.3) as shown in Scheme 4.5. Because the resin was newly bought, so the loading value 
had to be tested before use. The determined loading value is 0.84 mmol/g, which is a bit 
higher than the resin used before (0.67 mmol/g). This is not hard to understand because 
the loading value of the resin that has been stored for a long time always decreases due to 
the adsorption of moisture or the damage of the resin beads. All the coupling and Fmoc 
deprotection steps were carried out under argon atmosphere. The resin was at first swollen 
in DCM for 2 h, followed by the Fmoc deprotection by treating the resin twice with 20 % 
piperidine/DMF under the standard microwave irradiation condition (20 W, Tmax = 60 °C, 
ΔT = ± 5 °C, 1.5 + 5 min). Then the resin was thoroughly washed with DMF and the 
liberation of the free amino groups was confirmed by a positive Kaiser test. The first 
amino acid Fmoc-Arg(Pbf)-OH (3 eq) was attached to the resin with the help of the 
coupling reagent PyBOP (3 eq) and the base DIPEA (6 eq) in DMF by microwave 
irradiation for 20 min (20 W, Tmax = 60 °C, ΔT = ± 5 °C). Then this coupling was repeated 
to ensure a complete reaction of all accessible amino groups on the resin. The successful 
quantitative coupling reactions were confirmed by a negative Kaiser test. Then after the 
Fmoc deprotection, the next three amino acids: Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, 
Fmoc-Gly-OH and the Boc-butanedionic monohydrazide (132) were attached in the same 
manner. All the completion of the coupling steps were verified with the Kaiser test. If 
necessary, the coupling steps were repeated. Then the resin was thoroughly washed with 3 
× DCM, 3 × MeOH, 3 × DCM and dried under vacuum for 1 h. To cleave the peptide, the 
resin was transferred to a glass peptide synthesis vessel and the product was cleaved from 
the resin by using a mixture of TFA/H2O/TIS (95:2.5:2.5) for 3 h. Under these acidic 
conditions, all side-chain protecting groups were simultaneously removed. After 
precipitation from diethyl ether, the crude product was purified by RP18-MPLC using 
appropriate conditions (H2O/MeOH + 0.1 % TFA). After the purification steps, the 
product was obtained with a purity of 99 % according to analytical HPLC analysis. Pure 
product was then transferred into its hydrochloride salt by dissolving it in water with 
hydrochloric acid and lyophilizing several times.  
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Scheme 4.5 Microwave-assisted Fmoc SPPS procedure for the peptide-derived hydrazide 135. 
The second peptide-derived hydrazide 136 was prepared according to the similar 
synthetic route of 135. This compound 136 (Figure 4.20) contains the peptide sequence 
GKWK instead GKWR in hydrazide 135. After the cleavage and purification steps, the 
product was obtained with 98 % purity according to analytical HPLC analysis.  
 
Figure 4.20 The peptide-derived hydrazide 136 was also prepared by using microwave-assisted SPPS. 
The peptide-derived hydrazide 138 (Scheme 4.6) was synthesized under similar 
conditions as described for 135. The Rink amide MBHA resin was swollen in DCM for 2 
h, followed by the Fmoc deprotection by using 20 % piperidine/DMF. Then the first 
amino acid Fmoc-Lys(Alloc)-OH was attached to the resin with the help of PyBOP and 
DIPEA. Afterwards the three amino acids: Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, 
Fmoc-Gly-OH and Boc-butanedionic monohydrazide (132) were attached to the resin 
accordingly. Then the Alloc protecting group was removed with Pd(PPh3)4 (0.1 eq) in the 
presence of PhSiH3 (24 eq) in DCM for 10 min (20 W, Tmax = 30 °C, ΔT = ± 5 °C). After 
washing with DCM and DMF, the Boc protected GCP unit (111) was attached to the 
lysine side chain by using the coupling reagent PyBOP and the base DIPEA. After the 
washing cycle, the product was cleaved from the resin using a mixture of TFA/H2O/TIS 
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(95:2.5:2.5) for 3 h. After the purification and the counterion exchange steps, the product 
was obtained with 96 % purity according to the analytical HPLC analysis. 
 
Scheme 4.6 Microwave-assisted Fmoc SPPS procedure of peptide-derived hydrazide 138. 
According to a similar synthetic route as depicted for 138 the peptide-derived 
hydrazide 139 (Figure 4.21) was prepared. Hydrazide 139 contains the same amino acid 
sequence GKWK and the artificial GCP group but featuring the GCP group at a different 
position. Hydrazide 139 was obtianed with a purity of 95 % as determined by analytical 
HPLC analysis. For comparison the peptide-derived hydrazide 140 with the peptide 
sequence GAFE was designed as a negative contol for the inhibition of β-tryptase. 
Hydrazide 140 was prepared according to the synthetic route as described for 135. The 
product was obtained with a purity of 91 % according to analytical HPLC analysis. 
 
Figure 4.21 The hydrazides 139 and 140 were also prepared with the help of microwave-assisted SPPS.  
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4.2.2 Generation of Dynamic Combinatorial Libraries (DCLs) 
The previous section has already described the design and synthesis of five different 
peptide-derived hydrazides (135-136, 138-140) used in this project. Five different di- and 
tri-aldehydes (A-E) used here were commercially available. All the structures of these ten 
building blocks are depicted in Figure 4.22.  
 
Figure 4.22 Structures of peptide-derived hydrazides (including short names of the peptide arms for easy 
comparison with the inhibition results) and aldehydes chosen as the building blocks of the DCLs. The 
headgroups of hydrazides and aldehydes which are subjected to the formation of the corresponding acyl 
hydrazones (colored purple) are colored red and blue, respectively. The structures of five quasi-peptide 
subunits are abbreviated as R with related numbers (R1-R5). 
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The IC50 values of all the ten building blocks were measured first to see how they 
alone can inhibit β-tryptase according to the described procedure in Chapter 4.1.4. As 
shown in Table 4.3, the four peptide-derived hydrazides (135-136, 138-139) show some 
inhibitory activities for β-tryptase with IC50 values only in micromolar range. Hydrazide 
135 containing the best peptide sequence GKWR from the previous combinatorial library 
shows the most efficient inhibition of the enzyme among all the five hydrazides. IC50 
values of the two hydrazides (138-139) containing GCP groups are a bit lower than 
hydrazide 136 which consists of the same peptide sequence but with no GCP group 
attaching to the lysine side chain. As expected, hydrazide 140 with the negatively charged 
peptide arm shows no inhibition of the enzyme even at a high concentration of 1 mM. 
Moreover, all the aldehydes show no inhibition even at a very high concentration of 10 
mM. Therefore, the aldehydes should rather provide the structural scaffold to build up the 
multivalent ligands than contribute to the enzyme inhibition.  
Table 4.3 IC50 values [µM] for β-tryptase of the hydrazides and aldehydes used in the DCLs. 
Hydrazides IC50 [µM] Aldehydes IC50 [µM] 
135 12.65 ± 0.61 A > 10000 
136 61.05 ± 3.97 B > 10000 
138 23.58 ± 1.17 C > 10000 
139 24.50 ± 2.87 D  > 10000 
140 > 1000 E > 10000 
 
As described above, in order to identify the potent inhibitors from the libraries, a 
dynamic deconvolution strategy was utilized.225-227 By removing a specific building block 
from the full library (containing all the ten building blocks), each sub-library can be built 
up, thus the importance of this missing component to form active compounds can be 
tested by comparing the activity of sub-library to that of the full library. 
The maximum non-symmetrical library size N can be calculated by equation 10,225 
where n is the number of hydrazide and mp is the number of aldehyde with different 
functionality degree p (e.g. p = 2 for di-aldehyde and p = 3 for tri-aldehyde). The library 
resulting from five hydrazides (n = 5), four di-aldehydes (m2 = 4) and one tri-aldehyde 
(m3 = 1) would contain 225 possible constituents (assuming all the aldehyde groups are 
reacted to form acyl hydrazones, not counting partially formed species). 
𝑁 = ∑  𝑚𝑝𝑛
𝑝 𝑝                           (10) 
However, since all the di- or tri-aldehydes are symmetrical, some of the combinations 
with hydrazides are identical, thus to remove the repetitive numbers the library size 
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number is reduced to Nsym, which is the symmetrical library not considering combination 
orders (equation 11).  
𝑁𝑠𝑦𝑚 = ∑  [
𝑚𝑝
𝑝!
∏ (𝑛 + 𝑖)𝑝−1𝑖=0 ]𝑝                   (11) 
Therefore, on accounting for this symmetry effects, the full library number is reduced 
to contain 95 different library members. Upon the sub-libraries, the library sizes reduced 
differently depending on the removal of hydrazide or aldehyde with different functionality 
degree. For example, the library number reduced to 60 by removing one hydrazide 
whereas it reduced to 80 or 60 respectively by the removal of the di-aldehyde or 
tri-aldehyde. Thus, approximately 37 % or 16 % of the library constituents can be 
removed simultaneously from the full library by the removal of one component. Dynamic 
deconvolution strategy therefore provides a rapid way to identify the important 
components required for the activity of the library constituents. 
In order to test the appropriate conditions for generating the DCLs, initial control 
experiment with one test library containing one hydrazide 136 and one aldehyde E was 
performed in 100 mM sodium acetate buffer at pH 4.0, upon agitation overnight. The 
resulting mixture was evaluated by analytical HPLC and electrospray ionization mass 
spectroscopy (ESI-MS). The HPLC runs (Figure 4.23) showed that at this conditions, this 
type of hydrazide and aldehyde do form a new compound. The ESI-MS verified that the 
new compound is the trivalent acyl hydrazone by assembly of hydrazide 136 and 
tri-aldehyde E. Thus, this condition can be used for the generation of DCLs. 
Therefore, the dynamic libraries can be easily generated in sodium acetate buffer 
solutions at pH 4.0 containing 10 % DMSO (v/v) to help dissolve the aromatic aldehydes 
and the acyl hydrazones, upon gently agitation for three days. Normally the generation of 
acyl hydrazone libraries can be accomplished within a few minutes to a couple of hours, 
depending on the combination of hydrazide and aldehyde as well as the pH of the solution 
(e.g. a lower pH results in a faster reaction). However, in our case, to ensure the complete 
reaction, the reaction mixture was agitated for three days. Longer reaction times (five and 
ten days) were also tested, but did not show any different results, indicating the 
equilibration is complete after three days. The formation of acyl hydrazones was 
monitored by analytical HPLC and ESI-MS. 
The full library was prepared by mixing all the ten building blocks (five hydrazides 
and five aldehydes) together in an aqueous acetate buffer solution (10 % DMSO) at room 
temperature. At the same time, 10 sub-libraries were generated under the same conditions 
by mixing all components except that one specific building block was omitted and 
replaced by the blank acetate buffer solution containing 10 % DMSO. Equilibration of all 
the libraries was carried out in the absence of the enzyme. The concentration of the 
hydrazide or aldehyde group of each building block was kept the same, e.g. stock 
solutions of the building blocks were prepared with 1 mM for monofunctional hydrazides, 
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0.5 mM for di-aldehydes and 0.33 mM for tri-aldehyde. The final concentration of the 
libraries amounted to 0.5 mM in total for both hydrazide and aldehyde groups. Together 
with a reference sample (acetate buffer containing 10 % DMSO) without any building 
blocks, this series of 12 samples was sufficient to screen the complete 95-membered 
library. After the resulting library mixtures were equilibrated for three days to ensure a 
complete equilibrium, the resulting acyl hydrazone libraries were adjusted to 
physiological conditions (pH 7.4) freezing-out the library composition. The libraries were 
then subsequently tested for inhibitory activity in the presence of β-tryptase. 
 
 
 
Figure 4.23 Analytical HPLC runs of peptide-derived hydrazide 136 (top), tri-aldehyde E (middle) and the 
resulting mixture with the formation of new acyl hydrazone (bottom). 
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4.2.3 Screening of DCLs by Dynamic Deconvolution Procedure 
After the complete equilibration of all the libraries, the subsequent enzyme screening 
was performed under physiological conditions. The active inhibitors can then be identified 
by comparing the screening results of the ten sub-libraries with the full library. The 
decrease in inhibitory effect or the increase in enzyme activity would indicate the absence 
of important components for generating efficient inhibitors of β-tryptase. Inhibition 
experiments were performed in white 96 well microplate via a high throughput assay 
using a fluorescence spectrophotometer. The heparin-stabilized human rhSkin β-tryptase 
and the substrate Tos-Gly-Pro-Arg-AMC were used for the enzyme assay. All screening 
measurements of DCLs were performed in 50 mM Tris-HCl buffer solution at pH 7.4, 
containing enzyme stabilizer heparin, together with NaCl and Triton-X. In the enzyme 
screening measurement (at 25 oC), 10 μL of β-tryptase was added to 180 μL Tris-HCl 
buffer, in which the enzyme was incubated with various equilibrated library mixtures (5 
µL) and finally the substrate (5 µL, final concentration 50 µM) was added. The solutions 
were thoroughly mixed and the rate of hydrolysis of the AMC substrate was determined 
by monitoring the fluorescence change at 460 nm for 15 min. Due to the high 
concentration of the initial libraries (the total concentration of hydrazides is 0.5 mM in the 
full library), the DCLs were diluted 5 to 50 times with acetate buffer solution containing 
10 % DMSO accordingly for the enzyme assay in order to significantly discriminate the 
inhibitory potency among all the libraries. Thus, total concentrations of hydrazides in the 
full library were tested from 10 to 100 μM, resulting in the final hydrazide concentration 
of the full library from 0.25 to 2.5 μM in the enzyme screening mixtures. However, the 
dilution should not be too high or too low depending on the overall inhibition of the 
libraries. The overall inhibition of the full library should be approximately 60 %-90 % to 
ensure the optimal observable effects. 
To identify the active components in the libraries, the dynamic deconvolution process 
was utilized. The enzyme screening results obtained from these libraries are shown in 
Figure 4.24, where the relative activities of the sub-libraries were normalized, compared 
to the full library. The full library tested here with final total concentration of hydrazides 
at 1.25 μM showed an inhibitory effect of 62 %. The inhibition of the enzyme activity by 
this library reveals the presence of at least one or more active species that are potent 
β-tryptase inhibitors in a given equilibrated library mixture. By determining the enzyme 
inhibitory effects of sub-libraries in which one individual building block each is missing, 
an increase in enzyme activity of the sub-libraries compared to full library indicates that 
the removed component has a significant contribution to the inhibitory effect, whereas a 
decrease in enzyme activity reveals that the omitted component hampered the inhibitory 
effect of more active species in the library mixture.  
The data in Figure 4.24 clearly showed that several active components were present in 
this library. As expected, the recognition building blocks, hydrazides (135-136, 138-139) 
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featuring peptide sequences with the combination of the basic and aromatic amino acids 
are necessary for the inhibition to occur. Hydrazide 138 (GKWK(GCP)) is the most active 
building block among all the five hydrazides. By removing 138 from the full library, the 
enzyme activity is restored by 47 % relative to the full library. Hydrazides 135 (GKWR) 
and 136 (GKWK) are less but similarly active with the restoration of enzyme activity of 
ca. 20-25 %. Hydrazide 139 (GK(GCP)WK) is the least active one in this set of positively 
charged peptide hydrazides with a recovery of 13 % enzyme activity. These results 
indicate that the artificial GCP group has significant influence on the inhibitory potency in 
either way (compare 136 with 138 and 139). It can significantly increase the enzyme 
inhibitory activity compared to analogous peptide chain solely based on proteinogenic 
amino acids (compare 136 and 138). However, this effect can be weakened depending on 
the position of the GCP group in the peptide chain (compare 138 and 139). The removal 
of the negatively charged 140 (GAFE) from the full library slightly decreases the enzyme 
activity, indicating hydrazones containing the negatively charged peptide hydrazide are 
not necessary for the enzyme inhibition.  
Similarly, for the scaffold building blocks, tri-aldehyde E is the most important 
component for providing multivalent ligands for the inhibition. Its removal restores 18 % 
of enzyme activity compared to the full library. Smaller effects were observed for the 
di-aldehydes B-D (ca. 5-10 % recovery) while A is the least active scaffold (nearly no 
recovery of the enzyme activity).  
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Figure 4.24 Dynamic deconvolution of dynamic combinatorial libraries of acyl hydrazones: DCL 
containing five peptide-derived hydrazide and five aldehyde building blocks, with normalized relative 
enzyme activity of all sub-libraries, compared to the full library. The individual columns represent the 
sub-libraries each lacking the specific building block below the column. The final total concentration of 
hydrazides in the full library is 1.25 μM. The y error bars represent the standard deviation.  
To further investigate the individual effects of the aldehyde scaffolds, a second 
size-reduced library containing all the aldehydes (A-E) but only the most active hydrazide 
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138 was generated and analyzed in the same way. The size of this full library is reduced to 
five different acyl hydrazones (not counting the partially formed species). Six 
sub-libraries were prepared accordingly by removing one specific building block. All 
libraries were then subjected to the enzyme assays. Different dilutions (10 and 50 times) 
of the libraries were used for enzyme inhibition. The full library was first tested with the 
same concentration of hydrazides at 1.25 μM in the screening mixture, resulting in an 
inhibitory effect of 95 %. It is not surprising that the inhibitory effect is much higher than 
the first library containing all the five hydrazides (62 %) due to the replacement of the less 
active building blocks by the more efficient one. In order to better discriminate the 
efficiencies of these scaffolds, libraries with lower concentration (hydrazides 
concentration at 0.25 μM) were analyzed as well, showing approximately 52 % enzyme 
inhibition. The results in Figure 4.25 revealed that the aromatic and rigid scaffolds E and 
C are the most active building blocks for active inhibitors: tri-aldehyde E is the most 
active scaffold (ca. 30 % recovery) in the library, followed by di-aldehyde C with a bit 
smaller effect (ca. 16 % recovery). Furthermore, the results showed that the removal of 
component 138 leads to full recovery of the enzyme activity relative to the full library, 
confirming that the aldehydes themselves have no inhibitory effects. This result is also 
confirmed by the enzyme inhibition measurement of the individual aldehydes which 
showed no inhibition even at a concentration of 10 mM (Table 4.3). Hence, the aldehydes 
only provide the structural scaffold to build up the multivalent inhibitors but they do not 
contribute to the enzyme inhibition. Therefore, building blocks 135-136, 138-139 as well 
as E and C are the most active components in this library. Consequently, the most active 
constituents are likely to be formed from the assembly of these hydrazides and aldehydes. 
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Figure 4.25 Dynamic deconvolution of dynamic combinatorial libraries of acyl hydrazones: DCL 
containing one peptide-derived hydrazide (138) and all five aldehyde building blocks, with normalized 
relative enzyme activity of all sub-libraries, compared to the full library. The individual columns represent 
the sub-libraries each lacking the specific building block below the column. The final total concentration of 
hydrazides in the full library is 0.25 μM. The y error bars represent the standard deviation. 
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4.2.4 Further Evaluation of Selected Species from DCLs 
As soon as the active components were identified with the dynamic deconvolution 
process, a more detailed study of the inhibitory properties was performed. To this aim, a 
set of representative library members (Figure 4.26) based on these two scaffolds E and C 
were separately synthesized by the combination of the active hydrazides and aldehydes 
selected from the libraries to further identify their enzyme binding affinity and the 
inhibition mechanism for β-tryptase.  
 
Figure 4.26 Schematic representation of individual acyl hydrazones 141-149. Substituents R1-R5 represent 
the peptide subunits of the hydrazides (see Figure 4.22). 
Syntheses of Acyl Hydrazones 
The acyl hydrazone 141 was synthesized from peptide-derived hydrazide 135 (3.5 eq) 
and tri-aldehyde E (1 eq) with slightly excess of hydrazide compared to the amount of the 
aldehyde headgroups (Scheme 4.7). The hydrazide and aldehyde were dissolved in MeOH 
and the reaction mixture was refluxed overnight under Ar atmosphere. After the solvent 
was removed, the crude product was purified by RP18-MPLC using appropriate 
conditions (MeOH/H2O + 0.1 % TFA). Pure product was transferred into its 
hydrochloride salt by dissolving it in water with hydrochloric acid and lyophilizing 
several times. The product was obtained as white solids with 93 % purity according to 
analytical HPLC analysis. The acyl hydrazones 141-149 were synthesized according to 
similar procedures. 
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Scheme 4.7 Synthesis of individual acyl hydrazone 141 by assembly of active hydrazide 135 and 
tri-aldehyde E in solution. 
All structures of acyl hydrazones 141-149 based on the tri-aldehyde E and di-aldehyde 
C are shown in Figure 4.27 and Figure 4.28, respectively. Compounds 141-144 were 
synthesized by the combination of the active hydrazides 135-136, 138-139 and 
tri-aldehyde E to further identify their inhibitory properties to β-tryptase. The acyl 
hydrazone 145 was synthesized from the assembly of inactive hydrazide 140 and the 
tri-aldehyde E to further verify the screening results of the DCLs. 
 
Figure 4.27 Structures of acyl hydrazones (141-145) based on the active tri-aldehyde scaffold E. 
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Compounds 146-148 were synthesized by the combination of active hydrazides 135, 
136, 138 and di-aldehyde C to study the inhibitory properties and compare with the 
compounds derived from tri-aldehyde E. Due to the reversibility of the interconverting 
library constituents, the homo- and hetero- library members should exist simultaneously. 
Therefore, the heterodimeric compound 149 containing two different active hydrazides 
135 and 138 was also synthesized to investigate the inhibitory activity compared to the 
homodimeric species 146 and 148 which contain only hydrazide 135 or 138. The resulting 
acyl hydrazones were then subjected to independent enzyme assays to investigate their 
inhibitory properties. 
Figure 4.28 Structures of acyl hydrazones (146-149) based on the active di-aldehyde scaffold C.  
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Enzyme Inhibition Assay 
As described in Chapter 4.1.4, in order to measure the kinetic parameters the 
hydrolysis of substrate Tos-Gly-Pro-Arg-AMC by rhSkin β-tryptase was determined using 
a fluorescence spectrophotometer. The enzyme assays were performed in white 96 well 
microplate in 50 mM Tris-HCl buffer at pH 7.4. The rate of hydrolysis in the presence of 
different concentrations of acyl hydrazones were measured at appropriate enzyme 
concentration and fixed substrate concentration (50 μM).  
The inhibition data for the interaction of acyl hydrazones and β-tryptase are 
summarized in Table 4.4. Due to the fact that for this type of compounds the Ki and IC50 
values are the same (see page 114), only the Ki values are displayed in the following table. 
The results showed that the compounds 141-143, 146-148 derived from the combination 
of the most active hydrazides 135-136, 138 and the aldehydes E or C have Ki values in 
the lower nanomolar range and are highly efficient inhibitors of β-tryptase. Compounds 
143 and 148 containing the peptide sequence GKWK(GCP) with the artificial GCP 
groups are approximately 5 times more efficient than 142 and 147, respectively, which 
consist of the same peptide sequence GKWK but without GCP groups. Obviously the 
attachment of GCP to the peptide side chain can improve the inhibition affinities of such 
peptide-derived acyl hydrazones. Moreover, the most potent trivalent inhibitors 141 (Ki = 
12.5 nM) and 143 (Ki = 22.5 nM) derived from the tri-aldehyde E are 14-fold and 8-fold 
more efficient than the best tetravalent inhibitor (RWKG)4 (Ki = 170 nM) from the 
previous combinatorial library, respectively. Even compounds 146 (Ki = 65.6 nM) and 148 
(Ki = 78.0 nM) derived from di-aldehyde C are two times more efficient than (RWKG)4 as 
well. Therefore, for this type of multivalent peptide ligands, they are indeed the best 
inhibitors of β-tryptase so far. More interesting, 141 and 146 even contain the same 
peptide sequence GKWR but with only three or two peptide arms attached to the aromatic 
rigid core instead a flexible lysine dendrimer, indicating the rigid scaffolds are superior to 
more flexible ones. These results suggest that multivalent ligands based on the rigid 
scaffolds could be more potent inhibitors of β-tryptase than that based on a flexible 
scaffold. Furthermore, the comparison of the multivalent acyl hydrazones with the 
monovalent peptide-derived hydrazides indicates a significant multivalency effect. For 
example, the trivalent compounds 141-143 derived from tri-aldehyde E, are three orders 
of magnitude more potent than the individual hydrazides 135, 136 and 138 which have Ki 
values between 12 and 60 μM (Table 4.3). In the case of the bivalent compounds 146-148, 
derived from di-aldehyde C, 146 and 147 are approximately 200 and 160 times more 
active than their monovalent analogs 135 and 136, respectively, while 148 is 300 times 
better than its monovalent counterpart 138. These results suggest that in contrast to the 
monovalent hydrazide which most likely binds to the active site of the enzyme, the 
inhibition mode of the multivalent acyl hydrazone might be due to a multivalent 
interaction based on preventing the entrance to the central pore of β-tryptase. 
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Table 4.4 Ki values [nM] of the compounds 141-149 for β-tryptase and the other two serine proteases 
trypsin and α-chymotrypsin (α-ChT). 
Compounds 
Ki [nM] 
a 
β-Tryptase Trypsin α-Chymotrypsin 
141 (135+E) 12.5 ± 0.8 > 100000 > 100000 
142 (136+E) 104.9 ± 31.0 > 100000 > 100000 
143 (138+E) 22.5 ± 2.1 > 100000 > 100000 
144 (139+E) 114 and 29900 b > 100000 > 100000 
145 (140+E) > 100000 > 100000 > 100000 
146 (135+C) 65.6 ± 2.3 > 100000 > 100000 
147 (136+C) 391.8 ± 24.4 > 100000 > 100000 
148 (138+C) 78.0 ± 3.1 > 100000 > 100000 
149 (135+C+138) 120.8 ± 3.9 > 100000 > 100000 
a Ki values were calculated by fitting the inhibition data to a 4-parameter equation. 
b A 
biphasic behavior was observed with two inhibitory processes, showing high affinity (Ki 
= 114.0 ± 19.3 nM) and low affinity (Ki = 29.93 ± 1.44 μM) modes of inhibition, 
respectively. (see Figure 4.29). 
 
Figure 4.29 Biphasic inhibition curve of β-tryptase by compound 144. The plot represents the sum of two 
overlapping sigmoid curves which is separated by the plateau. The IC50 values for the high affinity (114.0 ± 
19.3 nM) and low affinity (29.93 ± 1.44 μM) binding were estimated by GraFit program. 
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Compound 144 derived from hydrazide 139 (GK(GCP)WK) and the scaffold E 
showed a different inhibition manner. The inhibition data can be fitted best to biphasic 
kinetics (Figure 4.29), indicating two modes of inhibition with different affinities: one 
with high affinity (114.0 ± 19.3 nM) and the other one with low affinity (29.93 ± 1.44 
μM). Compound 144 is similarly active (Ki = 114 nM for the high affinity binding mode) 
as 142 (Ki = 105 nM) which contains hydrazide 136 (GKWK) but 5-fold less active than 
143 (Ki = 22.5 nM) which contains hydrazide 138 (GKWK(GCP)). This result is in 
agreement with the deconvolution results of the DCLs, but it is surprising because 
hydrazides 138 and 139 are actually isomers, which consist of the same peptide sequence 
GKWK (as in 136) attaching artificial GCP binding motif to lysine side chain but in a 
different position. These results suggest that the position of the GCP motif does 
significantly affect the inhibitory properties. Only when the GCP group is attached to the 
side chain of the lysine at the C-terminus of the hydrazide chain (as in 138) it increased 
the inhibitory affinity. When it is attached to the lysine side chain in the middle part of the 
hydrazide (as in 139) it is as active as lysine at this position (as in 136). The interpretation 
of the different inhibitory activity of these two acyl hydrazides 143 and 144 can be 
explained by the calculation results discussed in Chapter 4.2.5. 
To further verify the screening result of the DCLs, the unfavorable library member 145 
was also synthesized from the assembly of inactive hydrazide 140 (GAFE) and scaffold E. 
As predicted by the screening results of DCLs, it showed no inhibition of β-tryptase. This 
result also demonstrates that the inhibitory activity rather stems from the peptide arms of 
the acyl hydrazones than from the aromatic core of the scaffold or the acyl hydrazone 
linkage. The Ki values (Table 4.3) of the individual hydrazide and aldehyde are in 
agreement with this conclusion.  
Because of the reversibility of interconverting library constituents, the homo- and 
hetero- library members exist simultaneously. Therefore, the heterodimeric compound 149 
containing two different hydrazides 135 (GKWR) and 138 (GKWK(GCP)) was 
synthesized and its inhibitory properties were investigated for comparison with the 
homodimeric species 146 and 148 containing one hydrazide 135 or 138 in the two arms, 
respectively. The Ki value of 120 nM showed that the inhibitory activity of 149 is in a 
similar range but slightly lower than the corresponding homodimeric species 146 (Ki = 
65.6 nM) and 148 (Ki = 78 nM), which indicates that acyl hydrazones with identical 
peptide arms might be slightly favored for the inhibition of β-tryptase, at least for bivalent 
library species. 
In order to better understand the interaction between these series of acyl hydrazone 
inhibitors and the enzyme, the following experiments were done to investigate the enzyme 
selectivity, the reversibility and the inhibition mode of β-tryptase. 
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Enzyme Selectivity 
Enzyme selectivity was tested against the other two archetypal structurally similar 
serine proteases trypsin and α-chymotrypsin as mentioned in Chapter 4.1.4. However, 
none of the inhibitors showed any measureable inhibition of these two related enzymes 
even at a concentration of 100 μM (Table 4.4). Thus, these inhibitors seem to have no 
effect on these two related enzymes, indicating that this series of acyl hydrazones are 
highly specific for β-tryptase compared to other closely related serine proteases. This 
suggest that again most likely the compounds inhibit β-tryptase by protein surface binding 
to the negatively charged area around the entrance to the central pore of β-tryptase, as 
both enzymes are structurally rather similar to the tryptase monomer but without the 
acidic hot spots near the central pore of tryptase.  
Reversibility of Inhibition 
The tests on reversibility of β-tryptase inhibition were performed by two experiments 
according to similar procedure as described in Chapter 4.1.4. In the first dialysis 
experiment, 14 % recovery of tryptase activity was observed after 66 h which indicated 
that the interaction between the enzyme and the inhibitor are reversible. Additionally, the 
second experiment with addition of excess heparin to compete with β-tryptase for the 
interaction with the cationic ligand was done to verify the results. In this case, 16 % 
recovery of enzyme activity was observed. Hence, this test verified the results of dialysis 
experiment, showing that the activity of β-tryptase could be partially restored, thus 
indicating that the inhibition is in principle reversible. Also, it indicated that the binding 
of the inhibitor to the enzyme does not damage the active tetrameric structure of 
β-tryptase. 
Identification of Enzyme Inhibition Mode 
In order to further elucidate the mode of enzyme inhibition, the rate of enzyme reaction 
was measured at different inhibitor concentrations (0-0.1 μM) but always with a fixed 
enzyme concentration for different substrate concentrations (25, 50, 75, 100,150 and 200 
μM). The inhibition mechanism of the acyl hydrazone for β-tryptase was then 
characterized by constructing the Dixon plots, a plot of reciprocal velocities against 
inhibitor concentrations at different substrate concentrations (Figure 4.30). The plots have 
a common intersection on the x-axis which reveals that the constant Ki value is not 
affected by increasing the substrate concentration, thus indicating a noncompetitive 
inhibition.22-23  
In conclusion, it is possible to prove that the acyl hydrazone inhibitors do not compete 
with the substrate for the active cleavage sites and hence most likely bind to the anionic 
surface of β-tryptase through complementary electrostatic interactions. Therefore, this 
type of inhibitors from the combination of peptide-derived hydrazides and aromatic rigid 
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scaffold are reversible and noncompetitive inhibitors of β-tryptase. 
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Figure 4.30 Relative Dixon plot of reciprocal velocities (1/v) against inhibitor concentrations at the 
following fixed substrate concentrations: [S] = 25, 50, 75, 100, 150 and 200 µM. The y error bars represent 
the standard deviation. 
4.2.5 Molecular Mechanics Calculations 
All the findings of the previous experiments suggest that the most likely interaction 
mode is that the inhibitors sterically block the access of substrate to the active cleavage 
sites. In order to further verify how the inhibitors bind to β-tryptase, force field 
calculations were used to visualize possible binding modes between the inhibitor and 
β-tryptase. Compound 143 which consists of three peptide arms with artificial GCP 
groups was then chosen as a representative inhibitor for the calculation. Compared to 143, 
its isomer 144 contains similar peptide arms which differ only in the position of the 
artificial GCP binding motif attached to lysine side chain, resulting in significant 
difference in inhibitory activity. Therefore, to obtain further insight in their differences in 
inhibitory affinity to β-tryptase, molecular mechanics calculations of both 143 and 144 
were studied. 
The force field calculations were done by Wilhelm Sicking with the help of Schrödinger 
MacroModel Version 9.9 software. The enzyme input is based on the reported crystal 
structure of β-tryptase (PDB code: 1A0L). All water molecules and substrates of the PDB 
crystal structure were removed from the binding pore. The conformation of β-tryptase was 
fixed and the inhibitor was mobilized during the calculation. So the calculations began at 
a potential energy of the start conformation and a minimum potential was searched by 
simulating new conformations. The resulting structures were obtained from the result of 
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1000 calculation cycles. 
The calculation confirmed that both molecules can indeed bind to the surface of 
β-tryptase. The calculated conformations of inhibitors (143 and 144) and β-tryptase are 
shown in Figure 4.31. The two inhibitors bind to the enzyme in similar manner by 
interacting with acidic amino acids around the entrance to the central pore through 
electrostatic interactions, thus limiting the accessibility of the substrate to the active sites. 
A closer look (Figure 4.32) on the binding interactions of 143 with β-tryptase shows that 
the inhibitor can bind to the entrance to the central pore of the enzyme through a number 
of key interactions with protein residues Glu, Asp and Gln. It is bound to the surface of 
β-tryptase by 14 hydrogen bonds through the interaction with the two binding sites (the 
monomer-monomer interface and the binding site close to the active site) as described by 
the docking studies (see Figure 4.3). The three GCP groups of 143 interact with a 
significant number of anionic residues around the central pore forming H-bond assisted 
ion pairs to Glu-217A, Gln-221A, Asp-60B, Glu-217C, Gln-221C and Asp-60D, 
respectively. Additionally side chains of the three lysines interact with Asp-145A, 
Asp-147A, Glu-149A and Glu-149C through electrostatic interactions.  
The calculated binding modes and binding energies of 143 and 144 are quite similar, 
indicating that they bind to β-tryptase in principle in the same manner. However, in order 
to investigate why the inhibitory affinity to β-tryptase is so different between 143 and 144, 
the optimized conformations of these two individual inhibitors were also calculated. 
Therefore, to obtain the energy-minimized structures of 143 and 144, conformational 
searches were performed with 67000 and 76000 cycles, with resulting energies of -4336.5 
kJ/mol and -4372.0 kJ/mol, respectively. After 1000 cycles, the resulting minimum 
structures of 143 and 144 were already found several times with energies of -4330 kJ/mol 
and -4361 kJ/mol, respectively, which confirmed that the additional subsequent 
calculations do not result in pronounced structure changes. Normally, the absolute 
interaction energies obtained from force field calculations are difficult to compare for 
different molecules due to the uncertainties and approximations in these calculations. 
However, in this case isomers 143 and 144 are compared and the data are more reliable. 
The calculation studies of the individual molecules 143 and 144 showed that the 
energy of 144 is significantly lower by ca. 36 kJ/mol relative to its isomer 143 (Figure 
4.33). The results suggest that 144 has more stabilizing intramolecular interactions 
compared to 143. Hence, as both molecules bind to the enzyme with similar energies, the 
more stable isomer 144 is the less efficient inhibitor. Therefore, the calculations suggest 
that the improved inhibitory activity of 143 is not necessarily the result of stronger 
binding to the protein, but a less stable ground state conformation of the inhibitor itself. 
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Figure 4.31 Calculated structures of possible binding modes of inhibitors 143 (left) and 144 (right) to 
β-tryptase. The inhibitors were shown as spheres with carbon atoms colored green and cyan, respectively. 
All the hydrogen atoms of the inhibitors were removed for clarity. The inhibitors bind to the entrance of the 
central pore, thus limiting the accessibility to the active sites. The binding energies of 143 and 144 were 
found to be -53819 kJ/mol and -53812 kJ/mol after 1000 calculation cycles, respectively. 
 
Figure 4.32 The binding region of inhibitor 143 (shown as balls and sticks with carbon atoms colored green) 
on the surface of β-tryptase (shown as ribbon cartoon). Four monomers of the enzyme are named A, B, C 
and D. Key protein residues (Glu, Asp and Gln) that interact with 143 are displayed as sticks with carbon 
atoms colored cyan and numbered according to the protein sequence and different monomers. Polar 
interactions among protein residues and inhibitor are presented as black dash lines. 
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Figure 4.33 Calculated energy-minimized structures of 143 (left) and 144 (right). The structures are 
displayed as sticks with oxygen atoms colored red, nitrogen atoms colored blue, carbon atoms colored green 
and cyan, respectively. The minimal energies of 143 and 144 were found -4336.5 kJ/mol and -4372.0 kJ/mol 
after 67000 and 76000 calculation cycles, respectively. 
In conclusion, the hydrazone-based dynamic combinatorial libraries from five peptide 
hydrazides and five aldehydes which could contain 95 different library constituents were 
generated and tested to identify high affinity inhibitors of β-tryptase by using a dynamic 
deconvolution approach. Both two- and three-armed peptide hydrazones with a rigid core 
inhibit β-tryptase with lower nanomolar affinity in a reversible and noncompetitive way 
and are highly selectivity for tryptase compared to other related serine proteases (e.g. 
trypsin, α-chymotrypsin). The most potent compound 141 based on the tri-armed rigid 
scaffold is one order of magnitude more efficient than the best tetravalent inhibitor 
(RWKG)4 based on a flexible lysine dendrimer scaffold obtained from the previous 
combinatorial library. Small variations in the peptide arms induced by the artificial 
arginine analog GCP attached to the different position of the peptide arm lead to different 
binding affinities. The substitution of GCP at the C-terminal amino acid side chain can 
significantly improve the inhibitory activity of such inhibitors relative to only 
proteinogenic amino acids. Hence, it could be demonstrated here again that the use of 
tailor-made binding motifs such as the artificial arginine analog GCP can lead to more 
potent inhibitors. Additionally, due to the multivalency effect, more efficient inhibitors 
might be possible by using the scaffold with larger surface area, such as gold 
nanoparticles. In the next chapter, inhibitors based on such a scaffold will be prepared and 
investigate their inhibitory efficiency. 
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4.3 Surface Binding of Human β-Tryptase by Gold Nanoparticle-based 
Inhibitors 
The recognition of protein surfaces is challenging due to their solvent-exposed large 
size and structural complexity (see chapter 2.4). For this reason, the use of scaffolds with 
large complementary surfaces offering multivalent interactions is of particular advantage 
for protein surface binding. In the last decades gold nanoparticles were of great interest in 
the application in biotechnology and catalysis as they present fascinating and versatile 
properties that differ from their bulk material, such as the size-related electronic, magnetic 
and optical properties (quantum size effect).168 Gold nanoparticles (Au NPs) feature the 
surface plasmon resonance (SPR) due to the collective oscillation of the electron gas at 
the surface, which leads to an intense absorption band in the visible region around 520 nm, 
showing deep-red color and allowing easy detection by UV/Vis spectroscopy. 
Furthermore, gold nanoparticles feature large surface area, tunable size, and a wide series 
of functionalities such as thiol (through chemical bond) and amine (through physical bond) 
ligands. All these properties allow the possibility of using them as candidates for 
preparing receptors for protein surface recognition.164 The theoretical background 
information of gold nanoparticles as promising scaffold for protein surface binding has 
been described in Chapter 2.4. With the help of the DCL approach presented in the 
previous chapter, the peptide sequences combining the basic and aromatic amino acids as 
well as the artificial GCP binding motif attached to a rigid core scaffold have been shown 
to inhibit β-tryptase with high affinity. In order to further test the efficiency of these 
peptide sequences and increase the multivalency effect, similar peptide arms will now be 
used to attach to the gold nanoparticle scaffold, providing as recognition elements binding 
to the acidic surface area of β-tryptase. Alkanethiol chains incorporated with triethylene 
glycol (TEG) to prevent nonspecific interaction and denaturation will be used as a linker 
to stabilize the gold core. The design of the functional peptide ligands is based on the 
attachment of the peptide recognition unit to this thioalkylated TEG chain. The peptide 
ligands can then be attached to the surface of the gold nanoparticle scaffold, resulting in 
the functionalized nanoparticles to target the surface of β-tryptase. A ligand containing the 
alkanethiol chain but with a terminal hydroxyl group is also synthesized as a surface 
blocker. In the following sections the synthetic route to the thioalkylated TEG chain and 
the peptide ligands as well as the functionalized gold nanoparticles will be described. The 
characterization and the results from the enzyme assays will be presented as well. 
4.3.1 Synthesis of the Thioalkylated TEG Linker 
In order to couple the thiolalkylatd TEG chain to a peptide on solid support, a 
carboxylic acid group should be introduced to the terminal TEG chain and a suitable 
protecting group should be used for the thiol group to allow the simultaneous deprotection 
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and cleavage of the product from the resin. The synthetic route to such a compound is 
adapted from the literature with some modifications.269-271 As shown in Scheme 4.8, 
commercially available 5-Bromo-1-pentene (150) was reacted with excess triethylene 
glycol in the presence of sodium hydroxide as the base to give the monoether (151) which 
was purified by column chromatography to get rid of the diether. This compound was 
again alkylated with ethyl bromoacetate in the presence of the strong base sodium hydride 
to give the ester (152). The subsequent addition reaction of thioacetic acid to the terminal 
olefin of 152 (thiol ene reaction) was performed in the presence of a catalytic amount of 
azobis(isobutyronitrile) (AIBN) in THF under reflux to afford thioacetate (153). This 
reaction can be carried out either under UV light irradiation at room temperature or under 
reflux. Both these conditions lead to the decomposition of AIBN through elimination of 
nitrogen and generate radicals. They act as initiators to produce thiol radicals which 
subsequently add to the alkene. This thioacetate compound was then subjected to acidic 
hydrolysis to give the free thiol product (154), which was then directly protected by the 
trityl group to give trityl thioether (155). In the last step, saponification of the ethyl ester 
group with aqueous lithium hydroxide was carried out in the mixture of THF and MeOH 
(1:1, v/v) to afford the desired carboxylic acid (156). 
 
Scheme 4.8 Synthesis of the trityl protected thiolalkylatd TEG derived carboxylic acid (156) for the 
coupling with a peptide on solid support. 
The thiolalkylatd TEG ligand with the terminal hydroxyl group is used as a control 
ligand to adjust the surface functionalities and charges. It was synthesized according to 
the similar procedure but without incorporating the carboxylic acid. As shown in Scheme 
4.9, addition of thioacetic acid to the terminal olefin of the compound 151 afforded 
thioacetate (157), which was then subjected to acidic hydrolysis to give the ligand (158). 
Scheme 4.9 Synthesis of the thiolalkylatd TEG ligand (158). 
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4.3.2 Microwave-Assisted SPPS of Thiolalkylated Peptide Ligands 
As demonstrated in the last chapter, peptide sequences combining basic and aromatic 
amino acids as well as the artificial arginine analog GCP binding motif show efficient 
inhibitory affinity to β-tryptase. To further test their efficiency on the surface of gold 
nanoparticles, similar peptide sequences were used to incorporate with the linker (156) on 
the solid support, resulting in peptide-derived alkanethiols to attach to the surface of the 
gold nanoparticles. Because the length of the linker (156) is already long, tripeptide 
instead of tetrapeptide was used with the glycine missing.  
The thiolalkylated peptide ligand 161 (KWK(GCP)) contains the peptide sequence 
KWK with the artificial GCP group attached to the side chain of the C-terminal lysine. 
This peptide arm has shown high inhibitory affinity to β-tryptase (see Chapter 4.2). 
Ligand 161 was synthesized on the Rink amide MBHA resin (0.84 mmol/g) using a 
standard microwave-assisted Fmoc SPPS procedure (see Chapter 4.1.3). As shown in 
Scheme 4.10, the resin was first swollen in DCM for 2 h, followed by the Fmoc 
deprotection by treating with 20 % piperidine/DMF under the standard microwave 
irradiation condition. After a washing cycle with DMF, the first amino acid 
Fmoc-Lys(Alloc)-OH (3 eq) was attached to the resin with the help of the coupling 
reagent PyBop (3 eq) and the base DIPEA (6 eq) in DMF under standard microwave 
irradiation condition for 20 min. The coupling was then repeated and the negative Kaiser 
test confirmed the complete coupling of the free amino groups. After the Fmoc 
deprotection, Fmoc-Trp(Boc)-OH (3 eq) and Fmoc-Lys(Boc)-OH (3 eq) were coupled 
using the same conditions to obtain 159. After the Fmoc deprotection, the linker (156) 
was coupled to the resin with the help of HOBt (3.6 eq) and DIC (4.5 eq) to give 160. The 
next step is the removal of Alloc protecting group with the help of Pd(PPh3)4 (0.1 eq) in 
the presence of PhSiH3 (24 eq) in DCM, followed by the coupling of the Boc protected 
GCP unit (111) to the lysine side chain with the help of the coupling reagent PyBop (3 eq) 
and the base DIPEA (6 eq). Then the resin was thoroughly washed with 3 × DCM, 3 × 
MeOH, 3 × DCM and dried under vacuum for 1 h. To cleave the peptide, the resin was 
transferred to a glass peptide synthesis vessel and the product was cleaved from the resin 
by using a mixture of TFA/phenol/H2O/TIS (90:5:2.5:2.5) for 3 h. Under this condition, 
all side-chain protecting groups were simultaneously removed. Phenol is necessary as 
scavenger to provide protection for aromatic residues. The crude product was purified by 
RP18-MPLC using appropriate conditions (H2O/MeOH + 0.1 % TFA). After the 
purification steps, the product was obtained with a purity of 95 % according to analytical 
HPLC analysis. Pure product was then transferred into its hydrochloride salt by dissolving 
it in water with hydrochloric acid and lyophilizing several times. 
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Scheme 4.10 Microwave-assisted Fmoc SPPS procedure of thiolalkylated peptide ligand 161. 
The second thiolalkylated peptide ligand 162 (K(GCP)WK) with the GCP group at a 
different position (the side chain of the other lysine) was synthesized according to the 
similar synthetic route. Accordingly, peptide ligands 163 and 164 containing only the 
proteinogetic amino acids were also prepared. Ligand 163 contains the peptide sequence 
KWK for comparison with ligands 161 and 162 featuring one artificial arginine analog 
GCP group at one of the two lysine side chains. To further compare with the arginine, the 
best peptide sequence KWR from the previous library was synthesized as well. 
Additionally, thiolalkylated peptide ligand 165 was prepared with the negatively charged 
peptide sequence EWE featuring two glutamic acids to compare with the positively 
charged ligands 161-164. All the structures of these four ligands are depicted in Figure 
4.34. 
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Figure 4.34 Four other thiolalkylated peptide ligands 162-165 (including short names of the peptide arms 
for easy comparison) were also prepared via microwave-assisted Fmoc SPPS. 
4.3.3 Synthesis of Peptide Ligands as Control Molecules 
The preparation of the gold nanoparticles will be first tested with the ligand 161 
(KWK(GCP)) which features the efficient peptide sequence containing the artificial 
arginine analog GCP group and has been shown previously to be a potent binding unit to 
β-tryptase. In order to compare the enzyme inhibitory affinity of the functionalized gold 
nanoparticles with that of the free ligand, a model ligand with the same peptide sequence 
KWK(GCP) and a similar alkylated TEG linker but without the thiol group was 
synthesized (to prevent the possible formation of disulfide by the thiolalkylated peptide 
ligand 161). As shown in Scheme 4.11, the terminal alkenyl group of compound 152 was 
reduced by hydrogenation with a catalytic amount of palladium on activated charcoal in 
methanol to give the saturated ester 166, which was then subjected to saponification of the 
ethyl ester group with aqueous lithium hydroxide in the mixture of THF and MeOH (1:1, 
v/v) to afford the desired carboxylic acid (167).  
 
Scheme 4.11 Synthesis of the alkylated TEG derived carboxylic acid (167) for the coupling with a peptide 
sequence on solid support. 
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Then the peptide ligand 168 (Figure 4.35) was synthesized based on this alkylated 
TEG linker (167) by incorporating the same peptide sequence KWK(GCP) as ligand 161. 
It was synthesized on the Rink amide MBHA resin (0.84 mmol/g) according to the 
standard microwave-assisted Fmoc SPPS procedure as described for ligand 161. After the 
completion of all the coupling steps, the product was cleaved from the resin by using a 
mixture of TFA/H2O/TIS (90:2.5:2.5) for 3 h. After the purification steps, the product was 
obtained with a purity of 95 % according to analytical HPLC analysis.  
 
Figure 4.35 Structure of peptide ligand 168 containing the alkylated TEG chain. 
The peptide ligand 170 containing the same peptide sequence KWK(GCP) as ligand 
161 but without the alkylated TEG chain was also synthesized on the Rink amide MBHA 
resin (0.84 mmol/g) according to the standard microwave-assisted Fmoc SPPS procedure. 
As shown in Scheme 4.12, after the Fmoc deprotection, the amino acids 
Fmoc-Lys(Alloc)-OH, Fmoc-Trp(Boc)-OH and Ac-Lys(Boc)-OH were attached to the 
resin successively. After the removal of the Alloc protecting group, the Boc protected 
GCP moiety (111) was attached to the lysine side chain. Then the product was cleaved 
from the resin by using a mixture of TFA/ H2O/TIS (90: 2.5:2.5) for 3 h. After the 
purification steps, the product was obtained with a purity of 95 % according to analytical 
HPLC analysis.  
 
Scheme 4.12 Microwave-assisted Fmoc SPPS procedure of the peptide ligand 170. 
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4.3.4 Preparation of Functionalized Gold Nanoparticles 
A variety of methods for the preparation of gold colloids have been established. For 
example, the well-known Brust-Schiffrin method is based on the reduction of HAuCl4 in 
the presence of reducing agent sodium borohydride and stabilizing ligands such as 
alkylthiols (Figure 4.36). Most often this reaction is carried out in unpolar solvent such as 
toluene with HAuCl4 transferred to it by using a phase-transfer reagent such as 
tetraoctylammonium bromide. Thiol ligands can strongly bind to the gold surface due to 
the soft character of both sulfur and gold. Hence, the gold nanoparticle surface is 
stabilized by the long alkyl chains and prevented from aggregation in solution. The size of 
the particles can be controlled by the reaction conditions, such as temperature, the rate of 
the reduction and the thiol/gold ratio.272-273 This method is often combined with a 
successive Murray place-exchange reaction274 by using a wide range of functional thiols 
to obtain the functionalized gold nanoparticles for targeting biomolecules, cellular uptake, 
etc. 
 
Figure 4.36 Schematic representation of the generation of functionalized gold nanoparticles by using 
Brust-Schiffrin method and Murray place-exchange reaction. 
However, the biological application of the functionalized Au NPs requires the 
purification process to remove the remaining surfactants, reducing agents and the 
chemical precursors. In particular, the alkylthiol needs to be removed after the ligand 
exchange reaction to avoid biological toxicity because it might induce nonspecific 
hydrophobic interactions with the protein. Moreover, the initial hydrophobic alkylthiol 
ligands might cause solubility problems in the buffer solutions required for the biological 
applications and the difficulties in determining the ratio of different ligands on the surface 
of Au NPs. 
Recently, an alternative method to obtain water-soluble gold nanoparticles in a one step 
process by laser ablation has been established.275 In contrast to the bottom-up chemical 
method, this top-down physical approach can be used to produce metal nanoparticles with 
“bare” surfaces without the need of chemical precursors or reducing agents. Recently, 
Amendola et al. revealed the fundamental mechanisms of laser ablation in liquids and the 
parameters that influence the composition and the structure of the nanoparticles during the 
laser ablation.276 Laser ablation of a bulk metal plate in liquids leads to the formation of 
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the nanoparticles during the condensation of a plasma plume. This process starts with the 
absorption of the laser pulse by the bulk metal plate, resulting in the detachment of the 
ablated material. Then the expansion of a plasma plume containing the ablated material 
into the surrounding liquid occurs, and the energy is quenched by the liquid solution, 
generating a cavitation bubble which expands in the liquid and then collapses, followed 
by the slow growth and agglomeration of the nanoparticles. Laser generated gold 
nanoparticles have been demonstrated to have a novel surface chemistry. The groups of 
Meunier and Mafuné have revealed that the nanoparticles were partially oxidized to Au+ 
and Au3+ by the oxygen present in aqueous media by X-ray photoelectron spectroscopy 
(XPS) and IR spectroscopy.277-278 These Au-O compounds can be hydrolyzed to give a 
surface of Au-O
-
, thus leading to a negatively charged surface of the nanoparticles. The 
oxidized surface can react efficiently with OH
-
 and Cl
-
 to produce the surface charge 
which avoids the aggregation and the broadening of the plasmon bands of the 
nanoparticles (Scheme 4.13). When the pH value is above 5.8, the oxygen atoms are 
negatively charged (Au-O
-
) and show constant zeta potential value, resulting in smaller 
nanoparticles with high stability. However, Au-OH is dominant when the pH value is 
below 5.8 and the particles easily aggregate. Therefore, the size of the nanoparticles can 
be controlled by adjusting the pH value or using different salt concentrations. Recently, a 
report of Cuenya et al. confirmed these findings by investigating the formation and 
stability of the gold oxide on the surface of gold nanoparticles.279 Due to this partial 
oxidation, laser ablated gold nanoparticles act as electron acceptors and thus are easily 
modified by molecules bearing electron donor moieties such as thiols, disulfides, amines 
and carboxylates through covalent or electrostatic interactions. 
 
Scheme 4.13 Surface conversion of gold oxide compounds. 
In comparison with the chemical synthetic routes for nanoparticle, laser ablation has 
several advantages.280-281 Laser generated gold nanoparticles are negatively charged and 
thus have a high colloidal stability in aqueous solution or organic solvents. In contrast to 
the common chemical reduction routes which depend on the availability of reducing 
agents or the stabilizing ligands, laser ablation does not rely on chemical precursors, 
allowing the synthesis of ligand-free colloids and thus resulting in a high nanoparticle 
surface activity. This method is compatible with an almost unlimited variety of metals, 
surface functionalities and solvents. Furthermore, ligand-free nanoparticle surfaces allow 
a wide range of surface functionalities with higher conjugation efficiency and 
compatibility. In contrast, the place exchange reactions are limited with the type of the 
thiolated ligands. Moreover, the ligands around the nanoparticles are hardly to be entirely 
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replaced, resulting in the difficulties for quality and quantity analysis. However, besides 
these advantages, the limitations of laser ablation approach should be considered when 
preparing the nanoparticles by using this method. The major limitation of laser ablation is 
the control of the particle size, in particular when preparing ligand-free nanoparticles. The 
size distribution of the nanoparticles generated by laser ablation tends to be broadened 
due to the aggregation processes of the ablated atoms such as the post-ablation 
agglomeration of nanoclusters or the ejection of large fragments. It has been demonstrated 
that the decrease of diameter and a narrow size distribution can be obtained by selection 
of the laser fluence and the laser shots.282-283 The use of surfactants,284 cyclodextrins,285-286 
and biomolecules287 has also been shown to reduce the nanoparticle sizes. Even though 
big particles can be generated during laser ablation, they can be removed with various 
methods, such as centrifugation, membrane filtration, dialysis and size exclusion 
chromatography, etc.  
The generation of the functionalized gold nanoparticles can be achieved by either ex 
situ or in situ conjugation.283, 288-289 As depicted in Figure 4.37, the ex situ conjugation is 
proceeded by adding the ligands after the laser ablation while the in situ conjugation is 
achieved by conjugating the ligands to the gold nanoparticles simultaneously with their 
generation. Barcikowski et al. have demonstrated that the conjugation efficiencies of both 
ex situ and in situ are very high with in situ conjugation showing four times higher 
efficiency. Laser ablated gold nanoparticles by in situ and ex situ conjugation were shown 
to feature up to five-fold higher surface coverage compared to the functionalized 
nanoparticles generated by the conventional ligand exchange method.290  
 
Figure 4.37 Schematic representation of the generation of functionalized gold nanoparticles by laser-based 
ex situ (top) and in situ (bottom) conjugation. 
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In this work the functionalized gold nanoparticles with peptides were prepared by laser 
ablation approach by our cooperation partner Lisa Gamrad in the working group of Prof. 
Stephan Barcikowski in the Institute of Technical Chemistry at the University of 
Duisburg-Essen. Laser ablation of gold nanoparticles was carried out using a picosecond 
laser system providing < 10 ps laser pulses at a wavelength of 1064 nm (pulse energy > 
160 µJ, beam diameter: 2 mm), a power of 17 W, a repetition rate of 100 kHz and a focal 
length of 100 mm. The generation of the functionalized gold nanoparticles was done in 
two different ways depending on the types of conjugation.  
For ex situ conjugation, the gold nanoparticles were first prepared before adding the 
ligands. The ablation was carried out in 0.6 mM sodium phosphate buffer at pH 8.0 using 
a 30 mL batch chamber in a time range of 150 seconds. The experimental set up (Figure 
4.38, left) shows the laser beam focused through a quartz window on the 500 µm thick 
gold target (1 cm × 1.4 cm) which is fixed with a screw. In order to avoid accumulation of 
nanoparticles nearby the gold target, the solvent has to be stirred continuously during the 
ablation process. This was done with the help of an electrical driven motor which is fixed 
to the chamber cover and affects the movement of a Teflon stirrer blade dipping into the 
solvent. With the help of the software “LaserDesk”, it is possible to control the scanning 
unity such as the geometry, the scanning speed and the number of cycles that is equivalent 
to the duration of the ablation. A spiral with an external diameter of 6 mm and a scanning 
speed of 6 mm/s was used. After the generation of nanoparticles, the big particles with 
diameters over 10 nm were removed via centrifugation to obtain monodispersed 
nanoparticles. Then a series of concentrations of the ligands (0-1500 µM) was prepared in 
500 µL sodium phosphate buffer (0.6 mM, pH 6.0), followed by the addition of 1 mL 
monodispersed gold nanoparticles. In order to achieve one series of conjugates with the 
same gold concentration, the gold nanoparticles were always used from the same batch. 
Then the sample mixtures were adjusted to pH 6.0 and shaken for one hour to ensure the 
completion of the conjugation. 
For in situ conjugation, ligands have to be added to the ablation liquid (0.6 mM sodium 
phosphate buffer) before nanoparticle generation. The laser ablation experiments were 
performed in 1.5 mL sodium phosphate buffer solution (0.6 mM, pH 6.0) in the presence 
of the ligands that should be conjugated to the surface of the gold nanoparticles. The 
experimental set up (Figure 4.38, right) consists of a standard optical glass cuvette with 2 
mL volume where a gold ribbon (5.5 cm × 0.4 cm) with a thickness of 100 µm fixed on an 
inset can be placed. The “LaserDesk” software and the scanner were utilized for this type 
of ablation as well. A spiral with an external diameter of 3 mm and a scanning speed of 6 
mm/s was used in this experiment. The duration of the laser ablation was 7 seconds. A 
series of Au NPs samples with different ligand concentrations (0-1500 µM) were prepared 
individually and were also shaken for one hour after the ablation. 
RESULTS AND DISCUSSIONS 
128 
 
 
Figure 4.38 Schematic representation of the laser ablation of gold nanoparticles in liquids in absence of 
ligands in a batch chamber (left)291 and in presence of ligands in a cuvette (right). 
Ligand 161 containing the peptide sequence KWK(GCP) with a combination of basic 
and aromatic amino acids as well as the artificial GCP gtoup was first tried for the 
conjugation. Ligand 158 was also used as a control to adjust the surface functionalities 
and charges. Therefore, both monovalent and bivalent conjugations were prepared and 
analyzed. For the monovalent conjugation, only one type of ligand (161) was used during 
the ex situ or in situ conjugation. After the conjugation, the unbound ligands were 
removed from the conjugates by using ultracentrifugation and the surface coverage was 
tested with the help of UV/Vis spectroscopy. For the bivalent conjugation, two types of 
ligands (161 and 158) were used. Bivalent conjugation was performed as above described 
monovalent conjugation by adding both types of ligands to the gold colloids (ex situ) or 
the ablation liquid (in situ) at the same time. Figure 4.39 shows the structure overview of 
the monovalent conjugates (171) featuring the cationic ligand (161) and bivalent 
conjugates (172) featuring both the cationic ligand (161) and neutral ligand (158). 
 
Figure 4.39 Structure features of the monovalent conjugates (171) and bivalent conjugates (172).  
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4.3.5 Characterization of Conjugated Gold Nanoparticles 
Ex Situ Conjugation 
We have used more often the ex situ conjugation to prepare the conjugates because the 
gold concentration, the particle size and the size distribution can be easily controlled. For 
the first test experiment, the conjugates with ligand 161 were prepared by using low 
ligand concentrations (0-10 µM). The polydispersed gold nanoparticles were generated by 
laser ablation in sodium phosphate buffer (0.6 mM, pH 8.0), to which a series of 
concentrations of ligand 161 (in 0.6 mM sodium phosphate buffer, pH 6.0) was added and 
the mixture was adjusted to pH 6.0 and subjected to 1 h conjugation. Absorption spectra 
of the gold colloids were recorded to determine the gold concentration, surface plasmon 
resonance (SPR) wavelength and primary particle index (PPI). The absorbance at 380 nm 
is primarily caused by the interband transition of gold, which is a good parameter for the 
estimation of Au NPs concentrations.292 The gold concentration was then determined 
using the calibration curve of the absorbance at 380 nm (Figure 4.40) according to the 
Lambert-Beer law (A = εbc). A series of gold colloids with different gold concentrations 
were prepared by using different laser durations. After each laser ablation, the gold target 
was weighed to calculate the mass of gold in solution which was divided by the volume to 
obtain the mass concentration of the gold nanoparticles. The absorption spectra of these 
samples were measured and the calibration curve was then obtained by fitting the 
absorbance data at 380 nm against gold concentrations using linear regression analysis. 
The absorbance at 800 nm is mainly due to asymmetric aggregates. The PPI, which is a 
good indicator of the quality of the gold colloids, was calculated by the ratio of the 
absorbance at 380 nm and that at 800 nm. The SPR peaks mainly depend on the size of 
the gold nanoparticles.  
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Figure 4.40 Calibration curve for determining the gold concentration. 
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As shown in Figure 4.41, the gold concentration initially decreased with the increase of 
the ligand concentration and reached a minimum value at ligand concentrations of 3-5 µM 
before it started increasing again. This is due to the compensation of the charges: initially 
the surface of the gold nanoparticles is negatively charged, when conjugated with the 
positively charged ligands, it reached the isoelectric point at a specific ligand 
concentration and formed large aggregation and the particles precipitated. With higher 
ligand concentration, the surface of the gold nanoparticles became positively charged and 
much less aggregation was observed. The red shift of the SPR peaks with the increasing 
ligand concentrations also revealed the aggregation of the nanoparticles. The decrease of 
the PPI values indicated the aggregation as well. However, after a few days, the 
nanoparticles were all precipitated because the amount of the positively charged ligands 
on the surface of Au NPs is still too low to stabilize the nanoparticles for longer time. 
Therefore, in order to obtain relatively stable nanoparticles, the functionalized Au NPs 
should be prepared with even higher ligand concentrations.  
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Figure 4.41 a) Absorption spectra of conjugates of Au NPs with different ligand concentrations ([161] = 
0-10 µM) and plots of b) gold concentration, c) SPR peak, and d) PPI versus ligand concentration. 
Accordingly conjugates with higher ligand concentrations (15-1000 µM) were 
prepared and analyzed. In order to test the long-term stability, the UV/Vis spectra were 
recorded after 2 hours, 11 days and 15 days respectively. As shown in Figure 4.42, no 
aggregation of the nanoparticles was observed at these high ligand concentrations after the 
conjugation. The gold nanoparticles with lower ligand concentrations (below 587 μM) 
started to aggregate only after some days, whereas those with higher ligand concentrations 
have a good long-term stability. 
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Figure 4.42 a) Absorption spectra of conjugates of Au NPs with different ligand concentrations ([161] = 
15-1000 µM) and plots of b) gold concentration, c) SPR peak, and d) PPI versus ligand concentration. 
The hydrodynamic diameters of the Au NPs were measured with the help of dynamic 
light scattering (DLS) measurement. The DLS is a technique that is based on the different 
Rayleigh scattering properties of particles with different sizes. It measures the fluctuation 
in scattering intensity of the particles with time when irradiated with monochromatic and 
coherent laser light. The Brownian motion of the particles resuts in different scattering 
intensity and its speed depends on the size of the particles and the viscosity of the solvent. 
The diffusion constant as a characteristic for the mobility of the particle depends on the 
hydrodynamic radius of the spherical particles with the solvent shell which can be 
calculated with the help of the Stokes-Einstein equation (12). 
 
Where D is the diffusion constant, kB is Boltzmann’s constant, T is temperature, η is 
the viscosity and r is the radius of the particles.  
The intensity of scattering of a particle is proportional to the particle diameter by the 
power of six as large particles scatter much more light than smaller particles. Thus the 
intensity distribution weighs large particles much more than smaller ones. The 
polydispersity index (PDI) is a characteristic for defining the monodispersity of the 
system: the lower the PDI, the more monodisperse the system is. The intensity 
RESULTS AND DISCUSSIONS 
132 
 
distribution can be converted to a volume distribution and further to a number distribution. 
The hydrodynamic diameters of the conjugated Au NPs with different ligand 
concentrations obtained from DLS measurements are shown in Figure 4.43. The results 
showed that the nanoparticles with higher ligand concentrations have smaller sizes which 
indicated that the higher amounts of the ligands can better stabilize the nanoparticles. 
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Figure 4.43 Hydrodynamic diameter of Au NPs with different ligand concentrations ([161] = 15-1000 µM) 
obtained from DLS measurements. The y error bars represent the standard deviation from at least three 
measurements. 
The sizes of the gold nanoparticles were analyzed with analytical CPS disc centrifuge. 
The CPS disc centrifuge uses sedimentation to measure particle size distribution. Particles 
settle in a fluid according to Stokes’ Law (equation 13).  
 
Where vs is the settling velocity of the particles, ρp and ρf are the mass densities of the 
particles and the fluid, respectively, η is the viscosity, g is the gravitational acceleration 
and r is the radius of the particles. 
Sedimentation velocity increases proportionally with the square of the particle diameter. 
Hence a small difference in particle sizes causes a significant difference in settling rates. 
The particles with the same size settle at the same speed and arrive at a detector beam as a 
thin band. The time that is needed to reach the detector is used to calculate the size of the 
particles. This technique allows measuring a wide range of particle sizes (5 nm-50 μm).  
The size distributions of the Au NPs directly after the laser ablation as well as after the 
removal of big particles were analyzed by CPS disc centrifugation. As depicted in Figure 
4.44, the Au NPs were monodispersed after removing big particles by ultracentrifugation. 
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The sizes of conjugated Au NPs with ligand 161 were determined as well using disc 
centrifugation. The conjugates are a bit larger due to the surface coverage by the ligands 
compared to the ligand-free Au NPs (Figure 4.44, right). This result further confirmed the 
successful conjugation of the ligands to the surface of the Au NPs. However, the sizes 
measured by disc centrifugation are much smaller than those obtained from the DLS 
measurements. This is due to the fact that DLS measures the sizes of the solvated particles. 
Moreover, DLS weighs big particles more because they scatter more light than smaller 
ones, whereas the disc centrifugation could measure the particles more separately. 
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Figure 4.44 Number and surface size distribution of the gold nanoparticles before (left) and after (middle) 
the removal of big particles, as well as surface size distribution of the monovalent conjugated Au NPs with 
ligand 161 (right) obtained from the disc centrifugation measurements.  
In addition, the size distributions of the ligand-free and the conjugated Au NPs were 
determined by transmission electron microscopy (TEM). The results clearly show that the 
Au NPs are spherical particles with diameter around 6-7 nm (Figure 4.45). This finding is 
in agreement with the sizes determined by disc centrifugation. The sizes of the ligand-free 
and the conjugated Au NPs are similar because only the gold core could be seen by TEM. 
Besides monovalent conjugates with positively charged ligand (161) as the recognition 
unit for β-tryptase, bivalent conjugates with the second neutral ligand (158) as the surface 
control is also interesting. Therefore, after removing the big particles (> 10 nm) to obtain 
the monodispersed Au NPs, their monovalent (with ligand 161) and bivalent (with ligands 
161 and 158) conjugates were prepared with the help of ex situ conjugation. For the 
monovalent conjugation, a series of concentrations of ligand 161 (0-725 µM) was used. 
For the bivalent conjugation, the same concentration series of ligand 161 (0-725 µM) was 
taken and respectively ligand 158 was used with two-fold concentrations (0-1450 µM). 
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Figure 4.45 Top: TEM images of ligand-free Au NPs (left) and monovalent conjugated Au NPs with ligand 
(161) concentrations at 15 µM (middle) and 400 µM (right), respectively. Bottom: The corresponding 
surface size distributions of the ligand-free Au NPs and conjugates. 
Accordingly both the monovalent and bivalent conjugations were carried out as 
described above. After the laser ablation and 1 h conjugation, absorbance of the gold 
colloids was recorded to determine the gold concentration and PPI. As shown in Figure 
4.46, both of the monovalent and bivalent conjugates are stable with higher ligand 
concentrations. 
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Figure 4.46 Plots of gold concentration and PPI versus different ligand (161) concentrations (0-725 µM) of 
monovalent and bivalent conjugated Au NPs obtained from ex situ conjugation. 
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The purification of the conjugates (to remove the unbound ligands) was carried out by 
using the ultracentrifugation. After centrifugation, the supernatant was removed and the 
nanoparticles were redispersed in the same volume of the buffer solution by using 
ultrasonication. The centrifugation and redispersion steps were repeated three times. The 
combined supernatants were analyzed with the help of UV/Vis spectroscopy to determine 
the concentration of the unbound ligands. Then the surface coverage of the gold 
nanoparticles was calculated from these data by subtracting the unbound ligands from the 
total amount of the ligands used for the conjugation. The absorbance of ligand 161 was 
recorded and the unbound ligand concentration was evaluated using the calibration curve 
of the absorbance at 296 nm (Figure 4.47) according to the Lambert-Beer law (A = εbc). 
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Figure 4.47 Calibration curve for determining the concentration of ligand 161. 
Figure 4.48 illustrates the absorption spectra of the monovalent conjugated Au NPs 
before and after centrifugation, as well as that of the supernatant. It showed clearly that it 
is possible to remove the unbound ligand albeit with the loss of gold as indicated by the 
decrease of the absorbance at 380 nm. At the same time, the formation of bigger 
aggregates was also evident from the increase of the absorbance at 800 nm. This is 
because the particles formed agglomerates and it is difficult to redisperse all the Au NPs 
in buffer solution after centrifugation and also some of the particles stick to the vial. 
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Figure 4.48 Absorption spectra of the monovalent conjugated Au NPs before and after ultracentrifugation, 
as well as the supernatant. 
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The conjugation efficiency, defined as the percentage of total amount of ligand bound 
to the surface of the Au NPs, can be calculated. Figure 4.49 illustrates the surface 
coverage and conjugation efficiency of the conjugates obtained from the ex situ 
conjugation. Because the control ligand 158 does not contain any chromophore, only 
ligand 161 was used to determine the surface coverage for both monovalent and bivalent 
conjugates. As a result the monovalent conjugates exhibited very high conjugation 
efficiency (> 80 %) in the concentration range of 0.5-430 µM compared to the bivalent 
conjugates (ca. 40-80 %). The similar conjugation efficiency both at lower and higher 
ligand concentrations suggests that most likely a monolayer surface is first formed at low 
ligand concentrations which subsequently transformed into multilayers with increasing 
concentration of the ligand(s).  
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Figure 4.49 The concentration (top) and percentage (bottom) of ligand 161 conjugated to the surface of the 
gold nanoparticles compared to the total amount of ligand used for ex situ conjugation.  
After the centrifugation, the redispersed conjugated Au NPs were shown to have bigger 
size and higher polydispersity as depicted by DLS measurements (Figure 4.50) and disc 
centrifugation analysis (Figure 4.51). The particles seem to be bigger due to the big 
agglomeration as they come closer together during the centrifugation. Moreover, the DLS 
weighs bigger particles more as they scatter more light than smaller ones. A significant 
difference in the size distribution was obtained by TEM as shown in Figure 4.52. The 
results showed that the individual particle sizes could be seen after the removal of the 
unbound ligands and the sizes are similar to the conjugates before centrifugation (see 
Figure 4.45). Some agglomerates could be seen but most of the particles present the 
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smaller sizes as obtained before centrifugation. Why the agglomeration could not be seen 
from TEM is unclear at the moment. The big aggregates might be already lost during the 
sample preparation.  
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Figure 4.50 Hydrodynamic diameters (number distribution) of monovalent conjugated Au NPs before and 
after the removal of unbound ligand. The y error bars represent the standard deviation from at least three 
measurements. 
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Figure 4.51 Surface size distribution of monovalent conjugated Au NPs with ligand (161) concentrations at 
15 µM (left) and 400 µM (right) obtained from the disc centrifugation measurements before and after 
removal of unbound ligand. 
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Figure 4.52 Top: TEM images of monovalent conjugated Au NPs with ligand (161) concentrations at 15 
µM (left) and 400 µM (right) after the removal of unbound ligands. Bottom: The corresponding surface size 
distributions of the conjugates.  
In Situ Conjugation 
In situ conjugation was also tested in this work to take advantage of its high 
conjugation efficiency.290 Both monovalent and bivalent conjugated Au NPs were 
generated. For monovalent conjugation, a series of different ligand (161) concentrations 
(0-725 µM) was prepared in 1.5 mL sodium phosphate buffer (600 µM, pH 6.0). Each 
sample was added in an optical glass cuvette to which a gold ribbon was placed and 
subjected to the laser ablation for 7 seconds. The samples were then shaken for one hour 
to ensure the complete conjugation. The bivalent conjugation was performed in the same 
way by using the same concentrations of ligand 161 (0-725 µM) as the monovalent 
conjugation and respectively two-fold of the control ligand 158 (0-1450 µM) as the 
surface blocker. The absorption spectra of conjugated Au NPs were measured and the gold 
concentration as well as the PPI were evaluated in the same way as above described for 
the ex situ conjugation. As shown in Figure 4.53, the isoelectric point aggregation and 
precipitation was observed again at low ligand concentration (3-5 µM). The conjugated 
Au NPs are stable with high ligand concentrations. In comparison with the monovalent 
conjugated gold colloids, the bivalent conjugated gold colloids have lower gold 
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concentration and low quality, which indicated that bivalent conjugates formed bigger 
aggregates than the monovalent conjugates.  
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Figure 4.53 Plots of gold concentration and PPI versus different ligand (161) concentrations (0-725 µM) of 
monovalent and bivalent conjugates obtained from in situ conjugation. 
Figure 4.54 illustrated the number-weighted mean size of the monovalent and bivalent 
conjugates with different ligand concentrations obtained by DLS measurements. The 
results showed that conjugates with low ligand concentrations have large particle sizes 
due to the isoelectric point aggregation and those with high ligand concentrations have 
smaller particles sizes. This finding is in agreement with the results obtained from the 
absorption spectra, which also showed that the bivalent conjugates have larger particle 
size and are not as stable as the monovalent conjugates.  
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Figure 4.54 Hydrodynamic diameters of monovalent and bivalent conjugates obtained by DLS 
measurements. The y error bars represent the standard deviation from at least three measurements. 
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This result was further verified by the measurement of the zeta potential of the 
particles. When placing a particle with a net surface charge in the liquid, it attracts the 
counter ions close to its surface and results in the formation of the electrical double layer 
which contains the Stern layer and the diffuse layer. Within the diffuse layer, there is a 
slipping plane close to the Stern layer and the ions inside the slipping plane moves with 
the particle. Zeta potential is known as the electric potential that exists at the location of 
this slipping plane. It is often used to indicate the potential stability of the colloidal 
system. The greater the zeta potential, the more stable the suspension is. The general 
definition of the stable suspension is that the zeta potential should be more positive than 
+30 mV or more negative than -30 mV. Zeta potential of the particles can be measured 
using electrophoresis. By applying an electric field across the suspension, particles move 
towards the electrode of opposite charge with a constant velocity referred to the 
electrophoretic mobility (UE). The zeta potential (ζ) related to the electrophoretic mobility 
can be calculated by the Henry equation (14). 
 
Where ε is dielectric constant, η is the viscosity and f(ka) is Henry’s function. Two 
values 1.5 and 1.0 are generally used as approximations for f(ka) related to aqueous and 
non-aqueous medias, respectively. 
As shown in Figure 4.55, the monovalent conjugates have zeta potential values of +40 
mV with higher ligand concentrations (> 50 µM), whereas the bivalent conjugates have 
much lower zeta potential values of only +20 mV. This is because the neutral ligand (158) 
occupied some space on the particle surface and resulted in fewer amounts of the 
positively charged ligands (161) on the surface of the bivalent conjugated Au NPs. This 
result revealed that the bivalent conjugates have less surface charges and are not as stable 
as the monovalent conjugates. 
0 200 400 600 800
-60
-40
-20
0
20
40
60
 monovalent
 bivalent
Z
e
ta
 p
o
te
n
ti
a
l 
/ 
m
V
[161] / M  
Figure 4.55 Zeta potentials of monovalent and bivalent conjugates in sodium phosphate buffer (pH 6.0).  
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The surface coverage of the monovalent conjugates obtained by in situ conjugation 
was evaluated as described above for the ex situ conjugation. Figure 4.56 illustrates the 
surface coverage and conjugation efficiency of the monovalent conjugates. The results 
demonstrated that the monovalent conjugates obtained by in situ conjugation have a high 
conjugation efficiency (> 70 %) in the whole concentration range of 0.5-720 µM as also 
observed previously for the ex situ conjugation (see Figure 4.49). 
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Figure 4.56 The concentration (top) and percentage (bottom) of ligand 161 conjugated to the surface of the 
gold nanoparticles compared to the total amount of ligand used for in situ conjugation.  
In conclusion, monovalent and bivalent conjugated gold nanoparticles using positively 
charged peptide ligands can be successfully prepared by both ex situ and in situ 
conjugation. The ex situ conjugation is possible to control the gold concentration and the 
size distribution of the nanoparticles. Conjugates have good long-term stability but only 
with higher surface coverage after the removal of unbound ligands. Both of the methods 
showed very high conjugation efficiencies. In order to test the enzyme inhibition by the 
conjugates, the conjugated Au NPs with different ligand concentrations were determined 
for β-tryptase inhibition after removing the unbound ligands.  
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4.3.6 Enzyme Assay 
Enzyme Inhibition Assay 
The enzyme inhibition assay was performed in white 96 well microplate in 50 mM 
Tris-HCl buffer at pH 7.4 as described in Chapter 4.1.4. In order to measure the kinetic 
parameters the hydrolysis rate of substrate Tos-Gly-Pro-Arg-AMC by rhSkin β-tryptase in 
the presence of different concentrations of ligands and conjugates was determined at 
appropriate enzyme concentration and fixed substrate concentration. The kinetics of the 
enzymatic cleavage is monitored by measuring the increase of the fluorescence activity of 
the released AMC at 460 nm emission (380 nm excitation) over the time of 15 min. The 
assays (at 25 oC) were carried out in a final volume of 200 µL in assay buffer (165 µL) 
wherein the enzyme (10 µL, final concentration 0.25 nM) was incubated with various 
concentrations of conjugated Au NPs or free ligands (20 µL) and finally the substrate (5 
µL, final concentration 50 µM) was added. 
In this project, the Au NPs are used as the scaffolds to provide the multivalent 
interactions with the enzyme by attaching efficient ligands to their surface. In order to 
compare the enzyme inhibitory activity of the multivalent conjugates with the free ligands, 
the gold core should not interfere the inhibition results. Therefore, in order to test if the 
Au NPs themselves interfere the enzymatic activity, the enzyme assay in the presence of 
the ligand-free Au NPs was performed. A series of dilutions from the stock solution of Au 
NPs at a gold concentration of 313 µg/mL was prepared in 0.6 mM sodium phosphate 
buffer (pH 6.0) to determine their influence on the activity of β-tryptase. The enzyme 
inhibition results showed that in the presence of Au NPs, the rate of the product (AMC) 
conversion is lower compared to the sample without Au NPs, which could be due to the 
inhibition of the enzyme activity or the quenching fluorescence activity of the released 
AMC. However, whether the interference is resulted from the direct enzyme inhibition or 
the fluorescence quench of AMC needs to be investigated. Therefore, in order to test if the 
Au NPs have any influences on the fluorescence of the released product, fluorescence 
titration experiment of AMC with ligand-free Au NPs was carried out. The results 
demonstrated that the fluorescence of AMC is quenched by ligand-free Au NPs as shown 
in Figure 4.57. Hence, the observed decrease of fluorescence activity of AMC in the 
enzyme kinetic assay might be caused by the fluorescence quenching of AMC but not by 
the direct inhibition of the enzyme. 
RESULTS AND DISCUSSIONS 
143 
 
400 450 500
0
100
200
300
400
500
600
0 40 80 120
100
200
300
400
500
 
104 
In
te
n
s
it
y
 /
 a
.u
.
Wavelength / nm
0 
[Au NPs], g/mL 
In
te
n
s
it
y
 @
 4
6
0
 n
m
 
 
[Au NPs], g/mL
 
Figure 4.57 Fluorescence spectra of AMC in Tris buffer (50 mM, pH 7.4) in the presence of ligand-free Au 
NPs of increasing concentration (left) and plots of intensity at 460 nm versus Au NPs concentration (right). 
To further demonstrate the influence of the gold core from the conjugated Au NPs in 
the enzyme inhibition, a more direct experiment is to determine if the Au NPs affect the 
IC50 value of a standard inhibitor. Therefore, the IC50 value of the standard inhibitor 
p-aminobenzamidine (pAb， 25) was determined in the presence of ligand-free Au NPs. 
The result in Table 4.5 showed that the IC50 values of pAb in the presence of Au NPs with 
lower (36 µg/mL) or higher (60 µg/mL) gold concentrations are very similar to that in the 
absence of Au NPs, indicating that the Au NPs has no influence on the IC50 value of the 
inhibitor. Hence, the ligand-free Au NPs might influence the fluorescence activity of the 
enzyme assay, but if the conjugates have the same gold concentrations, they would have 
the same effect on the enzyme assay without interfering the IC50 values of the conjugates. 
Table 4.5 IC50 values [µM] of the standard inhibitor pAb for β-tryptase in the presence of Au NPs or 
phosphate buffer. 
Standard inhibitor IC50 values [µM] 
pAba 25.45 ± 0.68 
pAb with phosphate bufferb 23.02 ± 0.61 
pAb with Au NPs (36 µg/mL)b 22.36 ± 1.13 
pAb with Au NPs (60 µg/mL)b 22.03 ± 0.79 
a IC50 value of pAb was measured in Tris-HCl buffer. 
b IC50 values of pAb were 
measured in Tris-HCl buffer in the presence of 20 µL phosphate buffer or Au NPs in 
phosphate buffer. 
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Then, the IC50 values of conjugates with different surface functionalities were 
determined. Due to the instability of the bivalent conjugates after the removal of the 
unbound ligands, only the IC50 values of monovalent conjugates were determined after 
removing the unbound ligands. The IC50 values of the monovalent conjugates (171) refer 
to the ligand (161) concentration on the surface of the Au NPs needed for the half 
maximal inhibition of the enzyme. In order to compare with the ligand itself, the IC50 
values of the thiolalkylated peptide ligand (161) used for conjugation and the related 
alkylated peptide ligand (168) as well as the acetylated peptide ligand (170) as controls 
were also determined. The results summarized in Table 4.6 showed that the conjugates 
have low micromolar inhibitory affinity similar to the free ligands (161, 168, 170) 
featuring the same peptide sequence. It is surprising that the multivalent conjugated Au 
NPs are not superior to the single ligand. This might be due to the size of the Au NPs 
being so large that they do not fit to the entrance to the central pore of the enzyme. 
Moreover, the Au NPs might be not able to reach the two types of favored binding sites on 
the surface of β-tryptase which are situated at the monomer-monomer interfaces and 
around the active sites as described by the docking studies (Chapter 4.1.1) for this type of 
peptide ligands and thus only have moderate inhibitory activity. However, nevertheless 
this result demonstrated that the Au NPs at least do not disturb the enzyme inhibition and 
have no toxicity for this enzyme activity during the assay as often found when using NPs 
in the biological systems.293 The similar IC50 values of ligands featuring the same 
alkylated TEG linker but with (161) or without (168) the terminal thiol group indicates 
that the thiol group does not contribute to the enzyme inhibition. Moreover, the 
comparison of ligand 170 without the alkylated TEG linker with ligand 161 and ligand 
168 containing the alkylated TEG linker revealed that the linker has no influence in the 
enzyme inhibitory activity. This is also demonstrated by the neutral ligand 158 which 
showed no inhibition of β-tryptase even at a very high concentration of 1 mM. The 
single-armed ligands (161, 168, 170) containing the peptide sequence KWK with the 
artificial arginine analog GCP group attaching to the side chain of the C-terminal lysine 
have very low IC50 values compared to the single-armed peptide ligand RWKG (Ki = 306 
µM) in Wich’s work13 which contains arginine instead of lysine-derived GCP binding 
motif. Their IC50 values are also much lower than the above described standard inhibitor 
pAb featuring the guanidine analog amidine. These findings are in agreement with the 
previous results, demonstrating again that the artificial arginine analog GCP moiety can 
significantly improve the enzyme inhibitory activity compared to peptide ligand with just 
proteinogenic amino acids. However, why the single-armed ligands (161, 168, 170) have 
such low IC50 values compared to the peptide-derived hydrazide 138 (IC50 = 24 µM) 
featuring the same peptide sequence and the GCP group (see Chapter 4.2) is unclear at 
this moment.  
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Table 4.6 IC50 values [µM] of the monovalent conjugated Au NPs and ligands for β-tryptase. 
  Inhibitors IC50 values [µM] 
Conjugated Au NPs 
 Ex situ conjugates (171) 2.12 ± 0.49 
 In situ conjugates (171) 1.29 ± 0.22 
Ligands for 
comparison with the 
conjugates 
 161 2.25 ± 0.16 
 168 3.62 ± 0.10 
 170 1.03 ± 0.04 
 158 > 1000 
 
In order to further investigate how these single-armed inhibitors interact with 
β-tryptase, the mode of enzyme inhibition was determined by measuring the enzyme 
reaction rate at different substrate concentrations (0-500 µM) in the presence of different 
inhibitor concentrations (0, 1, 5, 10, 50 µM). The inhibition mode can then be illustrated 
by analyzing the data with the help of nonlinear regression (Figure 4.58) and the 
Lineweaver-Burk plots (Figure 4.59). The analyses of both plots clearly show that the 
enzyme inhibition is competitive. The nonlinear regression shows that the reaction rates 
rise slowly in the presence of inhibitor but have the tendency to reach the same Vmax at a 
higher substrate concentration. The half maximum reaction rate is reached at higher 
substrate concentration depending on the amount of the present inhibitor, which confirms 
that the Km value is increased in the presence of inhibitor. All these information is a sign 
for competitive inhibition mode. Moreover, the double-reciprocal Lineweaver-Burk plots 
show that they have an interception on the x-axis in the presence or in the absence of 
inhibitor, which is also indicative for a competitive inhibition. Hence, with the help of 
these experiments it is possible to prove that most likely these single-armed inhibitors 
compete with the substrate for the same binding site and hence act as competitive 
inhibitors of β-tryptase. 
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Figure 4.58 Nonlinear regression analysis of reaction velocity versus substrate concentration according to 
the Michaelis-Menten equation. 
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Figure 4.59 Lineweaver-Burk plots of 1/v against 1/[S] in the absence and in the presence of a fixed 
concentration of an inhibitor.  
 
  
RESULTS AND DISCUSSIONS 
147 
 
4.3.7 Molecular Modeling Studies 
The investigation of the enzyme inhibition mode in the above chapter led to the 
conclusion that the small single-armed inhibitor binds directly to the active catalytic sites 
buried inside the central pore of β-tryptase. To further verify how this type of inhibitors 
inhibits β-tryptase, docking studies were carried out to visualize possible binding modes 
between the inhibitor and β-tryptase. The calculations were done by Martin Ehlers in our 
working group by using the software Schrödinger MacroModel and Glide software 
(Version 2012 Update 2). The ligand 3D structure was minimized with the help of the 
optimized potential for liquid simulation (OPLS) 2005 force field. The enzyme input is 
based on the reported crystal structure of β-tryptase (PDB code: 1A0L) with all water 
molecules and substrates removed from the binding pore of the crystal structure. Then 
Glide was used to generate a receptor grid file of the active catalytic centers of β-tryptase, 
to obtain detailed information about possible binding sites. Because the tetrameric 
structure of the enzyme is symmetric, it is interesting to dock the more detailed and 
specific parts of the enzyme. Therefore, besides the full tetrameric tryptase structure, the 
“long-half”, “short-half”, and the “quarter” protein structures were prepared as well. Grids 
were then prepared for all the four types of protein structure. Ligand docking was then 
performed in the extra precision mode with sampling of nitrogen inversions and ring 
confirmations. The ligand conformations were simulated without any constrains or 
restrictions besides a penalization in the implemented scoring function (Glide) for 
nonplanar amide conformations. Post-docking minimizations were performed using a 
rejecting threshold of 0.5 kcal/mol. 
The calculations of ligand 170 and the four types of protein structures show some 
favored ligand conformations binding to the active site of β-tryptase. The docked binding 
surface area within the “short-half” structure of the enzyme is shown in Figure 4.60. It 
situates around one active site of the enzyme and spans over the interface of two 
monomers. As shown in Figure 4.61, the ligand interacts with the enzyme by binding to 
the active site with the GCP group and the monomer-monomer interface with the lysine 
side chain. A closer look with different views of the binding region reveals that the GCP 
moiety fits perfectly the geometry of the S1 binding pocket and is buried in this cavity.  
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Figure 4.60 Left: The tetrameric structure of β-tryptase (PDB code: 1A0L); the left side (“short-half”) is 
used for the calculations with the interaction area between the ligand and the enzyme represented as colored 
surface; the right, darker side (second “short-half”) is excluded from the calculations. Right: Close-up of the 
concave binding surface within the “short-half” structure involved in the calculations. The surface colors 
represent the positive (blue) and negative (red) surface electrostatic potentials.  
 
Figure 4.61 Different views of calculated images of the tripeptide ligand 170 (shown as ball and sticks) in 
the active site of β-tryptase. The GCP group fits perfectly in the S1 binding pocket (marked with the green 
circle). 
Figure 4.62 illustrates the key interactions between the ligand and the protein residues. 
The GCP group binds to the acidic S1 pocket by forming four hydrogen bond assisted ion 
pairs between the guanidinio group of the GCP moiety and the protein residues ASP-189, 
Ser-190 and Gly-219. The lysine side chain of the ligand binds to the monomer-monomer 
interface through the charge interaction with the protein residue Glu-217.  
A more detailed interaction diagram (Figure 4.63) shows clearly the distributions of the 
protein residues in a distance of 4 Å to the ligand and their possible interactions with the 
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ligand. The surrounding line represents the contact area featuring various surface 
characteristics. Besides the above described interactions of protein residues with GCP 
group and lysine side chain of the ligand, additional interactions are shown between the 
backbone of the ligand and the hydrophobic residue Ala-97, as well as the polar residues 
Gln-98 and Ser-214. 
 
Figure 4.62 Schematic representation of the interaction between the ligand (170) and the protein residues. 
The hydrogen bonds are presented as black dashed lines. 
 
Figure 4.63 The interaction diagram of the protein residues around the ligand (170) within a distance of 4 Å. 
The hydrogen bonds are presented as arrows with solid and dashed lines, showing the interactions of the 
ligand with the backbones and side chains of the protein residues, respectively. The surrounding line 
represents the contact area with different colors indicative of different surface characteristics (red = acidic, 
green = hydrophobic, blue = polar). The gray surrounding of some ligand atoms indicates a solvent exposed 
position. 
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Figure 4.64 Left: Overlay of the conformations of GCP moieties of three calculated ligands (161, 168 and 
170). Right: The acidic S1 binding pocket of the β-tryptase is addressed by the GCP moiety of the ligands. 
The docking studies were also performed with ligands featuring the same peptide 
sequence but containing the alkylated TEG chain with (161) or without (168) a terminal 
thiol group. The resulting conformations of these two ligands reveal a well-defined 
position of the GCP moiety but no define position of the alkylated TEG chain. As shown 
in Figure 4.64, the comparison of the three calculated ligands (161, 168 and 170) indicates 
that the GCP groups have the same binding positions. The binding regions of the three 
conformations of different ligands demonstrate a favorite binding position of the GCP 
group in a deep S1 cavity of the enzyme. These results demonstrated the importance of 
the GCP group for the efficient inhibition of β-tryptase. 
Therefore, the calculation results also confirm that most likely the ligands bind to the 
active site of β-tryptase and thus compete with the substrate for the same binding site. The 
artificial GCP group of the ligand fits perfectly to the S1 binding pocket of β-tryptase by 
interacting with residues ASP-189, Ser-190 and Gly-219 through four hydrogen bonds, 
while the lysine side chain binds to the monomer-monomer interface of the protein by 
interacting with the residue Glu-217. These findings are also in agreement with the 
docking studies described in Chapter 4.1.1. The calculations underline the importance of 
the GCP group for binding to the active site of the enzyme, which also explains the much 
more efficient inhibition of β-tryptase by this type of ligands containing the GCP group 
compared to other active site inhibitors such as the above described single-armed peptide 
ligand RWKG in Wich’s work13 and the standard inhibitor pAb. Hence, this type of small 
ligands containing the GCP group can already efficiently bind to the active site of the 
enzyme. However, when they were attached to the surface of the gold nanoparticles, most 
likely the large size of the conjugated Au NPs might not allow it to interact with the acidic 
hot spots around the entrance to the central pore of the enzyme. Probably only random 
binding to acidic areas on the protein surface occurs. Therefore, the access of the substrate 
to the active site might not be completely blocked by the conjugates, thus they only show 
moderate inhibition affinity similar to the single-armed ligands which compete with the 
substrate for binding to the active site of β-tryptase. 
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In conclusion, it is possible to generate and evaluate the monovalent and bivalent 
conjugated gold nanoparticles by ex situ or in situ conjugation with the help of laser 
ablation. Both the ex situ and in situ conjugations have shown high conjugation efficiency. 
The monovalent conjugates featuring the positively charged peptide ligands containing 
the artificial arginine analog GCP binding motif on the surface of the nanoparticles show 
long-term stability and could inhibit β-tryptase with low micromolar affinity. We could 
demonstrate that the conjugated nanoparticles do not disturb the enzyme activity when 
compared with the free ligand. The single-armed ligands inhibit β-tryptase with low 
micromolar affinity in a competitive way. It could be demonstrated by docking studies 
that the inhibition is based on the binding to the S1 pocket of the enzyme and thus the 
inhibitors compete with the substrate for the active site. The inhibition data of the 
single-armed ligands show that the artificial GCP groups can significantly improve the 
enzyme inhibitory activity compared to the ligands with only proteinogenic amino acids. 
In future studies, ligands with different characteristics can be conjugated to the surface of 
the gold nanoparticles and test for given biological targets.  
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5. SUMMARY AND OUTLOOK 
This thesis was focused on the discovery of novel and potent inhibitors for the serine 
protease β-tryptase which has a unique tetrameric structure consisting of four monomers 
with the A2B2 arrangement pointing towards to a central pore and four active sites buried 
inside the cavity. Not like the classical active site inhibitors of β-tryptase as mostly 
described in the literature, the multivalent ligands were designed by using new structures 
and new approaches to inhibit β-tryptase through protein surface recognition. The ligands 
featuring the basic residues were used to bind to the acidic hot spots around the entrance 
to the central pore, thus blocking the access to the active sites. Besides the proteinogenic 
amino acids, the artificial arginine analog GCP moiety was used as the tailor-made 
binding motif to improve the inhibitory affinity. The inhibitors were shown to efficiently 
bind to the protein surface through the electrostatic interactions and hydrogen bonding. 
The results are briefly summarized in the following text. 
5.1 New Tetravalent Peptide Ligands with Two Different Sets of Arms 
for the Inhibition of β-Tryptase 
The new design of tetravalent ligands in the first part of this thesis was based on the 
previous findings of tetravalent peptide ligands with four identical arms attached to a 
lysine dendrimer scaffold. Now docking studies revealed that there are at least two 
different kinds of binding sites on the enzyme: one at the interfaces of two monomers and 
one nearby the catalytic center. Hence, in order to bind to the two binding sites of the 
enzyme, the tetravalent peptide ligands 115-120 (Figure 5.1) with two different sets of 
arms and the artificial arginine analog GCP moiety were designed and synthesized by 
using standard Fmoc SPPS with an orthogonal protecting group strategy. To further test 
the influence of the artificial GCP moiety on the inhibition of β-tryptase, tetravalent 
ligands 124-125 with four identical arms terminating with the artificial GCP group were 
designed and synthesized by using microwave-assisted Fmoc SPPS. 
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Figure 5.1 Structure of tetravalent peptide ligands (115-120) with two different sets of arms (colored in red 
and blue, respectively) and tetravalent ligands (124-125) with four identical arms terminating with the 
artificial arginine analog GCP moiety. 
Enzyme assays of these ligands revealed that all the ligands could efficiently inhibit 
β-tryptase with lower micromolar to nanomolar affinity (Ki values between 13 μM and 
0.067 μM). The ligand 120 with two different sets of arms and the artificial arginine 
analog GCP group was shown to be the most efficient inhibitor in these series of peptide 
ligands. It was observed that inhibitor 120 has 60 and 200 times higher inhibitory affinity 
to the β-tryptase than inhibitors 115 and 117 by replacing amino acid arginine or lysine 
with the artificial GCP group, respectively. This finding revealed that the presence of the 
artificial GCP group can significantly improve the inhibitory affinity of such tetravalent 
peptide ligands. Furthermore, inhibitor 120 showed a biphasic inhibition mode: one with 
high affinity (Ki = 0.056 μM) and one with low affinity (Ki = 19.59 μM). This finding 
could result from the two different sets of arms binding to the two different binding sites 
of the enzyme with different binding affinities as identified from the docking studies. The 
tetravalent inhibitors 124-125 with four identical arms showed similar inhibitory affinities 
to β-tryptase which indicated that an additional glycine is not necessary and the peptide 
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arm consisting of the tripeptide and the terminal GCP group should have the appropriate 
length to bind to the surface of the enzyme. Furthermore, all the ligands showed no 
inhibition against other related serine proteases such as trypsin and α-chymotrypsin, 
which indicated the highly selective binding to β-tryptase. 
With the help of the dialysis experiments and the replacement experiments by the 
addition of excess heparin which restored the enzyme activity, it could be shown that 
these ligands inhibit the β-tryptase in a reversible way. The further investigation of the 
inhibition mode with the help of the interpretation of the nonlinear regression and the 
Lineweaver-Burk plots could show that the tetravalent inhibitors inhibit the enzyme in a 
noncompetitive mode. This finding indicated that most likely the inhibitors bind to the 
surface of the enzyme and do not compete with the substrate for the active sites. This is 
confirmed by the computational calculations of possible binding modes between the 
inhibitor and β-tryptase. As illustrated in Figure 5.2, the cationic residues of inhibitor 120 
bind to a cluster of acidic amino acids such as aspartic and glutamic acids that accumulate 
at the entrance to the central pore and around the active sites of β-tryptase, which agree 
very well with the findings of these two kinds of favored anionic binding sites from the 
docking studies. Therefore, the tetravalent inhibitors could span over the entrance to the 
central pore, thus limiting the access to the active sites.  
 
Figure 5.2 Representation of a possible binding mode of the inhibitor 120 (cyan) to the surface of β-tryptase. 
The cationic inhibitor could bind to the anionic residues (yellow sticks) and spread out across the central 
pore, thus blocking the access to the active sites. 
The artificial GCP moiety as the tailor-made binding motif has been shown to improve 
the enzyme inhibitory affinity compared to analogous ligands with only proteinogenic 
amino acids. The variation of its combinatorial position within the peptide arms could be 
interesting for developing even more efficient inhibitors of β-tryptase. Therefore, the 
artificial amino acid derived GCP building block AA-GCP 173 (Figure 5.3) can be used to 
incorporate into different positions in the peptide arms. The synthesis of 173 has been 
developed in this group and it can be easily implemented in the peptide arms by using 
SUMMARY AND OUTLOOK 
155 
 
standard Fmoc SPPS approach.294 
 
Figure 5.3 The amino acid guanidiniocarbonyl pyrrole binding motif (AA-GCP) 173 allows implementing 
the artificial arginine analog GCP units into different positions within the arms for the discovery of even 
more potent inhibitors of β-tryptase. 
Even though efficient inhibitors have been discovered from the design of the 
tetravalent ligands with two different sets of arms and the artificial GCP binding motif, 
the peptide sequences of the two different arms are yet to be optimized. Therefore, in 
order to improve the inhibitory affinity, a combinatorial approach would be possible for 
the discovery of even more efficient inhibitors of β-tryptase. As depicted in Figure 5.4, a 
combinatorial library of the four-armed peptide ligands with two different sets of arms 
each composed of a variable tetrapeptide unit (174) can be generated by using split and 
mix approach. Six different amino acids (Lys, Arg, Trp, Phe, Glu, AA-GCP) including the 
basic, aromatic, acidic amino acids and the artificial AA-GCP building block can be used 
in each variable position to ensure a sufficient structural and chemical diversity in the 
library. The optimized tetravalent peptide structure from the combinatorial library could 
possibly show more efficient inhibitory properties for β-tryptase. 
Figure 5.4 Combinatorial library consists of tetravalent peptide ligands with two different sets of arms each 
contains four combinatorial positions (Lys, Arg, Trp, Phe, Glu, AA-GCP) would allow for identifying more 
efficient inhibitors of β-tryptase.  
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5.2 New DCC Approach for the Discovery of Inhibitors of β-Tryptase 
The second part of this thesis was focused on the discovery of potent inhibitors of 
β-tryptase by using a new dynamic combinatorial approach with the help of dynamic 
deconvolution strategy. The DCLs were based on reversible acyl hydrazone formation 
between hydrazides and aldehydes. As depicted in Figure 5.5, five peptide-derived 
hydrazides comprising a tetrapeptide sequence with a glycine and a variable tripeptide 
part featuring cationic (Lys, Arg, lysine-derived GCP), aromatic (Trp), hydrophobic (Ala) 
and anionic (Glu) amino acids for sufficient structure diversity. All the hydrazides were 
synthesized via microwave-assisted SPPS. Five different di- and tri-aldehydes with 
structural complexity were used as scaffolds allowing building up the multivalent 
inhibitors. In order to identify the active components from the library, a dynamic 
deconvolution protocol was utilized. The full library and ten sub-libraries in which one 
building block is missing were generated under acidic conditions. After the complete 
equilibrium of all the libraries, the resulting mixtures were subjected to investigation of 
inhibitory activity of β-tryptase under the required physiological conditions. 
 
Figure 5.5 Hydrazide and aldehyde building blocks for generation of the hydrazone-based dynamic 
combinatorial libraries.  
The screening of the libraries revealed that the positively charged hydrazides (135-136, 
138-139) are of importance for enzyme inhibition while the negatively charged hydrazide 
140 is not necessary. This finding revealed the importance of the basic residues for the 
complementary electrostatic interactions with the acidic hot spots on the surface of the 
enzyme. Moreover, the peptide sequence and the artificial GCP group also played a key 
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role in binding to the enzyme. Hydrazide 138 featuring the artificial GCP group is the 
most active component in the library, which indicated that the GCP group can increase the 
inhibitory affinity. However, this effect relies on its position within the peptide arm as 
observed from 139 with much less activity. Further evaluation of the scaffolds by using 
the size-reduced libraries confirmed that the aromatic and rigid tri-aldehyde E and 
di-aldehyde C are the most active scaffolds in the library.  
The representative library members 141-149 as shown in Figure 5.6 were synthesized 
individually containing both the homo- and hetero-meric inhibitors and their inhibitory 
properties were determined using standard enzyme kinetic assays. The inhibition data is in 
agreement with the screening of the DCLs which showed that all the positively charged 
two- and three-armed inhibitors can efficiently inhibit β-tryptase with Ki values in low 
nanomolar range (12-392 nM) while the negatively charged compound 145 showed no 
inhibition (Ki > 100 μM) at all. Furthermore, in direct comparison with the monovalent 
hydrazides, these inhibitors show three orders of magnitude increase of affinity, which 
clearly indicates a significant multivalency effect. Furthermore, the two most potent 
inhibitors 141 (Ki = 12.5 nM) and 143 (Ki = 22.5 nM) are one order of magnitude more 
efficient than the best tetravalent inhibitor (RWKG)4 (Ki = 170 nM) from the previous 
combinatorial library. This finding suggests that rigid aromatic scaffolds are superior to 
more flexible ones. More interestingly, the five-fold difference in inhibitory affinity 
between 143 and 144 was illustrated with the help of computational calculations which 
revealed similar binding modes of them to β-tryptase but more stable intramolecular 
interactions in 144 than 143, thus resulting in a less inhibitory affinity to the enzyme. 
 
Figure 5.6 Acyl hydrazones derived from the tri- or di-aldehyde scaffolds and the five hydrazides. 
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Further experiments revealed the highly selective inhibition of β-tryptase by these 
inhibitors against other related serine proteases such as trypsin and α-chymotrypsin. 
Furthermore, the inhibition of β-tryptase by these inhibitors was demonstrated to be 
reversible by dialysis experiments. With the help of Dixon plots, it could be shown that 
these inhibitors feature a noncompetitive inhibition mode, suggesting most likely surface 
binding. The calculations confirmed that the inhibitors can indeed bind to the surface of 
β-tryptase blocking access to its central pore and thus shutting down the enzyme activity. 
One unexpected finding of these results was that the position of the artificial GCP 
group is very important for the inhibitory activity of the inhibitors. Hence, the continuing 
work on this topic should focus on the combinatorial variations within the peptide arms 
by incorporating the GCP units in different positions. The GCP group can be easily 
implemented into different positions within the peptide arms in the form of artificial 
amino acid derived arginine analogs (173, 175) as shown in Figure 5.7. These two 
building blocks with different length of side chains can be used as the normal amino acids 
in Fmoc SPPS with no limitations. Thus, a combinatorial approach can be utilized for 
optimizing the peptide sequences. 
 
Figure 5.7 The tailor-made amino acid derived GCP binding motifs (173, 175) allows a combinatorial 
structural optimization with the GCP units in different positions within the side chains of β-tryptase 
inhibitors. 
Another interesting finding of these results was that the rigid aromatic scaffolds for 
building up the multivalent inhibitors of β-tryptase are superior to the flexible ones. 
Therefore, the scaffold with four or five aldehyde groups can be used for the development 
of even more efficient inhibitors of β-tryptase. For example, the tetra-aldehyde (176) or 
penta-aldehyde (177) derived from biphenyl or calix[5]arene as shown in Figure 5.8 can 
be used. The syntheses of these compounds are already known in the literature.295-296  
 
Figure 5.8 Possible rigid scaffolds with four (176) or five (177) attachment aldehyde groups for 
constructing more potent inhibitors of β-tryptase. 
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Since this approach has shown a great power for identifying efficient enzyme inhibitors, 
it can be extended to discovery of receptors for other biological targets such as proteins or 
DNA. Therefore, DCLs can be generated by using new scaffolds and suitable peptide 
structures with the tailor-made binding motifs for targeting a specific biological molecule 
by means of DCLs. Furthermore, due to the addition of aniline could accelerated the 
equilibration and allow generation of DCLs under near physiological conditions, the 
preparation of new DCLs can be carried out in the presence of aniline, allowing biological 
targets templation to select the best inhibitors or receptors.  
5.3 Gold Nanoparticles as Scaffold for Protein Surface Binding 
The last part of this thesis was concerned with the development of novel inhibitors of 
β-tryptase by using gold nanoparticles as scaffold based on protein surface recognition 
event. A series of ligands featuring thiolalkylated TEG chain terminating with different 
recognition motifs and the artificial arginine analog GCP were synthesized via 
microwave-assisted SPPS for the conjugation of gold nanoparticles. The fabrication of the 
gold nanoparticles by laser ablation was carried out by our cooperation partner from the 
working group of Prof. Barcikowski. The monovalent and bivalent conjugated gold 
nanoparticles with one or two types of ligands were prepared by ex situ and in situ 
conjugation. As shown in Figure 5.9, in the first studies, the positively charged peptide 
ligand (161) containing the artificial arginine analog GCP was used for the monovalent 
conjugates (171). For bivalent conjugates (172), the neutral ligand (158) was used as a 
surface blocker in addition to the positively charged ligand (161). With the help of 
UV/Vis spectroscopy the gold concentration could be evaluated and the quality of the 
obtained gold colloids could be analyzed. It could be shown that the monovalent 
conjugates have very good long-term stability. The surface coverage value and the 
conjugation efficiency could be calculated after removing the unbound ligands by using 
ultracentrifugation. It could be shown that the conjugation efficiency of the monovalent 
conjugates is over 80 % with ligand concentrations at 0.5-430 μM. The surface of the Au 
NPs (d = 5 nm) is already saturated at 374 ligands per NP and multilayers are suggested 
with higher ligand amount. It could be shown that the particle sizes are around 5-6 nm by 
means of disc centrifugation and TEM experiments. The hydrodynamic diameters 
obtained by DLS measurements are a bit larger (20-30 nm) due to the solvation and the 
strong signals weighed by rather bigger particles. 
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Figure 5.9 Ligands (161, 158) used for the preparation of monovalent conjugates (171) and bivalent 
conjugates (172).  
In the first preliminary enzyme inhibition studies we could demonstrate that the Au 
NPs themselves have no interference with the determination of the IC50 values. Enzyme 
assays of the monovalent conjugates 171 and the related free ligand 161 revealed that both 
the conjugates and the ligand could efficiently inhibit β-tryptase with lower micromolar 
(IC50 = 1-3 μM). Even though the conjugates are not superior to the single-armed ligand, 
we could demonstrate that at least the conjugated Au NPs have no influence in the activity 
of this enzyme. The comparison of the single-armed ligand 161 with either the peptide 
ligand containing only the proteinogenic amino acids, e.g. RWKG or the small standard 
inhibitor pAb revealed that the presence of the artificial GCP binding motif can 
significantly improve the inhibitory activity.  
In order to further investigate the inhibitory activity of such single-armed ligand, the 
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ligands featuring the same peptide sequence KWK and the artificial GCP group, with (168) 
or without (170) the alkylated TEG chain were synthesized (Figure 5.10). The inhibition 
data revealed that these two ligands have similar inhibitory activities to ligand 161. 
Further investigation of the inhibition mode of this type of single-armed ligands with the 
help of the interpretation of the nonlinear regression and the Lineweaver-Burk plots could 
show that they inhibit the β-tryptase in a competitive way. This finding revealed that the 
ligands bind to the active site of the enzyme. This is confirmed by docking studies of the 
possible binding mode between the ligand and β-tryptase. As shown in Figure 5.11, the 
GCP moiety fits perfectly in the S1 binding pocket through the interaction with Asp-189, 
Ser-190 and Gly-219. Hence, this type of ligands inhibits β-tryptase by competing with 
the substrate for the same active site. 
 
Figure 5.10 Ligands (168, 170) used for comparison with ligand 171. 
 
Figure 5.11 Representation of the possible binding mode of the single-armed ligand 170 to the active site of 
β-tryptase. The GCP group fits perfectly in the S1 binding pocket (marked with the green circle) by 
interacting with Asp-189, Ser-190 and Gly-219. 
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Therefore, although more work in this project is still on-going, the preliminary results 
have shown that we are able to prepare and analyze the peptide conjugated Au NPs and 
apply these conjugates in enzyme inhibition. Even though the conjugates are not superior 
to the single ligand in this work so far, this is only the first result for only one trial ligand. 
The next step could be the preparation of conjugates with other peptide ligands (162-165) 
that have been synthesized in this work. These conjugates might be attractive for the 
interactions with different biological targets, such as proteins featuring different 
characteristics or nucleotides. The positively charged peptide conjugates featuring the 
artificial GCP moieties could be used for DNA binding and gene delivery. The negatively 
charged conjugates could be very interesting for the proteins feature positive surface 
patches, such as α-chymotrypsin or cytochrome c.  
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6. EXPERIMENTAL SECTION 
6.1 General Experimental and Analytical Methods 
Solvents and Chemicals 
All solvents were dried before use if necessary. Diethyl ether and THF were distilled 
from sodium with benzophenone as indicator. DCM was distilled from calcium hydride. 
DMF was distilled from calcium hydride under reduced pressure. Methanol was distilled 
before use. All solvents were stored under argon before use. Water for spectroscopic 
measurements was purified with a TKA MicroPure ultrapure water system. All other 
solvents and chemicals were used as supplied from commercial sources unless otherwise 
stated. 
Inert Gas  
Reactions under inert gas were carried out with Argon (99.998 %) from Air Liquide 
which was dried with Silica Gel Orange. 
Magnetic Stirrer  
Reactions were carried out by using magnetic stirring bars with the help of a MR 3001 
K magnetic stirrer from Heidolph. 
Rotary Evaporator 
Distillation of solvents was performed at 40 oC under appropriate pressure with the 
help of a Heidolph Hei-VAP Advantage rotary evaporator. 
Vacuum Pumps  
Vacuum was generated with a Vacuubrand CVC3000 pump. High vacuum was 
generated with a RC6 Vacuubrand chemistry hybrid pump. 
Thin layer Chromatography (TLC)  
Analytical TLC was carried out to monitor reactions on silica gel precoated plates on 
aluminium foils ALUGRAM SIL G/UV254 and C18 SiO2 aluminium foils ALUGRAM 
RP-18W/UV254 from Macherey-Nagel. The spots were visualized by fluorescence 
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quenching upon irradiation with 254 nm UV light or with the help of iodine vapors.  
Flash Chromatography  
Flash chromatography was performed on columns packed with Silica gel 60M with a 
spherical size of 40-63 μm from Macherey-Nagel. Organic solvents used for flash 
chromatography were distilled prior to use and the ratio of solvent mixtures were reported 
in volume. 
Orbital Shaker for Peptide Synthesis  
The standard solid phase peptide synthesis was carried out with IKA KS 130 basic 
orbital shaker. 
Microwave for Peptide Synthesis  
Microwave assisted SPPS were performed in the CEM Discover Systems with Gas 
Addition Kit Accessory. 
Analytical HPLC  
The analytical “Medium Performance Liquid Chromatography” (HPLC) was done with 
Dionex HPLC apparatus: P680 pump, ASI-100 automated sample injector, UVD-340U 
UV detector, UltiMate 3000 Column Compartment. The YMC ODS-A RP18 column with 
a pore size of 12 nm and a spherical size of 5 μM was utilized. The sizes of 15 cm × 3.0 
mm and 25 cm × 10 mm were used for the analytical and semi-preparative analysis, 
respectively. Commercially available HPLC grade solvents and ultrapure water were used 
as eluents and solvent mixtures were reported in volume percent. 
Preparative MPLC  
The preparative “High Performance Liquid Chromatography” (HPLC) was performed 
with an Armen Instrument Spot Flash Liquid Chromatography MPLC apparatus with 
YMC ODS-A columns with a pore size of 12 nm and a spherical size of 50 μM. Distilled 
or HPLC grade solvents and ultrapure water were used as eluents. Products were detected 
by means of a UV detector. 
Lyophilization  
Lyophilization was carried out in an Alpha 1-4 LD plus freeze drying apparatus from 
Christ. 
Nuclear Magnetic Resonance (NMR)  
1H and 13C NMR spectra in CDCl3 or DMSO-d6 were recorded with Bruker DMX 300, 
Bruker DRX 500 and Bruker Avance 700 spectrometer. The spectra were calibrated by the 
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residual signals of the deuterated solvents as internal standard. The chemical shifts are 
reported in ppm (δ value). The coupling constants are reported in Hertz. The following 
abbreviations for the description of the signal multiplicity are used: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad signal.  
Fourier Transform Infrared Spectroscopy (FT-IR)  
The IR spectra were measured on a Jasco FT/IR-430 with ATR attachment 
spectrometer. The bands are reported in cm-1 and the following abbreviations are utilized 
for the description of the band intensities: s = strong, m = middle, w = weak, br = broad. 
Mass Spectrometry (MS) 
High resolution ESI mass spectra were recorded with a Bruker BioTOF III 
spectrometer. 
Melting Point  
Melting points were measured in open end glass capillary tubes with Büchi Melting 
Point B-540 and are quoted uncorrected.  
pH Meter  
The pH was determined with the Knick pH-Meter 766 Calimatic. The pH-meter was 
calibrated with commercial available buffer standards (pH = 4.00 and 7.00). 
UV/Vis Spectroscopy  
UV/Vis spectra were recorded with Jasco V-660 or Thermo Scientific Evolution 201 
spectrometer in standard quartz microcuvettes with 1 cm width. All spectra are corrected 
against the background (assay buffer).  
Fluorescence Spectroscopy  
Fluorescence spectra were recorded in sterile Nunclon Surface 96-well plates from 
Nunc with a Varian Carey Eclipse Fluorescence spectrophotometer with microplate reader 
unit. 
Picosecond Laser  
Laser ablation of gold nanoparticles was carried out using an Ekspla Atlantic 
picosecond laser system providing < 10 ps laser pulses at a wavelength of 1064 nm (pulse 
energy > 160 µJ, beam diameter: 2 mm), a power of 17.03 W, a repetition rate of 100 kHz 
and a focal length of 100 mm. The generation of the functionalized gold nanoparticles 
was done in two different ways depending on the types of conjugation. 
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Dynamic Light Scattering  
DLS measurements were performed with a Zetasizer Nano-ZS from Malvern 
Instruments GmbH and analyzed with the software provided from the manufacturer.  
Centrifuge  
Precipitates of the peptides were centrifuged with a Rotofix 32 from Hettich. 
Ultracentrifuge  
The separation of big particles > 10 nm to obtain monomodal and monodisperse gold 
nanoparticles was carried out with Beckman Coulter OptimaTM MAX-XP with the 
conditions of 7 °C, 30000xg and 13 minutes. Purification of gold nanoparticles was done 
with the conditions of 7 °C, 30000xg and 31 minutes. 
Disc Centrifuge  
The particle sizes were determined by using a CPS Instruments analytical disc 
centrifuge (ADC) DC 24000 with 24000 RPM for 30 minutes. Measurements were done 
with 0.1 mL solution against a sucrose gradient detected by an UV/Vis detector at 400 nm. 
Transmission Electron Microscopy (TEM)  
The measurements were carried out using a Phillips CM 12 transmission electron 
microscope on a carbon-coated copper grid. Particle sizes were determined by counting 
1000 nanoparticles and taking their average value. 
Force Field Calculations  
Computational force field calculations were performed with the help of Schrödinger 
MacroModel Vers. 9.9 software. The calculations were carried out based on the force field 
OPLS (optimized potentials for liquid simulations) 2005 by using water as solvent. The 
structure of the enzyme was frozen while the inhibitor was put as mobilized during the 
calculation. The resulting structures were obtained from the result of 1000 calculation 
cycles. 
Docking Studies  
Docking studies were done by using Schrodinger MacroModel and Glide software 
(Version 2012 Update 2). Ligand preparation were done by the following steps: After 
generation of the 2D structure, they got converted into a 3D model, which was minimized 
in the OPLS 2005 force field using MacroModel with 1500 iterations and a convergence 
threshold of 0.05. Glide was used to generate a receptor grid file of the active centers of 
the tryptase, to get detailed information about possible binding motifs.  
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6.2 General procedures for the SPPS 
Kaiser Test 
In order to detect the free amino groups on the resin, two separate solutions of 
Ninhydrin (1 g) in ethanol (10 mL) and phenol (40 g) in ethanol (10 mL), respectively 
were prepared for the Kaiser test. A few resin beads were taken from the reaction and 
added to a mixture of the two solutions with each 0.3 mL, which was heated for 2 min at 
100-110 oC. Resin beads with free amino functionalities (-NH2) were colored dark blue or 
red while the resin beads without amino functions stayed white. 
6.2.1 General Procedures for Standard SPPS 
Standard solid phase peptide synthesis was performed in Schlenck glass vessels 
equipped with a frit and a stopper. The reaction mixtures were shaken on the orbital 
shaker under argon atmosphere. The solution was removed by filtration after the reaction 
and the resin beads were washed with the solvent. The solvent volume used for the 
coupling was chosen to fulfill the concentration of the reactants between 0.1-0.2 M, which 
has been demonstrated to be the most efficient concentrations for the SPPS. 
Fmoc Deprotection 
Fmoc protecting group was removed by treatment with 20 % piperidine in DMF two 
times each for 20 min. Then the resin was thoroughly washed six times with DMF each 
for 5 min. The completion of the Fmoc deprotection with the formation of free amino 
groups was monitored by a positive Kaiser test and repeated if necessary.  
Alloc Deprotection 
The removal of Alloc protecting group was achieved by treatment with Pd(PPh3)4 (0.1 
eq) in the presence of PhSiH3 (24 eq) in DCM two times each for 20 min. Then the resin 
was washed three times with DCM and three times with DMF each for 5 min. The 
completion of the Alloc deprotection was monitored by a positive Kaiser test and repeated 
if necessary. 
Coupling Procedure 
The Fmoc-protected Rink amide resin and Rink amide MBHA resin were used in this 
thesis. The resin was first swollen in DCM for 1-2 h. Then the Fmoc protecting group was 
removed by agitation in 20 % piperidine/DMF as described above. The amino acid (3 eq) 
was then attached to the resin (1 eq) using PyBop (3 eq) as the coupling reagent and 
DIPEA (6 eq) as the base in DMF under argon atmosphere at room temperature by 
shaking the reaction mixture for 6-12 h. Then the resin was washed with DMF for three 
times each for 5 min, followed by the repetition of the coupling and washing steps. The 
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quantitative attachment of the amino acids was monitored by a negative Kaiser test and 
repeated if necessary.  
Cleavage from the Resin 
After the completion of all the coupling steps and Fmoc deprotection if necessary, the 
resin was thoroughly washed with DCM (3 × 5 min), MeOH (3 × 5 min) and again DCM 
(3 × 5 min). Then the resin was dried under vacuum for 1 h. The cleavage of the product 
from the Rink amide resin or Rink amide MBHA resin was achieved by adding a mixture 
of TFA/H2O/TIS (95:2.5:2.5) to the resin and the suspension was shaken for 3 h at room 
temperature and washed twice with TFA. The filtrates were combined and concentrated 
under vacuum to get an oily residue to which the diethyl ether was added to precipitate the 
peptide. The resulting suspension was centrifuged and the supernatant solvent was 
decanted. The solid was washed once again by diethyl ether and centrifuged again before 
it was dissolved in water and freeze-dried to get the crude product. The crude product was 
then purified by RP18-MPLC using appropriate conditions (H2O/MeOH + 1 % TFA). 
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6.2.2 General Procedures for Microwave-Assisted SPPS 
Microwave-assisted solid phase peptide synthesis was carried out in a 
microwave-transparent polyethylene tubes equipped with a frit using a CEM Discover 
microwave apparatus. The reaction mixtures were bubbling with argon during the reaction 
steps. The solution was removed by filtration after the completion of a reaction step and 
the resin beads were washed with the solvent. The solvent volume used for the coupling 
was chosen to ensure the concentration of the reactants between 0.1-0.2 M. It also 
depends on the volume of the reaction tubes and normally 2-20 mL was suitable. 
Fmoc Deprotection 
Fmoc protecting group was removed by treatment with 20 % piperidine in DMF two 
times for 1.5 min and 5 min, respectively under irradiation condition (20 W, Tmax = 60 °C, 
ΔT = ± 5 °C). Then the resin was thoroughly washed six times with DMF each for 2 min 
with the help of argon bubbling. The completion of the Fmoc deprotection step was 
monitored by a positive Kaiser test and repeated if necessary.  
Alloc Deprotection 
The removal of Alloc protecting group was carried out by treatment with Pd(PPh3)4 
(0.1 eq) in the presence of PhSiH3 (24 eq) in DCM for 10 min at 20W and a maximum 
temperature of 30 oC. Then the resin was washed three times with DCM and three times 
with DMF each for 2 min with the help of argon bubbling. The completion of the Alloc 
deprotection was monitored by a positive Kaiser test and repeated if necessary. 
Coupling Procedure 
The Fmoc-protected Rink amide resin or Rink amide MBHA resin was first swollen in 
DCM for 1-2 h by shaking the reaction tube on the orbital shaker or with the help of argon 
bubbling. Then the Fmoc protecting group was removed by treatment with 20 % 
piperidine/DMF as described above. The amino acid (3 eq) was then attached to the resin 
(1 eq) using PyBop (3 eq) as the coupling reagent and DIPEA (6 eq) as the base in DMF 
under argon atmosphere by microwave irradiation (20 W, Tmax = 60 °C, ΔT = ± 5 °C) for 
20 min. The resin was then washed with DMF for three times each for 2 min with the help 
of argon bubbling, followed by the repetition of the coupling and washing steps. The 
quantitative attachment of the amino acids was monitored by a negative Kaiser test and 
repeated if necessary.  
Cleavage from the Resin 
Cleavage of the product from the resin was carried out without microwave irradiation. 
Therefore, after the completion of all the coupling steps and the final washing cycles, the 
resin was transferred into Schlenck glass vessels equipped with a frit and a stopper and 
treated with a mixture of TFA/H2O/TIS (95:2.5:2.5) according to the procedure described 
in Chapter 6.2.1.   
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6.3 Syntheses of Tetravalent Peptide Ligands 
6.3.1 SPPS of Tetravalent Ligands with Two Different Sets of Arms 
Synthesis of Tetravalent Peptide Ligand (RWKG)2(RLFG)2 (115) 
 
The synthesis of tetravalent ligand 115 was carried out according to standard solid 
phase peptide synthesis described in Chapter 6.2.1. Rink amide resin (100 mg, 0.99 
mmol/g, 0.099 mmol, 1 eq) was weighed out into a glass peptide synthesis vessel and 
allowed to swell in DCM (10 mL) for 1 h. Then, the Fmoc protecting group was removed 
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with 20 % piperidine/DMF and the resin was allowed to react with Fmoc-Lys(Fmoc)-OH 
(147 mg, 0.248 mmol, 2.5 eq) and PyBOP (129 mg, 0.248 mmol, 2.5 eq) in 4 % 
DIPEA/DMF (8 mL) for 6 h to introduce the first branching. After washing with DMF, 
the first coupling step was repeated with another 2.5 equivalents of the reactants to assure 
complete conversion of all accessible amino groups on the resin. Then, all Fmoc groups 
were removed under standard deprotection conditions and the resin was treated with 
Fmoc-Lys(Alloc)-OH (292 mg, 0.495 mmol, 5 eq) and PyBOP (258 mg, 0.495 mmol, 5 
eq) in 4 % DIPEA/DMF (8 mL) for 6 h to introduce the second branching. Then the Fmoc 
protecting group was removed, followed by the attachment of the first two arms of 
tetrapeptide sequences according to standard SPPS procedures: Fmoc-Gly-OH (147 mg, 
0.495 mmol, 5 eq), Fmoc-Lys(Boc)-OH (232 mg, 0.495 mmol, 5 eq), Fmoc-Trp(Boc)-OH 
(261 mg, 0.495 mmol, 5 eq) and Boc-Arg(Pbf)-OH (261 mg, 0.495 mmol, 5 eq) were 
coupled with the help of PyBOP (258 mg, 0.495 mmol, 5 eq) in 4 % DIPEA/DMF (8 mL) 
and the Fmoc protecting groups were respectively removed after each coupling step 
allowing the following coupling. Then, the removal of the Alloc protecting group was 
achieved with Pd(PPh3)4 (11.4 mg, 9.9 μmol, 0.1 eq) in the presence of PhSiH3 (292 μL, 
2.38 mmol, 24 eq) in DCM. After an intensive washing cycle with DCM (3 × 8 mL) and 
DMF (3 × 8 mL), the second two arms of tetrapeptide sequences were attached according 
to standard SPPS procedures: Fmoc-Gly-OH (147 mg, 0.495 mmol, 5 eq), Fmoc-Phe-OH 
(192 mg, 0.495 mmol, 5 eq), Fmoc-Leu-OH (175 mg, 0.495 mmol, 5 eq) and 
Boc-Arg(Pbf)-OH (261 mg, 0.495 mmol, 5 eq) were coupled with the help of PyBOP 
(258 mg, 0.495 mmol, 5 eq) in 4 % DIPEA/DMF (8 mL) and the Fmoc protecting groups 
were respectively removed after each coupling step. All the Kaiser tests showed 
quantitative reactions with deprotection and coupling steps. After the final coupling and 
washing steps, the resin was dried under reduced pressure for one hour. Then the product 
was cleaved from the solid support by treatment with a 10 mL mixture of TFA/TIS/H2O 
(95:2.5:2.5) for 3 h according to the standard procedure for Rink amide resin described in 
Chapter 6.2.1. Crude product was purified via RP18-MPLC using appropriate conditions 
(H2O/MeOH + 1 % TFA). Pure product was transferred into its hydrochloride salt by 
dissolving the product in water with 10 % 1 M aqueous hydrochloric acid and 
lyophilizing three times to give 115 as white solid with 95 % purity according to 
analytical HPLC analysis. 
C114H193Cl10N39O19  2600.45 g/mol 
Yield     40 mg, 15.4 µmol, 16 % 
Mp.     > 250 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 0.83 (d, J = 6.3 Hz, 6 H, 2 × Leu-CH3), 0.86 
(d, J = 6.4 Hz, 6 H, 2 × Leu-CH3), 1.16-1.80, 2.70-2.80 (m, 70 H, 20 × Lys-CH2, 12 × 
Arg-CH2, 2 × Leu-CH2, 2 × Leu-CH), 2.85-3.03 (m, 8 H, 2 × Trp-CH2, 2 × Phe-CH2), 
3.68-4.62 (m, 23 H, 4 × Gly-CH2, 15 × CH), 6.97-8.88 (m, 78 H, 10 × Trp-CH, 10 × 
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Phe-CH, 6 × NH3+, 22 × NH, 9 × NH2 ), 10.93 (s, 2 H, 2 × Trp-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 21.5, 22.0, 22.7, 23.0, 23.8, 23.9, 26.4, 27.4, 
28.3, 28.7, 29.2, 31.1, 31.4, 31.9, 38.5, 40.7, 42.1 (48 C, 4 × Leu-CH3, 20 × Lys-CH2, 12 
× Arg-CH2, 2 × Leu-CH2, 2 × Leu-CH, 2 × Phe-CH2,  2 × Trp-CH2, 4 × Gly-CH2), 51.5, 
52.6, 53.9, 64.1 (15 C, 15 × CH), 109.6, 111.3, 116.9, 118.2, 118.6, 120.9, 124.1, 124.9, 
126.2, 127.2, 128.0, 129.2, 133.8, 136.1, 137.7 (28 C, 12 × Phe-C, 16 × Trp-C), 157.0 (4 
C, 4 × Gua-Cq), 168.5, 171.2, 171.6, 171.8, 173.5 (19 C, 19 × CO-Cq). 
HRMS (ESI): m/z calculated for C114H185N39O192+ [M+2H]2+: 1202.7363; found: 
1202.7422. 
FT-IR (ATR): ~  [cm-1] = 3254 (br), 2971 (br), 2923 (br), 1645 (s), 1521 (s), 1456(m), 
1242 (m), 1066 (m). 
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Synthesis of Tetravalent Peptide Ligand (KWKG)2(KLFG)2 (116) 
 
The tetravalent peptide ligand 116 was synthesized accordingly on Rink amide MBHA 
resin (100 mg, 0.67 mmol/g, 0.067 mmol, 1 eq) following the above described SPPS 
procedure. After attaching the orthogonal protected lysine dendrimer on the resin, the 
amino acids Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 
0.335 mmol, 5 eq), Fmoc-Trp(Boc)-OH (177 mg, 0.335 mmol, 10 eq) and 
Boc-Lys(Boc)-OH (116 mg, 0.335 mmol, 5 eq) were attached to the first set of arms and 
Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Phe-OH (130 mg, 0.335 mmol, 5 eq), 
Fmoc-Leu-OH (118 mg, 0.335 mmol, 10 eq) and Fmoc-Lys(Boc)-OH (157 mg, 0.335 
mmol, 5 eq) to the second set of arms. After the cleavage and purification steps, the 
product was obtained as white solid with 95 % purity according to analytical HPLC 
analysis. 
C114H193Cl10N31O19  2656.48 g/mol 
Yield     26 mg, 9.8 µmol, 14 % 
Mp.     > 250 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 0.82 (d, J = 6.5 Hz, 6 H, 2 × Leu-CH3), 0.85 
(d, J = 6.5 Hz, 6 H, 2 × Leu-CH3), 1.18-1.76, 2.68-2.79 (m, 78 H, 36 × Lys-CH2, 2 × 
Leu-CH2, 2 × Leu-CH), 3.02-3.05 (m, 8 H, 2 × Trp-CH2, 2 × Phe-CH2), 3.69-4.64 (m, 23 
H, 4 × Gly-CH2, 15 × CH), 6.96-8.86 (m, 70 H, 10 × Trp-CH, 10 × Phe-CH, 10 × NH3+, 
18 × NH, 1 × NH2), 10.92 (s, 2 H, 2 × Trp-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 20.9, 21.0, 21.6, 23.0, 24.0, 26.3, 26.4, 27.4, 
28.7, 30.4, 31.2, 37.3, 38.3, 38.4, 38.5, 40.1, 40.2, 40.7, 42.1 (52 C, 4 × Leu-CH3, 36 × 
Lys-CH2, 2 × Leu-CH2, 2 × Leu-CH, 2 × Phe-CH2,  2 × Trp-CH2, 4 × Gly-CH2),  51.6, 
51.8, 52.6, 54.0 (15 C, 15 × CH), 109.7, 111.3, 118.3, 118.6, 121.0, 124.1, 126.3, 127.2, 
128.1, 129.3, 136.1, 137.7 (28 C, 12 × Phe-C, 16 × Trp-C), 168.4, 168.5, 168.7, 171.2, 
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171.3, 171.7 (19 C, 19 × CO-Cq). 
HRMS (ESI): m/z calculated for C114H185N31O192+ [M+2H]2+: 1146.2201; found: 
1146.7158. 
FT-IR (ATR): ~  [cm-1] = 3239 (br), 3053 (br), 2923 (br), 2871 (w), 1651 (s), 1539 (s), 
1456 (m), 1114 (m), 1056 (m). 
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Synthesis of Tetravalent Peptide Ligand (RWKG)2(KLFG)2 (117) 
 
The tetravalent peptide ligand 117 was synthesized accordingly on Rink amide MBHA 
resin (100 mg, 0.67 mmol/g, 0.067 mmol, 1 eq) following the above described SPPS 
procedure. After attaching the orthogonal protected lysine dendrimer on the resin, the 
amino acids Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 
0.335 mmol, 5 eq), Fmoc-Trp(Boc)-OH (177 mg, 0.335 mmol, 10 eq) and 
Boc-Arg(Pbf)-OH (176 mg, 0.335 mmol, 5 eq) were attached to the first set of arms and 
Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Phe-OH (130 mg, 0.335 mmol, 5 eq), 
Fmoc-Leu-OH (118 mg, 0.335 mmol, 10 eq) and Fmoc-Lys(Boc)-OH (157 mg, 0.335 
mmol, 5 eq) to the second set of arms. After the cleavage and purification steps, the 
product was obtained as white solid with 95 % purity according to analytical HPLC 
analysis. 
C114H193Cl10N35O19  2712.51 g/mol 
Yield     22 mg, 8.1 µmol, 12 % 
Mp.     > 250 oC (decomposition) 
1H NMR (700 MHz, DMSO-d6): δ [ppm] = 0.82 (d, J = 5.7 Hz, 6 H, 2 × Leu-CH3), 0.85 
(d, J = 5.7 Hz, 6 H, 2 × Leu-CH3), 1.15-1.83, 2.68-2.86 (m, 74 H, 28 × Lys-CH2, 6 × 
Arg-CH2, 2 × Leu-CH2, 2 × Leu-CH), 2.97-3.04 (m, 8 H, 2 × Trp-CH2, 2 × Phe-CH2), 
3.78-4.61 (m, 23 H, 4 × Gly-CH2, 15 × CH), 6.96-8.84 (m, 74 H, 10 × Trp-CH, 10 × 
Phe-CH, 8 × NH3+, 20 × NH, 5 × NH2 ), 10.91 (s, 2 H, 2 × Trp-NH). 
13C NMR (175 MHz, DMSO-d6): δ [ppm] = 20.9, 21.6, 22.0, 23.0, 23.8, 23.9, 26.2, 26.4, 
27.4, 28.3, 28.7, 30.3, 31.1, 31.4, 37.2, 38.2, 38.5, 40.7, 42.0 (50 C, 4 × Leu-CH3, 28 × 
Lys-CH2, 6 × Arg-CH2, 2 × Leu-CH2, 2 × Leu-CH, 2 × Phe-CH2,  2 × Trp-CH2, 4 × 
Gly-CH2), 51.4, 51.8, 52.7, 53.9 (15 C, 15 × CH), 109.6, 111.3, 118.2, 118.6, 120.9, 124.1, 
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126.3, 127.2, 128.0, 129.2, 136.1, 137.7 (28 C, 12 × Phe-C, 16 × Trp-C), 156.9 (2 C, 2 × 
Gua-Cq),  168.3, 168.4, 168.5, 168.6,168.8, 171.1, 171.2, 171.3, 171.5, 171.6, 171.8, 
173.7 (19 C, 19 × CO-Cq). 
HRMS (ESI): m/z calculated for C114H185N35O192+ [M+2H]2+:  1174.7302; found: 
1174.7286. 
FT-IR (ATR): ~  [cm-1] = 3216 (br), 3053 (br), 2932 (br), 1646 (s), 1521 (s), 1457 (m), 
1232 (m), 1085 (m). 
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Synthesis of Tetravalent Peptide Ligand (RWKG)2(KWKG)2 (118) 
 
The tetravalent peptide ligand 118 was synthesized accordingly on Rink amide MBHA 
resin (100 mg, 0.67 mmol/g, 0.067 mmol, 1 eq) following the above described SPPS 
procedure. After attaching the orthogonal protected lysine dendrimer on the resin, the 
amino acids Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 
0.335 mmol, 5 eq), Fmoc-Trp(Boc)-OH (177 mg, 0.335 mmol, 10 eq) and 
Boc-Arg(Pbf)-OH (176 mg, 0.335 mmol, 5 eq) were attached to the first set of arms and 
Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 0.335 mmol, 5 
eq), Fmoc-Trp(Boc)-OH (177 mg, 0.335 mmol, 10 eq) and Fmoc-Lys(Boc)-OH (157 mg, 
0.335 mmol, 5 eq) to the second set of arms. After the cleavage and purification steps, the 
product was obtained as white solid with 95 % purity according to analytical HPLC 
analysis. 
C118H199Cl12N39O19  2893.53 g/mol 
Yield     32 mg, 11.1 µmol, 16 % 
Mp.     > 250 oC (decomposition) 
1H NMR (700 MHz, DMSO-d6): δ [ppm] = 1.29-1.78, 2.74-2.92 (m, 84 H, 36 × Lys-CH2, 
6 × Arg-CH2), 3.00-3.03 (m, 8 H, 4 × Trp-CH2), 3.67-4.61 (m, 23 H, 4 × Gly-CH2, 15 × 
CH), 6.97-8.84 (m, 80 H, 20 × Trp-CH, 10 × NH3+, 20 × NH, 5 × NH2 ), 10.91 (s, 4 H, 4 
× Trp-NH). 
13C NMR (175 MHz, DMSO-d6): δ [ppm] = 20.9, 22.1, 22.4, 22.9, 23.9, 26.3, 26.5, 27.5, 
28.4, 28.8, 30.4, 30.8, 31.1, 38.3, 38.6, 40.0, 40.2 , 42.0 (50 C, 36 × Lys-CH2, 6 × 
Arg-CH2, 4 × Trp-CH2, 4 × Gly-CH2), 51.0, 51.6, 51.9, 52.7, 53.9, 54.0 (15 C, 15 × CH), 
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109.6, 111.3, 118.3, 118.7, 120.9, 124.2, 125.1, 127.1, 136.1 (32 C, 32 × Trp-C), 157.1 (2 
C, 2 × Gua-Cq), 168.5, 168.6,168.7, 168.8, 171.2, 171.3, 171.4, 171.6, 171.8, 171.9, 
173.7 (19 C, 19 × CO-Cq). 
HRMS (ESI): m/z calculated for C118H189N39O192+ [M+2H]2+: 1128.7519; found: 
1128.7384. 
FT-IR (ATR): ~  [cm-1] = 3222 (br), 3053 (br), 2932 (br), 1645 (s), 1520 (s), 1456 (m), 
1233 (m). 
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Synthesis of Tetravalent Peptide Ligand (RWKG)2(FRKG)2 (119) 
 
The tetravalent peptide ligand 119 was synthesized accordingly on Rink amide MBHA 
resin (100 mg, 0.67 mmol/g, 0.067 mmol, 1 eq) following the above described SPPS 
procedure. After attaching the orthogonal protected lysine dendrimer on the resin, the 
amino acids Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 
0.335 mmol, 5 eq), Fmoc-Trp(Boc)-OH (177 mg, 0.335 mmol, 10 eq) and 
Boc-Arg(Pbf)-OH (176 mg, 0.335 mmol, 5 eq) were attached to the first set of arms and 
Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 0.335 mmol, 5 
eq), Fmoc-Arg(Pbf)-OH (217 mg, 0.335 mmol, 5 eq) and Boc-Phe-OH (89 mg, 0.335 
mmol, 5 eq) to the second set of arms. After the cleavage and purification steps, the 
product was obtained as white solid with 95 % purity according to analytical HPLC 
analysis. 
C114H197Cl12N41O19  2871.48 g/mol 
Yield     20 mg, 7.0 µmol, 10 % 
Mp.     > 250 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.19-1.77, 2.74-3.00 (m, 80 H, 28 × Lys-CH2, 
12 × Arg-CH2), 3.10-3.15 (m, 8 H, 2 × Trp-CH2, 2 × Phe-CH2), 3.68-4.61 (m, 23 H, 4 × 
Gly-CH2, 15 × CH), 6.96-8.95 (m, 84 H, 10 × Trp-CH, 10 × Phe-CH, 8 × NH3+, 22 × NH, 
9 × NH2 ), 10.92 (s, 2 H, 2 × Trp-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.0, 22.1, 23.9, 24.8, 26.4, 27.4, 28.3, 28.7, 
28.9, 30.9, 31.4, 36.8, 38.5, 40.3, 42.0 (48 C, 28 × Lys-CH2, 12 × Arg-CH2, 2 × Phe-CH2,  
2 × Trp-CH2, 4 × Gly-CH2), 51.5, 52.4, 52.7, 52.8, 53.3 (15 C, 15 × CH), 109.6, 111.3, 
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118.3, 118.6, 120.9, 124.1, 127.1, 127.2, 128.6, 129.7, 135.0, 136.1 (28 C, 12 × Phe-C, 16 
× Trp-C), 157.1 (4 C, 4 × Gua-Cq),  168.0, 168.4, 168.6, 170.9, 171.2, 171.4, 171.7, 
171.8, 173.1 (19 C, 19 × CO-Cq). 
HRMS (ESI): m/z calculated for C114H187N41O192+ [M+2H]2+: 1217.7472; found: 
1217.7508. 
FT-IR (ATR): ~  [cm-1] = 3209 (br), 3053 (br), 2932 (br), 2869 (w), 1644 (s), 1531 (s), 
1455 (m), 1233 (m). 
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Synthesis of Tetravalent Peptide Ligand (RWKG)2(GCP-LFG)2 (120) 
 
The tetravalent peptide ligand 120 was synthesized accordingly on Rink amide MBHA 
resin (100 mg, 0.67 mmol/g, 0.067 mmol, 1 eq) following the above described SPPS 
procedure. After attaching the orthogonal protected lysine dendrimer on the resin, the 
amino acids Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Lys(Boc)-OH (157 mg, 
0.335 mmol, 5 eq), Fmoc-Trp(Boc)-OH (177 mg, 0.335 mmol, 10 eq) and 
Boc-Arg(Pbf)-OH (176 mg, 0.335 mmol, 5 eq) were attached to the first set of arms and 
Fmoc-Gly-OH (100 mg, 0.335 mmol, 5 eq), Fmoc-Phe-OH (130 mg, 0.335 mmol, 5 eq), 
Fmoc-Leu-OH (118 mg, 0.335 mmol, 10 eq) and Boc-GCP group (111) (133 mg, 0.335 
mmol, 5 eq) to the second set of arms. After the cleavage and purification steps, the 
product was obtained as white solid with 95 % purity according to analytical HPLC 
analysis. 
C116H179Cl8N39O21  2739.54 g/mol 
Yield     26 mg, 9.5 µmol, 10 % 
Mp.     > 250 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 0.82 (d, J = 6.4 Hz, 6 H, 2 × Leu-CH3), 0.87 
(d, J = 6.4 Hz, 6 H, 2 × Leu-CH3), 1.24-1.79, 2.75-3.01 (m, 58 H, 20 × Lys-CH2, 6 × 
Arg-CH2, 2 × Leu-CH2, 2 × Leu-CH), 3.16-3.20 (m, 8 H, 2 × Trp-CH2, 2 × Phe-CH2), 
3.77-4.63 (m, 21 H, 4 × Gly-CH2, 13 × CH), 6.90-8.82 (m, 74 H, 10 × Trp-CH, 10 × 
Phe-CH, 4 × GCP-CH, 4 × NH3+, 20 × NH, 9 × NH2), 10.90 (s, 2 H, 2 × Trp-NH), 12.09 
(s, 2 H, 2 × Gua-NH), 12.49 (s, 2 H, 2 × GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 21.5, 22.0, 22.9, 23.8, 24.2, 26.4, 27.5, 28.3, 
28.8, 31.1, 38.5, 40.1, 42.1 (42 C, 4 × Leu-CH3, 20 × Lys-CH2, 6 × Arg-CH2, 2 × 
Leu-CH2, 2 × Leu-CH, 2 × Phe-CH2,  2 × Trp-CH2, 4 × Gly-CH2), 51.5, 52.6, 53.9, 54.0 
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(13 C, 13 × CH), 109.6, 111.3, 113.6, 115.8, 116.9, 118.2, 118.6, 120.9, 124.0, 125.6, 
126.2, 127.2, 128.0, 129.2, 132.3, 136.1, 137.8 (36 C, 12 × Phe-C, 16 × Trp-C, 8 × 
GCP-C), 155.5, 157.0, 158.9, 159.7 (4 C, 4 × Gua-Cq), 168.3, 168.5, 171.1, 171.2, 171.3, 
171.9, 172.0 (21 C, 21 × CO-Cq ). 
HRMS (ESI): m/z calculated for C116H174N39O213+ [M+3H]3+: 816.7919; found: 
816.7965. 
FT-IR (ATR): ~  [cm-1] = 3242 (br), 3059 (br), 2933 (br), 2863 (w), 1645 (s), 1524 (s), 
1238 (m). 
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6.3.2 Microwave-Assisted SPPS of Tetravalent Ligands with Four Identical Arms 
Terminating with the GCP Moiety 
Synthesis of Tetravalent Peptide Ligand (GCP-RWKG)4) (124) 
 
Tetravalent peptide ligand 124 with four identical arms was synthesized according to 
the standard microwave-assisted solid phase peptide synthesis described in Chapter 6.2.2. 
The Rink amide MBHA resin (200 mg, 0.67 mmol/g, 0.134 mmol, 1 eq) was allowed to 
swell in DCM (10 mL) for 1 h. Then, the Fmoc protecting group was removed with 20 % 
piperidine/DMF, followed by a Kaiser test to confirm the completely formation of free 
amino functions. Then the first amino acid Fmoc-Lys(Fmoc)-OH (198 mg, 0.335 mmol, 
2.5 eq) was attached with the help of the coupling reagent PyBOP (175 mg, 0.335 mmol, 
2.5 eq) in 4 % DIPEA/DMF (5 mL). The first coupling step was repeated to ensure the 
quantitative reaction, which was confirmed by a negative Kaiser test. After removal of the 
Fmoc protecting group and the washing step, Fmoc-Lys(Fmoc)-OH (396 mg, 0.67 mmol, 
5 eq) was attached once again to the two branches with coupling reagent PyBOP (350 mg, 
0.67 mmol, 5 eq) in 4 % DIPEA/DMF (5 mL) to introduce the scaffold with four identical 
arms. Then after removing all the Fmoc protecting groups on the four branches of the 
lysine scaffold, the peptide sequence of the four arms were built by using the standard 
microwave-assisted SPPS procedure: Fmoc-Gly-OH (398 mg, 1.34 mmol, 10 eq), 
Fmoc-Lys(Boc)-OH (628 mg, 1.34 mmol, 10 eq), Fmoc-Trp(Boc)-OH (706 mg, 1.34 
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mmol, 10 eq), and Fmoc-Arg(Pbf)-OH (869 mg, 1.34 mmol, 10 eq), as well as the 
Boc-protected GCP group (111) (533 mg, 1.34 mmol, 10 eq) were coupled similarly with 
the help of PyBOP (700 mg, 1.34 mmol, 10 eq) in 4 % DIPEA/DMF (5 mL) and the Fmoc 
protecting groups were respectively removed after each coupling step. After the last 
coupling step and the final washing cycle, the resin was dried and the product was cleaved 
from the solid support without microwave irradiation according to the general procedure 
(TFA/TIS/H2O = 95:2.5:2.5) for the Rink amide MBHA resin as described in Chapter 
6.2.1. Crude peptide was purified by RP18-MPLC using appropriate conditions 
(H2O/MeOH + 0.05 % TFA). Pure product was transferred into its hydrochloride salt to 
give 124 as white solid with 95 % purity according to analytical HPLC analysis. 
C146H223Cl12N59O27  3662.15 g/mol 
Yield     10 mg, 2.7 µmol, 2 % 
Mp.     245-250 oC (decomposition) 
1H NMR (700 MHz, DMSO-d6): δ [ppm] = 1.15-1.76, 2.95-3.11 (m, 80 H, 12 × Arg-CH2, 
28 × Lys-CH2), 2.68-2.77 (m, 8 H, 4 × Trp-CH2), 3.64-4.57 (m, 23 H, 15 × CH, 4 × 
Gly-CH2), 6.91-8.70 (m, 100 H, 8 × GCP-CH, 20 × Trp-CH, 26 × NH, 17 × NH2, 4 × 
NH3+), 10.82 (s, 4 H, 4 × Trp-NH), 11.97 (s, 4 H, 4 × Gua-NH), 12.52 (s, 4 H, 4 × 
GCP-NH). 
13C NMR (175 MHz, DMSO-d6): δ [ppm] = 22.0, 22.1, 22.7, 22.9, 25.1, 26.5, 27.2, 28.7, 
28.9, 31.1, 31.2, 38.5, 38.6, 40.4, 42.0 (48 C, 28 × Lys-CH2, 12 × Arg-CH2, 4 × Trp-CH2, 
4 × Gly-CH2), 52.6, 52.7, 53.6 (15 C, 15 × CH), 109.8, 127.3, 136.0 (12 C, 12 × Trp-Cq), 
111.3, 118.2, 120.8, 123.7 (s, 20 C, 20 × Trp-CH), 113.7, 115.8 (8 C, 8 × GCP-CH), 125.7, 
132.2 (8 C, 8 × GCP-Cq), 155.5 (s, 4 C, 4 × GCP-Gua-Cq), 156.8 (4 C, 4 × Arg-Cq), 
159.1, 159.8, 168.5, 171.4, 171.5, 171.7 (27 C, 27 × CO-Cq). 
HRMS (ESI): m/z calculated for C146H215N59O274+ [M+4H]4+: 806.9317; found: 
806.9315. 
FT-IR (ATR): ~  [cm-1] = 3310 (br), 3055 (br), 2868 (w), 1643 (s), 1527 (s), 1470 (m).  
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Synthesis of Tetravalent Peptide Ligand (GCP-RWK)4 (125) 
 
The second tetravalent peptide ligand 125 with four identical arms was synthesized 
accordingly on Rink amide MBHA resin (200 mg, 0.67 mmol/g, 0.134 mmol, 1 eq) 
following the standard microwave-assisted SPPS procedure. After attaching the lysine 
dendrimer on the resin, the amino acids Fmoc-Lys(Boc)-OH (628 mg, 1.34 mmol, 10 eq), 
Fmoc-Trp(Boc)-OH (706 mg, 1.34 mmol, 10 eq), Fmoc-Arg(Pbf)-OH (869 mg, 1.34 
mmol, 10 eq), as well as the Boc-GCP group (111) (533 mg, 1.34 mmol, 10 eq) were 
coupled. After the cleavage and purification steps, the product was obtained as white solid 
with 95 % purity according to analytical HPLC analysis. 
C138H211Cl12N55O23  3433.94 g/mol 
Yield     17 mg, 5.0 µmol, 4 % 
Mp.     230-233 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.18-1.77, 2.89-3.19 (m, 80 H, 12 × Arg-CH2, 
28 × Lys-CH2), 2.68-2.78 (m, 8 H, 4 × Trp-CH2), 4.12-4.59 (m, 15 H, 15 × CH), 6.89-8.75 
(m, 96 H, 8 × GCP-CH, 20 × Trp-CH, 22 × NH, 17 × NH2, 4 × NH3+), 10.86 (d, J = 15.1, 
4 H, 4 × Trp-NH), 12.11 (s, 4 H, 4 × Gua-NH), 12.53 (s, 4 H, 4 × GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.1, 22.2, 22.8, 22.9, 25.2, 26.5, 27.3, 28.8, 
28.9, 31.5, 38.6, 40.1, 40.5 (44 C, 28 × Lys-CH2, 12 × Arg-CH2, 4 × Trp-CH2), 52.5, 52.7, 
53.6 (15 C, 15 × CH), 109.8, 127.3, 136.0 (12 C, 12 × Trp-Cq), 111.3, 118.2, 118.4, 120.8, 
123.7 (20 C, 20 × Trp-CH), 113.8, 115.9 (8 C, 8 × GCP-CH), 125.7, 132.3 (8 C, 8 × 
GCP-Cq), 155.6 (4 C, 4 × GCP-Gua-Cq), 156.9 (4 C, 4 × Arg-Cq), 159.1, 159.8, 171.1, 
171.3, 171.4 (23 C, 23 × CO-Cq). 
HRMS (ESI): m/z calculated for C138H202N55O233+ [M+3H]3+: 999.5446; found: 
999.5459. 
FT-IR (ATR): ~  [cm-1] = 3063 (br), 2939 (w), 1634 (s), 1538 (s), 1471 (m).  
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6.4 Syntheses of Peptide-Derived Hydrazides 
Synthesis of tert-butyl hydrazinecarboxylate (131) 
 
A solution of hydrazine monohydrate 130 (12.5 g, 250 mmol, 5 eq) in 50 mL dioxane 
was cooled to 0 oC and a cool solution of Boc2O (10.9 g, 50 mmol, 1 eq) in dioxane (100 
mL) was added dropwise under vigorous stirring. The reaction mixture was stirred at 
room temperature for 12 h. Then the solvent was removed, the residue was dissolved in 
ethyl acetate, washed with brine twice. The organic phase was dried over MgSO4 and 
evaporated under reduced pressure to give 131 as white crystal.  
C5H12N2O2  132.16 g/mol 
Yield   6.49 g, 49 mmol, 98 % 
Mp.   37 oC 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.46 (s, 9 H, 3 × CH3), 3.26 (s, 2 H, NH2), 5.84 
(s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ [ppm] = 28.47 (CH3), 80.65 (Cq), 158.17 (CO). 
HRMS (ESI): m/z calculated for C5H12N2O2Na+ [M+Na]+: 155.0791; found: 155.0813. 
FT-IR (ATR): ~  [cm-1] = 3277 (br), 3060 (br), 3275 (w), 2932 (w), 1635 (s), 1523 (s), 
1394 (w), 1280 (m), 1253 (m), 1197 (m), 1047 (w), 952 (w). 
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Synthesis of 4-(N’-tert-butoxycarbonyl-hydrazino)-4-oxo-butyric acid (132) 
 
A solution of 131 (1.32 g, 10 mmol, 1 eq) and succinic anhydride (1.0 g, 10 mmol, 1 eq) 
in 30 mL water was stirred at room temperature for 4 h. The reaction proceeded clean, and 
full conversion to 132 was confirmed by ESI-MS. The reaction mixture was lyophilized to 
give 132 as white solid which was used in SPPS without any further purification. 
C9H16N2O5  232.23 g/mol 
Yield   2.32 g, 10 mmol, quant. 
Mp.   40 oC 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.46 (s, 9 H, 3 × CH3), 2.53 (t, J = 6.7 Hz, 2 H, 
CH2), 2.66-2.74 (m, 2 H, CH2), 7.11 (s, 1H, NH), 8.42 (s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ [ppm] = 28.27 (CH3), 28.47 (CH2), 29.06 (CH2), 
82.21 (Cq), 156.30 (CO), 172.65 (CO), 176.45 (CO). 
HRMS (ESI): m/z calculated for C9H15N2O5
-
 [M-H]-: 231.0986, found: 231.0938. 
FT-IR (ATR): ~  [cm-1] = 3272 (br), 3053 (br), 2975 (w), 2931 (w), 1643 (s), 1524 (s), 
1396 (w), 1252 (m), 1198 (m), 1046 (w), 954 (w). 
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Microwave-Assisted SPPS of Hydrazide (135) 
 
The synthesis of 135 was carried out on Rink amide MBHA resin (200 mg, 0.84 
mmol/g, 0.168 mmol, 1 eq) according to the standard microwave-assisted SPPS procedure 
described in Chapter 6.2.2. The resin was swollen in DCM (10 mL) for 2 h, followed by 
the removal of Fmoc protecting group with 20 % piperidine/DMF. After a washing cycle 
with DMF, the first amino acid Fmoc-Arg(Pbf)-OH (327 mg, 0.504 mmol, 3 eq) was 
attached to the resin with the coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the 
base DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) by microwave irradiation 
condition for 20 min. The coupling was repeated and the resin was washed thoroughly 
and the Kaiser test showed a negative result. Then after the Fmoc deprotection, the 
Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), Fmoc-Lys(Boc)-OH (236 mg, 0.504 
mmol, 3 eq), Fmoc-Gly-OH (150 mg, 0.504 mmol, 3 eq) and Boc-butanedionic 
monohydrazide (132) (117 mg, 0.504 mmol, 3 eq) were coupled in the same manner. 
After the final washing cycles, the cleavage of the product from the resin was carried out 
without microwave irradiation by using a mixture of TFA/H2O/TIS (95:2.5:2.5) according 
to the general procedure for Rink amide MBHA resin as described in Chapter 6.2.1. The 
crude product was purified by RP18-MPLC using appropriate conditions (MeOH/H2O + 
0.1 % TFA). Pure product was transferred into its hydrochloride salt by dissolving in 
water with hydrochloric acid and lyophilizing three times to give 135 as a white solid with 
99 % purity according to analytical HPLC analysis. 
C29H48Cl2N12O6  731.67 g/mol 
Yield    56 mg, 76.5 μmol, 46 % 
Mp.    134 oC  
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1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.16-1.25 (m, 2 H, Lys-CH2), 1.40-1.73 (m, 
8 H, 2 × Lys-CH2, 2 × Arg-CH2), 2.46 (m, 4 H, 2 × CH2), 2.68-2.72 (m, 2 H, Arg-CH2), 
2.99-3.19 (m, 6 H, Lys-CH2, Trp-CH2, NH2), 3.70-3.71 (m, 2 H, Gly-CH2), 4.16-4.20 (m, 
2 H, Lys-CH, Arg-CH), 4.46-4.50 (m, 1 H, Trp-CH), 6.97 (t, J = 7.5 Hz, 1 H, Trp-CHar), 
7.05 (t, J = 7.6 Hz, 1 H, Trp-CHar), 7.11 (s, 1 H, NH2), 7.17 (s, 1 H, Trp-CHar), 7.31 (s, 1 
H, NH2), 7.33 (d, J = 8.1 Hz, 1 H, Trp-CHar), 7.57 (d, J = 7.8 Hz, 1 H, Trp-CHar),7.76 (t, J 
= 5.7 Hz, 1 H, NH), 7.89 (d, J = 8.0 Hz, 1 H, NH), 7.93 (brs, 3 H, Lys-NH3+), 8.09 (d, J = 
7.6 Hz, 1 H, NH), 8.16 (d, J = 7.7 Hz, 1 H, NH), 8.26 (t, J = 5.7 Hz, 1 H, NH), 10.88 (s, 1 
H, Trp-NH), 11.00 (s, 1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.10 (Lys-CH2), 25.00 (Arg-CH2), 26.52 
(Lys-CH2), 27.22 (Trp-CH2), 28.11 (CH2), 29.16 (Arg-CH2), 29.55 (CH2), 31.10 
(Lys-CH2), 38.54 (Lys-CH2), 40.39 (Arg-CH2), 42.17 (Gly-CH2), 52.08 (Arg-CH), 52.71 
(Lys-CH), 53.90 (Trp-CH), 109.94 (Trp-Cq), 111.37 (Trp-CHar), 118.33 (Trp-CHar), 
118.41 (Trp-CHar), 120.91 (Trp-CHar), 123.74 (Trp-CHar), 127.26 (Trp-Cq), 136.07 
(Trp-Cq), 156.92 (Gua-Cq), 169.25 (CO), 171.15 (CO), 171.35 (CO), 171.42 (CO), 171.65 
(CO), 173.33 (CO). 
HRMS (ESI): m/z calculated for C29H47N12O6+ [M+H]+: 659.3736; found: 659.3778. 
FT-IR (ATR): ~  [cm-1] = 3138 (br), 3045 (br), 2897 (br), 1637 (s), 1522 (s), 1403 (s), 
1339 (w), 1230 (m), 1092 (s), 745 (m). 
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Microwave-Assisted SPPS of Hydrazide (136) 
 
The peptide-derived hydrazide 136 was synthesized accordingly on Rink amide 
MBHA resin (200 mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described 
microwave-assisted SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 
3 eq) and the base DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used during 
the coupling steps. After Fmoc deprotection, the amino acids Fmoc-Lys(Boc)-OH (236 
mg, 0.504 mmol, 3 eq), Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), 
Fmoc-Lys(Boc)-OH (236 mg, 0.504 mmol, 3 eq), Fmoc-Gly-OH (150 mg, 0.504 mmol, 3 
eq) and Boc-butanedionic monohydrazide (132) (117 mg, 0.504 mmol, 3 eq) were 
coupled. After the cleavage and purification steps, the product was obtained as a white 
solid with 98 % purity according to analytical HPLC analysis. 
C29H48Cl2N10O6  703.66 g/mol 
Yield    51 mg, 72.5 μmol, 43 % 
Mp.    134 oC 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.17-1.29 (m, 4 H, 2 × Lys-CH2), 1.48-1.67 
(m, 8 H, 4 × Lys-CH2), 2.40-2.47 (m, 4 H, 2 × CH2), 2.67-2.76 (m, 4 H, 2 × Lys-CH2), 
3.00-3.19 (m, 2 H, Trp-CH2), 3.71-3.72 (m, 2 H, Gly-CH2), 4.14-4.21 (m, 2 H, 2 × 
Lys-CH), 4.46-4.50 (m, 1 H, Trp-CH), 6.97 (t, J = 7.5 Hz, 1 H, Trp-CHar), 7.04-7.08 (m, 2 
H, Trp-CHar, NH2), 7.18 (s, 1 H, Trp-CHar), 7.25 (s, 1 H, NH2), 7.33 (d, J = 8.1 Hz, 1 H, 
Trp-CHar), 7.58 (d, J = 7.4 Hz, 1 H, Trp-CHar), 7.85 (d, J = 7.4 Hz, 1 H, NH), 8.00 (brs, 6 
H, 2 × Lys-NH3+), 8.11 (d, J = 6.7 Hz, 1 H, NH), 8.20 (d, J = 8.2 Hz, 1 H, NH), 8.28 (brs, 
1 H, NH), 10.91 (s, 1 H, Trp-NH), 11.06 (s, 1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.06 (Lys-CH2), 22.10 (Lys-CH2), 26.49 
(Lys-CH2), 26.53 (Lys-CH2), 27.08 (Trp-CH2), 28.08 (CH2), 29.53 (CH2), 31.10 
(Lys-CH2), 31.32 (Lys-CH2), 38.45 (Lys-CH2), 38.54 (Lys-CH2), 42.15 (Gly-CH2), 52.24 
(Lys-CH), 52.68 (Lys-CH), 53.85 (Trp-CH), 109.94 (Trp-Cq), 111.31 (Trp-CHar), 118.25 
(Trp-CHar), 118.38 (Trp-CHar), 120.84 (Trp-CHar), 123.70 (Trp-CHar), 127.22 (Trp-Cq), 
136.03 (Trp-Cq), 169.19 (CO), 171.08 (CO), 171.19 (CO), 171.32 (CO), 171.65 (CO), 
173.39 (CO). 
HRMS (ESI): m/z calculated for C29H47N10O6+ [M+H]+: 631.3675; found: 631.3692. 
FT-IR (ATR): ~  [cm-1] = 3239 (br), 3038 (br), 2920 (br), 1642 (s), 1521 (s), 1339 (w), 
1232 (m), 1160 (w), 1098 (w), 745 (m).  
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Microwave-Assisted SPPS of Hydrazide (138) 
 
The peptide-derived hydrazide 138 was synthesized accordingly on Rink amide 
MBHA resin (200 mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described 
microwave-assisted SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 
3 eq) and the base DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used during 
the coupling steps. After Fmoc deprotection, the amino acids Fmoc-Lys(Alloc)-OH (228 
mg, 0.504 mmol, 3 eq), Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), 
Fmoc-Lys(Boc)-OH (236 mg, 0.504 mmol, 3 eq), Fmoc-Gly-OH (150 mg, 0.504 mmol, 3 
eq) and Boc-butanedionic monohydrazide (132) (117 mg, 0.504 mmol, 3 eq) were 
coupled. After the removal of Alloc protecting group with Pd(PPh3)4 (19.4 mg, 0.0168 
mmol, 0.1 eq) in the presence of PhSiH3 (495 μL, 4.032 mmol, 24 eq) in DCM, the 
Boc-GCP group (111) (200 mg, 0.504 mmol, 3 eq) was coupled. After the cleavage and 
purification steps, the product was obtained as a white solid with 96 % purity according to 
analytical HPLC analysis. 
C36H54Cl2N14O8   881.81 g/mol 
Yield     52 mg, 59.0 μmol, 35 % 
Mp.     176 oC 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.20-1.33 (m, 4 H, 2 × Lys-CH2), 1.46-1.69 
(m, 8 H, 4 × Lys-CH2), 2.37-2.47 (m, 4 H, 2 × CH2), 2.69-2.72 (m, 2 H, Lys-CH2), 
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2.97-3.02, 3.14-3.23 (m, 4 H, Lys-CH2, Trp-CH2), 3.69-3.71 (m, 2 H, Gly-CH2), 4.15-4.22 
(m, 2 H, 2 × Lys-CH), 4.47-4.52 (m, 1 H, Trp-CH), 6.87-6.88 (m, 1 H, GCP-CHar), 6.96 (t, 
J = 7.5 Hz, 1 H, Trp-CHar), 7.03-7.06 (m, 2 H, Trp-CHar, NH2), 7.16 (s, 1 H, Trp-CHar), 
7.25 (s, 1 H, NH2), 7.32 (d, J = 8.8 Hz, 1 H, Trp-CHar), 7.54-7.57 (m, 2 H, GCP-CHar, 
Trp-CHar), 7.83 (d, J = 8.8 Hz,, 1 H, NH),7.93 (brs, 3 H, Lys-NH3+), 8.06 (d, J = 8.1 Hz,, 
1 H, NH), 8.15 (d, J = 8.1 Hz,, 1 H, NH), 8.23 (brs, 1 H, NH), 8.50-8.68 (m, 5 H, 5 × NH), 
10.87 (s, 1 H, Trp-NH), 11.03 (s, 1 H, NH), 12.06 (s, 1 H, Gua-NH), 12.34 (s, 1 H, 
GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.05 (Lys-CH2), 22.74 (Lys-CH2), 26.50 
(Lys-CH2), 27.24 (Trp-CH2), 28.06 (CH2), 28.72 (Lys-CH2), 29.50 (CH2), 31.17 
(Lys-CH2), 31.77 (Lys-CH2), 38.50 (Lys-CH2), 38.73 (Lys-CH2), 42.11 (Gly-CH2), 52.41 
(Lys-CH), 52.55 (Lys-CH), 53.77 (Trp-CH), 109.92 (Trp-Cq), 111.28 (Trp-CHar), 112.45 
(GCP-CHar), 115.99 (GCP-CHar), 118.24 (Trp-CHar), 118.37 (Trp-CHar), 120.82 
(Trp-CHar), 123.68 (Trp-CHar), 125.33 (GCP-Cq), 127.23 (Trp-Cq), 132.95 (GCP-Cq), 
136.02 (Trp-Cq), 155.54 (Gua-Cq), 159.02 (CO), 159.64 (CO), 169.06 (CO), 171.09 (CO), 
171.14 (CO), 171.29 (CO), 171.50 (CO), 173.50 (CO). 
HRMS (ESI): m/z calculated for C36H53N14O8+ [M+H]+: 809.4165; found: 809.4177. 
FT-IR (ATR): ~  [cm-1] = 3188 (br), 3049 (br), 2926 (br), 1638 (s), 1523 (s), 1281 (s), 
1195 (m), 813 (w), 745 (m). 
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Microwave-Assisted SPPS of Hydrazide (139) 
 
The peptide-derived hydrazide 139 was synthesized accordingly on Rink amide 
MBHA resin (200 mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described 
microwave-assisted SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 
3 eq) and the base DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used during 
the coupling steps. After Fmoc deprotection, the amino acids Fmoc-Lys(Boc)-OH (236 
mg, 0.504 mmol, 3 eq), Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), 
Fmoc-Lys(Alloc)-OH (228 mg, 0.504 mmol, 3 eq), Fmoc-Gly-OH (150 mg, 0.504 mmol, 
3 eq) and Boc-butanedionic monohydrazide (132) (117 mg, 0.504 mmol, 3 eq) were 
coupled. After the removal of Alloc protecting group with Pd(PPh3)4 (19.4 mg, 0.0168 
mmol, 0.1 eq) in the presence of PhSiH3 (495 μL, 4.032 mmol, 24 eq) in DCM, the 
Boc-GCP group (111) (200 mg, 0.504 mmol, 3 eq) was coupled. After the cleavage and 
purification steps, the product was obtained as a white solid with 91 % purity according to 
analytical HPLC analysis.  
C36H54Cl2N14O8  881.81 g/mol 
Yield    53 mg, 60.1 μmol, 36 % 
Mp.    178 oC  
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.18-1.29 (m, 4 H, 2 × Lys-CH2), 1.42-1.70 
(m, 8 H, 4 × Lys-CH2), 2.36-2.47 (m, 4 H, 2 × CH2), 2.71-2.76 (m, 2 H, Lys-CH2), 
2.99-3.04, 3.15-3.19 (m, 4 H, Lys-CH2, Trp-CH2), 3.71-3.72 (m, 2 H, Gly-CH2), 4.13-4.21 
(m, 2 H, 2 × Lys-CH), 4.46-4.50 (m, 1 H, Trp-CH), 6.87-6.88 (m, 1 H, GCP-CHar), 6.97 (t, 
J = 7.4 Hz, 1 H, Trp-CHar), 7.03-7.06 (m, 2 H, Trp-CHar, NH2), 7.16 (s, 1 H, Trp-CHar), 
7.21 (s, 1 H, NH2), 7.32 (d, J = 8.2 Hz, 1 H, Trp-CHar), 7.54-7.58 (m, 2 H, GCP-CHar, 
Trp-CHar), 7.83 (d, J = 8.5 Hz,, 1 H, NH), 7.93 (brs, 3 H, Lys-NH3+), 8.09 (d, J = 7.9 Hz,, 
1 H, NH), 8.13 (d, J = 7.8 Hz,, 1 H, NH), 8.24 (t, J = 6.2 Hz,, 1 H, NH), 8.49-8.68 (m, 5 H, 
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5 × NH), 10.87 (s, 1 H, Trp-NH), 11.01 (s, 1 H, NH), 12.07 (s, 1 H, Gua-NH), 12.33 (s, 1 
H, GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.09 (Lys-CH2), 22.79 (Lys-CH2), 26.54 
(Lys-CH2), 27.07 (Trp-CH2), 28.07 (CH2), 28.74 (Lys-CH2), 29.51 (CH2), 31.29 
(Lys-CH2), 31.48 (Lys-CH2), 38.58 (Lys-CH2), 38.65 (Lys-CH2), 42.08 (Gly-CH2), 52.24 
(Lys-CH), 52.87 (Lys-CH), 53.77 (Trp-CH), 109.93 (Trp-Cq), 111.28 (Trp-CHar), 112.42 
(GCP-CHar), 116.00 (GCP-CHar), 118.23 (Trp-CHar), 118.37 (Trp-CHar), 120.83 
(Trp-CHar), 123.67 (Trp-CHar), 125.33 (GCP-Cq), 127.24 (Trp-Cq), 132.96 (GCP-Cq), 
136.02 (Trp-Cq), 155.53 (Gua-Cq), 159.01 (CO), 159.63 (CO), 169.17 (CO), 171.10 (CO), 
171.15 (CO), 171.27 (CO), 171.81 (CO), 173.36 (CO). 
HRMS (ESI): m/z calculated for C36H53N14O8+ [M+H]+: 809.4165; found: 809.4186. 
FT-IR (ATR): ~  [cm-1] = 3183 (br), 3044 (br), 2925 (br), 1638 (s), 1533 (s), 1281 (s), 
1195 (m), 814 (w), 745 (m). 
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Microwave-Assisted SPPS of Hydrazide (140) 
 
The peptide-derived hydrazide 140 was synthesized accordingly on Rink amide 
MBHA resin (200 mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described 
microwave-assisted SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 
3 eq) and the base DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used during 
the coupling steps. After Fmoc deprotection, the amino acids Fmoc-Glu(OtBu)-OH (214 
mg, 0.504 mmol, 3 eq), Fmoc-Phe-OH (195 mg, 0.504 mmol, 3 eq), Fmoc-Ala-OH (157 
mg, 0.504 mmol, 3 eq), Fmoc-Gly-OH (150 mg, 0.504 mmol, 3 eq) and Boc-butanedionic 
monohydrazide (132) (117 mg, 0.504 mmol, 3 eq) were coupled. After the cleavage and 
purification steps, the product was obtained as a white solid with 91 % purity according to 
analytical HPLC analysis.  
C23H33N7O8  535.55 g/mol 
Yield   31 mg, 57.9 μmol, 34 % 
Mp.   > 250 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.10-1.18 (m, 3 H, Ala-CH3), 1.70-1.83, 
1.89-2.00 (m, 2 H, Glu-CH2), 2.19-2.30 (m, 2 H, Glu-CH2), 2.36-2.46 (m, 4 H, 2 × CH2), 
2.79-3.07 (m, 2 H, Phe-CH2), 3.68-3.69 (m, 2 H, Gly-CH2), 4.15-4.24 (m, 2 H, Glu-CH, 
Ala-CH), 4.41-4.50 (m, 1 H, Phe-CH), 7.09 (s, 1 H, NH2), 7.15-7.19 (m, 2 H, 2 × 
Phe-CHar), 7.24-7.26 (m, 4 H, 3 × Phe-CHar, NH2), 7.82-8.18 (m, 4 H, 4 × NH), 10.98 (s, 
1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 18.03 (Ala-CH3), 27.31 (Glu-CH2), 28.03 
(CH2), 29.45 (CH2), 30.04 (Glu-CH2), 36.84 (Phe-CH2), 42.01 (Gly-CH2), 48.30 
(Ala-CH), 51.80 (Glu-CH), 54.23 (Phe-CH), 126.28 (Phe-CHar), 128.03 (Phe-CHar), 
128.08 (Phe-CHar), 129.18 (Phe-CHar), 129.22 (Phe-CHar), 137.80 (Phe-Cq), 170.73 (CO), 
171.12 (CO), 171.19 (CO), 172.25 (CO), 172.88 (CO), 173.77 (CO), 173.94 (CO). 
HRMS (ESI): m/z calculated for C23H34N7O8+ [M+H]+: 536.2463; found: 536.2399. 
FT-IR (ATR): ~  [cm-1] = 3197 (br), 3044 (br), 2925 (br), 1640 (s), 1524 (s), 1407 (w), 
1234 (m), 1197 (m), 1031 (w), 744 (m).  
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6.5 Syntheses of Acyl Hydrazones 
The acyl hydrazones were synthesized from peptide-derived hydrazides and the tri- or 
di- aldehydes with slightly excess hydrazides compared to the amounts of the aldehyde 
groups. 
Synthesis of acyl hydrazone 141 
 
Tri-aldehyde E (1.62 mg, 0.01 mmol, 1 eq) and hydrazide 135 (25.6 mg, 0.035 mmol, 
3.5 eq) were dissolved in 10 mL MeOH under argon atmosphere. Then the reaction 
mixture was allowed to proceed under reflux overnight. After the solvent was removed, 
the crude product was purified by RP18-MPLC using appropriate conditions (MeOH/H2O 
+ 0.1 % TFA). Pure product was transferred into its hydrochloride salt to obtain 141 as a 
white solid with 92 % purity according to analytical HPLC analysis. 
C96H144Cl6N36O18  2303.12 g/mol 
Yield     6 mg, 2.6 μmol, 26 % 
Mp.     215 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.19-1.24 (m, 6 H, 3 × Lys-CH2), 1.44-1.72 
(m, 24 H, 6 × Lys-CH2, 6 × Arg-CH2), 2.69-2.72 (m, 6 H, 3 × Lys-CH2), 2.91-3.19 (m, 12 
H, 3 × Arg-CH2, 3 × Trp-CH2), 3.73 (s, 6 H, 3 × Gly-CH2), 4.16-4.20 (m, 6 H, 3 × Lys-CH, 
3 × Arg-CH), 4.46-4.51 (m, 3 H, 3 × Trp-CH), 6.95 (q, J = 7.4 Hz, 3 H, 3 × Trp-CHar), 
7.03 (q, J = 7.2 Hz, 3 H, 3 × Trp-CHar), 7.13 (s, 3 H, NH2), 7.17 (s, 3 H, 3 × Trp-CHar), 
7.27 (s, 3 H, NH2), 7.31 (t, J = 8.6 Hz, 3 H, 3 × Trp-CHar), 7.55 (t, J = 7.5 Hz, 3 H, 3 × 
Trp-CHar), 7.72 (s, 3 H, 3 × NH), 7.88 (brs, 9 H, 3 × Lys-NH3+), 7.93-8.05 (m, 5 H, 5 × 
NH), 8.07-8.17 (m, 6 H, 3 × Phe-CHar, 3 × CH=N), 8.25-8.30 (m, 4 H, 4 × NH), 10.87 (s, 
3 H, 3 × Trp-NH), 11.40 (t, J = 10.9 Hz, 1 H, NH), 11.75 (s, 1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.09 (Lys-CH2), 24.96 (Arg-CH2), 26.45 
(Lys-CH2), 27.12 (Trp-CH2), 27.42 (CH2), 29.09 (Arg-CH2), 29.49 (CH2), 30.03 
(Lys-CH2), 30.88 (Lys-CH2), 38.47 (Lys-CH2), 40.32 (Arg-CH2), 43.93 (Gly-CH2), 52.06 
(Arg-CH), 52.80 (Lys-CH), 53.84 (Trp-CH), 109.94 (Trp-Cq), 111.34 (Trp-CHar), 118.23 
(Trp-CHar), 118.31 (Trp-CHar), 120.86 (Trp-CHar), 123.68 (Trp-CHar), 126.01 (Phe-CHar), 
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127.24 (Trp-Cq), 135.36 (Phe-Cq), 136.07 (Trp-Cq), 142.01 (CH=N), 156.87 (Gua-Cq), 
169.48 (CO), 171.23 (CO), 171.62 (CO), 171.92 (CO), 172.24 (CO), 173.20 (CO). 
HRMS (ESI): m/z calculated for C96H142N36O184+ [M+4H]4+: 522.0327; found: 522.0328. 
FT-IR (ATR): ~  [cm-1] = 3189 (br), 3044 (br), 2926 (br), 1647 (s), 1522 (s), 1339 (w), 
1237 (m), 1161 (w), 1098 (w), 1025 (w), 955 (w), 745 (m). 
  
EXPERIMENTAL SECTION 
198 
 
Synthesis of acyl hydrazone 142 
 
The synthesis of acyl hydrazone 142 from tri-aldehyde E (1.62 mg, 0.01 mmol, 1 eq) 
and hydrazide 136 (24.6 mg, 0.035 mmol, 3.5 eq) was carried out under analogous above 
described conditions. After purification steps, 142 was obtained as a white solid with 93 % 
purity according to analytical HPLC analysis. 
C96H144Cl6N30O18  2219.08 g/mol 
Yield     5 mg, 2.3 μmol, 23 % 
Mp.     216 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.18-1.27 (m, 12 H, 6 × Lys-CH2), 1.52-1.67 
(m, 24 H, 12 × Lys-CH2), 2.69-2.74 (m, 12 H, 6 × Lys-CH2), 3.04-3.19 (m, 6 H, 3 × 
Trp-CH2), 3.73 (s, 6 H, 3 × Gly-CH2), 4.16 (s, 6 H, 6 × Lys-CH), 4.48 (s, 3 H, 3 × 
Trp-CH), 6.96 (t, J = 7.3 Hz, 3 H, 3 × Trp-CHar), 7.01-7.13 (m, 6 H, 3 × Trp-CHar, NH2), 
7.18-7.23 (m, 6 H, 3 × Trp-CHar, NH2), 7.30-7.33 (m, 3 H, 3 × Trp-CHar), 7.56 (t, J = 8.0 
Hz, 3 H, 3 × Trp-CHar), 7.81-7.88 (m, 4 H, 4 × NH), 7.87 (brs, 18 H, 6 × Lys-NH3+), 
8.09-8.14 (m, 6 H, 3 × Phe-CHar, 3 × CH=N), 8.26-8.33 (m, 5 H, 5 × NH), 10.89 (s, 2 H, 
2 × Trp-NH), 11.43 (s, 1 H, NH), 11.79 (s, 1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.09 (Lys-CH2), 26.44 (Lys-CH2), 26.53 
(Lys-CH2), 27.02 (Trp-CH2), 30.88 (Lys-CH2), 31.23 (Lys-CH2), 38.45 (Lys-CH2), 38.53 
(Lys-CH2), 43.90 (Gly-CH2), 52.28 (Lys-CH), 52.80 (Lys-CH), 53.84 (Trp-CH), 109.93 
(Trp-Cq), 111.26 (Trp-CHar), 118.21 (Trp-CHar), 118.30 (Trp-CHar), 120.82 (Trp-CHar), 
123.65 (Trp-CHar), 127.18 (Trp-Cq), 132.54 (Phe-CHar), 135.50 (Phe-Cq), 136.04 (Trp-Cq), 
169.52 (CO), 171.18 (CO), 171.65 (CO), 173.39 (CO). 
HRMS (ESI): m/z calculated for C96H143N30O185+ [M+5H]5+: 401.0239; found: 401.0228. 
FT-IR (ATR): ~  [cm-1] = 3239 (br), 3038 (br), 2919 (br), 1646 (s), 1522 (s), 1339 (w), 
1235 (m), 1159 (w), 1102 (w), 1025 (w), 954 (w), 745 (m).  
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Synthesis of acyl hydrazone 143 
 
The synthesis of acyl hydrazone 143 from tri-aldehyde E (1.62 mg, 0.01 mmol, 1 eq) 
and hydrazide 138 (30.8 mg, 0.035 mmol, 3.5 eq) was carried out under analogous above 
described conditions. After purification steps, 143 was obtained as a white solid with 94 % 
purity according to analytical HPLC analysis. 
C117H162Cl6N42O24  2753.52 g/mol 
Yield     8 mg, 2.9 μmol, 29 % 
Mp.     229 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.19-1.33, 1.49-1.71 (m, 36 H, 18 × 
Lys-CH2), 2.71-2.76 (m, 6 H, 3 × Lys-CH2), 2.92-3.02 (m, 6 H, 3 × Trp-CH2), 3.16-3.25 
(m, 6 H, 3 × Lys-CH2), 3.69-3.76 (m, 6 H, 3 × Gly-CH2), 4.16-4.22 (m, 6 H, 6 × Lys-CH), 
4.49-4.52 (m, 3 H, 3 × Trp-CH), 6.87 (s, 3 H, 3 × GCP-CHar), 6.94-6.97 (m, 3 H, 3 × 
Trp-CHar), 7.02-7.09 (m, 6 H, 3 × Trp-CHar, NH2), 7.15-7.16 (m, 3 H, 3 × Trp-CHar), 7.23 
(s, 3 H, NH2), 7.30-7.33 (m, 3 H, 3 × Trp-CHar), 7.45 (s, 3 H, 3 × GCP-CHar), 7.55 (t, J = 
8.7 Hz, 3 H, 3 × Trp-CHar), 7.80 (brs, 9 H, 3 × Lys-NH3+), 7.84-8.01 (m, 6 H, 6 × NH), 
8.06-8.07 (m, 6 H, 6 × NH), 8.21-8.25 (m, 6 H, 3 × Phe-CHar, 3 × CH=N), 8.41-8.57 (m, 
13 H, 13 × NH), 10.81, 10.82 (s, 3 H, 3 × Trp-NH), 11.37(t, J = 18.1 Hz, 1 H, NH), 11.66 
(t, J = 9.5 Hz, 1 H, NH), 11.87 (s, 3 H, 3 × Gua-NH), 12.31 (s, 3 H, 3 × GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.09 (Lys-CH2), 22.75 (Lys-CH2), 26.50 
(Lys-CH2), 27.22 (Trp-CH2), 28.73 (Lys-CH2), 29.45 (CH2), 30.02 (CH2), 31.04 
(Lys-CH2), 31.73 (Lys-CH2), 34.26 (Lys-CH2), 38.60 (Lys-CH2), 38.74 (Lys-CH2), 42.29 
(Gly-CH2), 52.45 (Lys-CH), 52.56 (Lys-CH), 53.74 (Trp-CH), 109.89 (Trp-Cq), 111.27 
(Trp-CHar), 112.36 (GCP-CHar), 115.89 (GCP-CHar), 118.23 (Trp-CHar), 118.33 
(Trp-CHar), 120.82 (Trp-CHar), 123.64 (Trp-CHar), 125.33 (GCP-Cq), 127.21 (Trp-Cq), 
132.91 (GCP-Cq), 135.31 (Phe-CHar), 135.48 (Phe-Cq),  136.00 (Trp-Cq), 144.78 
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(CH=N), 155.43 (Gua-Cq), 159.05 (CO), 159.62 (CO), 168.34 (CO), 169.23 (CO), 169.34 
(CO), 171.14 (CO), 171.54 (CO), 171.92 (CO), 172.27 (CO), 173.54 (CO). 
HRMS (ESI): m/z calculated for C117H160N42O244+ [M+4H]4+: 634.5649; found: 
634.5649. 
FT-IR (ATR): ~  [cm-1] = 3272 (br), 3047 (br), 2940 (br), 1645 (s), 1541 (s), 1284 (s), 
1199 (m), 815 (w), 746 (m). 
  
EXPERIMENTAL SECTION 
201 
 
Synthesis of acyl hydrazone 144 
 
The synthesis of acyl hydrazone 144 from tri-aldehyde E (1.62 mg, 0.01 mmol, 1 eq) 
and hydrazide 139 (30.8 mg, 0.035 mmol, 3.5 eq) was carried out under analogous above 
described conditions. After purification steps, 144 was obtained as a white solid with 96 % 
purity according to analytical HPLC analysis. 
C117H162Cl6N42O24  2753.52 g/mol 
Yield     10 mg, 3.6 μmol, 36 % 
Mp.     231 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.19-1.29, 1.45-1.68 (m, 36 H, 18 × 
Lys-CH2), 2.74-2.75 (m, 6 H, 3 × Lys-CH2), 2.91-3.04 (m, 6 H, 3 × Trp-CH2), 3.15-3.19 
(m, 6 H, 3 × Lys-CH2), 3.73 (s, 6 H, 3 × Gly-CH2), 4.14-4.17 (m, 6 H, 6 × Lys-CH), 
4.45-4.49 (m, 3 H, 3 × Trp-CH), 6.86 (s, 3 H, 3 × GCP-CHar), 6.92-6.97 (m, 3 H, 3 × 
Trp-CHar), 7.00-7.09 (m, 6 H, 3 × Trp-CHar, NH2), 7.16-7.20 (m, 6 H, 3 × Trp-CHar, NH2), 
7.30 (t, J = 9.8 Hz, 3 H, 3 × Trp-CHar), 7.49 (s, 3 H, 3 × GCP-CHar), 7.55 (t, J = 9.1 Hz,, 3 
H, 3 × Trp-CHar), 7.85 (brs, 9 H, 3 × Lys-NH3+), 7.79-7.80, 7.91-7.92 (m, 6 H, 6 × NH), 
8.04-8.07 (m, 6 H, 6 × NH), 8.11-8.30 (m, 7 H, NH, 3 × Phe-CHar, 3 × CH=N), 8.43-8.62 
(m, 15 H, 15 × NH), 10.81, 10.84 (s, 3 H, 3 × Trp-NH), 11.35 (t, J = 13.8 Hz, 1 H, NH), 
11.67 (s, 1 H, NH), 11.97 (s, 3 H, 3 × Gua-NH), 12.30 (s, 3 H, 3 × GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.09 (Lys-CH2), 22.83 (Lys-CH2), 26.55 
(Lys-CH2), 27.01 (Trp-CH2), 28.70 (Lys-CH2), 29.47 (CH2), 31.23 (Lys-CH2), 38.61 
(Lys-CH2), 43.95 (Gly-CH2), 52.26 (Lys-CH), 52.99 (Lys-CH), 53.77 (Trp-CH), 109.90 
(Trp-Cq), 111.26 (Trp-CHar), 112.35 (GCP-CHar), 115.91 (GCP-CHar), 118.20 (Trp-CHar), 
118.30 (Trp-CHar), 120.81 (Trp-CHar), 123.58 (Trp-CHar), 123.63 (Trp-CHar), 125.31 
(GCP-Cq), 127.18 (Trp-Cq), 132.91 (GCP-Cq), 135.25 (Phe-CHar), 135.43 (Phe-Cq),  
136.00 (Trp-Cq), 144.56 (CH=N),  155.45 (Gua-Cq), 158.97 (CO), 159.59 (CO), 168.26 
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(CO), 169.39 (CO), 171.15 (CO), 171.84 (CO), 173.35 (CO). 
HRMS (ESI): m/z calculated for C117H160N42O244+ [M+4H]4+: 634.5649; found: 
634.5650. 
FT-IR (ATR): ~  [cm-1] = 3232 (br), 3049 (br), 2921 (br), 1648 (s), 1541 (s), 1284 (m), 
1252 (m), 1201 (w), 1098 (w), 1025 (w), 955 (w), 748 (m). 
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Synthesis of acyl hydrazone 145 
 
The synthesis of acyl hydrazone 145 from tri-aldehyde E (1.62 mg, 0.01 mmol, 1 eq) 
and hydrazide 140 (18.7 mg, 0.035 mmol, 3.5 eq) was carried out under analogous above 
described conditions. After purification steps, 145 was obtained as a white solid with 90 % 
purity according to analytical HPLC analysis. 
C78H99N21O24  1714.75 g/mol 
Yield    4 mg, 2.3 μmol, 23 % 
Mp.    149 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.14-1.19 (m, 9 H, 3 × Ala-CH3), 1.72-1.78, 
1.91-1.96 (m, 6 H, 3 × Glu-CH2), 2.19-2.22 (m, 6 H, 3 × Glu-CH2), 2.82-2.91 (m, 6 H, 3 
× Phe-CH2), 3.70 (s, 6 H, 3 × Gly-CH2), 4.14-4.22 (m, 6 H, 3 × Glu-CH, 3 × Ala-CH), 
4.42 (s, 3 H, 3 × Phe-CH), 7.09-7.26 (m, 21 H, 15 × Phe-CHar, 3 × NH2), 7.78-8.23 (m, 18 
H, 12 × NH, 3 × CH=N, 3 × CHar), 11.36 (t, J = 12.1 Hz, 1 H, NH) 11.56 (t, J = 10.5 Hz, 
1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 17.73 (Ala-CH3), 27.23 (Glu-CH2), 29.47 
(CH2), 30.05 (Glu-CH2), 34.32 (CH2), 36.80 (Phe-CH2), 44.21 (Gly-CH2), 48.53 
(Ala-CH), 51.84 (Glu-CH), 54.25 (Phe-CH), 126.26 (Phe-CHar), 126.28 (Phe-CHar), 
128.07 (Phe-CHar), 128.09 (Phe-CHar), 129.09 (Phe-CHar), 129.13 (Phe-CHar), 137.76 
(Phe-Cq), 137.79 (Phe-Cq), 169.21 (CO), 170.75 (CO), 172.31 (CO), 172.36 (CO), 172.90 
(CO), 173.97 (CO). 
HRMS (ESI): m/z calculated for C78H96N21O243- [M-3H]3-: 570.2318; found: 570.2401. 
FT-IR (ATR): ~  [cm-1] = 3264 (br), 3060 (br), 2930 (br), 1636 (s), 1531 (s), 1407 (w), 
1254 (m), 1198 (m), 1130 (m), 953 (w), 800 (w), 745 (m). 
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Synthesis of acyl hydrazone 146 
 
The synthesis of acyl hydrazone 146 from di-aldehyde C (1.34 mg, 0.01 mmol, 1 eq) 
and hydrazide 135 (18.3 mg, 0.025 mmol, 2.5 eq) was carried out under analogous above 
described conditions. After purification steps, 146 was obtained as a white solid with 98 % 
purity according to analytical HPLC analysis. 
C66H98Cl4N24O12  1561.45 g/mol 
Yield     6 mg, 3.8 μmol, 38 % 
Mp.     220 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.18-1.24 (m, 4 H, 2 × Lys-CH2), 1.44-1.71 
(m, 16 H, 4 × Lys-CH2, 4 × Arg-CH2), 2.63-2.74 (m, 4 H, 2 × Lys-CH2), 2.89-3.20 (m, 8 
H, 2 × Arg-CH2, 2 × Trp-CH2), 3.71-3.72 (m, 4 H, 2 × Gly-CH2), 4.16-4.20 (m, 4 H, 2 × 
Lys-CH, 2 × Arg-CH), 4.46-4.51 (m, 2 H, 2 × Trp-CH), 6.94-6.98 (m, 2 H, 2 × Trp-CHar), 
7.04 (t, J = 7.3 Hz, 2 H, 2 × Trp-CHar), 7.12 (s, 2 H, NH2), 7.16 (s, 2 H, 2 × Trp-CHar), 
7.25-7.26 (m, 2 H, NH2), 7.31-7.33 (m, 2 H, 2 × Trp-CHar), 7.54-7.57 (m, 2 H, 2 × 
Trp-CHar), 7.62-7.70 (m, 6 H, 6 H, 4 × Phe-CHar, 2 × NH), 7.86 (brs, 6 H, 2 × Lys-NH3+),  
8.00-8.17 (m, 6 H, 2 × CH=N, 4 × NH), 8.25-8.30 (m, 2 H, 2 × NH), 10.85 (s, 2 H, 2 × 
Trp-NH), 11.36 (s, 1 H, NH), 11.64 (s, 1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.08 (Lys-CH2), 24.94 (Arg-CH2), 26.48 
(Lys-CH2), 27.11 (Trp-CH2), 27.50 (CH2), 29.09 (Arg-CH2), 30.88 (Lys-CH2), 38.48 
(Lys-CH2), 40.34 (Arg-CH2), 42.35 (Gly-CH2), 52.06 (Arg-CH), 52.72 (Lys-CH), 53.82 
(Trp-CH), 109.91 (Trp-Cq), 111.26 (Trp-CHar), 118.23 (Trp-CHar), 118.29 (Trp-CHar), 
120.84 (Trp-CHar), 123.61 (Trp-CHar), 126.99 (Phe-CHar), 127.18 (Trp-Cq), 135.50 
(Phe-Cq), 136.03 (Trp-Cq), 142.19 (CH=N), 156.80 (Gua-Cq), 169.57 (CO), 171.23 (CO), 
171.62 (CO), 171.94 (CO), 172.29 (CO), 173.21 (CO), 173.63 (CO). 
HRMS (ESI): m/z calculated for C66H97N24O123+ [M+3H]3+: 472.5900; found: 472.5863. 
FT-IR (ATR): ~  [cm-1] = 3171 (br), 3048 (br), 2925 (br), 1638 (s), 1523 (s), 1231 (w), 
1167 (w), 1096 (w), 1024 (w), 952 (w), 745 (m).  
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Synthesis of acyl hydrazone 147 
 
The synthesis of acyl hydrazone 147 from di-aldehyde C (1.34 mg, 0.01 mmol, 1 eq) 
and hydrazide 136 (17.6 mg, 0.025 mmol, 2.5 eq) was carried out under analogous above 
described conditions. After purification steps, 147 was obtained as a white solid with 97 % 
purity according to analytical HPLC analysis. 
C66H98Cl4N20O12  1505.42 g/mol 
Yield     13 mg, 8.6 μmol, 86 % 
Mp.     182 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.17-1.29 (m, 8 H, 4 × Lys-CH2), 1.48-1.70 
(m, 16 H, 8 × Lys-CH2), 2.69-2.74 (m, 8 H, 4 × Lys-CH2), 3.04-3.09 (m, 4 H, 2 × 
Trp-CH2), 3.72 (s, 4 H, 2 × Gly-CH2), 4.12-4.21 (m, 4 H, 4 × Lys-CH), 4.47 (s, 2 H, 2 × 
Trp-CH), 6.94-6.99 (m, 2 H, 2 × Trp-CHar), 7.03-7.07 (m, 4 H, 2 × Trp-CHar, NH2), 
7.17-7.20 (m, 4 H, 2 × Trp-CHar, NH2), 7.31-7.33 (m, 2 H, 2 × Trp-CHar), 7.54-7.57 (m, 2 
H, 2 × Trp-CHar), 7.61 (s, 1 H, Phe-CHar), 7.66 (s, 1 H, Phe-CHar), 7.70 (s, 1 H, Phe-CHar), 
7.78-7.82 (m, 2 H, 2 × NH), 7.89 (brs, 12 H, 4 × Lys-NH3+), 8.00-8.02 (m, 2 H, 2 × 
CH=N), 8.07-8.34 (m, 6 H, 6 × NH), 10.86 (s, 2 H, 2 × Trp-NH), 11.36 (s, 1 H, NH), 
11.65 (s, 1 H, NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.11 (Lys-CH2), 26.49 (Lys-CH2), 26.56 
(Lys-CH2), 27.06 (Trp-CH2), 27.49 (CH2), 29.28 (CH2), 30.02 (CH2), 30.88 (Lys-CH2), 
31.27 (Lys-CH2), 38.53 (Lys-CH2), 38.60 (Lys-CH2), 42.35 (Gly-CH2), 52.28 (Lys-CH), 
52.78 (Lys-CH), 53.80 (Trp-CH), 109.93 (Trp-Cq), 111.27 (Trp-CHar), 118.22 (Trp-CHar), 
118.33 (Trp-CHar), 118.51 (Trp-CHar), 120.84 (Trp-CHar), 123.66 (Trp-CHar), 126.98 
(Phe-CHar), 127.22 (Trp-Cq), 136.03 (Trp-Cq), 142.21 (CH=N), 169.37 (CO), 169.60 (CO), 
171.17 (CO), 171.65 (CO), 171.94 (CO), 172.30 (CO), 173.37 (CO), 173.64 (CO). 
HRMS (ESI): m/z calculated for C66H97N20O123+ [M+3H]3+: 453.9193; found: 453.9185. 
FT-IR (ATR): ~  [cm-1] = 3176 (br), 3047 (br), 2925 (br), 1637 (s), 1523 (s), 1340 (w), 
1200 (m), 1174 (m), 1128 (m), 1026 (w), 954 (w), 835 (w), 798 (w), 744 (m).  
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Synthesis of acyl hydrazone 148 
 
The synthesis of acyl hydrazone 148 from di-aldehyde C (1.34 mg, 0.01 mmol, 1 eq) 
and hydrazide 138 (22 mg, 0.025 mmol, 2.5 eq) was carried out under analogous above 
described conditions. After purification steps, 148 was obtained as a white solid with 93 % 
purity according to analytical HPLC analysis. 
C80H110Cl4N28O16  1861.72 g/mol 
Yield     12 mg, 6.4 μmol, 64 % 
Mp.     214 oC (decomposition) 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.19-1.33 (m, 8 H, 4 × Lys-CH2), 1.47-1.68 
(m, 16 H, 8 × Lys-CH2), 2.69-2.71 (m, 4 H, 2 × Lys-CH2), 2.89-3.04(m, 4 H, 2 × 
Trp-CH2), 3.16-3.23 (m, 4 H, 2 × Lys-CH2), 3.71 (s, 4 H, 2 × Gly-CH2), 4.15-4.19 (m, 4 H, 
4 × Lys-CH), 4.48-4.49 (m, 2 H, 2 × Trp-CH), 6.87 (s, 2 H, 2 × GCP-CHar), 6.95 (t, J = 
7.5 Hz, 2 H, 2 × Trp-CHar), 7.02-7.06 (m, 4 H, 2 × Trp-CHar, NH2), 7.16 (s, 2 H, 2 × 
Trp-CHar), 7.21-7.23 (m, 2 H, NH2), 7.30-7.32 (m, 2 H, 2 × Trp-CHar), 7.51 (s, 2 H, 2 × 
GCP-CHar), 7.54-7.55 (m, 2 H, 2 × Trp-CHar), 7.60 (s, 1 H, Phe-CHar), 7.65 (s, 2 H, 2 × 
Phe-CHar), 7.69 (s, 1 H, Phe-CHar), 7.77-7.81 (m, 2 H, 2 × NH), 7.86 (brs, 6 H, 2 × 
Lys-NH3+),  7.99-8.18 (m, 6 H, 6 × NH), 8.26-8.30 (m, 2 H, 2 × CH=N), 8.46-8.64 (m, 8 
H, 8 × NH), 10.84 (s, 2 H, 2 × Trp-NH), 11.35 (s, 1 H, NH), 11.63 (s, 1 H, NH), 12.00 (s, 
2 H, 2 × Gua-NH), 12.32 (s, 2 H, 2 × GCP-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.09 (Lys-CH2), 22.75 (Lys-CH2), 26.48 
(Lys-CH2), 27.19 (Lys-CH2), 27.52 (Trp-CH2), 28.71 (Lys-CH2), 29.30 (CH2), 30.03 
(CH2), 30.93 (Lys-CH2), 31.71 (Lys-CH2), 38.54 (Lys-CH2), 38.73 (Lys-CH2), 42.25 
(Gly-CH2), 42.37 (Gly-CH2), 52.46 (Lys-CH), 52.58 (Lys-CH), 52.69 (Lys-CH), 53.84 
(Trp-CH), 109.93 (Trp-Cq), 111.26 (Trp-CHar), 112.41 (GCP-CHar), 115.95 (GCP-CHar), 
118.22 (Trp-CHar), 118.30 (Trp-CHar), 120.80 (Trp-CHar), 123.62 (Trp-CHar), 125.31 
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(GCP-Cq), 126.96 (Phe-CHar), 127.21 (Trp-Cq), 132.93 (GCP-Cq), 135.28 (Phe-Cq), 
136.01 (Trp-Cq), 142.17 (CH=N), 155.48 (Gua-Cq), 158.99 (CO), 159.62 (CO), 168.22 
(CO), 169.23 (CO), 169.44 (CO), 171.14 (CO), 171.57 (CO), 171.90 (CO), 172.27 (CO), 
173.49 (CO), 173.63 (CO). 
HRMS (ESI): m/z calculated for C80H109N28O163+ [M+3H]3+: 572.6187; found: 572.6192. 
FT-IR (ATR): ~  [cm-1] = 3273 (br), 3055 (br), 2930 (br), 1643 (s), 1540 (s), 1282 (s), 
1197 (m), 953 (w), 815 (w), 746 (m). 
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Synthesis of acyl hydrazone 149 
 
Di-aldehyde C (67 mg, 0.5 mmol, 10 eq) and hydrazide 135 (36.6 mg, 0.05 mmol, 1 eq) 
were dissolved in 10 mL MeOH under argon atmosphere. Then the reaction mixture was 
refluxed overnight. After the purification by RP18-MPLC, the product of 
mono-hydrazone with one aldehyde group was obtained, which was then subjected to 
react with hydrazide 138 by using equimolar amount in 10 mL MeOH under argon 
atmosphere. The reaction mixture was refluxed overnight and the crude product was 
purified by RP18-MPLC using appropriate conditions (MeOH/H2O + 0.1 % TFA). Pure 
product was transferred into its hydrochloride salt to give 149 as a white solid with 91 % 
purity according to analytical HPLC analysis. 
C73H104Cl4N26O14  1711.58 g/mol 
Yield     3 mg, 1.8 μmol, 18 % 
Mp.     210 oC (decomposition) 
1H NMR (700 MHz, DMSO-d6): δ [ppm] = 1.19-1.30 (m, 6 H, 3 × Lys-CH2), 1.42-1.71 
(m, 16 H, 6 × Lys-CH2, 2 × Arg-CH2), 2.69-2.71 (m, 4 H, 2 × Lys-CH2), 2.91-3.22 (m, 8 
H, Lys-CH2, Arg-CH2, 2 × Trp-CH2), 3.72 (s, 4 H, 2 × Gly-CH2), 4.15-4.23 (m, 4 H, 3 × 
Lys-CH, Arg-CH), 4.47-4.52 (m, 2 H, 2 × Trp-CH), 6.86 (s, 1 H, GCP-CHar), 6.95-6.98 
(m, 2 H, 2 × Trp-CHar), 7.02-7.07 (m, 3 H, 2 × Trp-CHar, NH2), 7.12 (s, 2 H, NH2), 
7.16-7.17 (m, 2 H, 2 × Trp-CHar), 7.20-7.26 (m, 2 H, NH2), 7.31-7.34 (m, 2 H, 2 × 
Trp-CHar), 7.47 (s, 1 H, GCP-CHar), 7.54-7.56 (m, 2 H, 2 × Trp-CHar), 7.62 (s, 1 H, 
Phe-CHar), 7.67-7.71 (m, 3 H, 3 × Phe-CHar), 7.77-7.91 (m, 8 H, 2 × NH, 2 × Lys-NH3+), 
7.95-8.19 (m, 6 H, 6 × NH), 8.24-8.33 (m, 2 H, 2 × CH=N), 8.42-8.64 (m, 5 H, 5 × NH), 
10.83, (s, 1 H, Trp-NH), 10.85 (s, 1 H, Trp-NH), 11.35 (s, 1 H, NH), 11.62 (d, J = 19.7 Hz, 
1 H, NH), 11.93 (s, 1 H, Gua-NH), 12.32 (s, 1 H, GCP-NH). 
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13C NMR (175 MHz, DMSO-d6): δ [ppm] = 22.07 (Lys-CH2), 22.74 (Lys-CH2), 24.93 
(Arg-CH2), 26.48 (Lys-CH2), 27.14 (Trp-CH2), 27.47 (CH2), 28.71 (Lys-CH2), 29.05 
(Arg-CH2), 29.27 (CH2), 30.00 (CH2), 30.94 (Lys-CH2), 31.69 (Lys-CH2), 38.50 
(Lys-CH2), 38.56 (Lys-CH2), 38.70 (Lys-CH2), 40.34 (Arg-CH2), 42.36 (Gly-CH2), 52.05 
(Arg-CH), 52.43 (Lys-CH), 52.60 (Lys-CH), 52.76 (Lys-CH), 53.78 (Trp-CH), 109.92 
(Trp-Cq), 111.27 (Trp-CHar), 112.33 (GCP-CHar), 115.90 (GCP-CHar), 118.21 (Trp-CHar), 
118.30 (Trp-CHar), 120.82 (Trp-CHar), 123.61 (Trp-CHar), 125.31 (GCP-Cq), 126.96 
(Phe-CHar), 127.22 (Trp-Cq), 129.91 (Phe-CHar), 132.99 (GCP-Cq), 135.26 (Phe-Cq), 
136.03 (Trp-Cq), 142.17 (CH=N), 156.83 (Gua-Cq), 159.02 (CO), 168.22 (CO), 169.39 
(CO), 169.58 (CO), 171.11 (CO), 171.23 (CO), 171.49 (CO), 171.54 (CO), 171.85 (CO), 
172.24 (CO), 173.19 (CO), 173.45 (CO), 173.61 (CO). 
HRMS (ESI): m/z calculated for C73H103N26O143+ [M+3H]3+: 522.6044; found: 522.6066. 
FT-IR (ATR): ~  [cm-1] = 3175 (br), 3048 (br), 2930 (br), 1637 (s), 1523 (s), 1232 (w), 
1165 (w), 1095 (w), 1011 (w), 952 (w), 744 (m). 
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6.6 Syntheses of Ligands for Au Nanoparticles 
6.6.1 Synthesis of the thioalkylated TEG linker as Precursor for SPPS 
Synthesis of Pent-1-en-5-yltriethylene glycol (151) 
 
A mixture of 4 ml of 50 % aqueous NaOH (2 g, 50 mmol, 1 eq) and triethylene glycol 
(75 g, 500 mmol, 10 eq) was stirred for 30 min in an oil bath at 100 oC under an argon 
atmosphere, and then 5-bromopent-1-ene (150) (7.45 g, 50 mmol, 1 eq) was added. The 
reaction mixture was heated at 100 oC for 24 h. The reaction mixture was cooled and 
adjusted pH to 7 by using 1 M HCl, diluted with 50mL brine, extracted four times with 
ethyl acetate. The combined organic layer was dried over MgSO4 and concentrated by 
rotary evaporation under reduced pressure to give yellow oil containing a mixture of 
mono- and di-ethers. Purification of the oil by flash chromatography on silica gel 
(cyclohexane/ethyl acetate = 1/4) to obtain 151 as a clear oil. 
C11H22O4  218.29 g/mol 
Yield   7.68 g, 35.2 mmol, 70 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.61-1.71 (m, 2 H, CH2), 2.05-2.12 (m, 2 H, 
CH2), 2.63 (br s, 1 H, OH), 3.45 (t, J = 6.6 Hz, 2 H, CH2), 3.54-3.71 (m, 12 H, 6 × CH2), 
4.91-5.03 (m, 2 H, CH2), 5.72-5.86 (m, 1 H, CH). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 28.83 (CH2), 30.30 (CH2), 61.83 (CH2), 70.17 
(CH2), 70.48 (CH2), 70.70 (CH2), 70.74 (CH2), 70.83 (CH2), 72.60 (CH2), 114.79 (CH2), 
138.35 (CH). 
HRMS (ESI): m/z calculated for m/z calculated for C11H22O4Na+ [M+Na]+: 241.1410; 
found: 241.1425. 
FT-IR (ATR): ~  [cm-1] = 3440 (br), 2865 (br), 1100 (s), 1066 (s), 911 (m).
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Synthesis of Pent-1-en-5-yltriethylene glycol-acetic acid ethyl ester (152) 
 
A solution of 151 (4.36 g, 20 mmol, 1 eq), KI (0.66 g, 4 mmol, 0.2 eq) and NaH (50 %, 
0.96 g, 20 mmol, 1 eq) in dry THF (30 mL) was stirred at room temperature under argon 
atmosphere for 30 min and then cooled down to 0 °C. Then ethyl bromoacetate (4.5 mL, 
40 mmol, 2 eq) was added and the reaction mixture was stirred for 3 h at 0 °C. The 
reaction mixture was then adjusted pH to 7.0 by 5 % citric acid aqueous solution and 
extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over 
MgSO4 and concentrated with a rotatory evaporator under reduced pressure. The brown 
oil was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate = 2/1) to 
give 152 as a clear oil. 
C15H28O6  304.38 g/mol 
Yield   4.47 g, 14.7 mmol, 73 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.25 (t, J = 7.1 Hz, 3 H, CH3),1.60-1.69 (m, 2 H, 
CH2), 2.01-2.12 (m, 2 H, CH2), 3.44 (t, J = 6.6 Hz, 2 H, CH2), 3.53-3.72 (m, 12 H, 6 × 
CH2), 4.12 (s, 2 H, CH2), 4.18 (q, J = 7.1 Hz, 2 H, CH2), 4.89-5.02 (m, 2 H, CH2), 
5.71-5.85 (m, 1 H, CH). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 14.27 (CH3), 28.87 (CH2), 30.30 (CH2), 60.83 
(CH2), 68.81 (CH2), 70.19 (CH2), 70.67 (CH2), 70.70 (CH2), 70.72 (CH2), 70.77 (CH2), 
70.97 (CH2), 114.74 (CH2), 138.35 (CH), 170.52 (CO). 
HRMS (ESI): m/z calculated for m/z calculated for C15H28O6Na+ [M+Na]+: 327.1778; 
found: 327.1861. 
FT-IR (ATR): ~  [cm-1] = 2866 (br), 1752 (m), 1201 (m), 1107 (s), 1030 (m), 912 (m).  
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Synthesis of Thioacetate (153) 
 
A solutions of 152 (5.33 g, 17.5 mmol, 1 eq) and a catalytic amount of AIBN (863 mg, 
5.25 mmol, 0.3 eq) in dry THF (45 mL) was purged with argon for 10 min and heated to 
reflux, then thioacetic acid (3.12 mL, 43.8 mmol, 2.5 eq) was rapidly added to the 
reaction mixture and the mixture was kept stirring under reflux overnight. The 
disappearance of the signal of double bonds (multi peaks at 5-6 ppm) and the appearance 
of a new single peak of methyl group (at around 2.3 ppm) monitored by 1H NMR 
indicated the complete reaction. Then the reaction mixture was concentrated under 
reduced pressure and purified by flash chromatography on silica gel (cyclohexane/ethyl 
acetate = 2/1) to afford 153 as a colorless oil. 
C17H32O7S  380.50 g/mol 
Yield   5.76 g, 15.1 mmol, 86 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.28 (t, J = 7.3 Hz, 3 H, CH3), 1.37-1.45 (m, 2 H, 
CH2), 1.53-1.61 (m, 4 H, 2 × CH2), 2.31 (s, 3 H, CH3), 2.86 (t, J = 7.2 Hz, 2 H, CH2), 3.44 
(t, J = 6.5 Hz, 2 H, CH2), 3.54-3.75 (m, 12 H, 6 × CH2), 4.14 (s, 2 H, CH2), 4.21 (q, J = 
7.1 Hz, 2 H, CH2). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 14.35 (CH3), 25.52 (CH2), 29.18 (CH2), 29.26 
(CH2), 29.50 (CH2), 30.76 (CH3), 60.93 (CH2), 68.88 (CH2), 70.25 (CH2), 70.73 (CH2), 
70.77 (CH2), 71.05 (CH2), 71.26 (CH2), 170.61 (CO), 196.08 (CO). 
HRMS (ESI): m/z calculated for m/z calculated for C17H32O7SNa+ [M+Na]+: 403.1761; 
found: 403.1838. 
FT-IR (ATR): ~  [cm-1] = 2864 (br), 1752 (m), 1687 (s), 1201 (m), 1104 (s), 1030 (m), 
952 (m).   
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Synthesis of Thiol (154) 
 
To a solution of 153 (3.8 g, 10 mmol, 1 eq) in absolute ethanol (40 mL) was added an 
aqueous solution of concentrated HCl (4.0 mL) and the resulting mixture was heated to 
reflux for 12 h. The 1H NMR of the reaction mixture showed that the single peak of 
methyl group (at around 2.3 ppm) was disappeared and a new quartet peak (at around 2.5 
ppm) was appeared, indicating the completion of the reaction. Then the mixture was cool 
down to room temperature and adjusted pH to 6 using 1 M NaOH. The solution was 
partially concentrated, diluted with brine (30 mL) and extracted with dichloromethane (5 
× 30 mL). The combined organic layer was dried with MgSO4 and concentrated with a 
rotatory evaporator under reduced pressure to get pale yellow oil. This product was used 
immediately to the next step without purification. 
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Synthesis of Trityl thioether (155) 
 
To a solution of 154 (3.38 g, 10 mmol, 1eq) in dry THF (15 mL) was added trityl 
chloride (8.64 g, 30 mmol, 3eq) under argon atmosphere. The reaction mixture was stirred 
at room temperature (2-4 days) until complete disappearance of 154 as monitored by 1H 
NMR (quartet peaks at 2.5 ppm). If necessary, 2 eq of trityl chloride was added and the 
mixture was stirred for another two days to complete the reaction. Then the reaction 
mixture was concentrated with a rotatory evaporator under reduced pressure and purified 
by flash chromatography on silica gel (cyclohexane/ethyl acetate = 2/1) to give 155 as a 
clear oil. 
C34H44O6S  580.77 g/mol 
Yield   4.1 g, 7 mmol, 70 % (over last two steps) 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.27 (t, J = 7.1 Hz, 3 H, CH3), 1.34-1.47 (m, 6 H, 
3 × CH2), 2.13  (t, J = 7.2 Hz, 2 H, CH2), 3.35 (t, J = 6.5 Hz, 2 H, CH2), 3.51-3.72 (m, 12 
H, 6 × CH2), 4.13 (s, 2 H, CH2), 4.20 (q, J = 7.1 Hz, 2 H, CH2), 7.15-7.30 (m, 10 H, 10 × 
CHar), 7.37-7.41 (m, 5 H, 5 × CHar). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 14.36 (CH3), 25.74 (CH2), 28.60 (CH2), 29.35 
(CH2), 32.07 (CH2), 60.92 (CH2), 66.54 (Cq), 68.90 (CH2), 70.22 (CH2), 70.73 (CH2), 
70.77 (CH2), 70.79 (CH2), 71.05 (CH2), 71.32 (CH2), 126.65 (CHar), 127.94 (CHar), 
129.74 (CHar), 145.19 (Cq), 170.60 (CO). 
HRMS (ESI): m/z calculated for m/z calculated for C34H44O6SNa+ [M+Na]+: 603.2751; 
found: 603.2799. 
FT-IR (ATR): ~  [cm-1] = 2862 (br), 1751 (m), 1444 (m), 1202 (m), 1108 (s), 1032 (m), 
742 (s), 699 (s). 
  
EXPERIMENTAL SECTION 
215 
 
Synthesis of Trityl-protected thioalkylated TEG acetic acid (156) 
 
To a solution of 155 (2.9 g, 5 mmol, 1 eq) in 1:1 THF/MeOH (50 mL) was added 
aqueous solution of lithium hydroxide (240 mg, 10 mmol in 10 mL H2O). The reaction 
mixture was stirred at room temperature for 12 h. The solution was acidified to pH 1 with 
1 M HCl, diluted with brine (20 mL) and extracted with dichloromethane (4 × 30 mL). 
The combined organic layers were washed with brine (20 mL), dried over MgSO4 and 
concentrated with a rotatory evaporator under reduced pressure to afford 156 as a pale 
yellow oil. 
C32H40O6S  552.72 g/mol 
Yield   2.7 g, 4.9 mmol, 98 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.22-1.47 (m, 6 H, 3 × CH2), 2.12 (t, J = 7.2 Hz, 
2 H, CH2), 3.37 (t, J = 6.6 Hz, 2 H, CH2), 3.54-3.74 (m, 12 H, 6 × CH2), 4.12 (s, 2 H, 
CH2), 7.16-7.28 (m, 10 H, 10 × CHar), 7.37-7.41 (m, 5 H, 5 × CHar). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 25.66 (CH2), 28.56 (CH2), 29.18 (CH2), 32.06 
(CH2), 66.54 (Cq), 69.26 (CH2), 70.27 (CH2), 70.48 (CH2), 70.56 (CH2), 70.83 (CH2), 
71.35 (CH2), 71.76 (CH2), 126.65 (CHar), 127.94 (CHar), 129.73 (CHar), 145.18 (Cq), 
172.03 (CO). 
HRMS (ESI): m/z calculated for m/z calculated for C32H40O6SNa+ [M+Na]+: 575.2438; 
found: 575.2537. 
FT-IR (ATR): ~  [cm-1] = 2862 (br), 1736 (m), 1443 (m), 1105 (s), 1032 (m), 741 (s), 
699 (s). 
  
EXPERIMENTAL SECTION 
216 
 
6.6.2 Synthesis of the thioalkylated TEG ligand 
Synthesis of Alkylated thioacetate (157) 
 
A solutions of 151 (650 mg, 3 mmol, 1 eq) and a catalytic amount of AIBN (148 mg, 0. 
9 mmol, 0.3 eq) in dry THF (20 mL) was heated to reflux, then thioacetic acid (535 µL, 
7.5 mmol, 2.5 eq) was added to the reaction mixture and the mixture was refluxed 
overnight. The reaction mixture was concentrated with a rotatory evaporator under 
reduced pressure and purified by flash chromatography on silica gel (cyclohexane/ethyl 
acetate = 1/1) to afford 157 as a clear oil.  
C13H26O5S  294.41 g/mol 
Yield   640 mg, 2.17 mmol, 72 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.33-1.44 (m, 2 H, CH2), 1.51-1.62 (m, 4 H, 2 × 
CH2), 2.29 (s, 3 H, CH3), 2.59 (br s, 1 H, OH), 2.84 (t, J = 7.3 Hz, 2 H, CH2), 3.42 (t, J = 
6.6 Hz, 2 H, CH2), 3.54-3.71 (m, 12 H, 6 × CH2). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 25.01 (CH2), 28.68 (CH2), 28.73 (CH2), 29.01 
(CH2), 30.28 (CH3), 61.40 (CH2), 69.74 (CH2), 70.04 (CH2), 70.26 (CH2), 70.30 (CH2), 
70.80 (CH2), 72.17 (CH2), 195.61 (CO). 
HRMS (ESI): m/z calculated for m/z calculated for C13H26O5SNa+ [M+Na]+: 317.1393; 
found: 317.1429. 
FT-IR (ATR): ~  [cm-1] = 2928 (br), 2864 (br), 1752 (m), 1687 (s), 1201 (m), 1104 (s), 
1030 (m), 952 (m). 
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Synthesis of Alkylated thiol (158) 
 
A solution of 157 (640 mg, 2.17 mmol, 1 eq) in methanol (20 mL) was purged with 
argon for 10 min, then an aqueous solution of concentrated HCl (2 mL) was added to the 
solution and the resulting mixture was heated to reflux overnight. Then the reaction 
mixture was cooled to room temperature and adjusted pH to 6 using 1 M NaOH. The 
solution was diluted with brine (20 mL) and extracted with dichloromethane (3 × 30 mL). 
The combined organic phases were dried over MgSO4 and concentrated was concentrated 
with a rotatory evaporator under reduced pressure and purified by flash chromatography 
on silica gel (cyclohexane/ethyl acetate = 1/1)  to afford 158 as a clear oil. 
C11H24O4S  252.37 g/mol 
Yield   450 mg, 1.78 mmol, 82 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 1.33 (t, J = 7.8 Hz, 1 H, SH), 1.40-1.48 (m, 2 H, 
CH2), 1.54-1.67 (m, 4 H, 2 × CH2), 2.52 (q, J = 7.3 Hz, 2 H, CH2), 3.45 (t, J = 6.5 Hz, 2 H, 
CH2), 3.56-3.72 (m, 12 H, 6 × CH2). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 24.66 (CH2), 25.04 (CH2), 29.15 (CH2), 33.95 
(CH2), 61.90 (CH2), 70.22 (CH2), 70.51 (CH2), 70.75 (CH2), 70.77 (CH2), 71.34 (CH2), 
72.60 (CH2). 
HRMS (ESI): m/z calculated for m/z calculated for C11H24O4SNa+ [M+Na]+: 275.1288; 
found: 275.1315. 
FT-IR (ATR): ~  [cm-1] = 2930 (br), 2861 (br), 1455 (w), 1350 (w), 1289 (w), 1247 (w), 
1097 (s), 1066 (s), 933 (w), 885 (w). 
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6.6.3 Microwave-Assited SPPS of Thiolalkylated Peptide Ligands 
Synthesis of Thiolalkylated Peptide Ligand (161) 
 
The synthesis of 161 was carried out on Rink amide MBHA resin (200 mg, 0.84 
mmol/g, 0.168 mmol, 1 eq) according to the standard microwave-assisted SPPS procedure 
described in Chapter 6.2.2. The resin was swollen in DCM (10 mL) for 2 h, followed by 
the removal of Fmoc protecting group with 20 % piperidine/DMF. After a washing cycle 
with DMF, the first amino acid Fmoc-Lys(Alloc)-OH (228 mg, 0.504 mmol, 3 eq) was 
attached to the resin with the coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the 
base DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) by microwave irradiation for 20 
min. The coupling was repeated and a negative Kaiser test confirmed the complete 
reaction. After the Fmoc deprotection, the Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq) 
and Fmoc-Lys(Boc)-OH (236 mg, 0.504 mmol, 3 eq) were coupled in the same manner. 
Then, after the Fmoc deprotection, the thiolalkylated TEG linker (156) (278 mg, 0.504 
mmol, 3 eq) was coupled to the resin with the help of DIC (95 µL, 0.605 mmol, 3.6 eq) 
and HOBt (102 mg, 0.756 mmol, 4.5 eq) in DMF. After the removal of Alloc protecting 
group with Pd(PPh3)4 (19.4 mg, 0.0168 mmol, 0.1 eq) in the presence of PhSiH3 (495 μL, 
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4.032 mmol, 24 eq) in DCM, the Boc-GCP group (111) (200 mg, 0.504 mmol, 3 eq) was 
coupled. After the final washing cycles, the cleavage of the product from the resin was 
carried out without microwave irradiation by using a mixture of TFA/phenol/H2O/TIS 
(95:5:2.5:2.5) according to the general procedure for Rink amide MBHA resin. The crude 
product was purified by RP18-MPLC using appropriate conditions (MeOH/H2O + 0.1 % 
TFA). Pure product was transferred into its hydrochloride salt by dissolving in water with 
hydrochloric acid and lyophilizing three times to give 161 as a white solid with 95 % 
purity according to analytical HPLC analysis. 
C43H69Cl2N11O10S  1003.05 g/mol 
Yield     49 mg, 48.8 μmol, 29 % 
Mp.     146 oC  
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.13-1.38 (m, 6 H, 2 × Lys-CH2, CH2), 
1.46-1.70 (m, 12 H, 4 × Lys-CH2, 2 × CH2), 2.46-2.48 (m, 2 H, CH2), 2.66-2.76 (m, 2 H, 
Lys-CH2), 2.95-2.99, 3.14-3.23 (m, 4 H, Lys-CH2, Trp-CH2), 3.34 (t, J = 6.3 Hz, 2 H, 
CH2), 3.43-3.54 (m, 12 H, 6 × CH2), 3.88 (s, 2 H, CH2), 4.16-4.21 (m, 1 H, Lys-CH), 
4.28-4.32 (m, 1 H, Lys-CH), 4.53-4.57 (m, 1 H, Trp-CH), 6.86-6.87 (m, 1 H, Pyr-CHar), 
6.95 (t, J = 7.4 Hz, 1 H, Trp-CHar), 7.03-7.05 (m, 2 H, Trp-CHar, NH2), 7.13 (s, 1 H, 
Trp-CHar), 7.28 (s, 1 H, NH2), 7.31 (d, J = 8.2 Hz, 1 H, Trp-CHar), 7.51-7.62 (m, 3 H, 
GCP-CHar, Trp-CHar, NH), 7.84 (brs, 3 H, Lys-NH3+), 7.90 (d, J = 8.1 Hz,, 1 H, NH), 8.22 
(d, J = 7.8 Hz,, 1 H, NH), 8.45-8.65 (m, 5 H, 5 × NH), 10.84 (s, 1 H, Trp-NH), 12.01 (s, 1 
H, Gua-NH), 12.32 (s, 1 H, Pyr-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.03 (Lys-CH2), 22.71 (Lys-CH2), 25.26 
(CH2), 26.59 (Lys-CH2), 27.37 (Trp-CH2), 27.52 (CH2), 28.72 (Lys-CH2), 28.80 (CH2), 
29.28 (CH2), 31.66 (Lys-CH2), 31.83 (Lys-CH2), 38.59 (Lys-CH2), 38.73 (Lys-CH2), 
51.70 (Lys-CH), 52.34 (Lys-CH), 53.53 (Trp-CH), 69.42 (CH2), 69.50 (CH2), 69.73 (CH2), 
70.17 (CH2), 70.22 (CH2), 109.86 (Trp-Cq), 111.22 (Trp-CHar), 112.38 (Pyr-CHar), 115.95 
(Pyr-CHar), 118.18 (Trp-CHar), 118.39 (Trp-CHar), 120.79 (Trp-CHar), 123.55 (Trp-CHar), 
125.29 (Pyr-Cq), 127.25 (Trp-Cq), 132.93 (Pyr-Cq), 136.00 (Trp-Cq), 155.46 (Gua-Cq), 
158.97 (CO), 159.62 (CO), 169.05 (CO), 171.06 (CO), 171.10 (CO), 173.41 (CO). 
HRMS (ESI): m/z calculated for C43H68N11O10S+ [M+H]+: 930.4866; found: 930.4952. 
FT-IR (ATR): ~  [cm-1] = 3172 (br), 3056 (br), 2925 (br), 2865 (br), 1645 (s), 1523 (m), 
1456 (w), 1346 (w), 1235 (w), 1088 (s), 742 (m).  
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Synthesis of Thiolalkylated Peptide Ligand (162) 
 
The peptide ligand 162 was synthesized accordingly on Rink amide MBHA resin (200 
mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described microwave-assisted 
SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the base 
DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used for coupling the amino 
acids, whereas DIC (95 µL, 0.605 mmol, 3.6 eq) and HOBt (102 mg, 0.756 mmol, 4.5 eq) 
were used for the attachment of the thiolalkylated TEG linker (156). After Fmoc 
deprotection, the amino acids Fmoc-Lys(Boc)-OH (236 mg, 0.504 mmol, 3 eq), 
Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), Fmoc-Lys(Alloc)-OH (228 mg, 0.504 
mmol, 3 eq) and thiolalkylated TEG linker (156) (278 mg, 0.504 mmol, 3 eq) were 
coupled. After the removal of Alloc protecting group with Pd(PPh3)4 (19.4 mg, 0.0168 
mmol, 0.1 eq) in the presence of PhSiH3 (495 μL, 4.032 mmol, 24 eq) in DCM, the 
Boc-GCP group (111) (200 mg, 0.504 mmol, 3 eq) was coupled. After the cleavage and 
purification steps, the product was obtained as a white solid with 91 % purity according to 
analytical HPLC analysis.  
C43H69Cl2N11O10S  1003.05 g/mol 
Yield     47 mg, 46.8 μmol, 28 % 
Mp.     148 oC  
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.12-1.38 (m, 6 H, 2 × Lys-CH2, CH2), 
1.45-1.71 (m, 12 H, 4 × Lys-CH2, 2 × CH2), 2.48 (t, J = 7.3 Hz, 2 H, CH2), 2.72-2.77 (m, 
2 H, Lys-CH2), 2.97-3.02, 3.14-3.21 (m, 4 H, Lys-CH2, Trp-CH2), 3.34 (t, J = 6.5 Hz, 2 H, 
CH2), 3.44-3.55 (m, 12 H, 6 × CH2), 3.89 (s, 2 H, CH2), 4.16-4.20 (m, 1 H, Lys-CH), 
4.28-4.32 (m, 1 H, Lys-CH), 4.52-4.56 (m, 1 H, Trp-CH), 6.86-6.87 (m, 1 H, Pyr-CHar), 
6.96 (t, J = 7.4 Hz, 1 H, Trp-CHar), 7.03-7.07 (m, 2 H, Trp-CHar, NH2), 7.15 (s, 1 H, 
Trp-CHar), 7.25 (s, 1 H, NH2), 7.31 (d, J = 8.1 Hz, 1 H, Trp-CHar), 7.54-7.55 (m, 1 H, 
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Pyr-CHar), 7.58 (d, J = 8.0 Hz, 1 H, Trp-CHar), 7.63 (d, J = 8.3 Hz, 1 H, NH), 7.87 (brs, 3 
H, Lys-NH3+), 7.92 (d, J = 8.2 Hz,, 1 H, NH), 8.19 (d, J = 7.8 Hz,, 1 H, NH), 8.47-8.67 (m, 
5 H, 5 × NH), 10.85 (s, 1 H, Trp-NH), 12.06 (s, 1 H, Gua-NH), 12.33 (s, 1 H, Pyr-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.07 (Lys-CH2), 22.72 (Lys-CH2), 25.26 
(CH2), 26.57 (Lys-CH2), 27.26 (Trp-CH2), 27.52 (CH2), 28.71 (Lys-CH2), 28.79 (CH2), 
29.28 (CH2), 31.39 (Lys-CH2), 31.84 (Lys-CH2), 38.59 (Lys-CH2), 38.66 (Lys-CH2), 
52.01 (Lys-CH), 52.15 (Lys-CH), 53.49 (Trp-CH), 69.42 (CH2), 69.48 (CH2), 69.67 (CH2), 
69.71 (CH2), 69.73 (CH2), 70.17 (CH2), 109.85 (Trp-Cq), 111.23 (Trp-CHar), 112.36 
(Pyr-CHar), 115.97 (Pyr-CHar), 118.17 (Trp-CHar), 118.40 (Trp-CHar), 120.80 (Trp-CHar), 
123.56 (Trp-CHar), 125.29 (Pyr-Cq), 127.27 (Trp-Cq), 132.95 (Pyr-Cq), 136.00 (Trp-Cq), 
155.49 (Gua-Cq), 158.95 (CO), 159.63 (CO), 169.15 (CO), 171.06 (CO), 171.36 (CO), 
173.27 (CO). 
HRMS (ESI): m/z calculated for C43H68N11O10S+ [M+H]+: 930.4866; found: 930.4730. 
FT-IR (ATR): ~  [cm-1] = 3169 (br), 3051 (br), 2918 (br), 2860 (br), 1645 (s), 1525 (m), 
1456 (w), 1347 (w), 1234 (w), 1090 (s), 743 (m). 
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Synthesis of Thiolalkylated Peptide Ligand (163) 
 
The peptide ligand 163 was synthesized accordingly on Rink amide MBHA resin (200 
mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described microwave-assisted 
SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the base 
DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used for coupling the amino 
acids, whereas DIC (95 µL, 0.605 mmol, 3.6 eq) and HOBt (102 mg, 0.756 mmol, 4.5 eq) 
were used for the attachment of the thiolalkylated TEG linker (156). After Fmoc 
deprotection, the amino acids Fmoc-Lys(Boc)-OH (236 mg, 0.504 mmol, 3 eq), 
Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), Fmoc-Lys(Boc)-OH (236 mg, 0.504 
mmol, 3 eq) and thiolalkylated TEG linker (156) (278 mg, 0.504 mmol, 3 eq) were 
coupled. After the cleavage and purification steps, the product was obtained as a white 
solid with 94 % purity according to analytical HPLC analysis. 
C36H63Cl2N7O8S   824.90 g/mol 
Yield     62 mg, 75.2 μmol, 45 % 
Mp.     92 oC 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.13-1.70 (m, 18 H, 6 × Lys-CH2, 3 × CH2), 
2.47-2.48 (m, 2 H, CH2), 2.67-2.77 (m, 4 H, 2 × Lys-CH2) 2.97-3.02, 3.14-3.18 (m, 2 H, 
Trp-CH2), 3.35 (t, J = 6.6 Hz, 2 H, CH2), 3.44-3.55 (m, 12 H, 6 × CH2), 3.90 (s, 2 H, CH2), 
4.16-4.20 (m, 1 H, Lys-CH), 4.27-4.31 (m, 1 H, Lys-CH), 4.52-4.56 (m, 1 H, Trp-CH), 
6.96 (t, J = 7.5 Hz, 1 H, Trp-CHar), 7.03-7.07 (m, 2 H, Trp-CHar, NH2), 7.15 (s, 1 H, 
Trp-CHar), 7.30-7.32 (m, 2 H, Trp-CHar, NH2), 7.58 (d, J = 7.9 Hz, 1 H, Trp-CHar), 7.65 (d, 
J = 8.2 Hz, 1 H, NH), 7.93 (d, J = 8.2 Hz, 1 H, NH), 7.98 (brs, 6 H, 2 × Lys-NH3+), 8.28 
(d, J = 7.9 Hz,, 1 H, NH), 10.88 (s, 1 H, Trp-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 22.04 (Lys-CH2), 22.07 (Lys-CH2), 25.27 
(CH2), 26.54 (Lys-CH2), 26.56 (Lys-CH2), 27.28 (Trp-CH2), 27.52 (CH2), 28.80 (CH2), 
29.28 (CH2), 31.40 (Lys-CH2), 31.61 (Lys-CH2), 38.49 (Lys-CH2), 38.51 (Lys-CH2), 
51.82 (Lys-CH), 52.14 (Lys-CH), 53.60 (Trp-CH), 69.43 (CH2), 69.50 (CH2), 69.69 (CH2), 
69.73 (CH2), 70.17 (CH2), 70.19 (CH2), 109.86 (Trp-Cq), 111.23 (Trp-CHar), 118.17 
(Trp-CHar), 118.40 (Trp-CHar), 120.80 (Trp-CHar), 123.56 (Trp-CHar), 127.24 (Trp-Cq), 
136.00 (Trp-Cq), 169.10 (CO), 171.09 (CO), 171.17 (CO), 173.29 (CO). 
EXPERIMENTAL SECTION 
223 
 
HRMS (ESI): m/z calculated for C36H62N7O8S+ [M+H]+: 752.4375; found: 752.4376. 
FT-IR (ATR): ~  [cm-1] = 3172 (br), 3051 (br), 2924 (br), 2860 (br), 1644 (s), 1525 (m), 
1456 (w), 1346 (w), 1234 (w), 1088 (s), 743 (m). 
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Synthesis of Thiolalkylated Peptide Ligand (164) 
 
The peptide ligand 164 was synthesized accordingly on Rink amide MBHA resin (200 
mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described microwave-assisted 
SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the base 
DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used for coupling the amino 
acids, whereas DIC (95 µL, 0.605 mmol, 3.6 eq) and HOBt (102 mg, 0.756 mmol, 4.5 eq) 
were used for the attachment of the thiolalkylated TEG linker (156). After Fmoc 
deprotection, the amino acids Fmoc-Arg(pbf)-OH (327 mg, 0.504 mmol, 3 eq), 
Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), Fmoc-Lys(Boc)-OH (236 mg, 0.504 
mmol, 3 eq) and thiolalkylated TEG linker (156) (278 mg, 0.504 mmol, 3 eq) were 
coupled. After the cleavage and purification steps, the product was obtained as a white 
solid with 95 % purity according to analytical HPLC analysis. 
C36H63Cl2N9O8S   852.91 g/mol 
Yield     34 mg, 40 μmol, 24 % 
Mp.     93 oC  
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.16-1.73 (m, 16 H, 3 × Lys-CH2, 2 × 
Arg-CH2, 3 × CH2), 2.67-2.73 (m, 4 H, CH2, Lys-CH2), 2.97-3.18 (m, 4 H, Arg-CH2, 
Trp-CH2), 3.35-3.37 (m, 2 H, CH2), 3.44-3.56 (m, 12 H, 6 × CH2), 3.89 (s, 2 H, CH2), 
4.19-4.23 (m, 1 H, Lys-CH), 4.26-4.31 (m, 1 H, Arg-CH), 4.52-4.56 (m, 1 H, Trp-CH), 
6.96 (t, J = 7.5 Hz, 1 H, Trp-CHar), 7.04 (t, J = 7.5 Hz, 1 H, Trp-CHar), 7.12-7.15 (m, 2 H, 
Trp-CHar, NH2), 7.31 (d, J = 8.0 Hz, 1 H, Trp-CHar), 7.37 (s, 1 H, NH2), 7.58 (d, J = 7.8 
Hz, 1 H, Trp-CHar), 7.63 (d, J = 8.0 Hz, 1 H, NH), 7.79 (t, J = 5.6 Hz, 1 H, NH), 
7.95-7.98 (m, 4 H, Lys-NH3+, NH), 8.27 (d, J = 8.1 Hz,, 1 H, NH), 10.88 (s, 1 H, 
Trp-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] =δ [ppm] = 22.03 (Lys-CH2), 24.49 (CH2), 
24.92 (Arg-CH2), 26.54 (Lys-CH2), 27.37 (Trp-CH2), 28.36 (CH2), 28.75 (CH2), 29.21 
(Arg-CH2), 31.57 (Lys-CH2), 37.72 (Lys-CH2), 38.50 (Arg-CH2), 51.81 (Lys-CH), 51.90 
(Arg-CH), 53.65 (Trp-CH), 69.43 (CH2), 69.50 (CH2), 69.68 (CH2), 69.73 (CH2), 70.12 
(CH2), 70.19 (CH2), 109.83 (Trp-Cq), 111.25 (Trp-CHar), 118.20 (Trp-CHar), 118.38 
(Trp-CHar), 120.80 (Trp-CHar), 123.57 (Trp-CHar), 127.24 (Trp-Cq), 136.00 (Trp-Cq), 
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156.89 (Gua-Cq), 169.10 (CO), 171.18 (CO), 173.16 (CO). 
HRMS (ESI): m/z calculated for C72H122N18O16S22+ [M+H]2+: 779.4358; found: 
779.4366 (disulfide). 
FT-IR (ATR): ~  [cm-1] = 3173 (br), 3051 (br), 2918 (br), 2865 (br), 1647 (s), 1525 (m), 
1456 (w), 1345 (w), 1240 (w), 1085 (s), 744 (m). 
  
EXPERIMENTAL SECTION 
226 
 
Synthesis of Thiolalkylated Peptide Ligand (165) 
 
The peptide ligand 165 was synthesized accordingly on Rink amide MBHA resin (200 
mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described microwave-assisted 
SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the base 
DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used for coupling the amino 
acids, whereas DIC (95 µL, 0.605 mmol, 3.6 eq) and HOBt (102 mg, 0.756 mmol, 4.5 eq) 
were used for the attachment of the thiolalkylated TEG linker (156). After Fmoc 
deprotection, the amino acids Fmoc-Glu(OtBu)-OH (214 mg, 0.504 mmol, 3 eq), 
Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq), Fmoc-Glu(OtBu)-OH (214 mg, 0.504 
mmol, 3 eq) and thiolalkylated TEG linker (156) (278 mg, 0.504 mmol, 3 eq) were 
coupled. After the cleavage and purification steps, the product was obtained as a white 
solid with 92 % purity according to analytical HPLC analysis. 
C34H51N5O12S  753.86 g/mol 
Yield    25 mg, 33 μmol, 20 % 
Mp.    60 oC  
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.32-1.39 (m, 2 H, CH2), 1.45-1.51 (m, 4 H, 
2 × CH2), 1.70-1.78 (m, 2 H, Glu-CH2), 1.86-1.94 (m, 2 H, Glu-CH2), 2.16-2.21 (m, 4 H, 
2 × Glu-CH2), 2.46-2.48 (m, 2 H, CH2), 2.93-2.98, 3.13-3.17 (m, 2 H, Trp-CH2), 3.35 (t, J 
= 6.6 Hz, 2 H, CH2), 3.43-3.54 (m, 12 H, 6 × CH2), 3.87 (s, 2 H, CH2), 4.16-4.20 (m, 1 H, 
Glu-CH), 4.30-4.34 (m, 1 H, Glu-CH), 4.50-4.55 (m, 1 H, Trp-CH), 6.96 (t, J = 7.5 Hz, 1 
H, Trp-CHar), 7.03-7.06 (m, 2 H, Trp-CHar, NH2), 7.13 (s, 1 H, Trp-CHar), 7.16 (s, 1 H, 
NH2), 7.30 (d, J = 8.1 Hz, 1 H, Trp-CHar), 7.58 (d, J = 8.0 Hz, 1 H, Trp-CHar), 7.64 (d, J = 
8.1 Hz,, 1 H, NH), 8.03 (d, J = 8.0 Hz,, 1 H, NH), 8.11 (d, J = 7.7 Hz, 1 H, NH), 10.79 (s, 
1 H, Trp-NH), 12.09 (s, 1 H, COOH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 25.27 (CH2), 27.29 (Trp-CH2), 27.46 
(Glu-CH2), 27.51 (CH2), 28.79 (CH2), 29.28 (CH2), 30.06 (Glu-CH2), 30.20 (Glu-CH2), 
51.26 (Glu-CH), 51.91 (Glu-CH), 53.47 (Trp-CH), 69.41 (CH2), 69.50 (CH2), 69.64 
(CH2), 69.73 (CH2), 70.16 (CH2), 70.22 (CH2), 109.83 (Trp-Cq), 111.22 (Trp-CHar), 
118.16 (Trp-CHar), 118.38 (Trp-CHar), 120.80 (Trp-CHar), 123.54 (Trp-CHar), 127.23 
(Trp-Cq), 136.00 (Trp-Cq), 169.20 (CO), 170.82 (CO), 171.15 (CO), 172.96 (CO), 173.95 
(CO), 173.98 (CO). 
FT-IR (ATR): ~  [cm-1] = 3174 (br), 3051 (br), 2923 (br), 2866 (br), 1645 (s), 1525 (m), 
1457 (w), 1347 (w), 1233 (w), 1090 (s), 744 (m).  
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6.6.4 Syntheses of Alkylated Peptide Ligands 
Synthesis of Ethyl alkylated TEG acetate (166) 
 
A mixture of the 152 (640 mg, 2.1 mmol, 1 eq), a catalytic amount of Pd/C ( 50 mg) 
in methanol (30 ml) was vigorously stirred at room temperature for 4 h under hydrogen 
atmosphere. The resulting solution was filtered through a celite pad which was washed 
two times with methanol. The solvent was evaporated under reduced pressure to yield 166 
as a clear oil. 
C15H30O6  306.40 g/mol 
Yield   621 mg, 2 mmol, 95 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 0.89 (t, J = 6.9 Hz, 3 H, CH3), 1.26-1.33 (m, 7 H, 
CH3, 2 × CH2), 1.53-1.62 (m, 2 H, CH2), 3.44 (t, J = 6.8 Hz, 2 H, CH2), 3.57-3.75 (m, 12 
H, 6 × CH2), 4.14 (s, 2 H, CH2), 4.21 (q, J = 7.6 Hz, 2 H, CH2). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 14.17 (CH3), 14.35 (CH3), 22.67 (CH2), 28.41 
(CH2), 29.47 (CH2), 60.93 (CH2), 68.81 (CH2), 68.91 (CH2), 70.21 (CH2), 70.52 (CH2), 
70.75 (CH2), 70.80 (CH2), 71.06 (CH2), 71.67 (CH2), 170.62 (CO). 
HRMS (ESI): m/z calculated for C15H30O6Na+ [M+Na]+: 329.1935; found: 329.1911. 
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Synthesis of alkylated TEG acetic acid (167) 
 
To a solution of 166 (621 mg, 2 mmol) in 1:1 THF/MeOH (20 mL) was added 1 M 
aqueous solution of lithium hydroxide. The solution was purged with argon for 10 min 
and stirred at room temperature for 12 h. The solution was acidified to pH 1 with 1 M HCl, 
diluted with brine (20 mL) and extracted with dichloromethane (4 × 20 mL). The 
combined organic layers were washed with brine (20 mL), dried over MgSO4 and 
concentrated under reduced pressure to afford 167 as pale yellow oil. 
C13H26O6  278.34 g/mol 
Yield   548 mg, 1.97 mmol, 98 % 
1H NMR (300 MHz, CDCl3): δ [ppm] = 0.89 (t, J = 6.9 Hz, 3 H, CH3), 1.28-1.33 (m, 4 H, 
2 × CH2), 1.55-1.64 (m, 2 H, CH2), 3.47 (t, J = 6.9 Hz, 2 H, CH2), 3.58-3.78 (m, 12 H, 6 × 
CH2), 4.15 (s, 2 H, CH2). 
13C NMR (75 MHz, CDCl3): δ [ppm] = 14.16 (CH3), 22.63 (CH2), 28.34 (CH2), 29.28 
(CH2), 69.34 (CH2), 70.27 (CH2), 70.49 (CH2), 70.53 (CH2), 70.59 (CH2), 70.84 (CH2), 
71.75 (CH2), 71.79 (CH2), 171.94 (CO). 
HRMS (ESI): m/z calculated for C13H26O6Na+ [M+Na]+: 301.1622; found: 301.1598. 
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Synthesis of Alkane Peptide Ligand (168)  
 
The peptide ligand 168 was synthesized accordingly on Rink amide MBHA resin (200 
mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described microwave-assisted 
SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the base 
DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used for coupling the amino 
acids, whereas DIC (95 µL, 0.605 mmol, 3.6 eq) and HOBt (102 mg, 0.756 mmol, 4.5 eq) 
were used for the attachment of the alkylated TEG linker (167). After Fmoc deprotection, 
the amino acids Fmoc-Lys(Boc)-OH (236 mg, 0.504 mmol, 3 eq), Fmoc-Trp(Boc)-OH 
(265 mg, 0.504 mmol, 3 eq), Fmoc-Lys(Alloc)-OH (228 mg, 0.504 mmol, 3 eq) and 
alkylated TEG linker (167) (140 mg, 0.504 mmol, 3 eq) were coupled. After the removal 
of Alloc protecting group with Pd(PPh3)4 (19.4 mg, 0.0168 mmol, 0.1 eq) in the presence 
of PhSiH3 (495 μL, 4.032 mmol, 24 eq) in DCM, the Boc-GCP group (111) (200 mg, 
0.504 mmol, 3 eq) was coupled. After the cleavage and purification steps, the product was 
obtained as a white solid with 95 % purity according to analytical HPLC analysis. 
C43H69Cl2N11O10   970.98 g/mol 
Yield     70 mg, 72.1 µmol, 43 % 
Mp.     153 oC  
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 0.85 (t, J = 7.0 Hz, 3 H, CH3), 1.16-1.33 (m, 
8 H, 2 × CH2, 2 × Lys-CH2), 1.43-1.53 (m, 8 H, CH2, 3 × Lys-CH2), 1.61-1.72 (m, 2 H, 
Lys-CH2), 2.68-2.74 (m, 2 H, Lys-CH2), 2.97 (dd, 1 H, J1 = 14.8 Hz, J2 = 9.0 Hz, 
Trp-CH2), 3.15 (dd, J1 = 19.4 Hz, J2 = 4.8 Hz, 1 H, Trp-CH2), 3.21 (q, J = 6.8 Hz, 2 H, 
Lys-CH2), 3.34 (t, J = 6.6 Hz, 2 H, CH2), 3.42-3.56 (m, 12 H, 6 × CH2), 3.88 (s, 2 H, CH2), 
4.16-4.20 (m, 1 H, Lys-CH), 4.27-4.32 (m, 1 H, Lys-CH), 4.52-4.57 (m, 1 H, Trp-CH), 
6.87 (dd, J1 = 4.1 Hz, J2 = 2.4 Hz, 1 H, Pyr-CHar), 6.95 (t, J = 7.5 Hz, 1 H, Trp-CHar), 
7.02-7.05 (m, 2 H, Trp-CHar, NH2), 7.13 (s, 1 H, Trp-CHar), 7.29 (s, 1 H, NH2), 7.31 (d, J 
= 8.0 Hz, 1 H, Trp-CHar), 7.54 (dd, J1 = 4.1 Hz, J2 = 2.5 Hz, 1 H, Pyr-CHar), 7.57 (d, J = 
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7.9 Hz, 1 H, Trp-CHar), 7.61 (d, J = 8.2 Hz, 1 H, NH), 7.88-7.91 (m, 4 H, Lys-NH3+, NH), 
8.24 (d, J = 8.0 Hz,, 1 H, NH), 8.55 (t, J = 5.5 Hz,, 1 H, NH), 8.48, 8.67 (brs, 4 H, Gua × 
NH4+), 10.85 (s, 1 H, Trp-NH), 12.05 (s, 1 H, Gua-NH), 12.33 (s, 1 H, Pyr-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 13.93 (CH3), 21.93 (CH2), 22.04 (Lys-CH2), 
22.71 (Lys-CH2), 26.58 (Lys-CH2), 27.37 (Trp-CH2), 27.83 (CH2), 28.72 (Lys-CH2), 
28.85 (CH2), 31.66 (Lys-CH2), 31.83 (Lys-CH2), 38.57 (Lys-CH2), 38.72 (Lys-CH2), 
51.73 (Lys-CH), 52.35 (Lys-CH), 53.56 (Trp-CH), 69.42 (CH2), 69.50 (CH2), 69.69 (CH2), 
69.73 (CH2), 69.75 (CH2), 70.22 (CH2), 70.27 (CH2), 109.87 (Trp-Cq), 111.23 (Trp-CHar), 
112.41 (Pyr-CHar), 115.97 (Pyr-CHar), 118.18 (Trp-CHar), 118.39 (Trp-CHar), 120.79 
(Trp-CHar), 123.56 (Trp-CHar), 125.30 (Pyr-Cq), 127.25 (Trp-Cq), 132.95 (Pyr-Cq), 136.00 
(Trp-Cq), 155.52 (Gua-Cq), 158.97 (CO), 159.63 (CO), 169.06 (CO), 171.07 (CO), 171.11 
(CO), 173.43 (CO). 
HRMS (ESI): m/z calculated for C43H69N11O10+ [M+2H]2+: 449.7609; found: 449.7580. 
FT-IR (ATR): ~  [cm-1] = 3235 (br), 2928 (br), 2866 (br), 1652 (s), 1541 (s), 1457 (w), 
1282 (s), 1196 (w), 1096 (s), 744 (m). 
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Synthesis of Peptide Ligand (170) 
 
The peptide ligand 170 was synthesized accordingly on Rink amide MBHA resin (200 
mg, 0.84 mmol/g, 0.168 mmol, 1 eq) following the above described microwave-assisted 
SPPS procedure. The coupling reagent PyBop (262 mg, 0.504 mmol, 3 eq) and the base 
DIPEA (171 µL, 1.008 mmol, 6 eq) in DMF (5 mL) were used during the coupling steps. 
After Fmoc deprotection, the amino acids Fmoc-Lys(Alloc)-OH (228 mg, 0.504 mmol, 3 
eq), Fmoc-Trp(Boc)-OH (265 mg, 0.504 mmol, 3 eq) and Ac-Lys(Boc)-OH (145 mg, 
0.504 mmol, 3 eq) were coupled. After the removal of Alloc protecting group with 
Pd(PPh3)4 (19.4 mg, 0.0168 mmol, 0.1 eq) in the presence of PhSiH3 (495 μL, 4.032 
mmol, 24 eq) in DCM, the Boc-GCP group (111) (200 mg, 0.504 mmol, 3 eq) was 
coupled. After the cleavage and purification steps, the product was obtained as a white 
solid with 93 % purity according to analytical HPLC analysis. 
C32H47Cl2N11O6   752.69 g/mol 
Yield     40 mg, 53.1 µmol, 32 % 
Mp.     186 oC 
1H NMR (500 MHz, DMSO-d6): δ [ppm] = 1.16-1.33 (m, 4 H, 2 × Lys-CH2), 1.40-1.71 
(m, 8 H, 4 × Lys-CH2), 2.68-2.73 (m, 2 H, Lys-CH2), 2.99 (dd, 1 H, J1 = 14.8 Hz, J2 = 8.9 
Hz, Trp-CH2), 3.16 (dd, J1 = 15.1 Hz, J2 = 4.7 Hz, 1 H, Trp-CH2), 3.21 (q, J = 6.5 Hz, 2 H, 
Lys-CH2), 4.47-4.52 (m, 1 H, Trp-CH), 6.86 (dd, J1 = 4.0 Hz, J2 = 2.4 Hz, 1 H, Pyr-CHar), 
6.96 (t, J = 7.4 Hz, 1 H, Trp-CHar), 7.02-7.05 (m, 2 H, Trp-CHar, NH2), 7.13 (s, 1 H, 
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Trp-CHar), 7.24 (s, 1 H, NH2), 7.31 (d, J = 8.1 Hz, 1 H, Trp-CHar), 7.53-7.55 (m, 2 H, 
Pyr-CHar, Trp-CHar), 7.80 (d, J = 8.1 Hz, 1 H, NH), 7.90 (brs, 3 H, Lys-NH3+), 8.03 (d, J = 
7.9 Hz,, 1 H, NH), 8.07 (d, J = 7.5 Hz,, 1 H, NH), 8.54 (d, J = 5.5 Hz,, 1 H, NH), 8.49, 
8.67 (brs, 4 H, Gua × NH4+), 10.88 (s, 1 H, Trp-NH), 12.05 (s, 1 H, Gua-NH), 12.33 (s, 1 
H, Pyr-NH). 
13C NMR (125 MHz, DMSO-d6): δ [ppm] = 21.21 (Lys-CH2), 22.45 (CH3), 22.73 
(Lys-CH2), 26.58 (Lys-CH2), 27.13 (Trp-CH2), 28.73 (Lys-CH2), 31.07 (Lys-CH2), 31.73 
(Lys-CH2), 38.50 (Lys-CH2), 38.73 (Lys-CH2), 52.43 (Lys-CH), 52.76 (Lys-CH), 53.55 
(Trp-CH), 109.86 (Trp-Cq), 111.23 (Trp-CHar), 112.42 (Pyr-CHar), 115.97 (Pyr-CHar), 
118.21 (Trp-CHar), 118.34 (Trp-CHar), 120.79 (Trp-CHar), 123.56 (Trp-CHar), 125.30 
(Pyr-Cq), 127.27 (Trp-Cq), 132.96 (Pyr-Cq), 136.00 (Trp-Cq), 155.52 (Gua-Cq), 158.97 
(CO), 159.63 (CO), 169.62 (CO), 171.10 (CO), 171.75 (CO), 173.49 (CO). 
HRMS (ESI): m/z calculated for C32H47N11O6+ [M+2H]2+: 340.6850; found: 340.6855. 
FT-IR (ATR): ~  [cm-1] = 3184 (br), 3050 (br), 2934 (br), 1651 (s), 1547 (s), 1283 (s), 
1196 (m), 745 (m). 
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6.7 Preparation of the Functionalized Gold Nanoparticles 
Preparation of monovalent conjugates (171)  
 
Monovalent conjugated Au NPs 171 was carried out by attaching ligand 161 to the 
surface of Au NPs via ex situ or in situ conjugation. For ex situ conjugation, the gold 
nanoparticles were first prepared in the absence of ligand in 30 mL sodium phosphate 
buffer (0.6 mM, pH 6.0) by laser ablation for 150 s. Then the big particles (d > 10 nm) 
were removed by ultracentrifugation to get the monodispersed nanoparticles. In order to 
get the conjugated Au NPs with different surface density, a series of concentrations of the 
ligand in sodium phosphate buffer (each in 0.5 mL) resulting in the following final 
concentrations: 0 µM, 0.5 µM, 1.3 µM, 2.6 µM, 3.9 µM, 5.2 µM, 12.9 µM, 25.9 µM, 51.7 
µM, 206.9 µM, 413.8 µM, 620.7 µM, 724.2 µM were prepared. For the first try, higher 
ligand concentrations: 795 µM, 847 µM, 900 µM, 950 µM and 1000 µM were also 
prepared. Then to each solution of the ligand 1 mL of gold nanoparticles was added and 
the mixtures were shaken for 1 h. For in situ conjugation, the gold nanoparticles were 
prepared in the presence of the ligands. A series of concentrations of the ligand in sodium 
phosphate buffer (each in 1.5 mL) resulting in the following final concentrations: 0 µM, 
0.5 µM, 1.3 µM, 2.6 µM, 3.9 µM, 5.2 µM, 12.9 µM, 25.9 µM, 51.7 µM, 206.9 µM, 413.8 
µM, 620.7 µM, 724.2 µM were prepared. The laser ablation was performed in a cuvette 
where the solution and a gold ribbon were placed inside. For each ligand concentration, 
the laser ablation was carried out for 7 seconds. Afterwards, the Au NPs samples were 
shaken for 1 h to ensure the complete conjugation. After the conjugation, the unbound 
ligands were removed from the conjugates by using ultracentrifugation and the surface 
coverage was determined with the help of UV/Vis spectroscopy.   
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Preparation of bivalent conjugates (172)  
 
Bivalent conjugated Au NPs 172 was carried out by attaching the positively charged 
ligand 161 and the neutral ligand 158 to the surface of Au NPs via ex situ or in situ 
conjugation. It was prepared following the above described procedures by using two types 
of different ligands (161 and 158) instead of only using one type of ligand (161) for 
monovalent conjugation. In order to obtain different surface density, a series of 
concentrations of the ligand 161 in sodium phosphate buffer resulting in the following 
final concentrations: 0 µM, 0.5 µM, 1.3 µM, 2.6 µM, 3.9 µM, 5.2 µM, 12.9 µM, 25.9 µM, 
51.7 µM, 206.9 µM, 413.8 µM, 620.7 µM, 724.2 µM were prepared. Ligand 158 was 
used as the surface blocker with respectively double amount. For both ex situ and in situ 
conjugation, the Au NPs samples were shaken for 1 h to ensure the complete conjugation 
after the laser ablation. After the conjugation, the unbound ligands were removed from the 
conjugates by using ultracentrifugation and the surface coverage was determined with the 
help of UV/Vis spectroscopy.  
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6.8 Generation of the Dynamic Combinatorial Libraries 
 
The dynamic combinatorial libraries can be easily generated in 100 mM sodium 
acetate buffer solutions at pH 4.0 containing 10 % DMSO (v/v) to help dissolve the 
aromatic aldehydes and the acyl hydrazones, upon gently agitation for three days. The full 
library was prepared by mixing all the ten building blocks (five hydrazides and five 
aldehydes) together in an aqueous acetate buffer solution at room temperature. At the 
same time, ten sub-libraries were generated under the same conditions by mixing all 
components except one specific building block was omitted and replaced by the blank 
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acetate buffer solution containing 10 % DMSO. Equilibration of all the libraries was 
carried out in the absence of the enzyme. The concentrations of the hydrazide groups or 
aldehyde groups of each building block were kept the same. For example, the stock 
solutions of mono-hydrazides 135-136, 138-140 (1 mM), di-aldehydes A-D (0.5 mM) and 
tri-aldehyde E (0.33 mM) were prepared in sodium acetate buffer (100 mM, pH = 4.0, 
containing 10 % DMSO, v/v). Then, the full library was generated by adding all the five 
hydrazides and five aldehydes (each 10 μL) to sodium acetate buffer (100 mM, pH = 4.0, 
containing 10 % DMSO, v/v). The ten sub-libraries were performed under the same 
conditions except the building block to be removed was exchanged by sodium acetate 
buffer (100 mM, pH = 4.0, containing 10 % DMSO, v/v). The final concentration of the 
libraries amounted to 0.5 mM in total for both hydrazide and aldehyde groups. Together 
with a reference sample (acetate buffer containing 10 % DMSO) without any building 
blocks, this series of 12 samples was sufficient to screening the complete 95-membered 
library (not counting partially formed species). The mixtures of all the libraries were 
allowed to equilibrate at room temperature with shaking for 3 days to ensure a complete 
equilibrium and the resulting acyl hydrazones were adjusted to physiological conditions 
(pH 7.4) freezing-out the library composition and subsequently tested for inhibitory 
activity in the presence of β-tryptase. The second size-reduced library containing all the 
five aldehydes but only hydrazide 138, as well as the corresponding six sub-libraries were 
generated and analyzed in the same way. The full library was generated by adding 
hydrazide 138 (50 μL) and five aldehydes (each 10 μL) to sodium acetate buffer. The six 
sub-libraries were performed under the same conditions except the building block to be 
removed was exchanged by sodium acetate buffer. The final concentration of the libraries 
amounted to 0.5 mM in total for both hydrazide and aldehyde groups. 
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6.9 Enzyme Assay 
6.9.1 General Remarks 
The heparin-stabilized recombinant human rhSkin β-tryptase (134 kDa) used in this 
thesis was purchased from Promega (Catalog No. G7061) and delivered in a vial of 0.5 
mL aqueous solution at a mass concentration of 200 μg/mL. The β-tryptase is supplied in 
10 mM 2-(N-morpholino) ethanesulfonic acid (MES) buffer (pH 6.1), containing 10 % 
glycerol, 200 mM NaCl and 0.5 mg/mL heparin. For easier use it was separated into 
aliquots in 50 vials, so that it was available in single vials each containing 2 μg of the 
enzyme in 10 μL solution at the same concentration of 200 μg/mL. The fluorogenic 
substrate Tos-Gly-Pro-Arg-AMC used for β-tryptase was purchased from Bachem 
(Catalog No. I-1365).  
The other two related serine proteases trypsin (23 kDa) and α-chymotrypsin (25 kDa) 
from bovine pancreas used for selectivity assay were purchased from Merck (Catalog No. 
6502 and 230832, respectively) and delivered as white solids. The fluorogenic substrates 
Z-Phe-Arg-AMC and Suc-Leu-Tyr-AMC used for trypsin and α-chymotrypsin 
respectively were purchased from Bachem (Catalog No. I-1160 and I-1355, respectively).  
The cleavage of the fluorogenic substrates by the enzymes results in a strong increase 
of fluorescence emission at 460 nm (380 nm excitation) due to the release of the free 
AMC, which can be used to monitor the kinetics of the enzymatic cleavage. Therefore, in 
order to measure the kinetic parameters for the hydrolysis of the substrate by enzyme, the 
experiments were performed in a high throughput kinetic assay using a fluorescence 
spectrophotometer with a microplate reader unit and white 96 well plates by monitoring 
the fluorescence at 460 nm over the time of 15 min. The following fluorescence 
spectrometer settings were used for all enzyme assays. 
Spectrophotometer parameters 
Ex. wavelength 
Em. wavelength 
Ex. slit 
Em. slit 
Temperature 
Detector 
Sampling interval 
380 nm 
460 nm 
10 nm 
20 nm 
25 oC 
Manual (450 V) 
One measurement per minute 
 
The Tris-HCl buffers with different compositions and pH values were used as the assay 
buffers for the three enzymes which were prepared with the following components for a 
total volume of 100 mL. The required pH values were adjusted by using 1 M aqueous HCl 
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solution. 
 
 
  
Trypsin and α-Chymotrypsin (pH 8.0) 
Reagent Concentration Amount 
Tris 50 mM 0.606 g 
NaCl 100 mM 0.584 g 
EDTA 5 mM 146 mg 
H2O  100 mL 
β-Tryptase (pH 7.4) 
Reagent Concentration Amount 
Tris 50 mM 0.606 g 
NaCl 100 mM 0.584 g 
Heparin 50 μg/mL 5 mg 
Triton-X 0.02 % 20 μL 
H2O  100 mL 
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6.9.2 Enzyme Inhibition Assay 
Inhibition Assay for β-Tryptase 
Before the enzyme inhibition experiment, the enzyme was diluted in assay buffer and 
the final concentration of the enzyme had to be determined prior the tests in order to find 
appropriate concentration to make the slope of the linear graph between 15 and 30 in the 
absence of inhibitor. The stock solution of substrate was prepared in DMSO at a 
concentration of 2 mM. The enzyme kinetic assay was performed in a total volume of 200 
µL of analyte solution, containing the assay buffer, the enzyme, the solvent that used for 
preparation of the inhibitors and the substrate which were added to the white well plate in 
the following order. The mixture was thoroughly mixed and fluorescence activity at 460 
nm was measured over the time of 15 min. 
Addition order for enzyme concentration assay 
Assay buffer 
Enzyme 
DMSO or H2O 
Substrate 
165 μL 
10 μL 
20 μL 
5 μL, c(final) = 50 μM 
 
After finding the appropriate concentration of the enzyme (normally the final 
concentrations at 0.25 nM for DMSO and 0.1 nM for water depending on the different 
solvents for dissolving the inhibitor), the screening of the inhibitors was carried out in the 
Tris-HCl assay buffer. The kinetic assays were carried out in a final volume of 200 µL in 
assay buffer (165 µL) wherein the enzyme (10 µL) was incubated with DMSO (as a 
reference) or inhibitors (20 µL) and finally the substrate (5 µL, final concentration 50 µM) 
was added in the following order. All the solutions were thoroughly mixed and finally the 
increase of fluorescence activity was measured over the time of 15 min. All the inhibitors 
were first prepared as a stock solution of 1 mM in DMSO. The inhibitory activities (in %) 
of all the inhibitors was then first determined three-fold at an inhibitor concentration of 
100 µM to investigate their potential as potent inhibitors of β-tryptase. If the inhibition 
was higher than 80 % also the half maximal inhibitory concentration (IC50) and the 
absolute inhibition constant (Ki) was determined at various inhibitor concentrations. 
Addition order for enzyme inhibition assay 
Assay buffer 
Enzyme 
DMSO or Inhibitor 
Substrate 
165 μL 
10 μL, c(final) = 0.25 nM 
20 μL 
5 μL, c(final) = 50 μM 
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To determine the IC50 and Ki values, a series of the stock solution of inhibitors in 
DMSO resulting in the following final concentrations: 100 μM, 80 μM, 60 μM, 40 μM, 20 
μM, 10 μM, 8 μM, 6 μM, 4 μM, 2 μM, 1 μM, 0.1 μM were measured. Depending on the 
inhibitory activity, sometimes bigger and smaller concentrations were prepared 
(1000-0.01 μM). The resulting data of the residual enzyme activity (in %) compared to the 
reference sample were processed with the GraFit program by using the 4-parameter 
equation (9) as shown in Chapter 4.1.4 to calculate the IC50 values of the inhibitors. The 
Ki values were calculated from the IC50 values depending on the inhibition modes (see 
Chapter 2.1.2). For the noncompetitive inhibitors, the Ki values are independent of the 
substrate concentrations and equal to the IC50 values 
Selectivity Assay against Trypsin and α-Chymotrypsin 
Trypsin and α-chymotrypsin were chosen to check the enzyme selectivity. The assays 
were performed in a 50 mM Tris-HCl buffer at pH 8.0, containing 5 mM EDTA and 100 
mM NaCl. Fluorogenic substrates Z-Phe-Arg-AMC and Suc-Leu-Tyr-AMC were used for 
trypsin and α-chymotrypsin respectively. The stock solution of substrate was prepared in 
DMSO at a concentration of 2 mM. All the inhibitors were prepared as a stock solution of 
1 mM in DMSO. The kinetic assays (at 25 oC) were carried out in a final volume of 200 
µL by adding the enzyme (10 µL) to Tris-HCl buffer (pH 8.0, 165 µL) and then the 
addition of inhibitor (20 µL, final concentration 100 µM) and finally the substrate (5 µL, 
final concentration 50 µM) was added. All the solutions were thoroughly mixed and 
finally the increase of fluorescence activity was measured at 460 nm emission (380 nm 
excitation) over the time of 15 min. 
Reversibility of β-Tryptase Inhibition 
The first test on reversibility of β-tryptase inhibition was performed in a dialysis 
experiment. The Float-A-Lyzer G2 dialysis separation tubes (20 kDa) in which a mixture 
(total volume of 1000 µL) of assay buffer (Tris-HCl, 50 mM, pH 7.4, 750 µL), β-tryptase 
(50 µL, final concentration 0.5 nM) and inhibitor (200 µL, final concentration 200 µM) in 
buffer (containing 10 % DMSO) or pure buffer (containing 10 % DMSO, 200 µL) without 
inhibitor as the reference were contained. The dialysis tubes were floated vertically in the 
dialysate reservoir containing a stir bar to adjust the stirring rate to form a gentle rotating 
current. The samples were dialyzed at room temperature and with 4 complete buffer 
changes (every 12-24 h). The tests were done from time to time by taking a 100 µL 
sample from the dialysis tube, adding 95 µL assay buffer and the substrate (5 µL, final 
concentration 50 µM) before the mixtures were submitted to determine the residual 
activity of the enzyme using a fluorescence assay.  
In the second experiment to test the reversibility of enzyme inhibition, the enzyme (10 
µL) was incubated with the inhibitor (20 µL, final concentration 100 µM) or blank DMSO 
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(20 µL) in assay buffer (155 µL) for 5 minutes. Then either heparin in buffer (10 µL, final 
concentration 1 mg/mL) or buffer without heparin (10 µL) was added to the vials. All the 
mixtures were incubated for another 5 minutes, followed by the addition of substrate (5 
µL, final concentration 50 µM) and the fluorescence readout. The higher enzyme activity 
in the vial with heparin compared to the vial with buffer indicates a reversibility binding 
of the inhibitor to the enzyme. 
Mode of β-Tryptase Inhibition 
The inhibition mechanism was characterized with the interpretation of nonlinear 
regression fits and Lineweaver-Burk plots, as well as Dixon plots. In order to construct 
nonlinear regression fits and Lineweaver-Burk plots, the rate of the enzyme reaction was 
measured at different substrate concentrations (10-600 μM) but always with a fixed 
enzyme concentration for different inhibitor concentrations (0, 5, 10 and 100 μM). For 
Dixon plots, the rate of the enzyme reaction was determined at different inhibitor 
concentrations for different substrate concentrations (25, 50, 75, 150 and 200 μM). 
Screening of the Dynamic Combinatorial Libraries 
All screening measurements of DCLs were performed under similar conditions as 
above described. In the enzyme screening measurement (at 25 oC), 10 μL of β-tryptase 
was added to 180 μL Tris-HCl buffer, in which the enzyme was incubated with various 
equilibrated library mixtures (5 µL) in sodium acetate buffer (100 mM, pH 4.0, containing 
10 % DMSO, v/v) and finally the substrate (5 µL, final concentration 50 µM) was added 
in the following order. The solutions were thoroughly mixed and the rate of hydrolysis of 
the AMC substrate was determined by monitoring the fluorescence change at 460 nm for 
15 min. 
Addition order for DCLs screening 
Assay buffer 
Enzyme 
Acetate buffer or DCLs 
Substrate 
180 μL 
10 μL, c(final) = 0.125 nM 
5 μL 
5 μL, c(final) = 50 μM 
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6.10 Molecular Mechanics Calculations  
Molecular modeling calculations were performed with the help of Schrödinger 
MacroModel Vers. 9.9 software. The enzyme input is based on the reported crystal 
structure of β-tryptase (PDB code: 1A0L). All water molecules and substrates of the PDB 
crystal structure were removed from the binding pore. The calculations were carried out 
based on the force field OPLS (optimized potentials for liquid simulations) 2005 by using 
water as solvent to visualize the possible three dimensional structures of the interactions 
between the inhibitors and the enzyme. The structure of the enzyme was fixed while the 
inhibitor was put as mobilized during the calculation. So the calculations began at the 
potential energy of the start conformation and by simulating new conformations a 
minimal potential was searched. The resulting structures were obtained from the result of 
1000 calculation cycles. 
Docking studies were done by using Schrodinger MacroModel and Glide software 
(Version 2012 Update 2). Ligand preparation were done by the following steps: After 
generation of the 2D structure, they got converted into a 3D model, which was minimized 
in the OPLS 2005 force field using MacroModel with 1500 iterations and a convergence 
threshold of 0.05. Before starting the docking study on β-tryptase (PDB code: 1A0L), the 
ligand and water molecules within the crystal structure were deleted, followed by the 
preparation of protein structure with the protein preparation wizzard assigning bond 
orders, adding hydrogens and disulfides. After this basic preparation of ligand and protein 
structure files Glide was used to generate a receptor grid file of the active centers of the 
tryptase, to get detailed information about possible binding motifs. The long- and 
short-half, a quarter and the full tetrameric tryptase structures were prepared. Grids were 
prepared for all four versions of the protein structure. Ligand docking was done in the 
extra precision mode with sampling of nitrogen inversions and ring confirmations. The 
ligand conformations were simulated without any constrains or restrictions beside a 
penalization in the implemented scoring function (Glide) for nonplanar amid 
conformations. Post-docking minimizations were performed using a rejecting threshold of 
0.5 kcal/mol. 
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7. APPENDIX 
7.1 List of Abbreviations 
δ chemical shift 
oC Celsius 
λ wavelength 
μ micro 
ε extinction coefficient 
η viscosity 
ζ zeta potential 
Å Ångstrom 
A alanine 
AA amino acid 
abs absolute 
Ac acetyl 
AFM atomic force microscopy 
AIBN azobis(isobutyronitrile) 
Ala alanine 
Alloc allyloxycarbonyl 
AMC 7-amino-4-methyl-cumarine 
Ar argon 
Arg arginine 
Asp aspartic acid 
Au gold 
Au NPs gold nanoparticles 
Bn benzyl 
Boc tert-butyloxycarbonyl 
tBu tert-butyl 
br broad 
c concentration 
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ca. circa 
CDCl3 deuterated chloroform 
cm centimeter 
d doublet / diameter / day (s) 
D diffusion constant 
Da dalton 
DCL dynamic combinatorial library 
DCM dichloromethane 
DIC N,N’-diisopropylcarbodiimide 
DIPEA N,N -´diisopropylethyl amine 
DLS dynamic light scattering 
DMF N,N -´dimethyl formamide 
DMSO dimethyl sulfoxide 
DMSO-d6 deuterated dimethyl sulfoxide 
E glutamic acid / enzyme  
e.g. for example 
eq equivalent 
ES enzyme-substrate complex 
ESI electrospray ionization 
ESI-MS electrospray ionization mass spectrometry 
F phenylalanine 
Fmoc 9-fluorenylmethyloxycarbonyl 
FRET fluorescence resonance energy transfer 
FT-IR fourier-transform infrared 
g gram 
G glycine 
Gln glutamine 
Glu glutamic acid 
Gly glycine 
GCP guanidiniocarbonyl pyrrole 
h hour (s) 
His histidine 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
I inhibitor  
IC50 half maximal inhibitory concentration 
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IR infrared 
ITC isothermal titration calorimetry 
K lysine 
Ki dissociation (inhibition) constant 
kJ kilo Joule 
Km Michaelis constant 
L liter / leucine / loading value 
Leu leucine 
Lys lysine 
m milli / medium / multiplett / meter 
M mol/L 
m/z mass per charge 
max maximum 
MBHA p-methylbenzhydrylamine 
Me methyl 
MeOH methanol 
MHz megahertz 
min minute (s) 
μM micromolar 
mM millimolar 
Mp. melting point 
MPLC medium performance liquid chromatography 
MS mass spectrometry 
n nano 
nm nanometer 
nM nanomolar 
NMM N-methylmorpholin 
NMR nuclear magnetic resonance 
NPs nanoparticles 
p para 
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
Pd palladium 
Pd/C palladium on charcoal 
PDI polydispersity index 
pH pondus hydrogenii 
Phe phenylalanine 
PI isoelectric point 
PPI primary particle index 
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ppm parts per million 
Pro proline 
PyBOP benzotriazol-1-yl-N-oxy-tris(pyrrolidino)phosphonium 
hexafluorophosphate 
q quadruplet 
r radius 
R arginine 
RP reversed phase 
rt room temperature 
s singulett / strong / second (s) 
S substrate  
Ser serine 
SPPS solid phase peptide synthesis 
SPR surface plasmon resonance 
t time 
tR retention time 
T temperature 
TEG triethylene glycol 
TEM transmission electron microscopy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIS triisopropylsilane 
Tos tosyl 
Trt trityl 
Trp tryptophan 
Tyr tyrosine 
UE Electrophoretic mobility 
UV ultraviolet 
UV/Vis ultraviolet/visible 
V volume / valine  
v velocity 
v0 initial reaction rate 
Vmax maximum reaction velocity 
Val valine 
w weak 
W tryptophan 
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7.2 Supplementary Experimental Data 
7.2.1 HPLC Data 
 
Figure 7.1 Analytical HPLC run of four-armed peptide ligand 115 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 16.8 min; the peak 
integration is based on detection at 290 nm.  
 
Figure 7.2 Analytical HPLC run of four-armed peptide ligand 116 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 16.4 min; the peak 
integration is based on detection at 280 nm. 
 
Figure 7.3 Analytical HPLC run of four-armed peptide ligand 117 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 16.6 min; the peak 
integration is based on detection at 280 nm. 
 
Figure 7.4 Analytical HPLC run of four-armed peptide ligand 118 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 13.5 min; the peak 
integration is based on detection at 280 nm. 
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Figure 7.5 Analytical HPLC run of four-armed peptide ligand 119 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 13.4 min; the peak 
integration is based on detection at 290 nm. 
 
Figure 7.6 Analytical HPLC run of four-armed peptide ligand 120 with 95 % purity, solvent: 30 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 22.6 min; the peak 
integration is based on detection at 290 nm. 
 
Figure 7.7 Analytical HPLC run of four-armed peptide ligand 124 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 16.5 min; the peak 
integration is based on detection at 290 nm. 
 
Figure 7.8 Analytical HPLC run of four-armed peptide ligand 125 with 95 % purity, solvent: 10 % to 100 % 
MeOH/H2O (0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 15.9 min; the peak 
integration is based on detection at 290 nm. 
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Figure 7.9 Analytical HPLC run of peptide-derived hydrazide 135 with 99 % purity, solvent: 10 % to 40 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 12.2 min; the peak 
integration is based on detection at 280 nm. 
 
Figure 7.10 Analytical HPLC run of peptide-derived hydrazide 136 with 98 % purity, solvent: 10 % to 40 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 10.2 min; the peak 
integration is based on detection at 280 nm. 
 
Figure 7.11 Analytical HPLC run of peptide-derived hydrazide 138 with 96 % purity, solvent: 10 % to 40 % 
MeOH/H2O (0.05 % TFA) in 20 min, flow rate: 0.43 ml/min, retention time tR = 18.8 min; the peak 
integration is based on detection at 290 nm. 
 
Figure 7.12 Analytical HPLC run of peptide-derived hydrazide 139 with 91 % purity, solvent: 10 % to 40 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 22.5 min; the peak 
integration is based on detection at 290 nm. 
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Figure 7.13 Analytical HPLC run of peptide-derived hydrazide 140 with 91 % purity, solvent: 10 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 11.9 min; the peak 
integration is based on detection at 220 nm. 
 
Figure 7.14 Analytical HPLC run of acyl hydrazone 141 with 92 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 17.9 min; the peak 
integration is based on detection at 280 nm. 
 
Figure 7.15 Analytical HPLC run of acyl hydrazone 142 with 93 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 15.4 min; the peak 
integration is based on detection at 280 nm. 
 
Figure 7.16 Analytical HPLC run of acyl hydrazone 143 with 94 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 21.0 min; the peak 
integration is based on detection at 290 nm. 
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Figure 7.17 Analytical HPLC run of acyl hydrazone 144 with 96 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 20.1 min; the peak 
integration is based on detection at 290 nm. 
 
Figure 7.18 Analytical HPLC run of acyl hydrazone 146 with 98 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 16.3 min; the peak 
integration is based on detection at 290 nm. 
 
Figure 7.19 Analytical HPLC run of acyl hydrazone 147 with 97 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 16.5 min; the peak 
integration is based on detection at 305 nm. 
 
Figure 7.20 Analytical HPLC run of acyl hydrazone 148 with 93 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 19.5 min; the peak 
integration is based on detection at 290 nm. 
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Figure 7.21 Analytical HPLC run of acyl hydrazone 149 with 91 % purity, solvent: 20 % to 60 % 
MeOH/H2O (0.05 % TFA) in 25 min, flow rate: 0.43 ml/min, retention time tR = 19.4 min; the peak 
integration is based on detection at 305 nm. 
 
Figure 7.22 Analytical HPLC run of ligand 161 with 95 % purity, solvent: 50 % to 70 % MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 16.7 min; the peak integration is based on 
detection at 290 nm. 
 
Figure 7.23 Analytical HPLC run of ligand 162 with 91 % purity, solvent: 50 % to 70 % MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 17.9 min; the peak integration is based on 
detection at 290 nm. 
 
Figure 7.24 Analytical HPLC run of ligand 163 with 94 % purity, solvent: 50 % to 70 % MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 15.0 min; the peak integration is based on 
detection at 280 nm. 
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Figure 7.25 Analytical HPLC run of ligand 164 with 95 % purity, solvent: 50 % to 70 % MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 12.8 min; the peak integration is based on 
detection at 280 nm. 
 
Figure 7.26 Analytical HPLC run of ligand 165 with 92 % purity, solvent: 50 % to 100 % MeOH/H2O 
(0.05 % TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 17.7 min; the peak integration is based 
on detection at 280 nm. 
 
Figure 7.27 Analytical HPLC run of ligand 168 with 95 % purity, solvent: 50 % to 70 % MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR = 9.5 min; the peak integration is based on 
detection at 290 nm. 
 
Figure 7.28 Analytical HPLC run of ligand 170 with 93 % purity, solvent: 10 % to 50 % MeOH/H2O (0.05 % 
TFA) in 22 min, flow rate: 0.43 ml/min, retention time tR = 18.4 min; the peak integration is based on 
detection at 290 nm.  
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7.2.2 Enzyme Inhibition Data 
The following data is based on the β-tryptase inhibition assays for all the inhibitors. All 
the measurements were done in triplicate with the substrate concentration at 50 μM. The 
average value of the residual enzyme activity (in %) at different inhibitor concentrations 
were listed in the following tables. The IC50 values were calculated from these data with 
the help of GraFit program on the basis of nonlinear regression.  
Four-armed peptide ligand (RWKG)2(RLFG)2 (115) 
[115], μM Enzyme activity, % 
100 6.19 
80 7.79 
60 9.52 
40 14.97 
20 27.61 
10 32.68 
8 36.95 
6 39.62 
4 45.88 
2 56.86 
1 71.40 
0.1 91.63 
Four-armed peptide ligand (KWKG)2(KLFG)2 (116) 
[116], μM Enzyme activity, % 
100 5.83 
80 6.44 
60 7.81 
40 10.23 
20 32.86 
10 43.76 
6 55.54 
4 60.21 
2 67.16 
1 79.44 
0.1 87.99 
 
 
 
IC50 = 4.04 ± 0.81 μM 
IC50 = 12.77 ± 3.77 μM 
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Four-armed peptide ligand (RWKG)2(KLFG)2 (117) 
[117], μM Enzyme activity, % 
100 3.10 
80 3.47 
60 4.71 
40 12.70 
20 29.20 
10 53.10 
8 59.96 
6 61.87 
4 69.32 
2 80.79 
1 87.83 
0.1 99.69 
Four-armed peptide ligand (RWKG)2(KWKG)2 (118) 
[118], μM Enzyme activity, % 
100 2.16 
80 2.74 
60 3.37 
40 3.83 
20 22.61 
10 47.41 
8 55.81 
6 59.17 
4 66.53 
2 74.77 
1 88.88 
0.1 97.70 
Four-armed peptide ligand (RWKG)2(FRKG)2 (119) 
[119], μM Enzyme activity, % 
100 2.16 
80 2.27 
60 2.35 
40 2.53 
20 17.71 
10 41.56 
8 47.99 
6 57.93 
4 61.06 
2 76.08 
1 84.46 
0.1 99.99 
IC50 = 13.37 ± 2.45 μM 
IC50 = 10.37 ± 1.64 μM 
IC50 = 8.16 ± 1.14 μM 
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Four-armed peptide ligand (RWKG)2(GCP-LFG)2 (120) 
[120], μM Enzyme activity, % 
100 4.26 
80 6.00 
60 5.87 
40 10.06 
20 21.79 
10 29.76 
8 31.64 
4 35.73 
2 40.08 
1 41.40 
0.8 44.87 
0.6 44.21 
0.4 52.52 
0.2 61.43 
0.01 99.00 
Four-armed peptide ligand (GCP-RWKG)4 (124) 
[124], μM Enzyme activity, % 
100 2.51 
80 2.51 
60 3.13 
40 3.07 
20 15.53 
10 30.20 
8 41.93 
6 44.14 
4 53.44 
2 59.14 
1 81.39 
0.1 99.27 
Four-armed peptide ligand (GCP-RWK)4 (125) 
[125], μM Enzyme activity, % 
100 5.73 
80 6.23 
60 6.52 
40 9.37 
20 28.35 
10 52.67 
8 52.69 
6 60.17 
4 68.85 
2 75.04 
1 90.22 
0.1 99.99 
I: IC50 = 0.056 ± 0.026 μM 
II: IC50 = 19.59 ± 2.63 μM 
IC50 = 4.93 ± 0.96 μM 
IC50 = 10.67 ± 2.27 μM 
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Peptide-derived hydrazide 135 
[135], μM Enzyme activity, % 
800 3.39 
600 4.12 
400 4.36 
200 6.71 
100 11.83 
80 13.45 
60 16.78 
40 21.99 
20 34.71 
10 54.13 
6 68.12 
3 88.07 
1 95.40 
Peptide-derived hydrazide 136 
[136], μM Enzyme activity, % 
1000 7.91 
800 11.14 
600 12.32 
400 15.78 
200 25.01 
100 40.76 
80 45.87 
60 49.63 
40 58.91 
20 66.61 
10 79.66 
6 95.99 
3 99.00 
1 99.99 
Peptide-derived hydrazide 138 
[138], μM Enzyme activity, % 
1000 6.14 
800 6.74 
600 6.50 
400 9.54 
200 12.77 
100 20.96 
80 25.24 
60 28.87 
40 35.17 
20 53.39 
10 66.89 
6 77.62 
3 92.52 
1 97.62 
IC50 = 12.65 ± 0.61 μM 
IC50 = 61.05 ± 3.97 μM 
IC50 = 23.58 ± 1.17 μM 
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Peptide-derived hydrazide 139 
[139], μM Enzyme activity, % 
1000 11.75 
800 12.85 
600 12.45 
400 15.84 
200 19.12 
100 24.68 
80 25.78 
60 27.52 
40 36.05 
20 49.36 
10 64.13 
6 81.24 
3 92.15 
1 97.77 
Acyl hydrazone 141 
[141], μM Enzyme activity, % 
10 6.17 
5 8.27 
1 10.15 
0.8 9.78 
0.6 11.18 
0.4 13.26 
0.2 13.46 
0.1 14.34 
0.08 15.18 
0.06 18.65 
0.04 28.04 
0.02 44.39 
0.01 65.94 
0.001 105.28 
Acyl hydrazone 142 
[142], μM Enzyme activity, % 
10 7.98 
5 10.74 
1 17.50 
0.8 23.53 
0.6 33.36 
0.4 42.85 
0.1 50.38 
0.08 55.45 
0.06 63.31 
0.04 71.51 
0.02 87.12 
0.01 92.10 
0.001 100.11 
IC50 = 24.50 ± 2.87 μM 
IC50 = 0.0125 ± 0.0008 μM 
IC50 = 0.1049 ± 0.0310 μM 
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Acyl hydrazone 143 
[143], μM Enzyme activity, % 
10 11.07 
5 11.72 
1 14.47 
0.8 15.88 
0.6 17.89 
0.4 19.37 
0.2 23.36 
0.1 24.53 
0.08 29.33 
0.04 39.57 
0.02 63.32 
0.01 79.51 
0.001 99.90 
Acyl hydrazone 144 
[144], μM Enzyme activity, % 
100 3.65 
80 4.79 
60 5.58 
40 12.27 
32 34.23 
30 19.54 
28 36.81 
26 42.33 
25 38.35 
22 48.41 
20 48.82 
10 56.06 
6 59.78 
4 63.90 
2 65.77 
1 64.74 
0.8 65.33 
0.6 69.84 
0.4 73.88 
0.2 77.66 
0.1 87.80 
0.01 99.00 
Acyl hydrazone 146 
[146], μM Enzyme activity, % 
10 
5 
12.50 
13.89 
1 16.85 
0.8 18.24 
0.6 20.83 
0.4 24.29 
0.2 31.19 
0.1 45.90 
0.08 51.80 
0.06 60.30 
0.04 69.21 
0.02 86.52 
0.01 92.91 
0.001 99.99 
IC50 = 0.0225 ± 0.0021 μM 
I: IC50 = 0.1140 ± 0.0193 μM 
II: IC50 = 29.93 ± 1.44 μM 
IC50 = 0.0656 ± 0.0023 μM 
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Acyl hydrazone 147 
[147], μM Enzyme activity, % 
10 6.60 
2 18.03 
1 29.01 
0.8 32.78 
0.6 40.76 
0.4 52.74 
0.2 74.45 
0.1 87.83 
0.06 89.71 
0.04 98.89 
0.02 99.99 
Acyl hydrazone 148 
[148], μM Enzyme activity, % 
10 4.71 
5 4.28 
1 8.63 
0.8 11.40 
0.6 13.18 
0.4 18.47 
0.2 31.33 
0.15 36.63 
0.1 43.66 
0.08 55.35 
0.06 62.64 
0.04 73.33 
0.01 95.86 
0.001 104.34 
Acyl hydrazone 149 
[149], μM Enzyme activity, % 
10 12.67 
5 13.44 
1 18.7 
0.8 20.53 
0.6 23.12 
0.4 28.49 
0.2 42.51 
0.1 60.69 
0.08 70.86 
0.06 75.02 
0.04 85.09 
0.02 92.85 
0.01 99 
0.001 99.99 
IC50 = 0.3918 ± 0.0244 μM 
IC50 = 0.0780 ± 0.0031 μM 
IC50 = 0.1208 ± 0.0039 μM 
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Thiolalkylated ligand 161 
[161], μM Enzyme activity, % 
20 22.71 
10 30.66 
8 34.41 
6 38.92 
4 45.19 
2 61.03 
1 80.94 
0.5 91.64 
0.1 99 
0.01 99.99 
Thiolalkylated ligand 162 
[162], μM Enzyme activity, % 
1000 25.12 
800 30.83 
600 39.15 
400 50.13 
200 71.8 
100 86.65 
10 90.47 
Thiolalkylated ligand 163 
[163], μM Enzyme activity, % 
100 33.02 
80 33.5 
60 33.99 
40 37.36 
20 42.02 
10 51.71 
8 58.18 
6 61.74 
4 71.18 
2 82.98 
1 96.59 
0.5 99.99 
IC50 = 2.25 ± 0.16 μM 
IC50 = 374.65 ± 35.44 μM 
IC50 = 4.39 ± 0.30 μM 
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Thiolalkylated ligand 164 
[164], μM Enzyme activity, % 
10 18.67 
8 18.44 
6 18.04 
4 19.71 
2 18.65 
1 19.28 
0.1 63.58 
1 18.91 
0.8 22.73 
0.6 24.69 
0.4 31.99 
0.2 44.01 
0.1 63.61 
0.1 63.04 
0.08 70.82 
0.06 74.67 
0.04 78.68 
0.02 89.48 
0.01 93.22 
0.001 97.47 
Alkylated ligand 168 
[168], μM Enzyme activity, % 
100 7.37 
80 8.87 
60 9.55 
40 11.99 
20 18.29 
10 29.79 
8 34.51 
6 40.03 
4 48.94 
2 68.9 
1 83.1 
0.1 99.00 
Tripeptide ligand 170 
[170], μM Enzyme activity, % 
100 2.75 
80 1.93 
60 3.44 
40 3.38 
20 5.06 
10 8.91 
8 10.38 
6 13.34 
4 18.09 
2 35.82 
1 53.71 
0.1 99 
IC50 = 3.62 ± 0.10 μM 
IC50 = 1.03 ± 0.04 μM 
IC50 = 0.1271 ± 0.0052 μM 
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Ex situ conjugates 171 
[161], μM Enzyme activity, % 
8.74 18.35 
4.37 30.51 
4.11 31.16 
2.06 47.99 
1.75 53.10 
1.18 64.84 
0.87 64.72 
0.41 79.39 
0.24 87.34 
0 72.02 
In situ conjugates 172 
[161], μM Enzyme activity, % 
61.56 51.19 
25.13 51.70 
0.26 71.79 
0.05 74.78 
0 75.87 
 
  
IC50 = 2.12 ± 0.49 μM 
IC50 = 1.29 ± 0.22 μM 
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7.2.3 Screening of DCLs 
The following data were based on the enzyme screening data of the full library and 
sub-libraries. The relative activities of sub-libraries compared to the full library, as well as 
the normalized activity related to the full library were listed in the following tables. The 
name of the sub-libraries represents the lacking specific building blocks. 
Table 7.1 Relative and normalized activity of sub-libraries compared to the full library (inhibitory activity: 
62 %). 
Sub-libraries Relative activity, % Normalized activity, % 
135 13.28 21.41935 
136 15.10333 24.36022 
138 29.55667 47.67204 
139 8.19667 13.22043 
140 -3.93667 -6.34946 
A 0.39 0.62903 
B 5.87 9.46774 
C 5.06 8.16129 
D 2.74667 4.43011 
E 11.08 17.87097 
 
Table 7.2 Relative and normalized activity of sub-libraries compared to the size-reduced full library 
(inhibitory activity: 52 %). 
Sub-libraries Relative activity, % Normalized activity, % 
138 52.16667 99.99994 
A 1.9 3.64217 
B 1.03667 1.98722 
C 8.43 16.15973 
D 0.26333 0.50479 
E 15.86 30.40254 
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7.2.4 Determination of Enzyme Inhibition Modes 
The following data were based on the determination of enzyme inhibition modes by 
different kinds of inhibitors. 
Table 7.3 Nonlinear analysis of enzyme inhibition mode of four-armed peptide ligand 
(RWKG)2(GCP-LFG)2 (120). 
Nonlinear analysis 
 [120] = 0 μM [120] = 5 μM [120] = 10 μM [120] = 100 μM 
[S], μM v v v v 
600 127.47 61.755 33.835 6.54 
400 107.92 53.4 38.58 4.315 
300 57.50667 20.16 18.29 2.335 
200 27.31333 8.35 7.34 1.125 
100 12.79333 3.87 3.595 0.715 
50 2.80667 0.585 0.715 0.07 
10 81.425 38.725 30.32 3.1 
 
Table 7.4 Determination of enzyme inhibition mode of four-armed peptide ligand (RWKG)2(GCP-LFG)2 
(120) with the help of Lineweaver-Burk plots. 
Lineweaver-Burk 
 [120] = 0 μM [120] = 5 μM [120] = 10 μM [120] = 100 μM 
1/[S] 1/v 1/v 1/v 1/v 
0.00167 0.00784 – – 0.15291 
0.0025 0.00927 0.01873 0.02592 0.23175 
0.00333 0.01228 0.02582 0.03298 0.32258 
0.005 0.01739 0.0496 0.05467 0.42827 
0.01 0.03661 0.11976 0.13624 0.88889 
0.02 0.07817 0.2584 0.27816 1.3986 
0.025 0.10204 0.3876 0.42735 – 
0.05 0.20747 0.86207 0.88496 – 
0.1 0.35629 1.26582 1.3986 – 
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Table 7.5 Determination of enzyme inhibition mode of acyl hydrazone (141) with the help of Dixon plots. 
Dixon 
 [S] = 
25 μM 
[S] = 
50 μM 
[S] = 
75 μM 
[S] = 
100 μM 
[S] = 
150 μM 
[S] = 
200 μM 
[141], μM 1/v 1/v 1/v 1/v 1/v 1/v 
0.1 0.7266 0.33762 0.22597 0.19017 0.10815 0.06772 
0.08 0.66231 – 0.19897 0.14076 0.08418 0.05424 
0.06 0.55846 – 0.16071 0.11025 0.0686 0.04353 
0.04 0.3747 0.15339 0.11546 0.07569 0.04572 0.02961 
0.02 0.21583 0.09654 0.06531 0.04568 0.02737 0.01912 
0.01 0.14911 0.0722 0.05047 0.03561 0.02264 0.01585 
0.001 0.11322 0.05245 0.03591 0.02587 0.01658 0.01185 
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Table 7.6 Nonlinear analysis of enzyme inhibition mode of single-armed ligand (170). 
Nonlinear analysis 
 
[170] = 
0 μM 
[170] = 
1 μM 
[170] = 
5 μM 
[170] = 
10 μM 
[170] = 
50 μM 
[S], μM v v v v v 
400 82.68557 47.15248 19.43252 11.64199 2.79383 
300 81.27196 43.4512 14.82594 8.38411 2.42982 
200 56.64116 25.89424 7.77569 4.273 1.27449 
100 24.65435 10.87509 3.35119 2.07963 0.58519 
50 12.53852 5.08 1.54533 1.15346 0.29905 
25 5.78335 2.81226 0.69612 0.60259 0.16302 
10 2.7752 1.21561 0.33383 0.24 0.07634 
 
Table 7.7 Determination of enzyme inhibition mode of single-armed ligand (170) with the help of 
Lineweaver-Burk plots. 
Lineweaver-Burk 
 
[170] = 
0 μM 
[170] = 
1 μM 
[170] = 
5 μM 
[170] = 
10 μM 
[170] = 
50 μM 
1/[S] 1/v 1/v 1/v 1/v 1/v 
0.0025 0.01209 0.02121 0.05146 0.0859 0.35793 
0.00333 0.0123 0.02301 0.06745 0.11927 0.41155 
0.005 0.01766 0.03862 0.12861 0.23403 0.78463 
0.01 0.04056 0.09195 0.2984 0.48085 1.70885 
0.02 0.07975 0.19685 0.64711 0.86695 3.34387 
0.04 0.17291 0.35559 1.43653 1.65952 6.13423 
0.1 0.36033 0.82263 2.99556 4.16667 – 
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7.3 Curriculum Vitae 
The CV is not included in this online version of the thesis for reasons of data 
protection. 
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Journal 
Qian-Qian Jiang, Lina Bartsch, Wilhelm Sicking, Peter R. Wich, Dominik Heider, 
Daniel Hoffmann, Carsten Schmuck;  
A New Approach to Inhibit Human β-Tryptase by Protein Surface Binding of 
Four-Armed Peptide Ligands with Two Different Sets of Arms;  
Org. Biomol. Chem., 2013, 11, 1631–1639. Selected as “hot paper”. 
Poster Presentation 
Qian-Qian Jiang, Carsten Schmuck; 
Design of Multivalent Peptides as Potent Inhibitors for β-Tryptase;  
3rd European Chemistry Congress, Nürnberg, Germany, 29th Aug-2nd Sep 2010. 
Symposium in Supramolecular Chemistry, Essen, Germany, 24th-25th Feb 2011. 
Junges Chemie Symposium Ruhr, Essen, Germany, 22nd Sep 2011. 
 
Qian-Qian Jiang, Carsten Schmuck; 
Discovery of Potent Inhibitors of Human β-Tryptase from Dynamic Combinatorial 
Library; 
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